

Prevalence of Human Papillomavirus in Cervical Cancer

Journal of the National Cancer Institute

87, 796-802

DOI: [10.1093/jnci/87.11.796](https://doi.org/10.1093/jnci/87.11.796)

Citation Report

#	ARTICLE	IF	CITATIONS
3	SOGC Clinical Practice Guidelines. Journal of Obstetrics and Gynaecology Canada, 1995, 17, 1241-1243.	0.1	61
4	Human papillomavirus and cervical neoplasia: A case-control study in Taiwan. International Journal of Cancer, 1995, 62, 565-571.	2.3	92
5	Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nature Medicine, 1995, 1, 1297-1302.	15.2	1,015
6	Lack of Efficacy of Interferon- α Therapy in Recurrent, Advanced Cervical Cancer. Journal of Interferon and Cytokine Research, 1995, 15, 1011-1016.	0.5	14
7	Cancer Causes Revisited: Human Papillomavirus and Cervical Neoplasia. Journal of the National Cancer Institute, 1995, 87, 779-780.	3.0	89
8	Divergent Human Papillomavirus Type 16 Variants Are Serologically Cross-Reactive. Journal of Infectious Diseases, 1995, 172, 1584-1587.	1.9	56
9	New Epidemiology of Human Papillomavirus Infection and Cervical Neoplasia. Journal of the National Cancer Institute, 1995, 87, 1345-1347.	3.0	86
10	Generation of entire human papillomavirus genomes by long PCR: frequency of errors produced during amplification.. Genome Research, 1995, 5, 79-88.	2.4	25
11	Studies on in Vivo Induction of Cytotoxic T Lymphocyte Responses by Synthetic Peptides from E6 and E7 Oncoproteins of Human Papillomavirus Type 16. Viral Immunology, 1995, 8, 165-174.	0.6	30
12	CLINICAL ROLE OF HPV TESTING. Obstetrics and Gynecology Clinics of North America, 1996, 23, 811-851.	0.7	38
13	Worldwide variations in sperm counts. Urology, 1996, 48, 909-911.	0.5	44
14	Production of human papillomavirus type 45 virus-like particles in insect cells using a recombinant baculovirus. FEMS Microbiology Letters, 1996, 141, 111-116.	0.7	5
15	Virologic screening. European Journal of Obstetrics, Gynecology and Reproductive Biology, 1996, 65, 61-63.	0.5	4
16	Short-term fluctuations in the detection of cervical human papillomavirus DNA. Obstetrics and Gynecology, 1996, 88, 261-268.	1.2	69
17	p53 mutations and clonality in vulvar carcinomas and squamous hyperplasias: Evidence suggesting that squamous hyperplasias do not serve as direct precursors of human papillomavirus-negative vulvar carcinomas. Human Pathology, 1996, 27, 389-395.	1.1	74
18	Do human papillomaviruses cause cancer?. Current Diagnostic Pathology, 1996, 3, 123-125.	0.4	3
19	Human Papillomavirus Type 18: Association With Poor Prognosis in Early Stage Cervical Cancer. Journal of the National Cancer Institute, 1996, 88, 1361-1368.	3.0	170
20	The Current Status of Therapeutic HPV Vaccine. Annals of Medicine, 1996, 28, 471-477.	1.5	22

#	ARTICLE	IF	CITATIONS
21	Serum Antibodies to HPV 16 Virus-Like Particles Are Not Associated with Penile Cancer in Chinese Males. <i>Viral Immunology</i> , 1996, 9, 23-25.	0.6	9
22	Chronic estrogen-induced cervical and vaginal squamous carcinogenesis in human papillomavirus type 16 transgenic mice.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1996, 93, 2930-2935.	3.3	270
23	Socioeconomic differences in cervical cancer: two case-control studies in Colombia and Spain.. <i>American Journal of Public Health</i> , 1996, 86, 1532-1538.	1.5	37
24	Gain of chromosome 3q defines the transition from severe dysplasia to invasive carcinoma of the uterine cervix.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1996, 93, 479-484.	3.3	430
25	Viruses In Human Tumorsâ€“Reminiscences And Perspectives. <i>Advances in Cancer Research</i> , 1996, 68, 1-22.	1.9	21
26	Cancer in Circumpolar Inuit 1969-1988. <i>Acta OncolÃ³gica</i> , 1996, 35, 621-628.	0.8	37
27	Detection of human papillomavirus in vulval carcinoma using semi-nested PCR and restriction enzyme typing: a rapid and sensitive technique. <i>Journal of Clinical Pathology</i> , 1996, 49, M236-M239.	2.1	5
28	Papillomavirus infections â€” a major cause of human cancers. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 1996, 1288, F55-F78.	3.3	771
29	Roots and perspectives of contemporary papillomavirus research. <i>Journal of Cancer Research and Clinical Oncology</i> , 1996, 122, 3-13.	1.2	67
30	Papillomavirus-like particles and HPV vaccine development. <i>Seminars in Cancer Biology</i> , 1996, 7, 373-382.	4.3	93
31	Risk factors for invasive cervical cancer in Latino women. <i>Journal of Medical Systems</i> , 1996, 20, 277-293.	2.2	16
32	The Role of HPV DNA Testing in Cervical Neoplasia. <i>Journal of Obstetrics and Gynaecology Research</i> , 1996, 22, 611-620.	0.6	4
33	Hybrid Captureâ„¢ Method for Detection of Human Papillomavirus DNA in Clinical Specimens: A Tool for Clinical Management of Equivocal Pap Smears and for Population Screening. <i>Journal of Obstetrics and Gynaecology Research</i> , 1996, 22, 629-636.	0.6	108
34	Generation of tumor-specific cytolytic T lymphocytes from peripheral blood of cervical cancer patients by in vitro stimulation with a synthetic human papillomavirus type 16 E7 epitope. <i>American Journal of Obstetrics and Gynecology</i> , 1996, 175, 1586-1593.	0.7	80
35	A non-radioactive PCR enzyme-immunoassay enables a rapid identification of HPV 16 and 18 in cervical scrapes after GP5+/6+ PCR. , 1996, 49, 223-229.		44
36	Detection by PCR of human papillomavirus genotypes in cervical lesions of Senegalese women. , 1996, 49, 259-263.		20
37	Cervical carcinoma in surinam. , 1996, 77, 1329-1333.		15
38	Type 73 human papillomavirus in esophageal squamous cell carcinoma: A novel association. <i>Cancer</i> , 1996, 77, 2440-2444.	2.0	26

#	ARTICLE	IF	CITATIONS
39	Type of human papillomavirus is related to clinical features of cervical carcinoma. <i>Cancer</i> , 1996, 78, 1935-1941.	2.0	70
40	Can papilloma virus testing be used to improve cervical cancer screening?. , 1996, 65, 768-773.		64
41	Novel HPV types present in oral papillomatous lesions from patients with HIV infection. , 1996, 66, 453-456.		94
42	A population-based case-control study of human papillomavirus-type-16 seropositivity and incident high-grade dysplasia of the uterine cervix. , 1996, 68, 415-419.		20
43	PCR-based high-risk HPV test in cervical cancer screening gives objective risk assessment of women with cytomorphologically normal cervical smears. , 1996, 68, 766-769.		192
44	Human papillomavirus vaccines for cervical cancer. <i>Current Opinion in Immunology</i> , 1996, 8, 643-650.	2.4	83
45	Characterization of human papillomavirus type 57b: Transforming activity and comparative sequence analysis as probes for biological determinants associated with high-risk oncogenic viruses. <i>Virus Genes</i> , 1996, 12, 165-178.	0.7	13
46	Production of human papillomavirus type 45 virus-like particles in insect cells using a recombinant baculovirus. <i>FEMS Microbiology Letters</i> , 1996, 141, 111-116.	0.7	9
47	The role of vaccines in the control of STDs: HPV vaccines.. <i>Sexually Transmitted Infections</i> , 1996, 72, 398-403.	0.8	7
48	Type-Specific Prevalence of Human Papillomavirus DNA among Jamaican Colposcopy Patients. <i>Journal of Infectious Diseases</i> , 1996, 173, 718-721.	1.9	10
49	FRA3B Extends Over a Broad Region and Contains a Spontaneous HPV16 Integration Site: Direct Evidence for the Coincidence of Viral Integration Sites and Fragile Sites. <i>Human Molecular Genetics</i> , 1996, 5, 187-195.	1.4	220
50	Correlation of apoptosis with tumour cell differentiation, progression, and HPV infection in cervical carcinoma.. <i>Journal of Clinical Pathology</i> , 1996, 49, 134-138.	1.0	52
51	Randomised double-blind trial of recombinant interferon-beta for condyloma acuminatum.. <i>Sexually Transmitted Infections</i> , 1996, 72, 111-114.	0.8	10
52	The Natural History of Human Papillomavirus Type 16 Capsid Antibodies among a Cohort of University Women. <i>Journal of Infectious Diseases</i> , 1996, 174, 927-936.	1.9	294
53	Promoter Activity of Sequences Located Upstream of the Human Papillomavirus Types 16 and 18 Late Regions. <i>Journal of General Virology</i> , 1996, 77, 2193-2200.	1.3	11
54	Oncogenic human papillomaviruses and ploidy in cervical lesions.. <i>Journal of Clinical Pathology</i> , 1996, 49, 892-896.	1.0	31
55	Difficulty in Elucidating the Male Role in Cervical Cancer in Colombia, a High-Risk Area for the Disease. <i>Journal of the National Cancer Institute</i> , 1996, 88, 1068-1075.	3.0	69
56	Serologic Association Between Human Papillomavirus Type 16 Infection and Esophageal Cancer in Shaanxi Province, China. <i>Journal of the National Cancer Institute</i> , 1996, 88, 1467-1471.	3.0	58

#	ARTICLE	IF	CITATIONS
57	Malignant transformation of human ectocervical cells immortalized by HPV 18: in vitro model of carcinogenesis by cigarette smoke. <i>Carcinogenesis</i> , 1996, 17, 577-583.	1.3	23
58	Human Papillomavirus Infections in Nonmelanoma Skin Cancers From Renal Transplant Recipients and Nonimmunosuppressed Patients. <i>Journal of the National Cancer Institute</i> , 1996, 88, 802-811.	3.0	288
59	Association Between Human Papillomavirus Type and Clonal Status of Cervical Squamous Intraepithelial Lesions. <i>Journal of the National Cancer Institute</i> , 1996, 88, 355-358.	3.0	71
60	Male Sexual Behavior and Human Papillomavirus DNA: Key Risk Factors for Cervical Cancer in Spain. <i>Journal of the National Cancer Institute</i> , 1996, 88, 1060-1067.	3.0	209
61	Treasure Hunt for Human Papillomaviruses in Nonmelanoma Skin Cancers. <i>Journal of the National Cancer Institute</i> , 1996, 88, 781-782.	3.0	9
62	Sexual Behavior and Partner Characteristics Are the Predominant Risk Factors for Genital Human Papillomavirus Infection in Young Women. <i>Journal of Infectious Diseases</i> , 1996, 174, 679-689.	1.9	291
63	Breast Cancer Prevention in African-American Women. <i>Journal of the National Cancer Institute</i> , 1996, 88, 1334-1334.	3.0	0
64	Is the Evidence Implicating Human Papillomavirus Type 16 in Esophageal Cancer Hard to Swallow?. <i>Journal of the National Cancer Institute</i> , 1996, 88, 1424-1424.	3.0	3
65	Antithrombotic Agents and Thromboembolic Disease. <i>New England Journal of Medicine</i> , 1997, 337, 1383-1384.	13.9	14
66	Sonography in Giant-Cell Arteritis. <i>New England Journal of Medicine</i> , 1997, 337, 1385-1386.	13.9	57
67	Human Papillomaviruses and Anogenital Cancers. <i>New England Journal of Medicine</i> , 1997, 337, 1386-1388.	13.9	67
68	Identification of Tobacco-Specific Carcinogen in the Cervical Mucus of Smokers and Nonsmokers. <i>Journal of the National Cancer Institute</i> , 1997, 89, 868-873.	3.0	198
69	Papillomavirus Is Resistant to Desiccation. <i>Journal of Infectious Diseases</i> , 1997, 176, 1076-1079.	1.9	117
70	Human Papillomaviruses and cervical Cancer. <i>Advances in Cancer Research</i> , 1997, 71, 321-341.	1.9	118
71	Prevalence of Penile Human Papillomavirus DNA in Husbands of Women with and without Cervical Neoplasia: A Study in Spain and Colombia. <i>Journal of Infectious Diseases</i> , 1997, 176, 353-361.	1.9	120
72	Association Between Human Papillomavirus Type 18 Variants and Histopathology of Cervical Cancer. <i>Journal of the National Cancer Institute</i> , 1997, 89, 1227-1231.	3.0	55
73	Immunoglobulin G Responses Against Human Papillomavirus Type 16 Virus-Like Particles in a Prospective Nonintervention Cohort Study of Women With Cervical Intraepithelial Neoplasia. <i>Journal of the National Cancer Institute</i> , 1997, 89, 630-638.	3.0	83
74	Analysis of Cytokine Profiles in Patients With Human Papillomavirus-Associated Neoplasms. <i>Journal of the National Cancer Institute</i> , 1997, 89, 185-187.	3.0	40

#	ARTICLE	IF	CITATIONS
75	Anal cytological abnormalities and anal HPV infection in men with Centers for Disease Control group IV HIV disease.. Sexually Transmitted Infections, 1997, 73, 174-180.	0.8	33
76	Human papillomavirus, integration and cervical carcinogenesis: a clinicopathological perspective.. Journal of Clinical Pathology, 1997, 50, 1-3.	2.1	11
77	Human papillomavirus type 16 E5 protein (review). International Journal of Oncology, 1997, 11, 1297-304.	1.4	3
78	History of Genital Warts in 10,838 Women 20 to 29 Years of Age From the General Population. Sexually Transmitted Diseases, 1997, 24, 567-572.	0.8	47
79	Type-Specific Prevalence of Genital Human Papillomaviruses in Benign, Premalignant, and Malignant Biopsies in Patients From Greece. Sexually Transmitted Diseases, 1997, 24, 469-474.	0.8	13
80	A High Frequency of Human Papilloma Virus (HPV) DNA Type 16 in Biopsies of Cervical Squamous Cell Neoplasia of Uygur Women. International Journal of Surgical Pathology, 1997, 4, 219-225.	0.4	2
81	Androgen responsive adult human prostatic epithelial cell lines immortalized by human papillomavirus 18. Carcinogenesis, 1997, 18, 1215-1223.	1.3	358
82	Deletions of the Short Arm of Chromosome 3 in Solid Tumors and the Search for Suppressor Genes. Advances in Cancer Research, 1997, 71, 27-92.	1.9	278
83	Cofactors With Human Papillomavirus in a Population-Based Study of Vulvar Cancer. Journal of the National Cancer Institute, 1997, 89, 1516-1523.	3.0	155
84	Human Papillomavirus Infections: Current Concepts, New Developments. Journal of Obstetrics and Gynaecology Canada, 1997, 19, 369-381.	0.1	1
85	Sensitive issues in health education practice: cancer prevention and adolescents. Health Education, 1997, 97, 233-243.	0.4	2
86	Detection of human papillomavirus mRNA and cervical cancer cells in peripheral blood of cervical cancer patients with metastasis.. Journal of Clinical Oncology, 1997, 15, 1008-1012.	0.8	53
87	Present evidence on the value of HPV testing for cervical cancer screening: a model-based exploration of the (cost-)effectiveness. British Journal of Cancer, 1997, 76, 651-657.	2.9	71
88	The human papillomavirus E7 oncoprotein can uncouple cellular differentiation and proliferation in human keratinocytes by abrogating p21^{Cip1}-mediated inhibition of p27^{cdk2}. Genes and Development, 1997, 11, 2101-2111.	2.7	415
89	The future of HPV testing in clinical laboratories and applied virology research. Clinical and Diagnostic Virology, 1997, 8, 123-141.	1.8	34
90	Effects of β -Carotene and Other Factors on Outcome of Cervical Dysplasia and Human Papillomavirus Infection. Gynecologic Oncology, 1997, 65, 483-492.	0.6	90
91	Human Papillomavirus Analysis as a Prognostic Marker Following Conization of the Cervix Uteri. Gynecologic Oncology, 1997, 66, 108-113.	0.6	104
92	Epidemiology of Genital Human Papillomavirus Infection. American Journal of Medicine, 1997, 102, 3-8.	0.6	889

#	ARTICLE	IF	CITATIONS
93	The NIH Consensus Conference on Cervical Cancer: Implications for Practice. Primary Care Update for Ob/Gyns, 1997, 4, 179-183.	0.1	0
94	Role of human papillomaviruses in cancer of the respiratory and upper digestive tract. Clinics in Dermatology, 1997, 15, 415-425.	0.8	26
95	Anogenital premalignant and malignant tumors (including Buschke-Löwenstein tumors). Clinics in Dermatology, 1997, 15, 377-388.	0.8	42
96	Papillomavirus and HPV typing. Clinics in Dermatology, 1997, 15, 199-206.	0.8	105
97	Humoral immune response to human papillomavirus infection. Clinics in Dermatology, 1997, 15, 229-236.	0.8	40
98	Human papillomaviruses: General features. Clinics in Dermatology, 1997, 15, 181-198.	0.8	52
99	Human papillomavirus and other risk factors for cervical cancer. Biomedicine and Pharmacotherapy, 1997, 51, 268-275.	2.5	35
100	The role of human papilloma virus in skin cancer " current status. Journal of the European Academy of Dermatology and Venereology, 1997, 9, 103-110.	1.3	3
101	The carboxyl-terminal zinc-binding domain of the human papillomavirus E7 protein can be functionally replaced by the homologous sequences of the E6 protein. Virus Research, 1997, 52, 109-118.	1.1	19
102	Molecular analysis of episomal human papillomavirus type 16 DNA in a cervical carcinoma cell line. Virus Research, 1997, 51, 183-195.	1.1	6
103	Future vaccines and a global perspective. Lancet, The, 1997, 350, 1767-1770.	6.3	27
104	Human papillomavirus DNA and antibodies to human papillomaviruses 16 E2, L2, and E7 peptides as predictors of survival in patients with squamous cell cervical cancer.. Journal of Clinical Oncology, 1997, 15, 610-619.	0.8	37
105	Human Papillomavirus Infection and Risk Determinants for Squamous Intraepithelial Lesion and Cervical Cancer in Japan. Japanese Journal of Cancer Research, 1997, 88, 376-384.	1.7	35
106	Biological agents. Apmis, 1997, 105, 120-131.	0.9	3
107	HPV 16 infection in a patient with two primary squamous cell carcinomas: of the uterine cervix and the anal mucosa. Apmis, 1997, 105, 207-212.	0.9	1
108	The human papillomavirus-16 E6 oncoprotein decreases the vigilance of mitotic checkpoints. Oncogene, 1997, 15, 3025-3035.	2.6	115
109	Induction of p16 during immortalization by HPV 16 and 18 and not during malignant transformation. British Journal of Cancer, 1997, 75, 1410-1416.	2.9	102
110	A recurrent pattern of chromosomal aberrations and immunophenotypic appearance defines anal squamous cell carcinomas. British Journal of Cancer, 1997, 76, 1271-1278.	2.9	41

#	ARTICLE	IF	CITATIONS
111	Identification of human papillomavirus types 16 and 18 deoxyribonucleic acid sequences in bulky cervical cancer after chemotherapy. <i>American Journal of Obstetrics and Gynecology</i> , 1997, 176, 865-869.	0.7	5
112	HPV 16 DNA and mRNA in cervical brush samples quantified by PCR and microwell hybridization. <i>Journal of Virological Methods</i> , 1997, 69, 209-222.	1.0	17
113	Demonstration of human papillomavirus (HPV) genomic amplification and viral-like particles from CaSki cell line in SCID mice. <i>Journal of Virological Methods</i> , 1997, 65, 287-298.	1.0	7
114	Detection of human papillomavirus DNA in genital lesions by enzymatic in situ hybridization with Fast Red and laser scanning confocal microscopy. <i>The Histochemical Journal</i> , 1997, 29, 545-554.	0.6	5
115	Sequence Variation in the Upstream Regulatory Region of HPV 18 Isolates from Cervical Cancers. <i>Gynecologic Oncology</i> , 1997, 66, 282-289.	0.6	27
116	Detection and typing of human papillomaviruses by polymerase chain reaction in cervical scrapes of Croatian women with abnormal cytology. <i>European Journal of Epidemiology</i> , 1997, 13, 645-651.	2.5	14
117	Immunomanipulative strategies for the control of human papillomavirus associated cervical disease. <i>Immunologic Research</i> , 1997, 16, 387-400.	1.3	13
118	Human papillomavirus E6 and E7 oncoproteins alter cell cycle progression but not radiosensitivity of carcinoma cells treated with low-dose-rate radiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 1997, 37, 145-154.	0.4	68
119	DNA analysis indicates patient-specific human papillomavirus type 16 strains in Bowen's disease on fingers and in archival samples from genital dysplasia. <i>British Journal of Dermatology</i> , 1997, 136, 678-682.	1.4	26
120	Can HPV typing predict the behaviour of cervical epithelial neoplasia?. <i>Histopathology</i> , 1997, 31, 301-303.	1.6	7
121	Do HPV-negative cervical carcinomas exist?. , 1997, 181, 253-254.		125
122	Human papillomavirus infection and invasive cervical neoplasia: a study of prevalence and morphology. , 1997, 181, 270-275.		36
123	Polyamine measurements in the uterine cervix. <i>Journal of Cellular Biochemistry</i> , 1997, 67, 125-132.	1.2	10
124	Advanced-stage cervical carcinomas are defined by a recurrent pattern of chromosomal aberrations revealing high genetic instability and a consistent gain of chromosome arm 3q. , 1997, 19, 233-240.		228
125	Human papillomavirus (HPV) in head and neck cancer. , 1997, 79, 595-604.		324
126	Cervical specimens collected in liquid buffer are suitable for both cytologic screening and ancillary human papillomavirus testing. <i>Cancer</i> , 1997, 81, 89-97.	2.0	99
127	Lymphoepithelioma-like carcinoma of the uterine cervix. <i>Cancer</i> , 1997, 80, 91-97.	2.0	87
128	Human papillomavirus types 52 and 58 are prevalent in cervical cancers from Chinese women. , 1997, 70, 408-411.		107

#	ARTICLE	IF	CITATIONS
129	Evaluating cervical cancer screening programmes for developing countries. , 1997, 72, 210-216.		33
130	Genomic deletion and p53 inactivation in cervical carcinoma. , 1997, 72, 270-276.		24
131	Distinct manifestations of human papillomaviruses in the vagina. , 1997, 72, 412-415.		73
132	Human papillomavirus (HPV) in an Icelandic population: The role of HPV DNA testing based on hybrid capture and PCR assays among women with screen-detected abnormal pap smears. , 1997, 72, 446-452.		18
133	Human papillomavirus types 52 and 58 are prevalent in cervical cancer from Chinese women. , 1997, 73, 775-776.		39
134	Angiogenesis in histologically benign squamous mucosa is a sensitive marker for nearby cervical intraepithelial neoplasia. <i>Angiogenesis</i> , 1998, 2, 135-142.	3.7	4
135	Prospects for a prophylactic HPV vaccine: Rationale and future implications for cervical cancer screening. <i>Diagnostic Cytopathology</i> , 1998, 18, 5-9.	0.5	31
136	The Status of Human Papillomavirus and Tumor Suppressor Genes p53 and p16 in Carcinomas of Uterine Cervix from India. <i>Gynecologic Oncology</i> , 1998, 69, 205-209.	0.6	23
137	Detection of Human Papillomavirus Type 16 E6/E7 Oncogene Transcripts in Dysplastic and Nondysplastic Cervical Scrapes by Nested RT-PCR. <i>Gynecologic Oncology</i> , 1998, 69, 114-121.	0.6	66
138	HPV Prevalence among Mexican Women with Neoplastic and Normal Cervixes. <i>Gynecologic Oncology</i> , 1998, 70, 115-120.	0.6	67
139	Establishment and Characterization of a New HPV-Negative Squamous Cell Carcinoma Cell Line (Yumoto) from the Human Uterine Cervix. <i>Gynecologic Oncology</i> , 1998, 70, 339-347.	0.6	15
140	Expression of Human Papillomavirus Type 16 L1 Protein in <i>Escherichia coli</i> : Denaturation, Renaturation, and Self-Assembly of Virus-like Particles in Vitro. <i>Virology</i> , 1998, 243, 423-431.	1.1	58
141	Mice Expressing the E7 Oncogene of HPV16 in Epithelium Show Central Tolerance, and Evidence of Peripheral Anergising Tolerance, to E7-Encoded Cytotoxic T-Lymphocyte Epitopes. <i>Virology</i> , 1998, 244, 352-364.	1.1	43
142	Detection of Infectious Adeno-Associated Virus Particles in Human Cervical Biopsies. <i>Virology</i> , 1998, 247, 97-105.	1.1	50
143	Exploring the possibility of sexual-behavioural primary prevention interventions for cervical cancer. <i>Australian and New Zealand Journal of Public Health</i> , 1998, 22, 353-359.	0.8	13
144	Two case reports: Carcinoma of the cervix and carcinoma of the endometrium treated with radiotherapy after previous irradiation for benign uterine bleeding. <i>Journal of Medical Imaging and Radiation Oncology</i> , 1998, 42, 229-231.	0.6	0
145	Potential of E7 antisense RNA-induced antitumor immunity by co-delivery of IL-12 gene in HPV16 DNA-positive mouse tumor. <i>Gene Therapy</i> , 1998, 5, 1462-1471.	2.3	12
146	Detection of human papillomavirus in verrucous carcinoma from HIV-seropositive patients. <i>Journal of Cutaneous Pathology</i> , 1998, 25, 165-170.	0.7	41

#	ARTICLE	IF	CITATIONS
147	Mutations in the TP53 gene and protein expression of p53, MDM 2 and p21/WAF-1 in primary cervical carcinomas with no or low human papillomavirus load. <i>British Journal of Cancer</i> , 1998, 78, 69-72.	2.9	27
148	Telomerase activity and human papillomavirus in malignant, premalignant and benign cervical lesions. <i>British Journal of Cancer</i> , 1998, 78, 933-939.	2.9	48
149	Production of recombinant virus-like particles from human papillomavirus types 6 and 11, and study of serological reactivities between HPV 6, 11, 16 and 45 by ELISA: implications for papillomavirus prevention and detection. <i>FEMS Microbiology Letters</i> , 1998, 160, 111-118.	0.7	15
150	A population-based study of human papillomavirus deoxyribonucleic acid testing for predicting cervical intraepithelial neoplasia. <i>American Journal of Obstetrics and Gynecology</i> , 1998, 179, 1497-1502.	0.7	23
151	Cervical cancer in older women: A molecular analysis of human papillomavirus types, HLA types, and p53 mutations. <i>American Journal of Obstetrics and Gynecology</i> , 1998, 179, 56-61.	0.7	28
152	The role of human papillomavirus DNAs in cervical carcinoma and risk of lymph node metastasis. , 1998, 82, 886-892.		18
153	A multifaceted study of human papillomavirus and prostate carcinoma. , 1998, 82, 1118-1125.		61
154	Intraepithelial carcinoma of the cervix. <i>Cancer</i> , 1998, 83, 2243-2246.	2.0	11
155	Radiation-enhanced expression of E6/E7 transforming oncogenes of human papillomavirus-16 in human cervical carcinoma. <i>Cancer</i> , 1998, 83, 2346-2352.	2.0	55
156	Human papillomavirus types 52 and 58. , 1998, 75, 484-485.		29
157	Comparative analysis of human papillomavirus detection by hybrid capture assay and routine cytologic screening to detect high-grade cervical lesions. , 1998, 75, 525-528.		39
158	Immunoglobulin-A and -G responses against virus-like particles (VLP) of human papillomavirus type 16 in women with cervical cancer and cervical intra-epithelial lesions. , 1998, 75, 529-535.		46
159	International trends in the incidence of cervical cancer: I. Adenocarcinoma and adenosquamous cell carcinomas. , 1998, 75, 536-545.		264
160	The viral origin of cervical cancer in Rabat, Morocco. , 1998, 75, 546-554.		126
161	An increased risk of cervical intra-epithelial neoplasia grade II-III among human papillomavirus positive patients with theHLA-DQA1*0102-DQB1*0602 haplotype: A population-based caseâ€“control study of Norwegian women. , 1998, 76, 19-24.		46
162	Human papillomavirus and human immunodeficiency virus infections: relation with cervical dysplasia-neoplasia in African women. , 1998, 76, 480-486.		84
163	Antigen-specific immunotherapy for murine lung metastatic tumors expressing human papillomavirus type 16 E7 oncoprotein. , 1998, 78, 41-45.		116
164	HPV 16 and cigarette smoking as risk factors for high-grade cervical intra-epithelial neoplasia. , 1998, 78, 281-285.		118

#	ARTICLE	IF	CITATIONS
165	Viral characteristics of human papillomavirus infection and antioxidant levels as risk factors for cervical dysplasia. , 1998, 78, 594-599.		71
166	Morphological analysis of in situ hybridization signals in cervical intraepithelial neoplasia containing human papillomavirus type 16 or 18: Relationship with histological grade and DNA content. , 1998, 34, 180-186.		7
167	Human Papillomavirus and head and neck cancer: Epidemiology and molecular biology. , 1998, 20, 250-265.		243
168	HPV 16 E7 antibody levels in cervical cancer patients: Before and after treatment. Journal of Medical Virology, 1998, 54, 192-195.	2.5	24
169	Expression patterns of the human papillomavirus type 16 transcription factor E2 in low- and high-grade cervical intraepithelial neoplasia. , 1998, 186, 275-280.		29
170	Persistence of human papillomavirus DNA in cervical lesions after tith diathermic large loop excision. , 1998, 6, 214-219.		20
171	Cervial intraepithelial neoplasia III shows frequent allelic loss in 3p and 6p. , 1998, 22, 57-65.		44
172	Organotypic culture of HPV-transformed keratinocytes: a model for testing lymphocyte infiltration of (pre)neoplastic lesions of the uterine cervix. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 1998, 432, 323-330.	1.4	24
173	Aktuelle Studien zur Therapie des Zervix- karzinoms in den USA. Onkologe, 1998, 4, 180-184.	0.7	0
174	Human papillomavirus,Chlamydia trachomatis, and other risk factors associated with cervical cancer in China. International Journal of Clinical Oncology, 1998, 3, 81-87.	1.0	6
175	Detection of human papillomavirus (HPV) DNA in archival specimens of benign prostatic hyperplasia and prostatic cancer using a highly sensitive nested PCR method. Urological Research, 1998, 26, 165-169.	1.5	45
176	Vaccineâ€Induced Th1â€Type Responses are Dominant over Th2â€Type Responses in the Short Term whereas Preâ€Existing Th2 Responses are Dominant in the Longer Term. Scandinavian Journal of Immunology, 1998, 47, 459-465.	1.3	37
177	HPV typing and testing in gynaecological pathology: has the time come?. Histopathology, 1998, 33, 83-86.	1.6	43
178	Inverse modulation of IL-10 and IL-12 in the blood of women with preneoplastic lesions of the uterine cervix. Clinical and Experimental Immunology, 1998, 111, 219-224.	1.1	40
179	Production of recombinant virus-like particles from human papillomavirus types 6 and 11, and study of serological reactivities between HPV 6, 11, 16 and 45 by ELISA: implications for papillomavirus prevention and detection. FEMS Microbiology Letters, 1998, 160, 111-118.	0.7	14
180	Synthetic peptides of human papillomavirus type 18 E6 harboring HLA-A2.1 motif can induce peptide-specific cytotoxic T-cells from peripheral blood mononuclear cells of healthy donors. Virus Research, 1998, 54, 23-29.	1.1	24
181	Is vaccination against human papillomavirus a possibility?. Lancet, The, 1998, 351, S22-S24.	6.3	29
182	Perinatal Transmission of Human Papillomavirus in Infants: Relationship Between Infection Rate and Mode of Delivery. Obstetrics and Gynecology, 1998, 91, 92-96.	1.2	116

#	ARTICLE	IF	CITATIONS
183	Human papillomavirus infection in esophageal carcinomas: A study of 121 lesions using multiple broad-spectrum polymerase chain reactions and literature review. <i>Human Pathology</i> , 1998, 29, 266-271.	1.1	77
184	TRIAGE OF THE ABNORMAL PAPANICOLAOU SMEAR IN PREGNANCY. <i>Primary Care - Clinics in Office Practice</i> , 1998, 25, 483-503.	0.7	10
185	Human papillomavirus detection in cervical intraepithelial neoplasia by the second-generation hybrid capture microplate test, comparing two different cervical specimen collection methods. <i>Clinical and Diagnostic Virology</i> , 1998, 10, 49-56.	1.8	37
186	Hepatic Dysfunction Associated with Troglitazone. <i>New England Journal of Medicine</i> , 1998, 338, 916-917.	13.9	444
187	A nested case-control study of dietary factors and the risk of incident cytological abnormalities of the cervix. <i>Nutrition and Cancer</i> , 1998, 30, 130-136.	0.9	32
188	Human Cervical Cancer-Associated Nuclear Matrix Proteins. <i>Experimental Cell Research</i> , 1998, 244, 14-25.	1.2	12
189	Novel Short-Fragment PCR Assay for Highly Sensitive Broad-Spectrum Detection of Anogenital Human Papillomaviruses. <i>American Journal of Pathology</i> , 1998, 153, 1731-1739.	1.9	476
190	Plasma concentrations of micronutrients during 12-month clinical trial of β -carotene in women with precursor cervical cancer lesions. <i>Nutrition and Cancer</i> , 1998, 30, 46-52.	0.9	34
191	Natural History of Cervicovaginal Papillomavirus Infection in Young Women. <i>New England Journal of Medicine</i> , 1998, 338, 423-428.	13.9	2,116
192	HPV testing in cervical screening. <i>Sexually Transmitted Infections</i> , 1998, 74, 300-301.	0.8	1
193	Association of Rare Human Papillomavirus Types with Genital Premalignant and Malignant Lesions. <i>Journal of Infectious Diseases</i> , 1998, 178, 252-255.	1.9	49
194	Prevalence and Risk Factors for Human Papillomavirus Infection of the Anal Canal in Human Immunodeficiency Virus (HIV)-Positive and HIV-Negative Homosexual Men. <i>Journal of Infectious Diseases</i> , 1998, 177, 361-367.	1.9	470
195	DNA-EIA to detect high and low risk HPV genotypes in cervical lesions with E6/E7 primer mediated multiplex PCR. <i>Journal of Clinical Pathology</i> , 1998, 51, 38-43.	1.0	16
196	Causes of Cervical Cancer in the Philippines: a Case-Control Study. <i>Journal of the National Cancer Institute</i> , 1998, 90, 43-49.	3.0	161
197	Dietary Fat Intake and the Risk of Coronary Heart Disease in Women. <i>New England Journal of Medicine</i> , 1998, 338, 917-919.	13.9	8
198	Cardiovascular Medicine at the Turn of the Millennium. <i>New England Journal of Medicine</i> , 1998, 338, 919-920.	13.9	6
199	Recombinant Hirudin Compared with Low-Molecular-Weight Heparin to Prevent Thromboembolic Complications after Total Hip Replacement. <i>New England Journal of Medicine</i> , 1998, 338, 920-921.	13.9	1
200	Human Papillomaviruses and Anogenital Cancer. <i>New England Journal of Medicine</i> , 1998, 338, 921-922.	13.9	6

#	ARTICLE	IF	CITATIONS
201	Cutaneous Melanoma Metastases. <i>New England Journal of Medicine</i> , 1998, 338, 922-923.	13.9	0
202	Diarrhea Associated with Mesalamine in a Patient with Chronic Nongranulomatous Enterocolitis. <i>New England Journal of Medicine</i> , 1998, 338, 923-925.	13.9	16
203	Case 33-1997: A 75-Year-Old Man with Chest Pain, Hemoptysis, and a Pulmonary Lesion. <i>New England Journal of Medicine</i> , 1998, 338, 925-926.	13.9	0
204	Human papillomavirus 16 E6 oncoprotein binds to interferon regulatory factor-3 and inhibits its transcriptional activity. <i>Genes and Development</i> , 1998, 12, 2061-2072.	2.7	532
205	Molecular events in uterine cervical cancer. <i>Sexually Transmitted Infections</i> , 1998, 74, 101-109.	0.8	39
206	Hybrid capture II, a new sensitive test for human papillomavirus detection. Comparison with hybrid capture I and PCR results in cervical lesions. <i>Journal of Clinical Pathology</i> , 1998, 51, 737-740.	1.0	113
207	Human Papillomavirus, Anal Squamous Intraepithelial Lesions, and Human Immunodeficiency Virus in a Cohort of Gay Men. <i>Journal of Infectious Diseases</i> , 1998, 178, 45-52.	1.9	70
208	Risk Factors for Cervical Cancer in Thailand: a Case-Control Study. <i>Journal of the National Cancer Institute</i> , 1998, 90, 50-57.	3.0	179
209	Prognostic Value of Intratumoral Interferon Gamma Messenger RNA Expression in Invasive Cervical Carcinomas. <i>Journal of the National Cancer Institute</i> , 1998, 90, 287-294.	3.0	80
210	Human Papillomavirus Infection and Anogenital Neoplasia in Human Immunodeficiency Virus-Positive Men and Women. <i>Journal of the National Cancer Institute Monographs</i> , 1998, 1998, 15-20.	0.9	123
211	Papillomaviruses and Cervical Cancer: Pathogenesis and Vaccine Development. <i>Journal of the National Cancer Institute Monographs</i> , 1998, 1998, 27-30.	0.9	33
212	Kaposi's Sarcoma (KS), KS-associated Herpesvirus, and the Criteria for Causality in the Age of Molecular Biology. <i>American Journal of Epidemiology</i> , 1998, 147, 217-221.	1.6	85
213	Low Incidence of Microsatellite Instability in Patients With Cervical Carcinomas. <i>Diagnostic Molecular Pathology</i> , 1998, 7, 276-282.	2.1	14
214	A Two-Tier Polymerase Chain Reaction Direct Sequencing Method for Detecting and Typing Human Papillomaviruses in Pathological Specimens. <i>Diagnostic Molecular Pathology</i> , 1998, 7, 317-323.	2.1	28
215	Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1998, 95, 1800-1805.	3.3	301
216	Detection of Genital Human Papillomavirus and Associated Cytological Abnormalities Among College Women. <i>Sexually Transmitted Diseases</i> , 1998, 25, 243-250.	0.8	67
217	Development of a Multi-Item Scale to Quantitatively Assess Sexual Behaviors and the Transmission of High- and Low-Risk Human Papillomaviruses. <i>Sexually Transmitted Diseases</i> , 1998, 25, 509-515.	0.8	3
218	Persistence of Human Papillomavirus DNA in Cervical Lesions After Treatment With Diathermic Large Loop Excision. <i>Infectious Diseases in Obstetrics and Gynecology</i> , 1998, 6, 214-219.	0.4	8

#	ARTICLE	IF	CITATIONS
219	Human papillomavirus genotype as a major determinant of the course of cervical cancer.. Journal of Clinical Oncology, 1998, 16, 2613-2619.	0.8	149
220	Management of warts in practice. Practice Nursing, 1998, 9, 15-17.	0.1	1
221	Genotyping of 27 Human Papillomavirus Types by Using L1 Consensus PCR Products by a Single-Hybridization, Reverse Line Blot Detection Method. Journal of Clinical Microbiology, 1998, 36, 3020-3027.	1.8	597
222	Comparison of PCR- and Hybrid Capture-Based Human Papillomavirus Detection Systems Using Multiple Cervical Specimen Collection Strategies. Journal of Clinical Microbiology, 1998, 36, 3248-3254.	1.8	198
223	A case-control study of human papillomavirus and cervical squamous intraepithelial lesions (SIL) in Harris County, Texas: differences among racial/ethnic groups. Cadernos De Saude Publica, 1998, 14, S149-S159.	0.4	20
224	From Focus Groups to Workshops: Developing a Culturally Appropriate Cervical Cancer Prevention Intervention for Rural Latinas. International Quarterly of Community Health Education, 1999, 19, 83-102.	0.4	7
225	PapilomavÃrus humano associado a lesÃµes de cÃ©rvice uterina. Revista Da Sociedade Brasileira De Medicina Tropical, 1999, 32, 235-240.	0.4	28
226	Comparative response of normal and of human papillomavirus-16 immortalized human epithelial cervical cells to benzo[a]pyrene.. Oncology Reports, 1999, 6, 1371-6.	1.2	17
227	Human Papillomavirus Cervical Infection and Associated Risk Factors in a Region of Argentina With a High Incidence of Cervical Carcinoma. Infectious Diseases in Obstetrics and Gynecology, 1999, 7, 237-243.	0.4	14
228	Cervical cancer, Pap smear and HPV testing, An update of the role of organized Pap smear screening and HPV testing. Acta Obstetricia Et Gynecologica Scandinavica, 1999, 78, 467-477.	1.3	14
229	Detection of Human Papillomavirus Types 16 and 18 mRNA in Peripheral Blood of Advanced Cervical Cancer Patients and Its Association With Prognosis. Journal of Clinical Oncology, 1999, 17, 1391-1391.	0.8	67
230	Short-term follow up of cervical squamous intraepithelial lesions associated with HIV and human papillomavirus infections in Africa. International Journal of STD and AIDS, 1999, 10, 363-368.	0.5	10
231	Prevalence and Predictors of Squamous Cell Abnormalities in Papanicolaou Smears From Women Infected With HIV-1. Journal of Acquired Immune Deficiency Syndromes (1999), 1999, 21, 33-41.	0.9	182
232	Interleukin 2 gene therapy of residual disease in mice carrying tumours induced by HPV 16.. International Journal of Oncology, 1999, 14, 593-7.	1.4	14
233	Vaccines for human papillomavirus-associated anogenital disease and cervical cancer: practical and theoretical approaches. Expert Opinion on Investigational Drugs, 1999, 8, 761-776.	1.9	6
234	Epidemiologic Evidence and Human Papillomavirus Infection as a Necessary Cause of Cervical Cancer. Journal of the National Cancer Institute, 1999, 91, 506-511.	3.0	196
235	Pernicious Papillomavirus Infection. New England Journal of Medicine, 1999, 341, 1687-1688.	13.9	16
236	Nucleotide sequences and further characterization of human papillomavirus DNA present in the CaSki, SiHa and HeLa cervical carcinoma cell lines.. Journal of General Virology, 1999, 80, 1725-1733.	1.3	172

#	ARTICLE	IF	CITATIONS
237	Human Papillomavirus Infection and Esophageal Cancer: a Nationwide Seroepidemiologic Case-Control Study in Sweden. <i>Journal of the National Cancer Institute</i> , 1999, 91, 156-162.	3.0	72
238	Cervicovaginal Human Papillomavirus Infection in Human Immunodeficiency Virus-1 (HIV)-Positive and High-Risk HIV-Negative Women. <i>Journal of the National Cancer Institute</i> , 1999, 91, 226-236.	3.0	450
239	Seroreactivity to Human Papillomavirus Types 16, 18, 31, and 45 Virus-Like Particles in a Case-Control Study of Cervical Squamous Intraepithelial Lesions. <i>Journal of Infectious Diseases</i> , 1999, 180, 1424-1428.	1.9	56
240	Identifying Women With Cervical Neoplasia. <i>JAMA - Journal of the American Medical Association</i> , 1999, 281, 1605-10.	3.8	507
241	Use of a Hybrid Capture Assay of Self-Collected Vaginal Swabs in Rural Uganda for Detection of Human Papillomavirus. <i>Journal of Infectious Diseases</i> , 1999, 180, 1316-1319.	1.9	93
242	Women battering in primary care practice. <i>Family Practice</i> , 1999, 16, 343-352.	0.8	59
243	Distribution of 14 high risk HPV types in cervical intraepithelial neoplasia detected by a non-radioactive general primer PCR mediated enzyme immunoassay. <i>Journal of Clinical Pathology</i> , 1999, 52, 17-22.	1.0	18
244	Detection of Human Papillomavirus DNA in Cytologically Normal Women and Subsequent Cervical Squamous Intraepithelial Lesions. <i>Journal of the National Cancer Institute</i> , 1999, 91, 954-960.	3.0	225
245	IFN- γ , Exhibits Potent Suppression of Human Papillomavirus E6/E7 Oncoprotein Expression. <i>Journal of Interferon and Cytokine Research</i> , 1999, 19, 1107-1116.	0.5	19
246	Sexual attitudes and their relation to cervical intraepithelial neoplasia in Maiduguri, Nigeria. <i>Journal of Obstetrics and Gynaecology</i> , 1999, 19, 412-416.	0.4	3
247	Genital Warts and Their Treatment. <i>Clinical Infectious Diseases</i> , 1999, 28, S37-S56.	2.9	92
248	Cervical cancer, Pap smear and HPV testing, An update of the role of organized Pap smear screening and HPV testing. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 1999, 78, 467-477.	1.3	5
249	Stratégie de dépistage par PCR des infections a papillomavirus humain (HPV) sur les prélèvements cervico-vaginaux. <i>Revue Francaise Des Laboratoires</i> , 1999, 1999, 23-28.	0.0	0
250	Intérêt de la détection des papillomavirus humains par hybridation en phase liquide en routine: comparaison avec l'examen cytologique classique pour le dépistage des lésions précancéreuses et cancéreuses du col utérin. <i>Revue Francaise Des Laboratoires</i> , 1999, 1999, 29-33.	0.0	0
252	Identification of peptides presented by HLA class I molecules on cervical cancer cells with HPV-18 infection. <i>Immunology Letters</i> , 1999, 67, 167-177.	1.1	14
253	Expression, purification and immunological characterization of the transforming protein E7, from cervical cancer-associated human papillomavirus type 16. <i>Clinical and Experimental Immunology</i> , 1999, 115, 397-403.	1.1	49
254	Cervical cytology and colposcopy in young patients attending genitourinary medicine clinics: invalid intrusion or preventive opportunity and definitive audit?. <i>Cytopathology</i> , 1999, 10, 2-7.	0.4	0
255	Four-dimensional factor analysis of confocal image sequences (4D-FAMIS) to detect and characterize low copy numbers of human papillomavirus DNA by FISH in HeLa and SiHa cells. <i>Journal of Microscopy</i> , 1999, 193, 227-243.	0.8	15

#	ARTICLE	IF	CITATIONS
256	Human papillomavirus in malignant cervical lesions in Surinam, a high-risk country, compared to the Netherlands, a low-risk country. <i>International Journal of Gynecological Cancer</i> , 1999, 9, 206-211.	1.2	36
257	Prevalence of cervical cancer and feasibility of screening in rural China: a pilot study for the Shanxi Province Cervical Cancer Screening Study. <i>International Journal of Gynecological Cancer</i> , 1999, 9, 411-417.	1.2	38
258	Evaluation of cellular immune responses in rhesus monkeys subjected to adenovirus-mediated gene transfer into the cervix. <i>Cancer Gene Therapy</i> , 1999, 6, 220-227.	2.2	4
259	Expression of human papillomavirus 16 E2 protein in <i>Schizosaccharomyces pombe</i> delays the initiation of mitosis. <i>Oncogene</i> , 1999, 18, 4015-4021.	2.6	29
260	Hybrid Capture II-based human papillomavirus detection, a sensitive test to detect in routine high-grade cervical lesions: a preliminary study on 1518 women. <i>British Journal of Cancer</i> , 1999, 80, 1306-1311.	2.9	201
261	The molecular genetics of cervical carcinoma. <i>British Journal of Cancer</i> , 1999, 80, 2008-2018.	2.9	179
262	A quantitative polymerase chain reaction-enzyme immunoassay for accurate measurements of human papillomavirus type 16 DNA levels in cervical scrapings. <i>British Journal of Cancer</i> , 1999, 81, 114-121.	2.9	25
263	Nucleotide Sequence and Characterization of Human Papillomavirus Type 83, a Novel Genital Papillomavirus. <i>Virology</i> , 1999, 260, 165-172.	1.1	27
264	Expression of Matrix Metalloproteinase-9 in Squamous Cell Carcinoma of the Uterine Cervix—Clinicopathologic Study Using Immunohistochemistry and mRNA in Situ Hybridization. <i>Gynecologic Oncology</i> , 1999, 72, 380-386.	0.6	57
265	Do “High-Risk” Human Papillomavirus (HPV) Types Lead to Cancer by Evading the Immune System?. <i>Gynecologic Oncology</i> , 1999, 73, 169-170.	0.6	3
266	To the Editor. <i>Gynecologic Oncology</i> , 1999, 73, 170-171.	0.6	11
267	Presence of an Eosinophilic Infiltrate in Cervical Squamous Carcinoma Results from a Type 2 Immune Response. <i>Gynecologic Oncology</i> , 1999, 74, 188-195.	0.6	20
268	Generation of Tumor-Specific Cytotoxic T Lymphocytes by Stimulation with HPV Type 16 E7 Peptide-Pulsed Dendritic Cells: An Approach to Immunotherapy of Cervical Cancer. <i>Gynecologic Oncology</i> , 1999, 74, 448-455.	0.6	19
269	Synthesis of IFN- γ by CD8+ T Cells Is Preserved in HIV-Infected Women with HPV-Related Cervical Squamous Intraepithelial Lesions. <i>Gynecologic Oncology</i> , 1999, 75, 379-386.	0.6	19
270	Human Papillomavirus Testing in Primary Screening for Cervical Cancer of Human Immunodeficiency Virus-Infected Women, 1990–1998. <i>Gynecologic Oncology</i> , 1999, 75, 427-431.	0.6	19
271	Reply. <i>Gynecologic Oncology</i> , 1999, 75, 521-522.	0.6	0
272	Human papillomavirus vaccines. <i>Seminars in Cancer Biology</i> , 1999, 9, 431-445.	4.3	69
273	Naturally Occurring, Nonregressing Canine Oral Papillomavirus Infection: Host Immunity, Virus Characterization, and Experimental Infection. <i>Virology</i> , 1999, 265, 365-374.	1.1	80

#	ARTICLE	IF	CITATIONS
274	The association between cigarette smoking and low-grade cervical abnormalities in reproductive-age women. <i>Cancer Causes and Control</i> , 1999, 10, 339-344.	0.8	6
275	Decreased programmed cell death in the uterine cervix associated with high risk human papillomavirus infection. <i>Pathology and Oncology Research</i> , 1999, 5, 95-103.	0.9	44
276	Interrelation of lymphocyte subpopulations in peripheral blood under cervical papillomavirus infection. <i>Folia Microbiologica</i> , 1999, 44, 721-725.	1.1	6
277	Chimeric Virus-like Particles of the Human Papillomavirus Type 16 (HPV 16) as a Prophylactic and Therapeutic Vaccine. <i>Archives of Medical Research</i> , 1999, 30, 269-274.	1.5	63
278	Cervicography screening for cervical cancer among 8460 women in a high-risk population. <i>American Journal of Obstetrics and Gynecology</i> , 1999, 180, 290-298.	0.7	56
279	AIDS-associated malignancies: research perspectives. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 1999, 1423, C1-C9.	3.3	12
280	Papillomaviruses: prophylactic vaccine prospects. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 1999, 1423, M1-M8.	3.3	20
281	Papillomavirus-like particle vaccines for cervical cancer. <i>Trends in Molecular Medicine</i> , 1999, 5, 209-215.	2.6	75
282	Human papillomavirus cervical infection and associated risk factors in a region of Argentina with a high incidence of cervical carcinoma. , 1999, 7, 237-243.		10
283	Differential binding of viral peptides to HLA-A2 alleles. Implications for human papillomavirus type 16 E7 peptide-based vaccination against cervical carcinoma. <i>European Journal of Immunology</i> , 1999, 29, 1292-1303.	1.6	48
284	Detection and typing of human papillomavirus in cervical carcinomas in Russian women. <i>Cancer</i> , 1999, 85, 2011-2016.	2.0	57
285	Mucosal oncogenic human papillomaviruses and extragenital Bowen disease. <i>Cancer</i> , 1999, 86, 282-287.	2.0	73
286	Different profiles of allelic losses in cervical carcinoma cases in Surinam and the Netherlands. <i>Cancer</i> , 1999, 86, 997-1004.	2.0	29
287	HPV 16 antibody prevalence in Jamaica and the United States reflects differences in cervical cancer rates. , 1999, 80, 339-344.		39
288	Photodynamic therapy in women with cervical intraepithelial neoplasia using topically applied 5-aminolevulinic acid. , 1999, 81, 34-38.		75
289	Smoking and oral contraceptives as risk factors for cervical carcinoma in situ. , 1999, 81, 357-365.		91
290	Uniform distribution of HPV 16 E6 and E7 variants in patients with normal histology, cervical intra-epithelial neoplasia and cervical cancer. , 1999, 82, 203-207.		107
291	Papillomavirus and p53 codon 72 polymorphism. , 1999, 82, 616-617.		10

#	ARTICLE	IF	CITATIONS
292	Human papillomavirus infection, cervical dysplasia and invasive cervical cancer in Honduras: A case-control study. , 1999, 82, 799-803.		34
293	HPV typing and HPV16E6-sequence variations in synchronous lesions of cervical squamous-cell carcinoma from Swedish patients. , 1999, 83, 34-37.		27
294	Favorable clinical outcome of cervical cancers infected with human papilloma virus type 58 and related types. , 1999, 84, 553-557.		77
295	Human papillomavirus genotype spectrum in Czech women: Correlation of HPV DNA presence with antibodies against HPV-16, 18, and 33 virus-like particles. , 1999, 58, 378-386.		31
296	High prevalence of human papillomavirus type 58 in Chinese women with cervical cancer and precancerous lesions. , 1999, 59, 232-238.		92
297	Do HPV-negative cervical carcinomas exist??revisited. , 1999, 189, 1-3.		65
298	Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. , 1999, 189, 12-19.		7,095
300	Crystal Structure of the Human Papillomavirus Type 18 E2 Activation Domain. Science, 1999, 284, 1673-1677.	6.0	67
301	Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase I–II trial. European Journal of Cancer, 1999, 35, 946-952.	1.3	210
302	Viral disease update. Current Problems in Dermatology, 1999, 11, 37-70.	0.1	10
303	Detection of p16 gene alteration in cervical cancer using tissue microdissection and LOH study. Cancer Letters, 1999, 136, 101-108.	3.2	30
305	HPV 18-induced pigmented bowenoid papulosis of the neck. Journal of the American Academy of Dermatology, 1999, 40, 633-634.	0.6	21
306	An overview of sexually transmitted diseases. Part II. Journal of the American Academy of Dermatology, 1999, 41, 661-680.	0.6	83
307	Relation of human papilloma virus status to cervical lesions and consequences for cervical-cancer screening: a prospective study. Lancet, The, 1999, 354, 20-25.	6.3	627
308	Screening for cervical neoplasia by self-assessment for human papillomavirus DNA. Lancet, The, 1999, 354, 1970.	6.3	81
309	Secretion of vascular endothelial growth factor in adenocarcinoma and squamous cell carcinoma of the uterine cervix. Obstetrics and Gynecology, 1999, 94, 78-82.	1.2	18
310	Risk factors for human papillomavirus and cervical precancerous lesions, and the role of concurrent HIV-1 infection. International Journal of Gynecology and Obstetrics, 1999, 65, 171-181.	1.0	55
311	Prevalence and genotyping of HPV in cervical cancer among Australian women. International Journal of Gynecology and Obstetrics, 1999, 67, 163-168.	1.0	15

#	ARTICLE	IF	CITATIONS
312	HPV in situ hybridization with catalyzed signal amplification and polymerase chain reaction in establishing cerebellar metastasis of a cervical carcinoma. <i>Human Pathology</i> , 1999, 30, 587-591.	1.1	8
313	EPIDEMIOLOGY OF GENITAL HUMAN PAPILOMAVIRUS. <i>Hematology/Oncology Clinics of North America</i> , 1999, 13, 245-257.	0.9	16
314	IMMUNOTHERAPEUTIC STRATEGIES FOR CERVICAL SQUAMOUS CARCINOMA. <i>Hematology/Oncology Clinics of North America</i> , 1999, 13, 259-273.	0.9	12
315	Colonization of in Vitro-Formed Cervical Human Papillomavirus-Associated (Pre)Neoplastic Lesions with Dendritic Cells. <i>American Journal of Pathology</i> , 1999, 154, 775-784.	1.9	49
316	Short Fragment Polymerase Chain Reaction Reverse Hybridization Line Probe Assay to Detect and Genotype a Broad Spectrum of Human Papillomavirus Types. <i>American Journal of Pathology</i> , 1999, 155, 1473-1478.	1.9	92
317	Balance of IgG Subclasses toward Human Papillomavirus Type 16 (HPV16) L1-Capsids Is a Possible Predictor for the Regression of HPV16-Positive Cervical Intraepithelial Neoplasia. <i>Biochemical and Biophysical Research Communications</i> , 1999, 258, 128-131.	1.0	16
318	Purification of Virus-like Particles of Recombinant Human Papillomavirus Type 11 Major Capsid Protein L1 from <i>Saccharomyces cerevisiae</i> . <i>Protein Expression and Purification</i> , 1999, 17, 477-484.	0.6	89
319	Withdrawing low risk women from cervical screening programmes: mathematical modelling study & Commentary: trials versus models in appraising screening programmes. <i>BMJ: British Medical Journal</i> , 1999, 318, 356-361.	2.4	42
320	Association Between Subjective Sleep Quality and Depression on Immunocompetence in Low-Income Women at Risk for Cervical Cancer. <i>Psychosomatic Medicine</i> , 1999, 61, 496-507.	1.3	55
321	Human Papillomavirus and the Risk of Cervical Cancer. <i>Hospital Practice (1995)</i> , 1999, 34, 103-111.	0.5	9
322	Glutathione S-Transferase M1 Genotypes and the Risk of Squamous Carcinoma of the Cervix: A Population-based Case-Control Study. <i>American Journal of Epidemiology</i> , 1999, 150, 568-572.	1.6	30
323	Secretion of Vascular Endothelial Growth Factor in Adenocarcinoma and Squamous Cell Carcinoma of the Uterine Cervix. <i>Obstetrics and Gynecology</i> , 1999, 94, 78-82.	1.2	8
324	Screening for Genital Human Papillomavirus. <i>Diagnostic Molecular Pathology</i> , 1999, 8, 26-31.	2.1	18
325	New Method for Automatic Identification and Typing of Single and Multiple Superimposed Human Papillomavirus Sequences. <i>Diagnostic Molecular Pathology</i> , 1999, 8, 216-221.	2.1	4
326	Genital Human Papillomavirus Infection Among Women Recruited for Routine Cervical Cancer Screening or for Colposcopy Determined by Hybrid Capture II and Polymerase Chain Reaction. <i>Diagnostic Molecular Pathology</i> , 1999, 8, 157.	2.1	78
327	Use of the Same Archival Papanicolaou Smears for Detection of Human Papillomavirus by Cytology and Polymerase Chain Reaction. <i>Diagnostic Molecular Pathology</i> , 1999, 8, 20-25.	2.1	4
328	Rapid Test for Identification of a Human Papillomavirus 16 E6 L83V Variant. <i>Diagnostic Molecular Pathology</i> , 1999, 8, 97-100.	2.1	12
329	The integration of HPV-18 DNA in cervical carcinoma. <i>Journal of Clinical Pathology</i> , 1999, 52, 275-282.	2.1	88

#	ARTICLE	IF	CITATIONS
330	Clinical Relevance of HPV 16/18 Testing Methods in Cervical Squamous Cell Carcinoma. Applied Immunohistochemistry & Molecular Morphology, 2000, 8, 300-309.	2.0	7
331	Molecular Mechanism of Carcinogenesis by Human Papillomavirus. Journal of Dermatology, 2000, 27, 73-86.	0.6	47
332	Prediction of Cervical Intraepithelial Neoplasia Grade 2-3 Using Risk Assessment and Human Papillomavirus Testing in Women With Atypia on Papanicolaou Smears. Obstetrics and Gynecology, 2000, 96, 410-416.	1.2	0
333	Detection of T Helper Responses, But Not of Human Papillomavirus-Specific Cytotoxic T Lymphocyte Responses, After Peptide Vaccination of Patients With Cervical Carcinoma. Journal of Immunotherapy, 2000, 23, 255-266.	1.2	151
334	Human Papillomaviruses and Cervical Neoplasia: A Model for Carcinogenesis. International Journal of Gynecological Pathology, 2000, 19, 16-28.	0.9	189
335	Clinical Relevance of HPV 16/18 Testing Methods in Cervical Squamous Cell Carcinoma. Applied Immunohistochemistry and Molecular Morphology, 2000, 8, 300-309.	0.6	0
336	Determinants of Low-Risk and High-Risk Cervical Human Papillomavirus Infections in Montreal University Students. Sexually Transmitted Diseases, 2000, 27, 79-86.	0.8	62
337	Human Papillomavirus Detection by the Hybrid Capture II Assay: A Reliable Test to Select Women With Normal Cervical Smears at Risk for Developing Cervical Lesions. Diagnostic Molecular Pathology, 2000, 9, 145-150.	2.1	61
338	Strategies to reduce the risk of virus-related cancers. Annals of Oncology, 2000, 11, 1091-1096.	0.6	8
339	Role of routine human papillomavirus subtyping in cervical screening. Current Opinion in Obstetrics and Gynecology, 2000, 12, 11-14.	0.9	10
340	Concordance of human papillomavirus in the cervix and urine among inner city adolescents. Pediatric Infectious Disease Journal, 2000, 19, 722-729.	1.1	59
341	Single-Tube Real-Time Nested Polymerase Chain Reaction for Detecting Human Papillomavirus DNA. Diagnostic Molecular Pathology, 2000, 9, 151-157.	2.1	19
342	Increased Risk of Cervical Disease Among Human Immunodeficiency Virus-Infected Women With Severe Immunosuppression and High Human Papillomavirus Load. Obstetrics and Gynecology, 2000, 96, 403-409.	1.2	10
343	Detection of human papillomavirus DNA in bronchopulmonary carcinomas by Hybrid Capture II. , 2000, 88, 1347-1352.		38
344	Human papillomavirus-associated carcinomas in Hawaii and the mainland U.S. , 2000, 88, 1464-1469.		32
345	Combined analysis of germline polymorphisms of p53, GSTM1, GSTT1, CYP1a1, and CYP2e1. , 2000, 88, 2082-2091.		91
346	Photodetection of cervical intraepithelial neoplasia using 5-aminolevulinic acid-induced porphyrin fluorescence. , 2000, 88, 2275-2282.		82
347	HPV-based cervical cancer screening in a population at high risk for HIV infection. International Journal of Cancer, 2000, 85, 206-210.	2.3	72

#	ARTICLE	IF	CITATIONS
348	Seroepidemiology of human papillomavirus type 73: A sexually transmitted low-risk virus. <i>International Journal of Cancer</i> , 2000, 85, 353-357.	2.3	14
349	Molecular cloning and immunogenicity of renal cell carcinoma-associated antigen G250. , 2000, 85, 865-870.		152
350	Longitudinal follow-up of antibody response to selected antigens of human papillomaviruses and herpesviruses in patients with invasive cervical carcinoma. , 2000, 86, 351-355.		20
351	Analysis of mutations in the URR and E6/E7 oncogenes of HPV 16 cervical cancer isolates from central China. , 2000, 86, 695-701.		43
352	Seroresponses to virus-like particles of human papillomavirus types 16, 18, 31, 33, and 45 in San People of Southern Africa. , 2000, 60, 331-336.		16
353	Seroresponses to human papillomavirus types 16, 18, 31, 33, and 45 virus-like particles in South African women with cervical cancer and cervical intraepithelial neoplasia. , 2000, 60, 403-410.		33
354	Human papillomavirus (HPV) DNA in penile carcinomas in Argentina: Analysis of primary tumors and lymph nodes. , 2000, 61, 65-69.		76
355	High prevalence of human papillomavirus type 16 infection among children. , 2000, 61, 70-75.		50
356	Simultaneous molecular karyotyping and mapping of viral DNA integration sites by 25-color COBRA-FISH. , 2000, 28, 92-97.		54
357	Ubiquitous presence of E6 and E7 transcripts in human papillomavirus?Positive cervical carcinomas regardless of its type. <i>Journal of Medical Virology</i> , 2000, 62, 251-258.	2.5	65
358	Deletion of the FHIT gene in neoplastic and invasive cervical lesions is related to high-risk HPV infection but is independent of histopathological features. <i>Journal of Pathology</i> , 2000, 192, 502-510.	2.1	39
359	Decreased synthesis and expression of TGF-?1, ?2, and ?3 in epithelium of HPV 16-positive cervical precancer: a study by microdissection, quantitative RT-PCR, and immunocytochemistry. <i>Journal of Pathology</i> , 2000, 192, 494-501.	2.1	35
360	Distribution of 37 mucosotropic HPV types in women with cytologically normal cervical smears: The age-related patterns for high-risk and low-risk types. <i>International Journal of Cancer</i> , 2000, 87, 221-227.	2.3	243
361	Human papillomavirus type 16 E6/E7-specific cytotoxic T lymphocytes in women with cervical neoplasia. <i>International Journal of Cancer</i> , 2000, 88, 92-98.	2.3	79
362	Primary cervical carcinomas show 2 common regions of deletion at 3P, 1 within theFHIT gene: Evaluation of allelic imbalance atFHIT, RB1 andTP53 in relation to survival. <i>International Journal of Cancer</i> , 2000, 88, 217-222.	2.3	16
363	Identification in humans of HPV-16 E6 and E7 protein epitopes recognized by cytolytic T lymphocytes in association with HLA-B18 and determination of the HLA-B18-specific binding motif. <i>European Journal of Immunology</i> , 2000, 30, 2281-2289.	1.6	47
364	Regulation of cell growth and HPV genes by exogenous estrogen in cervical cancer cells. <i>International Journal of Gynecological Cancer</i> , 2000, 10, 157-164.	1.2	50
365	Investigation of the association of esophageal carcinoma with human papillomaviruses. <i>Ecological Management and Restoration</i> , 2000, 13, 122-124.	0.2	25

#	ARTICLE	IF	CITATIONS
366	Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacille Calmette-Guérin (BCG) hsp65 and HPV16 E7. <i>Clinical and Experimental Immunology</i> , 2000, 121, 216-225.	1.1	161
367	Expression of topoisomerase II and Ki67 in cervical carcinoma – clinicopathological study using immunohistochemistry. <i>Apmis</i> , 2000, 108, 209-215.	0.9	24
368	Comparison of human papillomavirus genotypes in archival cervical cancer specimens from Alaska natives, Greenland natives and Danish Caucasians. <i>Microbes and Infection</i> , 2000, 2, 121-126.	1.0	26
369	Socioeconomic characteristics of patients with squamous cell carcinoma of the uterine cervix treated with radiotherapy in the 1992 to 1994 patterns of care study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2000, 47, 443-450.	0.4	27
370	Interactions of the PDZ-protein MAGI-1 with adenovirus E4-ORF1 and high-risk papillomavirus E6 oncoproteins. <i>Oncogene</i> , 2000, 19, 5270-5280.	2.6	281
371	Development of squamous cell carcinoma by two high-risk human papillomaviruses (HPVs), a novel HPV-67 and HPV-31 from bowenoid papulosis. <i>British Journal of Dermatology</i> , 2000, 143, 604-608.	1.4	43
372	High risk human papillomavirus in women with normal cervical cytology prior to the development of abnormal cytology and colposcopy. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2000, 107, 600-604.	1.1	56
373	The Triage of Women with ASCUS Cytology Using Human Papillomavirus DNA Testing. <i>Journal of Lower Genital Tract Disease</i> , 2000, 4, 1-6.	0.9	1
374	Finding of HPV DNA in pap smear confers increased risk of invasive cervical cancer that is positive for the same type of virus. <i>Evidence-based Oncology</i> , 2000, 1, 71-72.	0.1	0
375	Amplification of human genomic sequences by human papillomaviruses universal consensus primers. <i>Journal of Virological Methods</i> , 2000, 87, 171-175.	1.0	8
376	The planning of cervical cancer screening programmes in eastern Europe: is viral testing a suitable alternative to smear testing?. <i>Health Care Management Science</i> , 2000, 3, 323-329.	1.5	12
377	Dissimilar Immunogenicities of Human Papillomavirus E7 and Adenovirus E1A Proteins Influence Primary Tumor Development. <i>Virology</i> , 2000, 277, 48-57.	1.1	19
378	The Human Papillomavirus E7 Protein Is Able to Inhibit the Antiviral and Anti-growth Functions of Interferon- α . <i>Virology</i> , 2000, 277, 411-419.	1.1	115
379	Neutralization of Human Papillomavirus (HPV) Pseudovirions: A Novel and Efficient Approach to Detect and Characterize HPV Neutralizing Antibodies. <i>Virology</i> , 2000, 278, 570-577.	1.1	53
380	Development and Assessment of a General Theory of Cervical Carcinogenesis Utilizing a Severe Combined Immunodeficiency Murine-Human Xenograft Model. <i>Gynecologic Oncology</i> , 2000, 77, 137-148.	0.6	33
381	Differential Distribution of Sequence Variations in HPV-16 E6. <i>Gynecologic Oncology</i> , 2000, 79, 11-17.	0.6	3
382	Retrovirus-Mediated Delivery of HPV16 E7 Antisense RNA Inhibited Tumorigenicity of CaSki Cells. <i>Gynecologic Oncology</i> , 2000, 78, 293-301.	0.6	38
383	True. <i>British Journal of Cancer</i> , 2000, 82, 1585-1592.	2.9	301

#	ARTICLE	IF	CITATIONS
384	Association between high-risk HPV types, HLA DRB1* and DQB1* alleles and cervical cancer in British women. <i>British Journal of Cancer</i> , 2000, 82, 1348-1352.	2.9	110
385	p53 codon 72 polymorphism in vulval cancer and vulval intraepithelial neoplasia. <i>British Journal of Cancer</i> , 2000, 83, 1287-1290.	2.9	14
386	Construction of a recombinant adenovirus vector of human papillomavirus type 16 L1_E7C. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2000, 12, 21-24.	0.7	0
387	High prevalence of serum antibodies to Ras and type 16 E4 proteins of human papillomavirus in patients with precancerous lesions of the uterine cervix. <i>Archives of Virology</i> , 2000, 145, 603-623.	0.9	16
388	Association of human papillomavirus infection with carcinoma of the cervix uteri and its precursor lesions: theoretical and practical implications. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2000, 437, 227-233.	1.4	41
389	Trichloroethylene and cancer: epidemiologic evidence.. <i>Environmental Health Perspectives</i> , 2000, 108, 161-176.	2.8	191
390	Efficacy in treatment of subclinical cervical HPV infection without intraepithelial neoplasia: systematic review. <i>Sao Paulo Medical Journal</i> , 2000, 118, 109-115.	0.4	2
391	Propagation of Human Papillomavirus Type 59 in the Athymic Mouse Xenograft System. <i>Intervirolgy</i> , 2000, 43, 112-118.	1.2	8
392	Papillomaviruses. , 2000, , 303-326.		0
393	Human Papillomavirus: Epidemiology, Transmission, and Pathogenesis. <i>Clinics in Laboratory Medicine</i> , 2000, 20, 235-255.	0.7	50
394	Evaluation of Abnormal Cervical Cytology. <i>Clinics in Laboratory Medicine</i> , 2000, 20, 303-343.	0.7	7
395	Human Papillomavirus in Cervical Neoplasia: Role, Risk Factors, and Implications. <i>Clinics in Laboratory Medicine</i> , 2000, 20, 257-270.	0.7	10
396	Diagnosis of Human Papillomavirus Gynecologic Infections. <i>Clinics in Laboratory Medicine</i> , 2000, 20, 271-287.	0.7	4
397	An Exploratory Statistical Analysis of the effect of Demographic risk factors on uterine Cervical squamous Intraepithelial Lesion. <i>Calcutta Statistical Association Bulletin</i> , 2000, 50, 307-324.	0.1	1
398	Screening for Cervical Cancer. , 2000, 290, 1651a-1651.		8
399	Sexual behaviour and smoking as determinants of cervical HPV infection and of CIN3 among those infected: a case-control study nested within the Manchester cohort. <i>British Journal of Cancer</i> , 2000, 83, 1565-1572.	2.9	218
400	Uneven distribution of HPV 16 E6 prototype and variant (L83V) oncoprotein in cervical neoplastic lesions. <i>British Journal of Cancer</i> , 2000, 83, 307-310.	2.9	56
401	A systematic review of the role of human papilloma virus (HPV) testing within a cervical screening programme: summary and conclusions. <i>British Journal of Cancer</i> , 2000, 83, 561-565.	2.9	131

#	ARTICLE	IF	CITATIONS
402	Correspondence Re: Sherman ME, Tabbara SO, Scott DR, Kurman RJ, Glass AG, Manos MM, et al. "ASCUS, Rule Out HSIL": Cytologic Features, Histologic Correlates, and human Papillomavirus Detection. <i>Mod Pathol</i> 1999;12:335-42. <i>Modern Pathology</i> , 2000, 13, 208-208.	2.9	8
403	ASCUS-LSIL Triage Study. <i>Acta Cytologica</i> , 2000, 44, 726-742.	0.7	234
404	Papillomavirus-Like Particle Vaccines. <i>Journal of the National Cancer Institute Monographs</i> , 2000, 2000, 50-54.	0.9	41
405	Association Between DQB1 and Cervical Cancer in Patients With Human Papillomavirus and Family Controls. <i>Obstetrics and Gynecology</i> , 2000, 95, 134-140.	1.2	0
406	Cervical Neoplasia and Repeated Positivity of Human Papillomavirus Infection In Human Immunodeficiency Virus-seropositive and -seronegative Women. <i>American Journal of Epidemiology</i> , 2000, 151, 1148-1157.	1.6	124
407	Epidemiology of Cervical Cancer. <i>Cancer Investigation</i> , 2000, 18, 584-590.	0.6	71
408	Mixed blessings: Cervical cancer screening in Recife, Brazil. <i>Medical Anthropology: Cross Cultural Studies in Health and Illness</i> , 2000, 19, 41-63.	0.6	12
409	Effect of Total Plasma Homocysteine on Cervical Dysplasia Risk. <i>Nutrition and Cancer</i> , 2000, 37, 128-133.	0.9	19
410	HPV DNA Testing in Cervical Cancer Screening. <i>JAMA - Journal of the American Medical Association</i> , 2000, 283, 87.	3.8	466
411	PCR based high risk HPV testing is superior to neural network based screening for predicting incident CIN III in women with normal cytology and borderline changes. <i>Journal of Clinical Pathology</i> , 2000, 53, 606-611.	1.0	86
412	A longitudinal study of HPV detection and cervical pathology in HIV infected women. <i>Sexually Transmitted Infections</i> , 2000, 76, 257-261.	0.8	44
413	Concurrent and Sequential Acquisition of Different Genital Human Papillomavirus Types. <i>Journal of Infectious Diseases</i> , 2000, 182, 1097-1102.	1.9	169
414	Contraceptive and reproductive risk factors for cervical intraepithelial neoplasia in American Indian women. <i>International Journal of Epidemiology</i> , 2000, 29, 983-990.	0.9	25
415	Molecular Cloning and Nucleotide Sequence Analysis of a Novel Human Papillomavirus (Type 82) Associated with Vaginal Intraepithelial Neoplasia. <i>Vaccine Journal</i> , 2000, 7, 91-95.	2.6	18
416	Risk Factors for Cervical Intraepithelial Neoplasia in Southwestern American Indian Women. <i>American Journal of Epidemiology</i> , 2000, 152, 716-726.	1.6	23
417	A Mouse Fibroblast Cell Model to Study Human Papillomavirus-Associated Tumorigenesis. <i>Biochemical and Biophysical Research Communications</i> , 2000, 270, 119-124.	1.0	8
418	Cost-effectiveness of screening for anal squamous intraepithelial lesions and anal cancer in human immunodeficiency virus-negative homosexual and bisexual men. <i>American Journal of Medicine</i> , 2000, 108, 634-641.	0.6	206
419	Prevalence of Human Papillomavirus DNA in Different Histological Subtypes of Cervical Adenocarcinoma. <i>American Journal of Pathology</i> , 2000, 157, 1055-1062.	1.9	349

#	ARTICLE	IF	CITATIONS
420	A new PCR-based assay amplifies the E6&E7 genes of most mucosal human papillomaviruses (HPV). <i>Virus Research</i> , 2000, 67, 127-139.	1.1	46
421	Usefulness of human papilloma virus testing in the screening of cervical cancer precursor lesions: a retrospective study in 314 cases. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2000, 93, 71-75.	0.5	8
422	Enhanced oncogenicity of human papillomavirus type 16 (HPV16) variants in Japanese population. <i>Cancer Letters</i> , 2000, 156, 159-165.	3.2	66
423	Boosting with recombinant vaccinia increases HPV-16 E7-specific T cell precursor frequencies of HPV-16 E7-expressing DNA vaccines. <i>Vaccine</i> , 2000, 18, 2015-2022.	1.7	81
424	An overview of sexually transmitted diseases. Part III. Sexually transmitted diseases in HIV-infected patients. <i>Journal of the American Academy of Dermatology</i> , 2000, 43, 409-436.	0.6	109
425	Human papillomavirus infections: Epidemiology, pathogenesis, and host immune response. <i>Journal of the American Academy of Dermatology</i> , 2000, 43, S18-S26.	0.6	91
426	Evidence for a Causal Association Between Human Papillomavirus and a Subset of Head and Neck Cancers. <i>Journal of the National Cancer Institute</i> , 2000, 92, 709-720.	3.0	2,586
427	Viral load of human papilloma virus 16 as a determinant for development of cervical carcinoma in situ: a nested case-control study. <i>Lancet, The</i> , 2000, 355, 2189-2193.	6.3	338
428	Association between activated K-ras and c-erbB-2 oncogenes with &high-risk& and &low-risk& Human Papilloma Virus types in preinvasive cervical lesions. <i>Mutation Research - Genetic Toxicology and Environmental Mutagenesis</i> , 2000, 469, 127-134.	0.9	17
429	Developing HPV virus-like particle vaccines to prevent cervical cancer: a progress report. <i>Journal of Clinical Virology</i> , 2000, 19, 67-74.	1.6	62
430	Human papillomavirus and cancer: the epidemiological evidence. <i>Journal of Clinical Virology</i> , 2000, 19, 1-5.	1.6	490
431	Comparison of papillomavirus and immunodeficiency virus evolutionary patterns in the context of a papillomavirus vaccine. <i>Journal of Clinical Virology</i> , 2000, 19, 43-56.	1.6	29
432	Public health paradoxes and the epidemiological impact of an HPV vaccine. <i>Journal of Clinical Virology</i> , 2000, 19, 101-111.	1.6	69
433	Prospects for phase III&IV HPV vaccination trials in the Nordic countries and in Estonia. <i>Journal of Clinical Virology</i> , 2000, 19, 113-122.	1.6	10
434	Human papilloma virus status and chromosomal imbalances in primary cervical carcinomas and tumour cell lines. <i>European Journal of Cancer</i> , 2000, 36, 542-548.	1.3	45
435	Structure of Small Virus-like Particles Assembled from the L1 Protein of Human Papillomavirus 16. <i>Molecular Cell</i> , 2000, 5, 557-567.	4.5	417
436	Cervical cancer screening in Europe. <i>European Journal of Cancer</i> , 2000, 36, 2272-2275.	1.3	15
437	The cause of invasive cervical cancer could be multifactorial. <i>Biomedicine and Pharmacotherapy</i> , 2000, 54, 54-59.	2.5	51

#	ARTICLE	IF	CITATIONS
438	Prediction of cervical intraepithelial neoplasia grade 2-3 using risk assessment and human papillomavirus testing in women with atypia on papanicolaou smears. <i>Obstetrics and Gynecology</i> , 2000, 96, 410-416.	1.2	62
439	Increased risk of cervical disease among human immunodeficiency virus-infected women with severe immunosuppression and high human papillomavirus load. <i>Obstetrics and Gynecology</i> , 2000, 96, 403-409.	1.2	120
440	Association between DQB1 and cervical cancer in patients with human papillomavirus and family controls. <i>Obstetrics and Gynecology</i> , 2000, 95, 134-140.	1.2	22
441	Immune-response modifiers: a new paradigm in the treatment of human papillomavirus. <i>Current Therapeutic Research</i> , 2000, 61, 584-596.	0.5	14
442	Part III. Cervical cancer screening: Can we do better?. <i>Disease-a-Month</i> , 2000, 46, 406-420.	0.4	1
443	Epstein-Barr virus (EBV) genes expression in cervical intraepithelial neoplasia and invasive cervical cancer: A comparative study with human papillomavirus (HPV) infection. <i>Human Pathology</i> , 2000, 31, 318-326.	1.1	57
444	Consistent high viral load of human papillomavirus 16 and risk of cervical carcinoma in situ: a nested case-control study. <i>Lancet, The</i> , 2000, 355, 2194-2198.	6.3	295
445	CANCER: Preventing Cervical Cancer. <i>Science</i> , 2000, 288, 1753-1755.	6.0	53
447	ATTITUDES OF ADOLESCENT/YOUNG ADULT WOMEN TOWARD HUMAN PAPILLOMAVIRUS VACCINATION AND CLINICAL TRIALS. <i>Health Care for Women International</i> , 2000, 21, 375-391.	0.6	80
448	Advances in Cervical Screening Technology. <i>Modern Pathology</i> , 2000, 13, 275-284.	2.9	62
449	DNA Vaccination Prevents and/or Delays Carcinoma Development of Papillomavirus-Induced Skin Papillomas on Rabbits. <i>Journal of Virology</i> , 2000, 74, 9712-9716.	1.5	54
450	Caveolin-1 Expression Is Down-Regulated in Cells Transformed by the Human Papilloma Virus in a p53-Dependent Manner. Replacement of Caveolin-1 Expression Suppresses HPV-Mediated Cell Transformation. <i>Biochemistry</i> , 2000, 39, 13916-13924.	1.2	84
451	Population-Based Study of Human Papillomavirus Infection and Cervical Neoplasia in Rural Costa Rica. <i>Journal of the National Cancer Institute</i> , 2000, 92, 464-474.	3.0	515
452	Viral carcinogenesis: revelation of molecular mechanisms and etiology of human disease. <i>Carcinogenesis</i> , 2000, 21, 405-426.	1.3	306
453	CANCER SCREENING IN THE ELDERLY POPULATION. <i>Hematology/Oncology Clinics of North America</i> , 2000, 14, 89-112.	0.9	14
454	Human papillomavirus infection: An emerging problem in anal and other squamous cell cancers. <i>Gastroenterology</i> , 2001, 120, 1046-1048.	0.6	14
455	New developments in our understanding of the aetiology and pathology of cervical neoplasia. <i>Reviews in Gynaecological Practice</i> , 2001, 1, 41-52.	0.1	0
456	Variation in the E2-binding domain of HPV 16 is associated with high-grade squamous intraepithelial lesions of the cervix. <i>British Journal of Cancer</i> , 2001, 84, 1058-1063.	2.9	29

#	ARTICLE	IF	CITATIONS
457	Cervical Coinfection with Human Papillomavirus (HPV) Types as a Predictor of Acquisition and Persistence of HPV Infection. <i>Journal of Infectious Diseases</i> , 2001, 184, 1508-1517.	1.9	182
458	Papillomavirus capsid protein expression in <i>Escherichia coli</i> : purification and assembly of HPV11 and HPV16 L1. <i>Journal of Molecular Biology</i> , 2001, 307, 173-182.	2.0	167
459	Female genital schistosomiasis: facts and hypotheses. <i>Acta Tropica</i> , 2001, 79, 193-210.	0.9	122
460	Detection and Typing of Human Papillomavirus DNA in Penile Carcinoma. <i>American Journal of Pathology</i> , 2001, 159, 1211-1218.	1.9	399
461	A Novel Strategy for Human Papillomavirus Detection and Genotyping with SybrGreen and Molecular Beacon Polymerase Chain Reaction. <i>American Journal of Pathology</i> , 2001, 159, 1651-1660.	1.9	52
462	Human papillomavirus in cutaneous squamous cell carcinoma and cervix of a patient with psoriasis and extensive ultraviolet radiation exposure. <i>Journal of the American Academy of Dermatology</i> , 2001, 44, 681-686.	0.6	13
463	Human papillomavirus as a risk factor for oral squamous cell carcinoma: A meta-analysis, 1982-1997. <i>Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics</i> , 2001, 91, 622-635.	1.6	388
464	Immunological analyses of human papillomavirus capsids. <i>Vaccine</i> , 2001, 19, 1783-1793.	1.7	132
465	Vaccine regimen for prevention of sexually transmitted infections with human papillomavirus type 16. <i>Vaccine</i> , 2001, 19, 3583-3590.	1.7	28
466	Pre-clinical safety and efficacy of TA-CIN, a recombinant HPV16 L2E6E7 fusion protein vaccine, in homologous and heterologous prime-boost regimens. <i>Vaccine</i> , 2001, 19, 3652-3660.	1.7	119
467	Antibody, cytokine and cytotoxic T lymphocyte responses in chimpanzees immunized with human papillomavirus virus-like particles. <i>Vaccine</i> , 2001, 19, 3733-3743.	1.7	52
468	A DNA vaccine based on a shuffled E7 oncogene of the human papillomavirus type 16 (HPV 16) induces E7-specific cytotoxic T cells but lacks transforming activity. <i>Vaccine</i> , 2001, 19, 4276-4286.	1.7	53
469	The importance of biological factors (bcl-2, bax, p53, PCNA, MI, HPV and angiogenesis) in invasive cervical cancer. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2001, 97, 223-230.	0.5	66
470	Using a new HPV detection system in epidemiological research: change of views on cervical dyskaryosis?. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2001, 98, 199-204.	0.5	3
471	Polymorphisms in codon 31 of p21 and cervical cancer susceptibility in Korean women. <i>Cancer Letters</i> , 2001, 165, 59-62.	3.2	54
472	Analysis of E6 variants of human papillomavirus type 33, 52 and 58 in Japanese women with cervical intraepithelial neoplasia/cervical cancer in relation to their oncogenic potential. <i>Cancer Letters</i> , 2001, 170, 19-24.	3.2	54
473	Physical status of the E2 human papilloma virus 16 viral gene in cervical preneoplastic and neoplastic lesions. <i>Journal of Clinical Virology</i> , 2001, 21, 129-134.	1.6	66
474	Pathology of AIDS-related lymphomas and other AIDS-defining neoplasms. <i>European Journal of Cancer</i> , 2001, 37, 1236-1250.	1.3	37

#	ARTICLE	IF	CITATIONS
475	HPV-related neoplasias in HIV-infected individuals. <i>European Journal of Cancer</i> , 2001, 37, 1227-1235.	1.3	64
476	Cervical cancer detection by hybrid capture and evaluation of local risk factors. <i>International Journal of Gynecology and Obstetrics</i> , 2001, 73, 41-46.	1.0	11
477	Cervical neoplasia risk in women provided hormonal contraception without a Pap smear. <i>Contraception</i> , 2001, 63, 57-60.	0.8	15
478	Human immunodeficiency virus type 1-related nucleic acids and papillomavirus DNA in cervicovaginal secretions of immunodeficiency virus-infected women. <i>Obstetrics and Gynecology</i> , 2001, 97, 999-1004.	1.2	12
479	Changing rates of adenocarcinoma and adenosquamous carcinoma of the cervix in England. <i>Lancet, The</i> , 2001, 357, 1490-1493.	6.3	156
480	Human papillomavirus genotypes in rural Mozambique. <i>Lancet, The</i> , 2001, 358, 1429-1430.	6.3	114
481	Natural history of cervical human papillomavirus. <i>Lancet, The</i> , 2001, 358, 1550.	6.3	3
482	HUMAN PAPILOMAVIRUSES. <i>Obstetrics and Gynecology Clinics of North America</i> , 2001, 28, 653-666.	0.7	11
484	PRIMARY TREATMENT OF CONDYLOMATA ACUMINATA WITH VIABLE BACILLUS CALMETTE-GUERIN. <i>Journal of Urology</i> , 2001, 165, 834-836.	0.2	26
485	Antibodies against Human Papillomavirus Type 16 and 18 E6 and E7 Proteins in Cervicovaginal Washings and Serum of Patients with Cervical Neoplasia. <i>Viral Immunology</i> , 2001, 14, 415-424.	0.6	23
486	Asian-American Variants of Human Papillomavirus 16 and Risk for Cervical Cancer: a Case-Control Study. <i>Journal of the National Cancer Institute</i> , 2001, 93, 1325-1330.	3.0	248
487	The Papanicolaou smear and cervical cancer. , 2001, , 306-325.		0
488	Prevalence of Human Papillomavirus in Elderly Women with Cervical Cancer. <i>Gynecologic and Obstetric Investigation</i> , 2001, 52, 248-251.	0.7	10
490	Fibroblast Growth Factor Receptor 3 (FGFR3) Analyses of the S249C Mutation and Protein Expression in Primary Cervical Carcinomas. <i>Analytical Cellular Pathology</i> , 2001, 23, 45-49.	2.1	12
491	Low frequency of p53 mutations in cervical carcinomas among Brazilian women. <i>Brazilian Journal of Medical and Biological Research</i> , 2001, 34, 727-733.	0.7	10
492	Animal Models in Virology. , 2001, 9, 15-30.		0
493	Low Serum and Red Blood Cell Folate Are Moderately, but Nonsignificantly Associated with Increased Risk of Invasive Cervical Cancer in U.S. Women. <i>Journal of Nutrition</i> , 2001, 131, 2040-2048.	1.3	32
494	Human Papillomavirus and Prognosis of Invasive Cervical Cancer: A Population-Based Study. <i>Journal of Clinical Oncology</i> , 2001, 19, 1906-1915.	0.8	139

#	ARTICLE	IF	CITATIONS
495	Apoptotic Changes in Cervical Intraepithelial Neoplasia. <i>Gynecologic and Obstetric Investigation</i> , 2001, 52, 38-42.	0.7	3
496	New Developments in the Treatment of Cervical Cancer. <i>Oncology Research and Treatment</i> , 2001, 24, 340-345.	0.8	2
498	Detection of Human Papillomavirus DNA in Primary and Metastatic Lesions of Carcinoma of the Cervix in Women from Okinawa, Japan. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2001, 24, 160-166.	0.6	29
499	Relationship Between Telomerase Activation and HPV 16/18 Oncogene Expression in Squamous Intraepithelial Lesions and Squamous Cell Carcinomas of the Uterine Cervix. <i>International Journal of Gynecological Pathology</i> , 2001, 20, 177-185.	0.9	25
500	Cervical HPV DNA Detection as a Predictor of a Recurrent SIL Diagnosis Among Untreated Women. <i>Journal of Lower Genital Tract Disease</i> , 2001, 5, 138-143.	0.9	0
501	Human Immunodeficiency Virus Type 1-Related Nucleic Acids and Papillomavirus DNA in Cervicovaginal Secretions of Immunodeficiency Virus-Infected Women. <i>Obstetrics and Gynecology</i> , 2001, 97, 999-1004.	1.2	3
502	Genital Human Papillomavirus Types in Immunocompetent and Immunodepressed Women in Northeast Italy. <i>Journal of Lower Genital Tract Disease</i> , 2001, 5, 12-20.	0.9	0
503	Human Papillomavirus. <i>Sexually Transmitted Diseases</i> , 2001, 28, 125-130.	0.8	53
504	Screening for human papillomavirus infection in asymptomatic women in Hungary. <i>Human Reproduction</i> , 2001, 16, 2235-2237.	0.4	10
505	Are Psychological Factors Involved in the Development of Cervical Cancer?. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2001, 23, 13-19.	0.1	2
506	Human Papillomavirus Infections: Epidemiology, Pathogenesis, and Therapy. <i>Journal of Cutaneous Medicine and Surgery</i> , 2001, 5, 43-60.	0.6	67
507	Immunity to human papillomaviruses: Implications for vaccine design. <i>Perspectives in Medical Virology</i> , 2001, 5, 451-478.	0.1	1
508	Chapter 18 Topical sensitizationâ€”non-oncologic indicationsâ€”HPV-infections. <i>Comprehensive Series in Photosciences</i> , 2001, , 283-300.	0.3	0
509	â€œLow-riskâ€”and â€œHigh-riskâ€”HPV-infection and K-ras Gene Point Mutations in Human Cervical CancerA Study of 31 Cases. <i>Pathology Research and Practice</i> , 2001, 197, 597-603.	1.0	5
510	Human Papillomavirus Testing for Triage in a Referral Population. <i>Journal of Lower Genital Tract Disease</i> , 2001, 5, 29-32.	0.9	0
511	Rapid real time PCR to distinguish between high risk human papillomavirus types 16 and 18. <i>Journal of Clinical Pathology</i> , 2001, 54, 24-29.	2.1	39
512	Human papillomavirus infections of the vulva. <i>Der Gynakologe</i> , 2001, 34, 883-897.	1.0	5
513	Cervical cancer screening from pap smear to human papillomavirus DNA testing. <i>Comprehensive Therapy</i> , 2001, 27, 202-208.	0.2	4

#	ARTICLE	IF	CITATIONS
514	Prevention of cervical cancer with vaccines. <i>Current Oncology Reports</i> , 2001, 3, 322-328.	1.8	8
515	Identification of a promoter in position 56 within the long control region of human papillomavirus type 18. <i>Archives of Virology</i> , 2001, 146, 2069-2084.	0.9	6
516	Expression of cyclin-dependent kinase inhibitors p16MTS1, p21WAF1, and p27KIP1 in HPV-positive and HPV-negative cervical adenocarcinomas. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2001, 439, 55-61.	1.4	107
517	Significance of high-risk human papillomavirus detection by polymerase chain reaction in primary cervical cancer screening. <i>Cytopathology</i> , 2001, 12, 75-83.	0.4	18
518	Distribution of HPV 53, HPV 73 and CP8304 in genital epithelial lesions with different grades of dysplasia. <i>International Journal of Gynecological Cancer</i> , 2001, 11, 198-204.	1.2	39
519	c-myc gene amplification detected in preinvasive intraepithelial cervical lesions. <i>International Journal of Gynecological Cancer</i> , 2001, 11, 462-465.	1.2	17
520	Epidemiologic and mucosal immunologic aspects of HPV infection and HPV-related cervical neoplasia in the lower female genital tract: A review. <i>International Journal of Gynecological Cancer</i> , 2001, 11, 9-17.	1.2	48
521	Prophylactic and Therapeutic Vaccines for Genital Papillomavirus Infection. <i>Journal of Investigative Dermatology Symposium Proceedings</i> , 2001, 6, 238-243.	0.8	4
522	Human Papillomavirus and Skin Cancer. <i>Journal of Investigative Dermatology Symposium Proceedings</i> , 2001, 6, 203-206.	0.8	35
523	Comparative analysis of human papillomavirus infections in cervical scrapes and biopsy specimens by general SPF10 PCR and HPV genotyping. <i>Journal of Pathology</i> , 2001, 194, 51-58.	2.1	83
524	DNA image cytometry and human papillomavirus (HPV) detection help to select smears at high risk of high-grade cervical lesions. <i>Journal of Pathology</i> , 2001, 194, 171-176.	2.1	20
525	Oncogene lineages of human papillomavirus type 16 E6, E7 and E5 in preinvasive and invasive cervical squamous cell carcinoma. <i>Journal of Pathology</i> , 2001, 195, 307-311.	2.1	20
526	High-risk HPV testing in women with borderline and mild dyskaryosis: long-term follow-up data and clinical relevance. <i>Journal of Pathology</i> , 2001, 195, 300-306.	2.1	72
527	HPV testing in cervical screening. <i>Pharmacoepidemiology and Drug Safety</i> , 2001, 10, 33-36.	0.9	3
528	Successful treatment of recurrent vulvar intraepithelial neoplasia resistant to interferon and isotretinoin with cidofovir. <i>Journal of Medical Virology</i> , 2001, 64, 195-198.	2.5	31
529	Detection of multiple human papillomavirus types in the lower genital tract correlates with cervical dysplasia. <i>Journal of Medical Virology</i> , 2001, 64, 550-559.	2.5	97
530	Chromosome 3p tumor-suppressor gene alterations in cervical carcinomas. <i>Molecular Carcinogenesis</i> , 2001, 30, 159-168.	1.3	15
531	Correlation of human papillomavirus 16 and 18 with cervical neoplasia in histological typing and clinical stage in Taiwan: An in-situ polymerase chain reaction approach. <i>Journal of Surgical Oncology</i> , 2001, 78, 101-109.	0.8	9

#	ARTICLE	IF	CITATIONS
532	The effects of p53 status and human papillomavirus infection on the clinical outcome of patients with Stage IIIB cervical carcinoma treated with radiation therapy alone. <i>Cancer</i> , 2001, 91, 80-89.	2.0	54
533	De novo establishment and cost-effectiveness of Papanicolaou cytology screening services in the Socialist Republic of Vietnam. <i>Cancer</i> , 2001, 91, 928-939.	2.0	51
534	Endometrioid adenocarcinomas of the uterine corpus in women younger than 50 years of age can be divided into two distinct clinical and pathologic entities based on anatomic location. <i>Cancer</i> , 2001, 92, 2578-2584.	2.0	19
535	Natural T-helper immunity against human papillomavirus type 16 (hpv16) e7-derived peptide epitopes in patients with hpv16-positive cervical lesions: Identification of 3 human leukocyte antigen class ii-restricted epitopes. <i>International Journal of Cancer</i> , 2001, 91, 612-618.	2.3	129
536	Epidemiology of HPV infection among Mexican women with normal cervical cytology. <i>International Journal of Cancer</i> , 2001, 91, 412-420.	2.3	277
537	Mortality in dry-cleaning workers: An update. <i>American Journal of Industrial Medicine</i> , 2001, 39, 121-132.	1.0	56
538	Cervical cancer vaccines: Emerging concepts and developments. <i>Journal of Cellular Physiology</i> , 2001, 186, 169-182.	2.0	81
539	Human papillomavirus (HPV) study of 691 pathological specimens from Quebec by PCR-direct sequencing approach. <i>Journal of Medical Virology</i> , 2001, 63, 284-292.	2.5	42
540	Human papillomavirus variants and squamous neoplasia of the cervix. <i>Journal of Pathology</i> , 2001, 193, 295-302.	2.1	102
541	Cost-effectiveness of monolayers and human papillomavirus testing compared to that of conventional Papanicolaou smears for cervical cancer screening: Protocol of the study of the French Society of Clinical Cytology. <i>Diagnostic Cytopathology</i> , 2001, 24, 412-420.	0.5	18
542	Chromosome 6p21.2, 18q21.2 and human papilloma virus (HPV) DNA can predict prognosis of cervical cancer after radiotherapy. <i>International Journal of Cancer</i> , 2001, 96, 286-296.	2.3	18
543	Differential sensitivity of human papillomavirus type 16+ and type 18+ cervical carcinoma cells to CD95-mediated apoptosis. <i>International Journal of Cancer</i> , 2001, 93, 823-831.	2.3	28
544	HLA class II alleles associated with infection by HPV16 in cervical cancer in situ. <i>International Journal of Cancer</i> , 2001, 93, 817-822.	2.3	92
545	Hybrid capture-II and LCR-E7 PCR assays for HPV typing in cervical cytologic samples. <i>International Journal of Cancer</i> , 2001, 94, 222-227.	2.3	41
546	Cancer incidence in women with or at risk for HIV. <i>International Journal of Cancer</i> , 2001, 94, 753-757.	2.3	77
547	Cancer of the uterine cervix may be significantly associated with a gene polymorphism coding for increased IL-10 production. <i>International Journal of Cancer</i> , 2001, 94, 792-794.	2.3	97
548	Human T cell responses to HPV 16 E2 generated with monocyte-derived dendritic cells. <i>International Journal of Cancer</i> , 2001, 94, 807-812.	2.3	16
549	Effect of BPV1 E2-Mediated Inhibition of E6/E7 Expression in HPV16-Positive Cervical Carcinoma Cells. <i>Gynecologic Oncology</i> , 2001, 80, 168-175.	0.6	30

#	ARTICLE	IF	CITATIONS
550	Aberrant Expression of Cyclin D1 Is Associated with Poor Prognosis in Early Stage Cervical Cancer of the Uterus. <i>Gynecologic Oncology</i> , 2001, 81, 341-347.	0.6	85
551	Synthetic Peptides Induce a Cytotoxic Response against Human Papillomavirus Type-18. <i>Gynecologic Oncology</i> , 2001, 82, 77-83.	0.6	10
552	The Significance of Human Papillomavirus Viral Load in Prediction of Histologic Severity and Size of Squamous Intraepithelial Lesions of Uterine Cervix. <i>Gynecologic Oncology</i> , 2001, 83, 95-99.	0.6	101
553	NHPV16 VLP Vaccine Induces Human Antibodies That Neutralize Divergent Variants of HPV16. <i>Virology</i> , 2001, 279, 361-369.	1.1	110
554	Complete Nucleotide Sequence and Analysis of a Novel Human Papillomavirus (HPV 84) Genome Cloned by an Overlapping PCR Method. <i>Virology</i> , 2001, 279, 109-115.	1.1	28
555	Induction of Type-Specific Neutralizing Antibodies by Capsomeres of Human Papillomavirus Type 33. <i>Virology</i> , 2001, 283, 353-357.	1.1	46
556	Relationships between 80 Human Papillomavirus Genotypes and Different Grades of Cervical Intraepithelial Neoplasia: Association and Causality. <i>Virology</i> , 2001, 283, 139-147.	1.1	57
557	Effect of Preexisting Neutralizing Antibodies on the Anti-tumor Immune Response Induced by Chimeric Human Papillomavirus Virus-like Particle Vaccines. <i>Virology</i> , 2001, 290, 350-360.	1.1	63
558	Prospective study of antibody to human papilloma virus type 16 and risk of cervical, endometrial, and ovarian cancers (United States). <i>Cancer Causes and Control</i> , 2001, 12, 335-341.	0.8	24
559	Elevated serum homocysteine levels and increased risk of invasive cervical cancer in US women. <i>Cancer Causes and Control</i> , 2001, 12, 317-324.	0.8	49
560	Associations between smoking and adenocarcinomas and squamous cell carcinomas of the uterine cervix (United States). <i>Cancer Causes and Control</i> , 2001, 12, 153-161.	0.8	67
561	Metastatic MHC class I-negative mouse cells derived by transformation with human papillomavirus type 16. <i>British Journal of Cancer</i> , 2001, 84, 374-380.	2.9	15
562	“Low-risk” and “High-risk” HPV-infection and K-ras Gene Point Mutations in Human Cervical Cancer. <i>Pathology Research and Practice</i> , 2001, 197, 597-603.	1.0	3
563	Abnormal cervical cytology in bone marrow transplant recipients. <i>Bone Marrow Transplantation</i> , 2001, 28, 393-397.	1.3	51
564	Staurosporine-induced apoptosis of HPV positive and negative human cervical cancer cells from different points in the cell cycle. <i>Cell Death and Differentiation</i> , 2001, 8, 234-244.	5.0	34
565	Detection of Epstein-Barr virus-determined nuclear antigen-2 mRNA by in situ hybridization. <i>Journal of Virological Methods</i> , 2001, 93, 23-32.	1.0	14
566	Chromosomal positioning of human T-lymphotropic type 1 proviruses by fluorescence in situ hybridisation. <i>Journal of Virological Methods</i> , 2001, 93, 65-74.	1.0	5
567	Cervical cancer in Latin America. <i>Seminars in Oncology</i> , 2001, 28, 188-197.	0.8	18

#	ARTICLE	IF	CITATIONS
568	Genital Human Papillomavirus Types in Immunocompetent and Immunodepressed Women in Northeast Italy: Prevalence and Cytomorphological Correlations. <i>Journal of Lower Genital Tract Disease</i> , 2001, 5, 12-20.	0.9	6
569	Human Papillomavirus Testing for Triage in a Referral Population. <i>Journal of Lower Genital Tract Disease</i> , 2001, 5, 29-32.	0.9	1
570	Cervical HPV DNA Detection as a Predictor of a Recurrent SIL Diagnosis Among Untreated Women. <i>Journal of Lower Genital Tract Disease</i> , 2001, 5, 138-143.	0.9	1
571	Human papillomavirus and cervical carcinogenesis. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2001, 15, 663-676.	1.4	53
572	Current methods of testing for human papillomavirus. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2001, 15, 677-700.	1.4	46
573	Human papillomavirus as a form of risk assessment. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2001, 15, 759-768.	1.4	3
574	The role of human papillomavirus vaccines in cervical neoplasia. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2001, 15, 783-799.	1.4	16
575	Human papillomavirus DNA in plasma of patients with cervical cancer. <i>BMC Cancer</i> , 2001, 1, 2.	1.1	95
576	Human Papillomavirus Type 16 Variants and Risk of Cervical Cancer. <i>Journal of the National Cancer Institute</i> , 2001, 93, 315-318.	3.0	196
577	Prevalence of Anti-Human Papillomavirus Type 16, 18, 31, and 58 Virus-Like Particles in Women in the General Population and in Prostitutes. <i>Journal of Clinical Microbiology</i> , 2001, 39, 4344-4348.	1.8	51
578	Nonisotopic Detection of Human Papillomavirus DNA in Clinical Specimens Using a Consensus PCR and a Generic Probe Mix in an Enzyme-Linked Immunosorbent Assay Format. <i>Journal of Clinical Microbiology</i> , 2001, 39, 3530-3536.	1.8	30
579	Cell-Mediated Immune Response to Human Papillomavirus Infection. <i>Vaccine Journal</i> , 2001, 8, 209-220.	2.6	200
580	Vaccines in oncology: background and clinical potential. <i>British Journal of Radiology</i> , 2001, 74, 991-1002.	1.0	9
581	Polymorphism of the WAF1 gene is related to susceptibility to cervical cancer in Japanese women. <i>International Journal of Molecular Medicine</i> , 2001, 7, 261-4.	1.8	24
582	Motif analysis of HLA class II molecules that determine the HPV associated risk of cervical carcinogenesis. <i>International Journal of Molecular Medicine</i> , 2001, 8, 405-12.	1.8	10
583	A Prospective Study of Human Papillomavirus (HPV) Type 16 DNA Detection by Polymerase Chain Reaction and Its Association with Acquisition and Persistence of Other HPV Types. <i>Journal of Infectious Diseases</i> , 2001, 183, 8-15.	1.9	242
584	HPV co-factors related to the development of cervical cancer: results from a population-based study in Costa Rica. <i>British Journal of Cancer</i> , 2001, 84, 1219-1226.	2.9	183
585	Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women. <i>British Journal of Cancer</i> , 2001, 84, 1616-1623.	2.9	382

#	ARTICLE	IF	CITATIONS
586	HPV presence precedes abnormal cytology in women developing cervical cancer and signals false negative smears. <i>British Journal of Cancer</i> , 2001, 85, 398-404.	2.9	102
587	HPV16 E6 gene variations in invasive cervical squamous cell carcinoma and cancer in situ from Russian patients. <i>British Journal of Cancer</i> , 2001, 84, 791-795.	2.9	23
588	Dendritic cells induce the death of human papillomavirus transformed keratinocytes. <i>FASEB Journal</i> , 2001, 15, 2521-2523.	0.2	28
589	Human Papillomavirus Virus-Like Particles Are Efficient Oral Immunogens when Coadministered with <i>Escherichia coli</i> Heat-Labile Enterotoxin Mutant R192G or CpG DNA. <i>Journal of Virology</i> , 2001, 75, 4752-4760.	1.5	82
590	Gps2, a Protein Partner for Human Papillomavirus E6 Proteins. <i>Journal of Virology</i> , 2001, 75, 151-160.	1.5	55
591	Feedback Regulation between Orphan Nuclear Receptor TR2 and Human Papilloma Virus Type 16. <i>Journal of Biological Chemistry</i> , 2001, 276, 27316-27321.	1.6	7
592	Papillomavirus-Like Particles Induce Acute Activation of Dendritic Cells. <i>Journal of Immunology</i> , 2001, 166, 5346-5355.	0.4	238
593	Determinants of Genital Human Papillomavirus Detection in a US Population. <i>Journal of Infectious Diseases</i> , 2001, 183, 1554-1564.	1.9	227
594	Seroepidemiology of low and high oncogenic risk types of human papillomavirus in a predominantly male cohort of STD clinic patients. <i>International Journal of STD and AIDS</i> , 2001, 12, 516-523.	0.5	47
595	Human Papillomavirus Infection and Associated Cervical Disease in Human Immunodeficiency Virus-Infected Women: Effect of Highly Active Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2001, 184, 547-551.	1.9	182
596	Photodynamic Effects Induced by Aminolevulinic Acid Esters on Human Cervical Carcinoma Cells in Culture. <i>Photochemistry and Photobiology</i> , 2001, 74, 617.	1.3	31
597	Both E6 and E7 Oncoproteins of Human Papillomavirus 16 Inhibit IL-18-Induced IFN- γ Production in Human Peripheral Blood Mononuclear and NK Cells. <i>Journal of Immunology</i> , 2001, 167, 497-504.	0.4	107
598	Prevalence and Risk Factors for Anal Human Papillomavirus Infection in Human Immunodeficiency Virus (HIV)-Positive and High-Risk HIV-Negative Women. <i>Journal of Infectious Diseases</i> , 2001, 183, 383-391.	1.9	295
599	Safety and Immunogenicity Trial in Adult Volunteers of a Human Papillomavirus 16 L1 Virus-Like Particle Vaccine. <i>Journal of the National Cancer Institute</i> , 2001, 93, 284-292.	3.0	540
600	Human Papillomaviruses and Cervical Cancer in Bangkok. I. Risk Factors for Invasive Cervical Carcinomas with Human Papillomavirus Types 16 and 18 DNA. <i>American Journal of Epidemiology</i> , 2001, 153, 723-731.	1.6	50
601	Prevalence, Incidence, and Type-Specific Persistence of Human Papillomavirus in Human Immunodeficiency Virus (HIV)-Positive and HIV-Negative Women. <i>Journal of Infectious Diseases</i> , 2001, 184, 682-690.	1.9	288
602	Human Papillomavirus Type 6b Virus-Like Particles Are Able To Activate the Ras-MAP Kinase Pathway and Induce Cell Proliferation. <i>Journal of Virology</i> , 2001, 75, 4150-4157.	1.5	35
603	Antigen Processing Defects in Cervical Carcinomas Limit the Presentation of a CTL Epitope from Human Papillomavirus 16 E6. <i>Journal of Immunology</i> , 2001, 167, 5420-5428.	0.4	101

#	ARTICLE	IF	CITATIONS
604	Neutralization of Human Papillomavirus Type 11 (HPVâ€11) by Serum from Women Vaccinated with Yeastâ€Derived HPVâ€11 L1 Virusâ€like Particles: Correlation with Competitive Radioimmunoassay Titer. <i>Journal of Infectious Diseases</i> , 2001, 184, 1183-1186.	1.9	73
605	Human Papillomavirus E6E7-Mediated Adenovirus Cell Killing: Selectivity of Mutant Adenovirus Replication in Organotypic Cultures of Human Keratinocytes. <i>Journal of Virology</i> , 2001, 75, 7602-7611.	1.5	56
607	Clinical and Prognostic Significance of Human Papillomavirus in a Chinese Population of Cervical Cancers. <i>Gynecologic and Obstetric Investigation</i> , 2001, 51, 202-207.	0.7	28
608	Selective Activation of Cervical Microvascular Endothelial Cells by Human Papillomavirus 16-E7 Oncoprotein. <i>Journal of the National Cancer Institute</i> , 2001, 93, 1843-1851.	3.0	14
609	Incidence, Prevalence, and Clearance of Typeâ€Specific Human Papillomavirus Infections: The Young Womenâ€s Health Study. <i>Journal of Infectious Diseases</i> , 2002, 186, 462-469.	1.9	247
610	High Prevalence of Human Papillomavirus (HPV) Infections and High Frequency of Multiple HPV Genotypes in Human Immunodeficiency Virus-Infected Women in Brazil. <i>Journal of Clinical Microbiology</i> , 2002, 40, 3341-3345.	1.8	168
611	A Prospective Study of High-Grade Cervical Neoplasia Risk Among Human Papillomavirus-Infected Women. <i>Journal of the National Cancer Institute</i> , 2002, 94, 1406-1414.	3.0	208
612	Established Human Papillomavirus Type 16-Expressing Tumors Are Effectively Eradicated Following Vaccination with Long Peptides. <i>Journal of Immunology</i> , 2002, 169, 350-358.	0.4	386
613	Results of Human Papillomavirus DNA Testing with the Hybrid Capture 2 Assay Are Reproducible. <i>Journal of Clinical Microbiology</i> , 2002, 40, 1088-1090.	1.8	70
614	Immunization and immunotherapy for cancers involving infection by a human papillomavirus in a mouse model. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 16232-16236.	3.3	23
615	GP5+/6+ PCR followed by Reverse Line Blot Analysis Enables Rapid and High-Throughput Identification of Human Papillomavirus Genotypes. <i>Journal of Clinical Microbiology</i> , 2002, 40, 779-787.	1.8	484
616	External Genital Warts: Diagnosis, Treatment, and Prevention. <i>Clinical Infectious Diseases</i> , 2002, 35, S210-S224.	2.9	308
617	Abnormal FHIT expression profiles in cervical intraepithelial neoplastic (CIN) lesions. <i>British Journal of Cancer</i> , 2002, 86, 376-381.	2.9	8
618	Clonality Analysis of Synchronous Lesions of Cervical Carcinoma Based on X Chromosome Inactivation Polymorphism, Human Papillomavirus Type 16 Genome Mutations, and Loss of Heterozygosity. <i>Journal of Experimental Medicine</i> , 2002, 195, 845-854.	4.2	15
619	Evaluation of Human Papillomavirus Testing in Primary Screening for Cervical Abnormalities. <i>JAMA - Journal of the American Medical Association</i> , 2002, 288, 1749.	3.8	394
620	Determinants of Cervical Human Papillomavirus Infection: Differences between Highâ€and Lowâ€Oncogenic Risk Types. <i>Journal of Infectious Diseases</i> , 2002, 185, 28-35.	1.9	63
621	Cancer and the Philippine Cancer Control Program. <i>Japanese Journal of Clinical Oncology</i> , 2002, 32, S52-S61.	0.6	41
622	The need for preventive drugs and vaccines in global cancer control: a challenge for public health and for industry. <i>Toxicology and Industrial Health</i> , 2002, 18, 84-90.	0.6	3

#	ARTICLE	IF	CITATIONS
623	Usefulness of DNA Ploidy Measurement on Liquid-Based Smears Showing Conflicting Results Between Cytology and High-Risk Human Papillomavirus Typing. <i>American Journal of Clinical Pathology</i> , 2002, 118, 708-713.	0.4	21
624	Failure to Detect Human Papillomavirus DNA in Malignant Epithelial Neoplasms of Conjunctiva by Polymerase Chain Reaction. <i>American Journal of Clinical Pathology</i> , 2002, 117, 429-436.	0.4	80
625	Tampon Samplings With Longer Cervicovaginal Cell Exposures Are Equivalent to Two Consecutive Swabs for the Detection of High-Risk Human Papillomavirus. <i>Sexually Transmitted Diseases</i> , 2002, 29, 628-636.	0.8	31
626	Do Condoms Prevent Genital HPV Infection, External Genital Warts, or Cervical Neoplasia?. <i>Sexually Transmitted Diseases</i> , 2002, 29, 725-735.	0.8	303
627	Genotyping of Human Papillomavirus in Liquid Cytology Cervical Specimens by the PGMV Line Blot Assay and the SPF10 Line Probe Assay. <i>Journal of Clinical Microbiology</i> , 2002, 40, 979-983.	1.8	129
629	Benefits and Costs of Using HPV Testing to Screen for Cervical Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2002, 287, 2372.	3.8	256
631	Association of Human Papillomavirus Type 58 Variant With the Risk of Cervical Cancer. <i>Journal of the National Cancer Institute</i> , 2002, 94, 1249-1253.	3.0	86
632	Identification and Characterization of 3 Novel Genital Human Papillomaviruses by Overlapping Polymerase Chain Reaction: candHPV89, candHPV90, and candHPV91. <i>Journal of Infectious Diseases</i> , 2002, 185, 1794-1797.	1.9	38
633	Natural History and Clinical Management of Anal Human Papillomavirus Disease in Men and Women Infected with Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 2002, 35, 1127-1134.	2.9	288
634	Ubiquitin-Fused and/or Multiple Early Genes from Cottontail Rabbit Papillomavirus as DNA Vaccines. <i>Journal of Virology</i> , 2002, 76, 7616-7624.	1.5	58
635	Seroprevalence of Human Papillomavirus Type 16 Infection in the United States. <i>Journal of Infectious Diseases</i> , 2002, 186, 1396-1402.	1.9	192
636	Cervical Cancer Vaccines: Progress and Prospects. <i>Journal of the Society for Gynecologic Investigation</i> , 2002, 9, 254-264.	1.9	5
637	Increased Risk of High-Grade Anal Neoplasia Associated with a Human Papillomavirus Type 16 E6 Sequence Variant. <i>Journal of Infectious Diseases</i> , 2002, 185, 1229-1237.	1.9	57
638	Collection, Processing, and Analysis of Preneoplastic Specimens. , 2002, , 33-45.		3
639	Integrated Human Papillomavirus Type 16 Is Frequently Found in Cervical Cancer Precursors as Demonstrated by a Novel Quantitative Real-Time PCR Technique. <i>Journal of Clinical Microbiology</i> , 2002, 40, 886-891.	1.8	315
640	Update on the Treatment of Cervical and Uterine Carcinoma: Focus on Topotecan. <i>Oncologist</i> , 2002, 7, 36-45.	1.9	18
641	T Cell Response to Human Papillomavirus 16 E7 in Mice: Comparison of Cr Release Assay, Intracellular IFN- γ Production, ELISPOT and Tetramer Staining. <i>Intervirology</i> , 2002, 45, 290-299.	1.2	24
642	Cervix. , 2002, , 249-286.		5

#	ARTICLE	IF	CITATIONS
643	Sexual Behavior, Human Papillomavirus Type 16 (HPV 16) Infection, and HPV 16 Seropositivity. Sexually Transmitted Diseases, 2002, 29, 182-187.	0.8	34
644	Optimizing the Hybrid Capture II Human Papillomavirus Test to Detect Cervical Intraepithelial Neoplasia. Obstetrics and Gynecology, 2002, 100, 972-980.	1.2	0
645	Prevalence of Preinvasive and Invasive Lesions of the Cervix in Sexual Workers. Journal of Lower Genital Tract Disease, 2002, 6, 76-79.	0.9	3
646	Human papillomaviruses in Amerindian women from Brazilian Amazonia. Epidemiology and Infection, 2002, 128, 485-489.	1.0	8
647	U.S. Centers for Disease Control and Prevention Guidelines for the Treatment of Sexually Transmitted Diseases: An Opportunity To Unify Clinical and Public Health Practice. Annals of Internal Medicine, 2002, 137, 255.	2.0	47
649	Clinical aspects and epidemiology of HPV infections. Perspectives in Medical Virology, 2002, , 1-29.	0.1	3
650	Nucleolin as Activator of Human Papillomavirus Type 18 Oncogene Transcription in Cervical Cancer. Journal of Experimental Medicine, 2002, 196, 1067-1078.	4.2	67
651	Human Papillomavirus and the Long-term Risk of Cervical Neoplasia. American Journal of Epidemiology, 2002, 156, 158-164.	1.6	72
652	A Controlled Trial of a Human Papillomavirus Type 16 Vaccine. New England Journal of Medicine, 2002, 347, 1645-1651.	13.9	1,548
653	Risk factors related to the development and mortality from invasive cervical cancer. Obstetrics and Gynecology Clinics of North America, 2002, 29, 817-842.	0.7	4
654	Management of precursor lesions of cervical carcinoma: history, host defense, and a survey of modalities. Obstetrics and Gynecology Clinics of North America, 2002, 29, 751-785.	0.7	7
655	Efficient triage of the "screen-positive" at-risk patient. Obstetrics and Gynecology Clinics of North America, 2002, 29, 735-750.	0.7	2
656	Costs and Benefits of Different Strategies to Screen for Cervical Cancer in Less-Developed Countries. Journal of the National Cancer Institute, 2002, 94, 1469-1483.	3.0	165
657	Human Papillomavirus and Cervical Neoplasia. Cancer Investigation, 2002, 20, 1080-1085.	0.6	45
658	Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study. Lancet, The, 2002, 359, 1085-1092.	6.3	561
659	Interleukin-2 inhibits proliferation of HPV-associated tumor cells and halts tumor growth in vivo. Biochemical and Biophysical Research Communications, 2002, 299, 818-824.	1.0	10
660	Imiquimod 5% cream in the treatment of anogenital warts in female patients. International Journal of Gynecology and Obstetrics, 2002, 77, 231-238.	1.0	25
661	Optimizing the hybrid capture II human papillomavirus test to detect cervical intraepithelial neoplasia ¹ . Obstetrics and Gynecology, 2002, 100, 972-980.	1.2	26

#	ARTICLE	IF	CITATIONS
662	Persistent HPV infection is associated with a greater risk of developing cervical lesions than a single positive test. Evidence-Based Obstetrics and Gynecology, 2002, 4, 148-149.	0.3	0
663	Persistent human papillomavirus infection and cervical neoplasia. Lancet Oncology, The, 2002, 3, 11-16.	5.1	196
665	Hybrid Capture II HPV Test detects at least 15 human papillomavirus genotypes not included in its current high-risk probe cocktail. Journal of Clinical Virology, 2002, 25, 89-97.	1.6	147
666	The viral etiology of cervical cancer. Virus Research, 2002, 89, 183-190.	1.1	169
667	Strategies for HPV prevention. Virus Research, 2002, 89, 285-293.	1.1	55
668	Roscovitine inhibits ongoing DNA synthesis in human cervical cancer. Cancer Letters, 2002, 180, 7-12.	3.2	20
669	Primary prevention of uterine cervix cancer: focus on vaccine history and current strategy. Obstetrics and Gynecology Clinics of North America, 2002, 29, 843-868.	0.7	6
671	The Politics of Priority Setting for Reproductive Health: Breast and Cervical Cancer in Ghana. Reproductive Health Matters, 2002, 10, 47-58.	1.3	52
672	Cáncer de Cérvix uterino. Semergen, 2002, 28, 145-151.	0.2	4
673	Controversias y avances en el cribado del cáncer. FMC Formacion Medica Continuada En Atencion Primaria, 2002, 9, 530-540.	0.0	0
674	New developments in the treatment of invasive cervical cancer. Obstetrics and Gynecology Clinics of North America, 2002, 29, 659-672.	0.7	18
675	Significado del test del VPH en pacientes con citologías diagnosticadas como ASCUS y dentro de la normalidad. Clinica E Investigacion En Ginecologia Y Obstetricia, 2002, 29, 329-333.	0.1	0
676	Microtiter Format for Simultaneous Multianalyte Detection and Development of a PCR-Chemiluminescent Enzyme Immunoassay for Typing Human Papillomavirus DNAs. Clinical Chemistry, 2002, 48, 1654-1660.	1.5	24
677	Immunotherapy of human papillomavirus-associated malignancies and the challenges posed by T-CELL tolerance. Frontiers in Bioscience - Landmark, 2002, 7, d853.	3.0	5
678	The role of human papillomaviruses in human cancers. Frontiers in Bioscience - Landmark, 2002, 7, d641-649.	3.0	72
679	Utility of HPV DNA Detection in Thin-Layer, Liquid-Based Tests with Atypical Squamous Metaplasia. Acta Cytologica, 2002, 46, 808-812.	0.7	7
682	American Cancer Society Guideline for the Early Detection of Cervical Neoplasia and Cancer. Ca-A Cancer Journal for Clinicians, 2002, 52, 342-362.	157.7	782
683	Gynecologic brachytherapy I: Proper incorporation of brachytherapy into the current multimodality management of carcinoma of the cervix. Seminars in Radiation Oncology, 2002, 12, 40-52.	1.0	19

#	ARTICLE	IF	CITATIONS
684	Squamous cell carcinoma of the penile skin in a neovagina 20 years after male-to-female reassignment. <i>Journal of Plastic, Reconstructive and Aesthetic Surgery</i> , 2002, 55, 449-451.	1.1	60
685	Characterization of genital human papillomavirus infection in women who have or who are at risk of having HIV infection. <i>American Journal of Obstetrics and Gynecology</i> , 2002, 186, 21-27.	0.7	95
686	Antibodies to human papillomavirus 16 L1 virus-like particles as an independent prognostic marker in cervical cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2002, 186, 705-711.	0.7	24
687	Prevalence and genotype distribution of cervical human papillomavirus infection: Comparison between pregnant women and non-pregnant controls. <i>Journal of Medical Virology</i> , 2002, 67, 583-588.	2.5	58
688	Genotype spectrum of cervical human papillomavirus infection among sexually transmitted disease clinic patients in Hong Kong. <i>Journal of Medical Virology</i> , 2002, 68, 273-277.	2.5	24
689	Comparisons of HPV DNA detection by MY09/11 PCR methods. <i>Journal of Medical Virology</i> , 2002, 68, 417-423.	2.5	158
690	Parenteral and oral immunization with a plasmid DNA expressing the human papillomavirus 16-L1 gene induces systemic and mucosal antibodies and cytotoxic T lymphocyte responses. <i>Journal of Medical Virology</i> , 2002, 66, 86-95.	2.5	25
691	single-cell cytokine analysis allows detection of cervical T-cell responses against human papillomavirus type 16 L1 in women infected with genital HPV. <i>Journal of Medical Virology</i> , 2002, 67, 234-240.	2.5	14
692	Serologic response to human oncogenic papillomavirus types 16, 18, 31, 33, 39, 58 and 59 virus-like particles in colombian women with invasive cervical cancer. <i>International Journal of Cancer</i> , 2002, 97, 796-803.	2.3	68
693	Determinants of cervical cancer rates in developing countries. <i>International Journal of Cancer</i> , 2002, 100, 199-205.	2.3	68
694	Prevalence of human papillomavirus in cervical cancer: A multicenter study in China. <i>International Journal of Cancer</i> , 2002, 100, 327-331.	2.3	75
695	Human papillomavirus genotype prevalence in high-grade squamous intraepithelial lesions and colposcopically normal women from Zimbabwe. <i>International Journal of Cancer</i> , 2002, 100, 729-732.	2.3	35
696	Impact of multiple HPV infection on response to treatment and survival in patients receiving radical radiotherapy for cervical cancer. <i>International Journal of Cancer</i> , 2002, 102, 237-243.	2.3	80
697	Cancer incidence patterns among Vietnamese in the United States and Ha Noi, Vietnam. <i>International Journal of Cancer</i> , 2002, 102, 412-417.	2.3	62
698	Host genetic control of HPV 16 titer in carcinomain situ of the cervix uteri. <i>International Journal of Cancer</i> , 2002, 101, 526-531.	2.3	56
699	Absolute risk of a subsequent abnormal pap among oncogenic human papillomavirus DNA-positive, cytologically negative women. <i>Cancer</i> , 2002, 95, 2145-2151.	2.0	84
700	Determination of features indicating progression in atypical squamous cells with undetermined significance. <i>Cancer</i> , 2002, 99, 113-117.	2.0	34
701	Human papillomavirus in cervical cancer. <i>Current Oncology Reports</i> , 2002, 4, 175-184.	1.8	74

#	ARTICLE	IF	CITATIONS
702	Evidence of Diversifying Selection in Human Papillomavirus Type 16 E6 But Not E7 Oncogenes. <i>Journal of Molecular Evolution</i> , 2002, 55, 491-499.	0.8	27
703	Epstein-Barr virus and human papillomavirus infections and oropharyngeal squamous cell carcinomas. <i>Clinical and Experimental Medicine</i> , 2002, 2, 137-141.	1.9	32
704	PrÄvention des Zervixkarzinoms. <i>Onkologe</i> , 2002, 8, 1053-1063.	0.7	0
705	The production of human papillomavirus type 16 L1 vaccine product from <i>Escherichia coli</i> inclusion bodies. <i>Bioprocess and Biosystems Engineering</i> , 2002, 25, 121-128.	1.7	22
706	Human papillomavirus molecular biology and pathogenesis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2002, 16, 231-240.	1.3	87
707	Sequence variations of the late upstream region of HPV16 in cervical intraepithelial neoplasm and invasive carcinoma. <i>International Journal of Gynecological Cancer</i> , 2002, 12, 99-104.	1.2	2
708	Route of administration of chimeric BPV1 VLP determines the character of the induced immune responses. <i>Immunology and Cell Biology</i> , 2002, 80, 21-29.	1.0	30
709	Du dÄ©pistage Ä la prise en charge des atypies cytologiques mineures ou mal dÄ©finies du col: ProgrÄ©s rÄ©cents. <i>Revue Francaise Des Laboratoires</i> , 2002, 2002, 41-48.	0.0	0
710	Actualisation de la conduite Ä tenir en cas de lÄ©sions Ä papillomavirus humains (HPV). <i>Revue Francaise Des Laboratoires</i> , 2002, 2002, 55-59.	0.0	0
711	c-Src Activation by the E5 oncoprotein enables transformation independently of PDGF receptor activation. <i>Oncogene</i> , 2002, 21, 1695-1706.	2.6	22
712	The DNA repair protein, O6-Methylguanine-DNA methyltransferase is a proteolytic target for the E6 human papillomavirus oncoprotein. <i>Oncogene</i> , 2002, 21, 5940-5945.	2.6	77
713	Human Papillomavirus in Larynx. <i>Laryngoscope</i> , 2002, 112, 700-707.	1.1	72
714	Papillomaviruses and cancer: from basic studies to clinical application. <i>Nature Reviews Cancer</i> , 2002, 2, 342-350.	12.8	3,356
715	Identification of molecular markers for the early detection of human squamous cell carcinoma of the uterine cervix. <i>British Journal of Cancer</i> , 2002, 86, 274-281.	2.9	45
716	Primary screening for cervical cancer precursors by the combined use of liquid-based cytology, computer-assisted cytology and HPV DNA testing. <i>British Journal of Cancer</i> , 2002, 86, 382-388.	2.9	22
717	Prevalence and determinants of HPV infection among Colombian women with normal cytology. <i>British Journal of Cancer</i> , 2002, 87, 324-333.	2.9	218
718	The epidemiology of conjunctival squamous cell carcinoma in Uganda. <i>British Journal of Cancer</i> , 2002, 87, 301-308.	2.9	110
719	Childhood indicators of susceptibility to subsequent cervical cancer. <i>British Journal of Cancer</i> , 2002, 87, 989-993.	2.9	27

#	ARTICLE	IF	CITATIONS
720	Pap Test Results Among Low-Income Youth: Prevalence of Dysplasia and Practice Implications. JOGNN - Journal of Obstetric, Gynecologic, and Neonatal Nursing, 2002, 31, 294-304.	0.2	4
721	Human papilloma virus (HPV) DNA associated with prognosis of cervical cancer after radiotherapy. International Journal of Radiation Oncology Biology Physics, 2002, 52, 1345-1351.	0.4	72
722	Autofluorescence spectroscopy for the diagnosis of cervical intraepithelial neoplasia. BJOG: an International Journal of Obstetrics and Gynaecology, 2002, 109, 947-951.	1.1	42
723	Adenoassociated Virus Type 2-Induced Inhibition of the Human Papillomavirus Type 18 Promoter in Transgenic Mice. Virology, 2002, 293, 172-181.	1.1	17
724	Enhanced Immunogenicity of HPV 16 E7 Fusion Proteins in DNA Vaccination. Virology, 2002, 294, 47-59.	1.1	69
725	Codon Modified Human Papillomavirus Type 16 E7 DNA Vaccine Enhances Cytotoxic T-Lymphocyte Induction and Anti-tumour Activity. Virology, 2002, 301, 43-52.	1.1	87
726	Evidence of an Association between Human Papillomavirus and Impaired Chemotherapy-Induced Apoptosis in Cervical Cancer Cells. Gynecologic Oncology, 2002, 85, 59-66.	0.6	29
727	Male Circumcision, Penile Human Papillomavirus Infection, and Cervical Cancer in Female Partners. New England Journal of Medicine, 2002, 346, 1105-1112.	13.9	707
728	Cervical concentrations of interleukin-10 and interleukin-12 do not correlate with plasma levels. Journal of Clinical Immunology, 2002, 22, 23-27.	2.0	42
729	Serum selenium and the risk of cervical cancer among women in the United States. Cancer Causes and Control, 2002, 13, 517-526.	0.8	12
730	Risk factors for progression of squamous cell cervical carcinoma in-situ to invasive cervical cancer: results of a multinational study. Cancer Causes and Control, 2002, 13, 683-690.	0.8	8
731	Why phase II trials in cervical chemoprevention are negative: what have we learned?. Cancer Causes and Control, 2002, 13, 855-873.	0.8	17
732	The Use of Vaccines in the Prevention and Treatment of Cervical Cancer. Clinical Oncology, 2002, 14, 193-200.	0.6	13
733	Human Papillomavirus (HPV) Infection in Southern Africa: Prevalence, Immunity, and Vaccine Prospects. IUBMB Life, 2002, 53, 253-258.	1.5	23
734	Interference of papillomavirus E6 protein with single-strand break repair by interaction with XRCC1. EMBO Journal, 2002, 21, 4741-4748.	3.5	130
735	Atomic model of the papillomavirus capsid. EMBO Journal, 2002, 21, 4754-4762.	3.5	232
736	Role of HPV DNA testing in predicting cervical intraepithelial lesions: Comparison of HC HPV and ISH HPV. Diagnostic Cytopathology, 2003, 29, 149-155.	0.5	30
737	Correlation of manual screening and automated (AutoPap 300) analysis of conventional cervicovaginal smears with HPV typing using Digene HC II assay. Diagnostic Cytopathology, 2003, 29, 256-261.	0.5	4

#	ARTICLE	IF	CITATIONS
738	Effect of plasma micronutrients on clearance of oncogenic human papillomavirus (HPV) infection (United States). <i>Cancer Causes and Control</i> , 2003, 14, 319-326.	0.8	25
739	Characterization of Human Papillomavirus Infection, P53 and Ki-67 Expression in Cervix Cancer of Mozambican Women. <i>Pathology Research and Practice</i> , 2003, 199, 303-311.	1.0	17
740	Variants of human papillomavirus types 53, 58 and 66 identified in Central Brazil. <i>Virus Genes</i> , 2003, 26, 83-87.	0.7	16
741	Detection of Bone Sialoprotein in Human (Pre)neoplastic Lesions of the Uterine Cervix. <i>Calcified Tissue International</i> , 2003, 73, 9-14.	1.5	14
742	The detection of HPV DNA improves the recognition of cervical intraepithelial lesions. <i>Archives of Gynecology and Obstetrics</i> , 2003, 268, 29-34.	0.8	8
743	Esophageal cancer in Germany is associated with Epstein-Barr-virus but not with papillomaviruses. <i>Medical Microbiology and Immunology</i> , 2003, 192, 137-140.	2.6	36
744	Dendritic cell-based tumor vaccine for cervical cancer I: in vitro stimulation with recombinant protein-pulsed dendritic cells induces specific T cells to HPV16 E7 or HPV18 E7. <i>Journal of Cancer Research and Clinical Oncology</i> , 2003, 129, 511-520.	1.2	38
745	Economic evaluation of human papillomavirus screening in Germany. <i>European Journal of Health Economics</i> , 2003, 4, 209-215.	1.4	17
746	Folate, vitamin B12, and homocysteine status. <i>Nutrition</i> , 2003, 19, 497-502.	1.1	22
747	Genotyping of 22 human papillomavirus types by DNA chip in Korean women: Comparison with cytologic diagnosis. <i>American Journal of Obstetrics and Gynecology</i> , 2003, 188, 56-62.	0.7	86
748	Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance. <i>American Journal of Obstetrics and Gynecology</i> , 2003, 188, 1383-1392.	0.7	140
749	Serum antibody response to the heat shock protein 60 of <i>Chlamydia trachomatis</i> in women with developing cervical cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2003, 189, 1287-1292.	0.7	34
750	Toward a reduction of the global burden of cervical cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2003, 189, S37-S39.	0.7	18
751	Cancer Statistics for Hispanics, 2003. <i>Ca-A Cancer Journal for Clinicians</i> , 2003, 53, 208-226.	157.7	123
752	Relationship between HPV typing and abnormality of G1 cell cycle regulators in cervical neoplasm. <i>Gynecologic Oncology</i> , 2003, 91, 476-485.	0.6	49
753	A functional interferon regulatory factor-1 (IRF-1)-binding site in the upstream regulatory region (URR) of human papillomavirus type 16. <i>Virology</i> , 2003, 310, 280-286.	1.1	14
754	Human papillomavirus type 45 propagation, infection, and neutralization. <i>Virology</i> , 2003, 312, 1-7.	1.1	54
755	Suppression of human papillomavirus gene expression in vitro and in vivo by herpes simplex virus type 2 infection. <i>Virology</i> , 2003, 314, 147-160.	1.1	11

#	ARTICLE	IF	CITATIONS
756	Human papillomavirus type 59 immortalized keratinocytes express late viral proteins and infectious virus after calcium stimulation. <i>Virology</i> , 2003, 314, 562-571.	1.1	9
757	HPV oligonucleotide microarray-based detection of HPV genotypes in cervical neoplastic lesions. <i>Gynecologic Oncology</i> , 2003, 89, 210-217.	0.6	75
758	Induction of tumor-specific cytotoxicity in tumor infiltrating lymphocytes by HPV16 and HPV18 E7-pulsed autologous dendritic cells in patients with cancer of the uterine cervix. <i>Gynecologic Oncology</i> , 2003, 89, 271-280.	0.6	25
759	Measurement of Brn-3a levels in Pap smears provides a novel diagnostic marker for the detection of cervical neoplasia. <i>Gynecologic Oncology</i> , 2003, 90, 366-371.	0.6	12
760	Reduced Fhit expression in cervical carcinoma: correlation with tumor progression and poor prognosis. <i>Gynecologic Oncology</i> , 2003, 90, 331-337.	0.6	22
761	Association between high-risk human papillomavirus DNA load and precursor lesions of cervical cancer in Mexican women. <i>Gynecologic Oncology</i> , 2003, 90, 310-317.	0.6	57
762	Value of human papillomavirus testing after conization by loop electrosurgical excision for high-grade squamous intraepithelial lesions. <i>Gynecologic Oncology</i> , 2003, 90, 587-592.	0.6	82
763	HPV testing can reduce the number of follow-up visits in women treated for cervical intraepithelial neoplasia grade 3. <i>Gynecologic Oncology</i> , 2003, 91, 67-73.	0.6	63
764	New approaches for the management of cervical cancer. <i>Gynecologic Oncology</i> , 2003, 90, S22-S27.	0.6	35
765	DNA replicative functions of highly-expressed, codon-optimized human papillomavirus proteins E1 and E2. <i>Journal of Virological Methods</i> , 2003, 108, 83-90.	1.0	14
766	Correlation of cervical carcinoma and precancerous lesions with human papillomavirus (HPV) genotypes detected with the HPV DNA chip microarray method. <i>Cancer</i> , 2003, 97, 1672-1680.	2.0	118
767	The role of TP53 in Cervical carcinogenesis. <i>Human Mutation</i> , 2003, 21, 307-312.	1.1	146
768	Prevalence of human papillomavirus infection in women in Busan, South Korea. <i>International Journal of Cancer</i> , 2003, 103, 413-421.	2.3	116
769	Prevalence of specific types of human papillomavirus and cervical squamous intraepithelial lesions in consecutive, previously unscreened, West-African women over 35 years of age. <i>International Journal of Cancer</i> , 2003, 103, 803-809.	2.3	89
770	Mucosal immunoglobulin-A and -G responses to oncogenic human papilloma virus capsids. <i>International Journal of Cancer</i> , 2003, 104, 328-335.	2.3	25
771	Identification of a naturally processed HLA-A*0201 HPV18 E7 T cell epitope by tumor cell mediated in vitro vaccination. <i>International Journal of Cancer</i> , 2003, 104, 345-353.	2.3	18
772	Hypermethylation of the tumor suppressor gene RASSF1A and frequent concomitant loss of heterozygosity at 3p21 in cervical cancers. <i>International Journal of Cancer</i> , 2003, 105, 204-209.	2.3	65
773	Ectopic chromosome around centrosome in metaphase cells as a marker of high-risk human papillomavirus-associated cervical intraepithelial neoplasias. <i>International Journal of Cancer</i> , 2003, 106, 167-171.	2.3	13

#	ARTICLE	IF	CITATIONS
774	Persistence and load of high-risk HPV are predictors for development of high-grade cervical lesions: A longitudinal French cohort study. <i>International Journal of Cancer</i> , 2003, 106, 396-403.	2.3	351
775	Human papillomavirus type 16 E6 variants and HLA class II alleles among Japanese women with cervical cancer. <i>International Journal of Cancer</i> , 2003, 106, 919-922.	2.3	54
776	A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/18 vaccine. <i>International Journal of Cancer</i> , 2003, 106, 896-904.	2.3	159
777	Human papillomavirus type 16 and 18 L1 protein peptide binding to VERO and HeLa cells inhibits their VLPs binding. <i>International Journal of Cancer</i> , 2003, 107, 416-424.	2.3	13
778	Condom use promotes regression of cervical intraepithelial neoplasia and clearance of human papillomavirus: A randomized clinical trial. <i>International Journal of Cancer</i> , 2003, 107, 811-816.	2.3	171
779	Multiple-primer DNA sequencing method. <i>Electrophoresis</i> , 2003, 24, 1145-1151.	1.3	34
780	Decreased expression of human papillomavirus E2 protein and transforming growth factor- β 1 in human cervical neoplasia as an early marker in carcinogenesis. <i>Journal of Surgical Oncology</i> , 2003, 84, 17-23.	0.8	12
781	Human papillomavirus type-16 variants in Quechua aboriginals from Argentina. <i>Journal of Medical Virology</i> , 2003, 69, 546-552.	2.5	44
782	High prevalence of HPV 16 in South African women with cancer of the cervix and cervical intraepithelial neoplasia. <i>Journal of Medical Virology</i> , 2003, 71, 265-273.	2.5	42
783	Moderate variation of the oncogenic potential among high-risk human papillomavirus types in gynecologic patients with cervical abnormalities. <i>Journal of Medical Virology</i> , 2003, 71, 585-592.	2.5	9
784	Typing of human papillomavirus in Zimbabwean patients with invasive cancer of the uterine cervix. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2003, 82, 762-766.	1.3	34
785	Routine genotyping of human papillomavirus samples in Denmark. <i>Apmis</i> , 2003, 111, 398-404.	0.9	22
786	Detection of human papillomavirus type 16 in bowenoid papulosis and nonbowenoid tissues. <i>International Journal of Dermatology</i> , 2003, 42, 474-476.	0.5	9
787	Association of human papillomavirus viral load with HPV16 and high-grade intraepithelial lesion. <i>International Journal of Gynecological Cancer</i> , 2003, 13, 154-158.	1.2	21
788	The role of steroid contraceptive hormones in the pathogenesis of invasive cervical cancer: A review. <i>International Journal of Gynecological Cancer</i> , 2003, 13, 103-110.	1.2	57
789	Risk contribution of sexual behavior and cigarette smoking to cervical neoplasia. <i>International Journal of Gynecological Cancer</i> , 2003, 13, 617-625.	1.2	25
790	Human papillomavirus DNA in cervical lesions from Morocco and its implications for cancer control. <i>Clinical Microbiology and Infection</i> , 2003, 9, 144-148.	2.8	18
791	Lichen sclerosus is frequently present in penile squamous cell carcinomas but is not always associated with oncogenic human papillomavirus. <i>British Journal of Dermatology</i> , 2003, 148, 934-938.	1.4	88

#	ARTICLE	IF	CITATIONS
792	The presence of high-risk HPV combined with specific p53 and p16INK4a expression patterns points to high-risk HPV as the main causative agent for adenocarcinoma in situ and adenocarcinoma of the cervix. <i>Journal of Pathology</i> , 2003, 201, 535-543.	2.1	133
793	The interaction between steroid hormones, human papillomavirus type 16, E6 oncogene expression, and cervical cancer. <i>International Journal of Gynecological Cancer</i> , 2003, 13, 834-842.	1.2	11
794	Human Papillomavirus (HPV) Education in Middle and High Schools of Vermont. <i>Journal of School Health</i> , 2003, 73, 253-257.	0.8	18
795	Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. <i>British Journal of Cancer</i> , 2003, 88, 63-73.	2.9	1,288
796	Incidence and survival rate of women with cervical cancer in the Greater Amsterdam area. <i>British Journal of Cancer</i> , 2003, 89, 834-839.	2.9	54
797	Prevention of Cervical Cancer in Africa: A Daunting Task?. <i>African Journal of Reproductive Health</i> , 2003, 7, 7.	1.1	17
798	Comprehensive Evaluation of the Older Woman. <i>Mayo Clinic Proceedings</i> , 2003, 78, 1157-1185.	1.4	25
799	Clinical significance of serum human papillomavirus DNA in cervical carcinoma. <i>Obstetrics and Gynecology</i> , 2003, 102, 1344-1351.	1.2	8
800	Human Papillomavirus and Cervical Cancer. <i>Clinical Microbiology Reviews</i> , 2003, 16, 1-17.	5.7	1,764
801	Human Papillomaviruses: Are we Ready to Break Through?. <i>Biotechnology and Biotechnological Equipment</i> , 2003, 17, 9-16.	0.5	1
802	A review of paediatric oral biopsies in Turkey. <i>International Dental Journal</i> , 2003, 53, 26-32.	1.0	56
803	Long-term follow-up of patients treated with recombinant human interferon gamma for cervical intraepithelial neoplasia. <i>International Journal of Gynecology and Obstetrics</i> , 2003, 82, 179-185.	1.0	8
804	HPV testing and visual inspection for cervical cancer screening in resource-poor regions. <i>International Journal of Gynecology and Obstetrics</i> , 2003, 83, 311-313.	1.0	19
805	Human papillomavirus type 18 and rapidly progressing cervical intraepithelial neoplasia. <i>Lancet, The</i> , 2003, 361, 40-43.	6.3	64
806	Prevention of cervical cancer in resource-poor settings. <i>Lancet, The</i> , 2003, 361, 2160.	6.3	2
807	Cervical cancer. <i>Lancet, The</i> , 2003, 361, 2217-2225.	6.3	831
808	Multiple HPV infection in cervical cancer screened by HPV DNA chip. <i>Cancer Letters</i> , 2003, 198, 187-192.	3.2	70
809	Immunisation with modified HPV16 E7 genes against mouse oncogenic TC-1 cell sublines with downregulated expression of MHC class I molecules. <i>Vaccine</i> , 2003, 21, 1125-1136.	1.7	55

#	ARTICLE	IF	CITATIONS
810	Effect of vaccine delivery system on the induction of HPV16L1-specific humoral and cell-mediated immune responses in immunized rhesus macaques. <i>Vaccine</i> , 2003, 21, 1539-1547.	1.7	46
811	Enhanced tumour growth after DNA vaccination against human papilloma virus E7 oncoprotein: evidence for tumour-induced immune deviation. <i>Vaccine</i> , 2003, 21, 2506-2515.	1.7	8
812	Singularity in cancer causation: are breast and ovarian cancer each due to a single cause? Proposals for investigation. <i>Medical Hypotheses</i> , 2003, 60, 112-115.	0.8	1
813	TUMOR-ASSOCIATED ANTIGENS: FROM DISCOVERY TO IMMUNITY. <i>International Reviews of Immunology</i> , 2003, 22, 81-112.	1.5	42
814	Human papillomavirus-associated digital squamous cell carcinoma: Literature review and report of 21 new cases. <i>Journal of the American Academy of Dermatology</i> , 2003, 48, 385-393.	0.6	142
815	Ha-ras oncogene mutation associated to progression of papillomavirus induced lesions of uterine cervix. <i>Journal of Clinical Virology</i> , 2003, 27, 263-269.	1.6	27
816	Molecular detection of human papillomavirus in 594 uterine cervix samples from Moroccan women (147 biopsies and 447 swabs). <i>Journal of Clinical Virology</i> , 2003, 27, 286-295.	1.6	19
817	Anal cancer: an HIV-associated cancer. <i>Hematology/Oncology Clinics of North America</i> , 2003, 17, 859-872.	0.9	51
818	Relationship between HPV typing and abnormality of G1 cell cycle regulators in cervical neoplasm. <i>Gynecologic Oncology</i> , 2003, , .	0.6	0
819	Treatment of Cancer with Mushroom Products. <i>Archives of Environmental Health</i> , 2003, 58, 533-537.	0.4	46
820	Inclusion of HPV testing in routine cervical cancer screening for women above 29 years in Germany: results for 8466 patients. <i>British Journal of Cancer</i> , 2003, 88, 1570-1577.	2.9	258
821	In vitro and in vivo growth suppression of human papillomavirus 16-positive cervical cancer cells by e6 siRNA. <i>Molecular Therapy</i> , 2003, 8, 762-768.	3.7	171
823	Cervical Cancer Vaccines: Recent Advances in HPV Research. <i>Viral Immunology</i> , 2003, 16, 111-121.	0.6	62
824	Simultaneous Quantitation of Antibodies to Neutralizing Epitopes on Virus-Like Particles for Human Papillomavirus Types 6, 11, 16, and 18 by a Multiplexed Luminex Assay. <i>Vaccine Journal</i> , 2003, 10, 108-115.	3.2	245
825	Polymer-Based Enzyme-Linked Immunosorbent Assay Using Human Papillomavirus Type 16 (HPV16) Virus-Like Particles Detects HPV16 Clade-Specific Serologic Responses. <i>Journal of Clinical Microbiology</i> , 2003, 41, 2827-2834.	1.8	20
826	Cellular Immune Responses to Human Papillomavirus (HPV) 16 L1 in Healthy Volunteers Immunized with Recombinant HPV 16 L1 Virus-Like Particles. <i>Journal of Infectious Diseases</i> , 2003, 188, 327-338.	1.9	159
827	Increased Risk of High-Grade Cervical Squamous Intraepithelial Lesions and Invasive Cervical Cancer among African Women with Human Immunodeficiency Virus Type 1 and 2 Infections. <i>Journal of Infectious Diseases</i> , 2003, 188, 555-563.	1.9	154
828	Microbial keratitis. <i>British Journal of Ophthalmology</i> , 2003, 87, 805-806.	2.1	38

#	ARTICLE	IF	CITATIONS
829	Efficiency of the Hybrid Capture 2 HPV DNA Test in Cervical Cancer Screening. <i>American Journal of Clinical Pathology</i> , 2003, 120, 492-499.	0.4	65
830	Human papillomavirus type 6 virus-like particles present overlapping yet distinct conformational epitopes. <i>Journal of General Virology</i> , 2003, 84, 1493-1497.	1.3	9
831	Real-Time PCR-Based System for Simultaneous Quantification of Human Papillomavirus Types Associated with High Risk of Cervical Cancer. <i>Journal of Clinical Microbiology</i> , 2003, 41, 3221-3228.	1.8	103
832	RNA Interference of Human Papillomavirus Type 18 E6 and E7 Induces Senescence in HeLa Cells. <i>Journal of Virology</i> , 2003, 77, 6066-6069.	1.5	191
833	Interactions between Papillomavirus L1 and L2 Capsid Proteins. <i>Journal of Virology</i> , 2003, 77, 4818-4826.	1.5	123
834	Does human papillomavirus cause pterygium?. <i>British Journal of Ophthalmology</i> , 2003, 87, 806-808.	2.1	18
835	Responding to readers' and authors' needs. <i>British Journal of Ophthalmology</i> , 2003, 87, 808-808.	2.1	0
836	Oncogenic Human Papillomavirus DNA Loads in Human Immunodeficiency Virus-Positive Women with High-Grade Cervical Lesions Are Strongly Elevated. <i>Journal of Clinical Microbiology</i> , 2003, 41, 2763-2767.	1.8	66
837	Comparison between Prototype Hybrid Capture 3 and Hybrid Capture 2 Human Papillomavirus DNA Assays for Detection of High-Grade Cervical Intraepithelial Neoplasia and Cancer. <i>Journal of Clinical Microbiology</i> , 2003, 41, 4022-4030.	1.8	55
838	Population-Based Human Papillomavirus Prevalence in Lampang and Songkla, Thailand. <i>Journal of Infectious Diseases</i> , 2003, 187, 1246-1256.	1.9	130
839	Longitudinal Study of Cervical Squamous Intraepithelial Lesions in Human Immunodeficiency Virus (HIV)-Seropositive and At-Risk HIV-Seronegative Women. <i>Journal of Infectious Diseases</i> , 2003, 188, 128-136.	1.9	157
840	Type-Specific Detection of Human Papillomaviruses in a Routine Laboratory Setting – Improved Sensitivity and Specificity of PCR and Sequence Analysis Compared to Direct Hybridisation. <i>Clinical Chemistry and Laboratory Medicine</i> , 2003, 41, 787-91.	1.4	24
841	Adenovirus E1A, Not Human Papillomavirus E7, Sensitizes Tumor Cells to Lysis by Macrophages Through Nitric Oxide- and TNF-Dependent Mechanisms Despite Up-Regulation of 70-kDa Heat Shock Protein. <i>Journal of Immunology</i> , 2003, 170, 4119-4126.	0.4	18
842	Baseline Cytology, Human Papillomavirus Testing, and Risk for Cervical Neoplasia: A 10-Year Cohort Analysis. <i>Journal of the National Cancer Institute</i> , 2003, 95, 46-52.	3.0	386
843	Attitudes towards HPV testing: a qualitative study of beliefs among Indian, Pakistani, African-Caribbean and white British women in the UK. <i>British Journal of Cancer</i> , 2003, 88, 42-46.	2.9	114
844	Survival of cervix cancer patients in Kampala, Uganda: 1995–1997. <i>British Journal of Cancer</i> , 2003, 89, 65-69.	2.9	50
845	Boosting with recombinant vaccinia increases HPV-16 E7-Specific T cell precursor frequencies and antitumor effects of HPV-16 E7-Expressing sindbis virus replicon particles. <i>Molecular Therapy</i> , 2003, 8, 559-566.	3.7	43
846	Seroprevalence of human papillomavirus-16, -18, -31, and -45 in a population-based cohort of 10,000 women in Costa Rica. <i>British Journal of Cancer</i> , 2003, 89, 1248-1254.	2.9	116

#	ARTICLE	IF	CITATIONS
847	Ki-67 immunocytochemistry in liquid based cervical cytology: useful as an adjunctive tool?. <i>Journal of Clinical Pathology</i> , 2003, 56, 681-686.	1.0	36
848	Production of Human Papillomavirus Type 16 Virus-Like Particles in Transgenic Plants. <i>Journal of Virology</i> , 2003, 77, 9211-9220.	1.5	176
849	Mucosal IgG and IgA Responses to Human Papillomavirus Type 16 Capsid Proteins in HPV16-Infected Women without Visible Pathology. <i>Viral Immunology</i> , 2003, 16, 159-168.	0.6	15
850	An adenoviral vector cancer vaccine that delivers a tumor-associated antigen/CD40-ligand fusion protein to dendritic cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 15101-15106.	3.3	68
851	Human Papillomavirus Type 16 and Immune Status in Human Immunodeficiency Virus-Seropositive Women. <i>Journal of the National Cancer Institute</i> , 2003, 95, 1062-1071.	3.0	204
852	Cervical human papillomavirus infections in commercial sex workers—risk factors and behaviours. <i>International Journal of STD and AIDS</i> , 2003, 14, 840-847.	0.5	26
853	Epidemiologic correlates of antibody response to human papillomavirus among women at low risk of cervical cancer. <i>International Journal of STD and AIDS</i> , 2003, 14, 258-265.	0.5	24
854	Denaturing High-Performance Liquid Chromatography for Detecting and Typing Genital Human Papillomavirus. <i>Journal of Clinical Microbiology</i> , 2003, 41, 5563-5571.	1.8	10
855	Potential Health and Economic Impact of Adding a Human Papillomavirus Vaccine to Screening Programs. <i>JAMA - Journal of the American Medical Association</i> , 2003, 290, 781.	3.8	288
856	Chapter 16: Prophylactic Human Papillomavirus Vaccines. <i>Journal of the National Cancer Institute Monographs</i> , 2003, 2003, 111-116.	0.9	54
857	Clinical Significance of Serum Human Papillomavirus DNA in Cervical Carcinoma. <i>Obstetrics and Gynecology</i> , 2003, 102, 1344-1351.	1.2	7
858	Chapter 12: Human Papillomavirus Technologies. <i>Journal of the National Cancer Institute Monographs</i> , 2003, 2003, 80-88.	0.9	173
859	<i>Chlamydia trachomatis</i> , Herpes Simplex Virus 2, and Human T-Cell Lymphotropic Virus Type 1 Are Not Associated With Grade of Cervical Neoplasia in Jamaican Colposcopy Patients. <i>Sexually Transmitted Diseases</i> , 2003, 30, 575-580.	0.8	34
860	The value of HPV DNA typing in the distinction between adenocarcinoma of endocervical and endometrial origin. <i>Pathology</i> , 2003, 35, 397-401.	0.3	18
861	CERVICAL CYTOLOGICAL SCREENING AND HUMAN PAPILLOMAVIRUS DNA TESTING IN FLANDERS. <i>Acta Clinica Belgica</i> , 2003, 58, 211-219.	0.5	8
862	Genital Human Papillomavirus Genotypes in Northwestern Tanzania. <i>Journal of Clinical Microbiology</i> , 2003, 41, 4451-4453.	1.8	22
863	Chapter 4: Genital Tract Infections, Cervical Inflammation, and Antioxidant Nutrients—Assessing Their Roles as Human Papillomavirus Cofactors. <i>Journal of the National Cancer Institute Monographs</i> , 2003, 2003, 29-34.	0.9	144
864	Chapter 1: Human Papillomavirus and Cervical Cancer—Burden and Assessment of Causality. <i>Journal of the National Cancer Institute Monographs</i> , 2003, 2003, 3-13.	0.9	675

#	ARTICLE	IF	CITATIONS
865	The Epidemiology of Cervical Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2003, 9, 348-359.	1.0	196
866	Development of HPV Vaccines for HPV-associated Head and Neck Squamous Cell Carcinoma. <i>Critical Reviews in Oral Biology and Medicine</i> , 2003, 14, 345-362.	4.4	62
867	Chapter 2: Natural History of Anogenital Human Papillomavirus Infection and Neoplasia. <i>Journal of the National Cancer Institute Monographs</i> , 2003, 2003, 14-19.	0.9	383
868	Occurrence of Cervical Infection with Multiple Human Papillomavirus Types is Associated with Age and Cytologic Abnormalities. <i>Sexually Transmitted Diseases</i> , 2003, 30, 581-587.	0.8	70
869	Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance. <i>American Journal of Obstetrics and Gynecology</i> , 2003, 188, 1383-1392.	0.7	542
870	ASC-US and HPV Testing. <i>American Journal of Nursing</i> , 2003, 103, 42-50.	0.2	1
871	American Cancer Society Guideline for the Early Detection of Cervical Neoplasia and Cancer. <i>Journal of Lower Genital Tract Disease</i> , 2003, 7, 67-86.	0.9	41
872	Topical Imiquimod 5% Cream as an Effective Treatment for External Genital and Perianal Warts in Different Patient Populations. <i>Sexually Transmitted Diseases</i> , 2003, 30, 124-128.	0.8	58
873	Distribution of Human Papillomavirus in a Family Planning Population in Nairobi, Kenya. <i>Sexually Transmitted Diseases</i> , 2003, 30, 137-142.	0.8	78
874	The Clinical Significance of HPV. <i>Nurse Practitioner</i> , 2003, 28, 8-19.	0.2	8
875	Evidence for the Association of Human Papillomavirus Infection and Cutaneous Squamous Cell Carcinoma in Immunocompetent Individuals. <i>Archives of Dermatology</i> , 2003, 139, 890-4.	1.7	109
876	The Role of Responsibility in Gynecological Oncology. <i>Linacre quarterly, The</i> , 2003, 70, 183-194.	0.1	0
877	The role of steroid contraceptive hormones in the pathogenesis of invasive cervical cancer: A review. <i>International Journal of Gynecological Cancer</i> , 2003, 13, 103-110.	1.2	61
878	Epidemiology of human papillomavirus infections: new options for cervical cancer prevention. <i>Salud Publica De Mexico</i> , 2003, 45, S326-39.	0.1	14
879	Incidence and mortality of cervical cancer in Latin America. <i>Salud Publica De Mexico</i> , 2003, 45, S306-14.	0.1	72
880	HPV DNA vaccines. <i>Frontiers in Bioscience - Landmark</i> , 2003, 8, d55-68.	3.0	30
881	Human papillomavirus prevalence among women with cervical intraepithelial neoplasia III and invasive cervical cancer from Goi�nia, Brazil. <i>Memorias Do Instituto Oswaldo Cruz</i> , 2003, 98, 181-184.	0.8	51
882	Ricerca di HPV-DNA e tipizzazione virale nella diagnostica di prevenzione del carcinoma della cervice uterina. <i>Microbiologia Medica</i> , 2003, 18, .	0.3	2

#	ARTICLE	IF	CITATIONS
883	Cost Effectiveness of a Potential Vaccine for Human papillomavirus. <i>Emerging Infectious Diseases</i> , 2003, 9, 37-48.	2.0	273
884	Prevalence of human papillomavirus types in women with pre-neoplastic and neoplastic cervical lesions in the Federal District of Brazil. <i>Memorias Do Instituto Oswaldo Cruz</i> , 2003, 98, 879-883.	0.8	44
885	Tipificación del virus papiloma humano (VPH) en lesiones preneoplásicas y carcinoma del cuello uterino en mujeres de la IX Región-Chile. <i>Revista Medica De Chile</i> , 2003, 131, 1382.	0.1	12
886	Defining reproductive tract infections and other gynaecological morbidities. , 0, , 11-29.		2
888	Correlation between histological criteria and human papillomavirus presence based on PCR assay in cervical biopsies. <i>International Journal of Gynecological Cancer</i> , 2004, 14, 126-132.	1.2	2
889	Double Cervix with Bilateral and Synchronous HSIL Associated with Different High-Risk HPV Types. <i>Acta Cytologica</i> , 2004, 48, 273-277.	0.7	5
890	Quantification of human papillomavirus DNA in the plasma of patients with cervical cancer. <i>International Journal of Gynecological Cancer</i> , 2004, 14, 903-910.	1.2	20
891	The exploding worldwide cancer burden. <i>International Journal of Gynecological Cancer</i> , 2004, 14, 1-11.	1.2	2
892	Screening, Diagnosis, and Staging of Cervical Cancer. , 2004, , 31-45.		3
893	Prevalence of human papillomavirus type 16 variants in the Federal District, Central Brazil. <i>Memorias Do Instituto Oswaldo Cruz</i> , 2004, 99, 281-282.	0.8	17
895	Relation between HPV-DNA and expression of p53, bcl-2, p21WAF-1, MIB-1, HER-2/neu and DNA ploidy in early cervical carcinoma: Correlation with clinical outcome. <i>Oncology Reports</i> , 2004, 12, 169-76.	1.2	10
896	Evaluating Human Papillomavirus Vaccination Programs. <i>Emerging Infectious Diseases</i> , 2004, 10, 1915-1923.	2.0	327
897	Gynecologists' Attitudes Regarding Human Papilloma Virus Vaccination: A Survey of Fellows of the American College of Obstetricians and Gynecologists. <i>Infectious Diseases in Obstetrics and Gynecology</i> , 2004, 12, 127-133.	0.4	106
899	High-Risk Papillomavirus Infection Is Associated with Altered Antibody Responses in Genital Tract: Non-specific Responses in HPV Infection. <i>Viral Immunology</i> , 2004, 17, 381-389.	0.6	17
900	HPV Testing for Triage of HIV-Infected Women with Papanicolaou Smears Read as Atypical Squamous Cells of Uncertain Significance. <i>Journal of Women's Health</i> , 2004, 13, 147-153.	1.5	20
902	Detection of antibodies against a human papillomavirus (HPV) type 16 peptide that differentiate high-risk from low-risk HPV-associated low-grade squamous intraepithelial lesions. <i>Journal of General Virology</i> , 2004, 85, 2643-2650.	1.3	21
903	Conserved Methylation Patterns of Human Papillomavirus Type 16 DNA in Asymptomatic Infection and Cervical Neoplasia. <i>Journal of Virology</i> , 2004, 78, 12762-12772.	1.5	165
904	Barriers to HIV testing: a survey of GUM clinic attendees. <i>Sexually Transmitted Infections</i> , 2004, 80, 247-248.	0.8	8

#	ARTICLE	IF	CITATIONS
905	Seroepidemiology of Infection with Human Papillomavirus 16, in Men and Women Attending Sexually Transmitted Disease Clinics in the United States. <i>Journal of Infectious Diseases</i> , 2004, 190, 1563-1574.	1.9	49
906	Virologic Versus Cytologic Triage of Women With Equivocal Pap Smears: A Meta-analysis of the Accuracy To Detect High-Grade Intraepithelial Neoplasia. <i>Journal of the National Cancer Institute</i> , 2004, 96, 280-293.	3.0	338
907	Spontaneous Regression of Grade 3 Vulvar Intraepithelial Neoplasia Associated with Human Papillomavirus-16-Specific CD4+ and CD8+ T-Cell Responses. <i>Cancer Research</i> , 2004, 64, 8761-8766.	0.4	56
908	Method for Testing for Human Papillomavirus Infection in Patients with Cervical Intraepithelial Disease. <i>Journal of Clinical Microbiology</i> , 2004, 42, 366-368.	1.8	5
909	Factors that may increase HIV testing uptake in those who decline to test. <i>Sexually Transmitted Infections</i> , 2004, 80, 249-249.	0.8	7
910	Codetection of a Mixed Population of HPV62 Containing Wild-Type and Disrupted E1 Open Reading Frame in a 45-Year-Old Woman with Normal Cytology. <i>Journal of Infectious Diseases</i> , 2004, 190, 1303-1309.	1.9	5
911	E6 and E7 Oncoproteins Induce Distinct Patterns of Chromosomal Aneuploidy in Skin Tumors from Transgenic Mice. <i>Cancer Research</i> , 2004, 64, 538-546.	0.4	50
912	Acquisition of High-Level Chromosomal Instability Is Associated with Integration of Human Papillomavirus Type 16 in Cervical Keratinocytes. <i>Cancer Research</i> , 2004, 64, 1359-1368.	0.4	170
913	Diagnosis and exclusion of gonorrhoea in women. <i>Sexually Transmitted Infections</i> , 2004, 80, 247-247.	0.8	2
914	A Population-Based Study of Vaginal Human Papillomavirus Infection in Hysterectomized Women. <i>Journal of Infectious Diseases</i> , 2004, 190, 458-467.	1.9	72
915	Expression of an E1A/E7 Chimeric Protein Sensitizes Tumor Cells to Killing by Activated Macrophages but Not NK Cells. <i>Journal of Virology</i> , 2004, 78, 4646-4654.	1.5	8
916	Anal Intraepithelial Neoplasia in Heterosexual and Homosexual HIV-Positive Men with Access to Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2004, 190, 1685-1691.	1.9	107
917	Increased Frequency of Bacterial Vaginosis and <i>Chlamydia trachomatis</i> in Pregnant Women with Human Papillomavirus Infection. <i>Gynecologic and Obstetric Investigation</i> , 2004, 58, 189-193.	0.7	39
918	Interlaboratory Reliability of Hybrid Capture 2. <i>American Journal of Clinical Pathology</i> , 2004, 122, 238-245.	0.4	99
919	The X-ray structure of the papillomavirus helicase in complex with its molecular matchmaker E2. <i>Genes and Development</i> , 2004, 18, 1981-1996.	2.7	145
920	Evaluation of Genital Sites and Sampling Techniques for Detection of Human Papillomavirus DNA in Men. <i>Journal of Infectious Diseases</i> , 2004, 189, 677-685.	1.9	218
921	Human Papillomavirus and Extragenital in situ Carcinoma. <i>Dermatology</i> , 2004, 209, 40-45.	0.9	25
922	Elevated Amount of Human Papillomavirus 31 DNA in a Squamous Cell Carcinoma Developed from Bowenoid Papulosis. <i>Dermatology</i> , 2004, 209, 329-332.	0.9	13

#	ARTICLE	IF	CITATIONS
923	Intracellular Expression Patterns of the Human Papillomavirus Type 59 E1 ^{E4} Protein in COS Cells, Keratinocytes, and Genital Epithelium. <i>Intervirolology</i> , 2004, 47, 321-327.	1.2	4
925	Single-chain antibodies: A therapeutic modality for cancer gene therapy (Review). <i>International Journal of Oncology</i> , 2004, 24, 765.	1.4	5
926	Association of HPV infection with prognosis after neoadjuvant chemotherapy in advanced uterine cervical cancer. <i>International Journal of Molecular Medicine</i> , 2004, 14, 101.	1.8	8
927	Chaperoning in GUM clinics. <i>Sexually Transmitted Infections</i> , 2004, 80, 250-250.	0.8	3
928	Delivery of Granulocyte-Macrophage Colony-Stimulating Factor in Bioadhesive Hydrogel Stimulates Migration of Dendritic Cells in Models of Human Papillomavirus-Associated (Pre)Neoplastic Epithelial Lesions. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 4342-4348.	1.4	11
929	Disease-Stage Variance in Functional CD4 ⁺ T-Cell Responses Against Novel Pan-Human Leukocyte Antigen-D Region Presented Human Papillomavirus-16 E7 Epitopes. <i>Clinical Cancer Research</i> , 2004, 10, 3301-3308.	3.2	29
930	Human papillomavirus (HPV) study of 2916 cytological samples by PCR and DNA sequencing: genotype spectrum of patients from the west German area. <i>Journal of Medical Microbiology</i> , 2004, 53, 125-128.	0.7	70
931	Distribution of human papillomavirus type 16 variants in human immunodeficiency virus type 1-positive and -negative women. <i>Journal of General Virology</i> , 2004, 85, 1237-1241.	1.3	18
932	Detection and Typing of Human Papillomavirus by E6 Nested Multiplex PCR. <i>Journal of Clinical Microbiology</i> , 2004, 42, 3176-3184.	1.8	266
933	Human papillomavirus oncogenic expression in the dysplastic portio; an investigation of biopsies from 190 cervical cones. <i>British Journal of Cancer</i> , 2004, 90, 1407-1413.	2.9	61
934	Human papillomavirus vaccine as a new way of preventing cervical cancer: a dream or the future?. <i>Annals of Oncology</i> , 2004, 15, 197-200.	0.6	23
935	Genomic imbalances in 70 snap-frozen cervical squamous intraepithelial lesions: associations with lesion grade, state of the HPV16 E2 gene and clinical outcome. <i>British Journal of Cancer</i> , 2004, 91, 2063-2070.	2.9	38
936	Human Papillomavirus Genotyping by the DNA Chip in the Cervical Neoplasia. <i>DNA and Cell Biology</i> , 2004, 23, 119-125.	0.9	27
937	Human Papillomavirus in Oral Exfoliated Cells and Risk of Head and Neck Cancer. <i>Journal of the National Cancer Institute</i> , 2004, 96, 449-455.	3.0	250
939	HPV in cervix and vagina. <i>Sexually Transmitted Infections</i> , 2004, 80, 249-250.	0.8	7
940	Induction of immune responses against human papillomaviruses by hypervariable epitope constructs. <i>Immunology</i> , 2004, 112, 321-327.	2.0	8
941	CEU Role of Human Papilloma Virus Testing in Cervical Cancer Prevention. <i>Journal of Midwifery and Women's Health</i> , 2004, 49, 4-13.	0.7	2
942	Correlation between histological criteria and human papillomavirus presence based on PCR assay in cervical biopsies. <i>International Journal of Gynecological Cancer</i> , 2004, 14, 126-132.	1.2	14

#	ARTICLE	IF	CITATIONS
943	Are Muslim women less susceptible to oncogenic human papillomavirus infection? A study from rural eastern India. <i>International Journal of Gynecological Cancer</i> , 2004, 14, 293-303.	1.2	27
944	HPV-DNA, vascular space invasion, and their impact on the clinical outcome in early-stage cervical carcinomas. <i>International Journal of Gynecological Cancer</i> , 2004, 14, 896-902.	1.2	30
945	Quantification of human papillomavirus DNA in the plasma of patients with cervical cancer. <i>International Journal of Gynecological Cancer</i> , 2004, 14, 903-910.	1.2	47
946	The exploding worldwide cancer burden: the impact of cancer on women*. <i>International Journal of Gynecological Cancer</i> , 2004, 14, 1-11.	1.2	66
947	Human papillomavirus genotyping by a polymerase chain reaction-based genechip method in cervical carcinoma treated with neoadjuvant chemotherapy plus radical surgery. <i>International Journal of Gynecological Cancer</i> , 2004, 14, 639-649.	1.2	57
948	Estrogen receptor, progesterone receptor, and bcl-2 are markers with prognostic significance in CIN III. <i>International Journal of Gynecological Cancer</i> , 2004, 14, 911-920.	1.2	20
949	SOC1 inhibits HPV-E7-mediated transformation by inducing degradation of E7 protein. <i>Oncogene</i> , 2004, 23, 3107-3115.	2.6	67
950	Viruses, chemicals and co-carcinogenesis. <i>Oncogene</i> , 2004, 23, 6492-6499.	2.6	44
951	Negative human papillomavirus testing in normal smears selects a population at low risk for developing high-grade cervical lesions. <i>British Journal of Cancer</i> , 2004, 90, 1803-1808.	2.9	67
952	Comparison of human papillomavirus genotypes in high-grade squamous intraepithelial lesions and invasive cervical carcinoma: evidence for differences in biologic potential of precursor lesions. <i>Modern Pathology</i> , 2004, 17, 1314-1322.	2.9	40
953	Interactive video behavioral intervention to reduce adolescent females' STD risk: a randomized controlled trial. <i>Social Science and Medicine</i> , 2004, 59, 1561-1572.	1.8	166
954	Effect of folic acid fortification of foods on folate intake in female smokers with cervical dysplasia. <i>Nutrition</i> , 2004, 20, 409-414.	1.1	9
955	Role of human papilloma virus testing in cervical cancer prevention*1. <i>Journal of Midwifery and Women's Health</i> , 2004, 49, 4-13.	0.7	14
956	Flow cytometric quantitation of the protective efficacy of dendritic cell based vaccines in a human papillomavirus type 16 murine challenge model. <i>Journal of Virological Methods</i> , 2004, 117, 9-18.	1.0	3
957	Restriction fragment length polymorphism of L1 amplicon using Rsa 1 detects five different human papillomavirus types and their co-infections among women attending a gynaecological outpatient department. <i>Journal of Virological Methods</i> , 2004, 117, 91-95.	1.0	15
958	Recurrent Respiratory Papillomatosis: A Longitudinal Study Comparing Severity Associated With Human Papilloma Viral Types 6 and 11 and Other Risk Factors in a Large Pediatric Population. <i>Laryngoscope</i> , 2004, 114, 1-23.	1.1	233
959	Genomic diversity of human papillomavirus-16, 18, 31, and 35 isolates in a Mexican population and relationship to European, African, and Native American variants. <i>Virology</i> , 2004, 319, 315-323.	1.1	81
960	Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. <i>Virology</i> , 2004, 321, 205-216.	1.1	325

#	ARTICLE	IF	CITATIONS
961	Propagation, infection, and neutralization of authentic HPV16 virus. <i>Virology</i> , 2004, 322, 213-219.	1.1	54
962	Human papillomavirus genomes in squamous cell carcinomas of the uterine cervix. <i>Virology</i> , 2004, 324, 439-449.	1.1	23
963	The human papillomavirus-18 genome is efficiently targeted by cellular DNA methylation. <i>Virology</i> , 2004, 324, 483-492.	1.1	88
964	TNF α polymorphism frequencies in HPV-associated cervical dysplasia. <i>Gynecologic Oncology</i> , 2004, 92, 675-679.	0.6	52
965	Physical state and expression of HPV DNA in benign and dysplastic cervical tissue: different levels of viral integration are correlated with lesion grade. <i>Gynecologic Oncology</i> , 2004, 92, 873-880.	0.6	165
966	Transcriptional activation of H- and N-ras oncogenes in human cervical cancer. <i>Gynecologic Oncology</i> , 2004, 92, 941-948.	0.6	32
967	Prognostic significance of lymph node variables and human papillomavirus DNA in invasive vulvar carcinoma. <i>Gynecologic Oncology</i> , 2004, 92, 856-865.	0.6	75
968	Prevalence of single and multiple HPV types in cervical carcinomas in Jakarta, Indonesia. <i>Gynecologic Oncology</i> , 2004, 93, 49-53.	0.6	63
969	A phase II trial of interleukin-12 in patients with advanced cervical cancer: clinical and immunologic correlates. <i>Gynecologic Oncology</i> , 2004, 92, 957-964.	0.6	52
970	Detection of hypermethylated genes in tumor and plasma of cervical cancer patients. <i>Gynecologic Oncology</i> , 2004, 93, 435-440.	0.6	80
971	A population-based study of cervical carcinoma and HPV infection in Latvia. <i>Gynecologic Oncology</i> , 2004, 93, 484-492.	0.6	24
972	Dominant human papillomavirus 16 infection in cervical neoplasia in young Japanese women; study of 881 outpatients. <i>Gynecologic Oncology</i> , 2004, 94, 509-514.	0.6	22
973	Comparative analysis of characteristics of women with cervical cancer in high- versus low-incidence regions. <i>Gynecologic Oncology</i> , 2004, 94, 803-810.	0.6	35
974	E2 sequence variations of HPV 16 among patients with cervical neoplasia seen in the Indian subcontinent. <i>Gynecologic Oncology</i> , 2004, 95, 363-369.	0.6	15
975	Characterization of HPV16 L1 loop domains in the formation of a type-specific, conformational epitope. <i>BMC Microbiology</i> , 2004, 4, 29.	1.3	25
976	Chromosomal amplifications, 3q gain and deletions of 2q33-q37 are the frequent genetic changes in cervical carcinoma. <i>BMC Cancer</i> , 2004, 4, 5.	1.1	109
977	Chemoprevention of Cancer. <i>Ca-A Cancer Journal for Clinicians</i> , 2004, 54, 150-180.	157.7	275
978	Interleukin-2 (IL-2) receptor- γ signalling is activated by c-Kit in the absence of IL-2, or by exogenous IL-2 via JAK3/STAT5 in human papillomavirus-associated cervical cancer. <i>Cellular Signalling</i> , 2004, 16, 1239-1247.	1.7	28

#	ARTICLE	IF	CITATIONS
979	P16 as a molecular biomarker of cervical adenocarcinoma. American Journal of Obstetrics and Gynecology, 2004, 190, 668-673.	0.7	49
980	Comparative study of MMP-2 (matrix metalloproteinase 2) immune expression in normal uterine cervix, intraepithelial neoplasias, and squamous cells cervical carcinoma. American Journal of Obstetrics and Gynecology, 2004, 190, 1278-1282.	0.7	34
981	The health care costs of cervical human papillomavirus-related disease. American Journal of Obstetrics and Gynecology, 2004, 191, 114-120.	0.7	118
982	Diagnoses and outcomes in cervical cancer screening: A population-based study. American Journal of Obstetrics and Gynecology, 2004, 191, 105-113.	0.7	218
983	Hybrid capture 2 viral load and the 2-year cumulative risk of cervical intraepithelial neoplasia grade 3 or cancer. American Journal of Obstetrics and Gynecology, 2004, 191, 1590-1597.	0.7	31
984	Persistence of human papillomavirus infection as a predictor for recurrence in carcinoma of the cervix after radiotherapy. American Journal of Obstetrics and Gynecology, 2004, 191, 1907-1913.	0.7	35
985	Human papillomavirus and cervical cancer: Issues for biobehavioral and psychosocial research. Annals of Behavioral Medicine, 2004, 27, 68-79.	1.7	60
986	The current management of cervical cancer. The Obstetrician and Gynaecologist, 2004, 6, 196-202.	0.2	3
987	Cancer in Jews: introduction and overview. Familial Cancer, 2004, 3, 177-192.	0.9	24
989	Cervical cancer screening. Current Oncology Reports, 2004, 6, 497-506.	1.8	14
990	Epidemiological and clinical aspects of human papillomavirus detection in the prevention of cervical cancer. Reviews in Medical Virology, 2004, 14, 95-105.	3.9	74
991	Cancer of the Uterine Cervix. BMC Women's Health, 2004, 4, S13.	0.8	32
992	Increased prevalence of squamous intraepithelial lesions in systemic lupus erythematosus: Association with human papillomavirus infection. Arthritis and Rheumatism, 2004, 50, 3619-3625.	6.7	145
993	Human papillomavirus-31-related types predict better survival in cervical carcinoma. Cancer, 2004, 100, 327-334.	2.0	34
994	Human papillomavirus infections. Cancer, 2004, 100, 225-227.	2.0	10
995	Immunocytochemical staining of p16INK4a protein from conventional Pap test and its association with human papillomavirus infection. Diagnostic Cytopathology, 2004, 31, 235-242.	0.5	28
996	P16INK4a as an adjunct marker in liquid-based cervical cytology. International Journal of Cancer, 2004, 108, 871-876.	2.3	69
997	Age, sexual behavior and human papillomavirus infection in oral cavity and oropharyngeal cancers. International Journal of Cancer, 2004, 108, 766-772.	2.3	418

#	ARTICLE	IF	CITATIONS
998	Human papillomavirus (HPV) type 16-specific CD8+ T cell responses in women with high grade vulvar intraepithelial neoplasia. <i>International Journal of Cancer</i> , 2004, 108, 857-862.	2.3	17
999	Association between war and cervical cancer among Vietnamese women. <i>International Journal of Cancer</i> , 2004, 110, 775-777.	2.3	16
1000	Against which human papillomavirus types shall we vaccinate and screen? the international perspective. <i>International Journal of Cancer</i> , 2004, 111, 278-285.	2.3	912
1001	Type-specific associations of human papillomavirus load with risk of developing cervical carcinoma in situ. <i>International Journal of Cancer</i> , 2004, 112, 854-859.	2.3	103
1002	Human papillomavirus type specific DNA and RNA persistence? implications for cervical disease progression and monitoring. <i>Journal of Medical Virology</i> , 2004, 73, 65-70.	2.5	136
1003	Detection of high-risk human papillomavirus E6 and E7 oncogene transcripts in cervical scrapes by nested RT-polymerase chain reaction. <i>Journal of Medical Virology</i> , 2004, 74, 107-116.	2.5	110
1004	Expression of hypoxic-inducible factor 1 α predicts metastasis-free survival after radiation therapy alone in stage IIIB cervical squamous cell carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 60, 513-521.	0.4	67
1005	High-throughput polymerase chain reaction chemiluminescent enzyme immunoassay for typing and quantifying human papillomavirus DNAs. <i>Analytical Biochemistry</i> , 2004, 332, 349-357.	1.1	5
1006	Peptide-based vaccines for cancer immunotherapy. <i>Expert Opinion on Biological Therapy</i> , 2004, 4, 181-198.	1.4	47
1007	Human papillomavirus cervical infection in Guarani Indians from the rainforest of Misiones, Argentina. <i>International Journal of Infectious Diseases</i> , 2004, 8, 13-19.	1.5	20
1008	Low-density addressable array for the detection and typing of the human papillomavirus. <i>Diagnostic Microbiology and Infectious Disease</i> , 2004, 48, 23-31.	0.8	15
1009	Sexual health issues after lung transplantation: importance of cervical screening. <i>Journal of Heart and Lung Transplantation</i> , 2004, 23, 894-897.	0.3	42
1010	Genetic polymorphisms of p73 G4C14-to-A4T14 at exon 2 and p53 Arg72Pro and the risk of cervical cancer in Japanese. <i>Cancer Letters</i> , 2004, 205, 55-60.	3.2	49
1011	HPV18 E6 and E7 genes affect cell cycle, pRB and p53 of cervical tumor cells and represent prominent candidates for intervention by use peptide nucleic acids (PNAs). <i>Cancer Letters</i> , 2004, 209, 37-49.	3.2	21
1012	Detection of cervical precancer and cancer in a hospital population. <i>European Journal of Cancer</i> , 2004, 40, 1225-1232.	1.3	33
1013	Correlates of underutilization of gynecological cancer screening among lesbian and heterosexual women. <i>Preventive Medicine</i> , 2004, 38, 105-113.	1.6	97
1014	Low prevalence of HPV infection and its natural history in normal oral mucosa among volunteers on Miyako Island, Japan. <i>Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics</i> , 2004, 98, 91-96.	1.6	63
1015	Differential antibody responses to a distinct region of human papillomavirus minor capsid proteins. <i>Vaccine</i> , 2004, 22, 670-680.	1.7	18

#	ARTICLE	IF	CITATIONS
1016	Dose-ranging studies of the safety and immunogenicity of human papillomavirus Type 11 and Type 16 virus-like particle candidate vaccines in young healthy women. <i>Vaccine</i> , 2004, 22, 2943-2952.	1.7	89
1017	Early assessment of the efficacy of a human papillomavirus type 16 L1 virus-like particle vaccine. <i>Vaccine</i> , 2004, 22, 2936-2942.	1.7	77
1018	High risk HPV load estimated by Hybrid Capture II [®] correlates with HPV16 load measured by real-time PCR in cervical smears of HPV16-infected women. <i>Journal of Clinical Virology</i> , 2004, 31, 140-147.	1.6	41
1019	The c-myc activation in cervical carcinomas and HPV 16 infections. <i>Mutation Research - Genetic Toxicology and Environmental Mutagenesis</i> , 2004, 557, 151-158.	0.9	45
1020	Vaccination to prevent and treat cervical cancer. <i>Human Pathology</i> , 2004, 35, 971-982.	1.1	102
1021	Increased secretion patterns of interleukin-10 and tumor necrosis factor-alpha in cervical squamous intraepithelial lesions. <i>Human Pathology</i> , 2004, 35, 1376-1384.	1.1	62
1022	Human Papillomavirus Deoxyribonucleic Acid Sequences and Clinical Outcomes of Cervical Cancer Patients Following Radiotherapy. <i>Taiwanese Journal of Obstetrics and Gynecology</i> , 2004, 43, 20-24.	0.5	1
1023	Molecular variants of HPV type 16 E6 among Mexican women with LSIL and invasive cancer. <i>Journal of Clinical Virology</i> , 2004, 29, 95-98.	1.6	35
1024	High prevalence of human papillomavirus type 58 in Mexican colposcopy patients. <i>Journal of Clinical Virology</i> , 2004, 29, 203-206.	1.6	44
1025	Multiple HPV genotypes in cervical carcinomas: improved DNA detection and typing in archival tissues. <i>Journal of Clinical Virology</i> , 2004, 29, 271-276.	1.6	53
1026	IL-10 Promoter nt - 1082A/G Polymorphism and Human Papillomavirus Infection in Cytologic Abnormalities of the Uterine Cervix. <i>Journal of Interferon and Cytokine Research</i> , 2004, 24, 245-251.	0.5	15
1027	Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. <i>Lancet, The</i> , 2004, 364, 1757-1765.	6.3	1,435
1028	Concordance of Prevalence of Human Papillomavirus DNA in Anogenital and Oral Infections in a High-Risk Population. <i>Journal of Clinical Microbiology</i> , 2004, 42, 1330-1332.	1.8	84
1029	Human Papillomavirus-32-Positive Extragenital Bowenoid Papulosis (BP) in a HIV Patient With Typical Genital BP Localization. <i>Sexually Transmitted Diseases</i> , 2004, 31, 619-622.	0.8	17
1030	Human papillomaviruses and cancer in Uganda. <i>European Journal of Cancer Prevention</i> , 2004, 13, 113-118.	0.6	24
1031	Human papillomavirus and cervical cytology in adolescents. <i>Adolescent Medicine Clinics</i> , 2004, 15, 301-321.	0.8	20
1032	Abnormal Vaginal Cytology in HIV-Infected and At-Risk Women After Hysterectomy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2004, 35, 484-491.	0.9	14
1033	Beyond Human Papillomavirus: The Cervix, Exogenous Secondary Factors, and the Development of Cervical Precancer and Cancer. <i>Journal of Lower Genital Tract Disease</i> , 2004, 8, 224-230.	0.9	32

#	ARTICLE	IF	CITATIONS
1034	Evidence-Based Screening and Management Guidelines Address the Realistic Concerns of Practicing Clinicians and Pathologists. <i>Journal of Lower Genital Tract Disease</i> , 2004, 8, 150-154.	0.9	3
1035	Human Papillomavirus and Abnormal Pap Test Results in Vietnamese-American Women: A Pilot Case-Control Study. <i>Journal of Lower Genital Tract Disease</i> , 2004, 8, 217-223.	0.9	7
1036	Optimal Cutoff of the Hybrid Capture II Human Papillomavirus Test for Self-Collected Vaginal, Vulvar, and Urine Specimens in a Colposcopy Referral Population. <i>Journal of Lower Genital Tract Disease</i> , 2004, 8, 33-37.	0.9	10
1037	Effect of HSV-2 Infection on the Expression of HPV 16 Genes in Caski Cells. <i>International Journal of Immunopathology and Pharmacology</i> , 2004, 17, 65-70.	1.0	8
1038	An Evaluation of Printed HPV Educational Materials. <i>Cancer Control</i> , 2005, 12, 103-106.	0.7	23
1039	Laser Capture Microdissection and PCR for Analysis of Human Papilloma Virus Infection. , 2005, 293, 295-300.		7
1040	Squamous Cell Carcinoma of the Penis in a Man with a Human Papilloma Virus 31 Infection. <i>Journal of Dermatology</i> , 2005, 32, 581-584.	0.6	2
1041	Therapeutic Vaccines for Cervical Cancer: Dendritic Cell-Based Immunotherapy. <i>Current Pharmaceutical Design</i> , 2005, 11, 3485-3500.	0.9	49
1042	Genital Human Papillomavirus Infection. <i>Clinics in Family Practice</i> , 2005, 7, 79-96.	0.3	1
1043	HPV Testing in Liquid Cytology Specimens. <i>Acta Cytologica</i> , 2005, 49, 120-126.	0.7	16
1044	Findings From ALTS. , 2005, 10, 128-137.		7
1045	A Population-Based Analysis of Temporal Trends in the Incidence of Squamous Anal Canal Cancer in Relation to the HIV Epidemic. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2005, 40, 451-455.	0.9	147
1046	Human Papillomavirus Infection in Women. <i>Infectious Diseases in Clinical Practice</i> , 2005, 13, 154-157.	0.1	0
1047	Characterization of HPV genotype profile in squamous cervical lesions in Portugal, a southern European population at high risk of cervical cancer. <i>European Journal of Cancer Prevention</i> , 2005, 14, 467-471.	0.6	27
1048	Hidradenoma Papilliferum with Oxyphilic Metaplasia. <i>American Journal of Dermatopathology</i> , 2005, 27, 102-110.	0.3	56
1049	Gynecologic Problems in Women with Autoimmune Diseases. <i>Handbook of Systemic Autoimmune Diseases</i> , 2005, 4, 141-160.	0.1	3
1051	Anti-tumor DNA vaccines based on the expression of human papillomavirus-16 E6/E7 oncoproteins genetically fused with the glycoprotein D from herpes simplex virus-1. <i>Microbes and Infection</i> , 2005, 7, 1541-1550.	1.0	31
1052	A cost-effectiveness analysis of four management strategies in the determination and follow-up of atypical squamous cells of undetermined significance. <i>Diagnostic Cytopathology</i> , 2005, 32, 125-132.	0.5	5

#	ARTICLE	IF	CITATIONS
1053	Stability of PreservCyt® for Hybrid Capture® (HC II) HPV test. <i>Diagnostic Cytopathology</i> , 2005, 32, 260-263.	0.5	6
1054	Bowen's carcinoma of the scrotal skin associated with human papillomavirus type 82. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2005, 19, 232-235.	1.3	11
1055	Human papillomavirus infection: biology, epidemiology, and prevention. <i>International Journal of Gynecological Cancer</i> , 2005, 15, 727-746.	1.2	198
1056	The clinicopathologic significance of laminin-5 gamma2 chain expression in cervical squamous carcinoma and adenocarcinoma. <i>International Journal of Gynecological Cancer</i> , 2005, 15, 1065-1072.	1.2	8
1057	The number of dyskaryotic cells on an initial ThinPrepR cervical sample showing mild dyskaryosis has predictive value. <i>Cytopathology</i> , 2005, 16, 120-124.	0.4	4
1058	Expression of the proapoptotic protein Bid is an adverse prognostic factor for radiotherapy outcome in carcinoma of the cervix. <i>British Journal of Cancer</i> , 2005, 92, 449-458.	2.9	18
1059	T-cell responses to human papillomavirus type 16 among women with different grades of cervical neoplasia. <i>British Journal of Cancer</i> , 2005, 93, 248-259.	2.9	73
1060	Human papillomavirus 16 infection in adenocarcinoma of the cervix. <i>British Journal of Cancer</i> , 2005, 93, 1301-1304.	2.9	23
1061	Can successful vaccines teach us how to induce efficient protective immune responses?. <i>Nature Medicine</i> , 2005, 11, S54-S62.	15.2	166
1062	Identification of a proliferation gene cluster associated with HPV E6/E7 expression level and viral DNA load in invasive cervical carcinoma. <i>Oncogene</i> , 2005, 24, 7094-7104.	2.6	122
1063	Human papillomavirus genotyping and p16INK4a expression in cervical intraepithelial neoplasia of adolescents. <i>Modern Pathology</i> , 2005, 18, 267-273.	2.9	68
1064	Prevalence of human papillomavirus DNA in various histological subtypes of cervical adenocarcinoma: a population-based study. <i>Modern Pathology</i> , 2005, 18, 528-534.	2.9	113
1065	Human papillomavirus (HPV) genotyping by HPV DNA chip in cervical cancer and precancerous lesions. <i>International Journal of Gynecological Cancer</i> , 2005, 15, 81-87.	1.2	28
1066	Polymorphism in the E6 gene of human papillomavirus type 16 in the cervical tissues of Korean women. <i>International Journal of Gynecological Cancer</i> , 2005, 15, 107-112.	1.2	26
1067	TP53 codon 72 polymorphism and risk for cervical cancer in Portugal. <i>Cancer Genetics and Cytogenetics</i> , 2005, 159, 143-147.	1.0	38
1068	The relative distribution of oncogenic types of human papillomavirus in benign, pre-malignant and malignant cervical biopsies. <i>Cancer Detection and Prevention</i> , 2005, 29, 37-41.	2.1	14
1069	What's New in Gynecology and Obstetrics. <i>Journal of the American College of Surgeons</i> , 2005, 201, 265-274.	0.2	2
1070	Recent innovations in colposcopy practice. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2005, 19, 779-792.	1.4	19

#	ARTICLE	IF	CITATIONS
1071	Gene Identification by cDNA Arrays in HPV-Positive Cervical Cancer. Archives of Medical Research, 2005, 36, 448-458.	1.5	29
1072	Human papillomavirus DNA detection and typing in male urine samples from a high-risk population from Argentina. Journal of Virological Methods, 2005, 124, 217-220.	1.0	16
1073	DNA recovery from Hybrid Capture II samples stored in specimen transport medium with denaturing reagent, for the detection of human papillomavirus by PCR. Journal of Virological Methods, 2005, 126, 197-201.	1.0	13
1074	Human papillomavirus genotyping by oligonucleotide microarray and p16INK4A expression in uterine cervical intraepithelial neoplasm and in invasive carcinoma in Korean women. Pathology International, 2005, 55, 491-496.	0.6	21
1075	Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2. Virology, 2005, 337, 365-372.	1.1	158
1076	Human papillomavirus type 18 variant lineages in United States populations characterized by sequence analysis of LCR-E6, E2, and L1 regions. Virology, 2005, 338, 22-34.	1.1	55
1077	HPV16-specific cytotoxic T lymphocyte responses are detected in all HPV16-positive cervical cancer patients. Gynecologic Oncology, 2005, 96, 92-102.	0.6	23
1078	HLA-DQB1 and cervical cancer in Venezuelan women. Gynecologic Oncology, 2005, 96, 349-354.	0.6	23
1079	Sensitivity to Fas-mediated apoptosis in high-risk HPV-positive human cervical cancer cells: Relationship with Fas, caspase-8, and Bid. Gynecologic Oncology, 2005, 97, 353-364.	0.6	38
1080	Comparison of type-specific human papillomavirus data from self and clinician directed sampling. Gynecologic Oncology, 2005, 97, 612-617.	0.6	31
1081	Human papillomavirus type and tobacco use as predictors of survival in early stage cervical carcinoma. Gynecologic Oncology, 2005, 98, 84-91.	0.6	21
1082	Detection of HPV genotypes in cervical lesions by the HPV DNA Chip and sequencing. Gynecologic Oncology, 2005, 98, 369-375.	0.6	61
1083	Detection and quantitation of human papillomavirus type 16, 18 and 52 DNA in the peripheral blood of cervical cancer patients. Gynecologic Oncology, 2005, 99, 615-621.	0.6	40
1084	Subvisual chromatin changes in cervical epithelium measured by texture image analysis and correlated with HPV. Gynecologic Oncology, 2005, 99, S16-S23.	0.6	35
1085	Prospects for therapeutic HPV vaccines. Gynecologic Oncology, 2005, 99, S249-S250.	0.6	1
1086	Inverse correlation of cellular immune responses specific to synthetic peptides from the E6 and E7 oncoproteins of HPV-16 with recurrence of cervical intraepithelial neoplasia in a cross-sectional study. Gynecologic Oncology, 2005, 99, S251-S261.	0.6	37
1087	Rapid enrichment of human papillomavirus (HPV)-specific polyclonal T cell populations for adoptive immunotherapy of cervical cancer. International Journal of Cancer, 2005, 114, 274-282.	2.3	22
1088	Human papillomavirus type 18 variants: Histopathology and E6/E7 polymorphisms in three countries. International Journal of Cancer, 2005, 114, 422-425.	2.3	44

#	ARTICLE	IF	CITATIONS
1089	HLA class II allele control of HPV load in carcinoma in situ of the cervix uteri. <i>International Journal of Cancer</i> , 2005, 117, 510-514.	2.3	24
1090	Hormonal contraceptive use, pregnancy and parity, and the risk of cervical intraepithelial neoplasia 3 among oncogenic HPV DNA-positive women with equivocal or mildly abnormal cytology. <i>International Journal of Cancer</i> , 2005, 117, 1007-1012.	2.3	40
1091	Age-related performance of human papillomavirus testing used as an adjunct to cytology for cervical carcinoma screening in a population with a low incidence of cervical carcinoma. <i>Cancer</i> , 2005, 105, 126-132.	2.0	19
1092	Socioeconomic status and the risk of cervical intraepithelial neoplasia grade 3 among oncogenic human papillomavirus DNA-positive women with equivocal or mildly abnormal cytology. <i>Cancer</i> , 2005, 104, 61-70.	2.0	56
1093	HPV DNA testing in the triage of atypical squamous cells of undetermined significance (ASCUS): Cost comparison of two methods. <i>Diagnostic Cytopathology</i> , 2005, 33, 138-143.	0.5	9
1094	Identification using phage display of peptides promoting targeting and internalization into HPV-transformed cell lines. <i>Journal of Molecular Recognition</i> , 2005, 18, 175-182.	1.1	23
1095	Prevalence of human papillomavirus genotypes in women from three clinical settings. <i>Journal of Medical Virology</i> , 2005, 75, 105-113.	2.5	39
1096	Detection and genotyping of human papillomavirus in cervical samples from Italian patients. <i>Journal of Medical Virology</i> , 2005, 75, 588-592.	2.5	41
1097	Human papillomavirus genotypes and their association with cervical neoplasia in a cohort of Western Australian women. <i>Journal of Medical Virology</i> , 2005, 76, 106-110.	2.5	25
1098	Tumor sensitivity to IFN- γ is required for successful antigen-specific immunotherapy of a transplantable mouse tumor model for HPV-transformed tumors. <i>Cancer Immunology, Immunotherapy</i> , 2005, 54, 477-488.	2.0	31
1100	Expression of cyclins, p53, and Ki-67 in cervical squamous cell carcinomas: overexpression of cyclin A is a poor prognostic factor in stage Ib and II disease. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2005, 446, 626-633.	1.4	24
1101	Risk factors of cervical carcinoma and countermeasures against them in mountainous area of Wufeng county, China. <i>Wuhan University Journal of Natural Sciences</i> , 2005, 10, 759-766.	0.2	3
1102	A virus-based vaccine may prevent cervical cancer. <i>Current Infectious Disease Reports</i> , 2005, 7, 125-131.	1.3	17
1103	Cancer incidence patterns among adolescents and young adults in the United States. <i>Cancer Causes and Control</i> , 2005, 16, 309-320.	0.8	100
1104	Human papillomavirus in head and neck cancer: Molecular biology and clinicopathological correlations. <i>Cancer and Metastasis Reviews</i> , 2005, 24, 19-34.	2.7	40
1105	Prevalence and distribution of high-risk human papilloma virus (HPV) types in invasive squamous cell carcinoma of the cervix and in normal women in Andhra Pradesh, India. <i>BMC Infectious Diseases</i> , 2005, 5, 116.	1.3	115
1106	Kinetics and isotype profile of antibody responses in rhesus macaques induced following vaccination with HPV 6, 11, 16 and 18 L1-virus-like particles formulated with or without Merck aluminum adjuvant. <i>Journal of Immune Based Therapies and Vaccines</i> , 2005, 3, 2.	2.4	48
1107	E-cadherin-dependent adhesion of dendritic and Langerhans cells to keratinocytes is defective in cervical human papillomavirus-associated (pre)neoplastic lesions. <i>Journal of Pathology</i> , 2005, 206, 346-355.	2.1	93

#	ARTICLE	IF	CITATIONS
1108	Detection of HPV DNA in Cervical Carcinomas after Treatment in India. <i>International Journal of Human Genetics</i> , 2005, 5, 27-31.	0.1	3
1109	Combined p53 and Retinoblastoma Protein Detection Identifies Persistent and Regressive Cervical High-Grade Squamous Intraepithelial Lesions. <i>American Journal of Surgical Pathology</i> , 2005, 29, 1062-1066.	2.1	26
1110	Validity of combined cytology and human papillomavirus (HPV) genotyping with adjuvant DNA-cytometry in routine cervical screening: Results from 31031 women from the Bonn-region in West Germany. <i>Oncology Reports</i> , 2005, 13, 915.	1.2	7
1111	The Role of Human Telomerase Catalytic Subunit mRNA Expression in Cervical Dysplasias. <i>Experimental Biology and Medicine</i> , 2005, 230, 263-270.	1.1	15
1112	New and Surprising Insights Into Pathogenesis of Multicentric Squamous Cancers in the Female Lower Genital Tract. <i>Journal of the National Cancer Institute</i> , 2005, 97, 1798-1799.	3.0	13
1113	Optimization and Validation of a Multiplexed Luminex Assay To Quantify Antibodies to Neutralizing Epitopes on Human Papillomaviruses 6, 11, 16, and 18. <i>Vaccine Journal</i> , 2005, 12, 959-969.	3.2	222
1114	Influence of beliefs about cervical cancer etiology on pap smear use among Latina immigrants. <i>Ethnicity and Health</i> , 2005, 10, 3-18.	1.5	97
1115	A Comparison of a Prototype PCR Assay and Hybrid Capture 2 for Detection of Carcinogenic Human Papillomavirus DNA in Women With Equivocal or Mildly Abnormal Papanicolaou Smears. <i>American Journal of Clinical Pathology</i> , 2005, 124, 722-732.	0.4	68
1116	Genomic Organization of Amplified MYC Genes Suggests Distinct Mechanisms of Amplification in Tumorigenesis. <i>Cancer Research</i> , 2005, 65, 1174-1179.	0.4	38
1117	CD4+ T Cell-Mediated Antigen-Specific Immunotherapy in a Mouse Model of Cervical Cancer. <i>Cancer Research</i> , 2005, 65, 2018-2025.	0.4	64
1118	Modifiable Risk Factors Associated with Clearance of Type-Specific Cervical Human Papillomavirus Infections in a Cohort of University Students. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005, 14, 1149-1156.	1.1	72
1119	Natural History and Possible Reactivation of Human Papillomavirus in Human Immunodeficiency Virus-Positive Women. <i>Journal of the National Cancer Institute</i> , 2005, 97, 577-586.	3.0	558
1120	Comparison between the Hybrid Capture II Test and a PCR-Based Human Papillomavirus Detection Method for Diagnosis and Posttreatment Follow-Up of Cervical Intraepithelial Neoplasia. <i>Journal of Clinical Microbiology</i> , 2005, 43, 3260-3266.	1.8	43
1121	Macrophages Kill Human Papillomavirus Type 16 E6-Expressing Tumor Cells by Tumor Necrosis Factor Alpha- and Nitric Oxide-Dependent Mechanisms. <i>Journal of Virology</i> , 2005, 79, 116-123.	1.5	32
1122	Different P105 Promoter Activities among Natural Variants of Human Papillomavirus Type 18. <i>Journal of Infectious Diseases</i> , 2005, 191, 739-742.	1.9	39
1123	A Novel Filtration-Based Processing Method of Liquid Cytology Specimens for Human Papillomavirus DNA Testing by Hybrid Capture II. <i>American Journal of Clinical Pathology</i> , 2005, 123, 250-255.	0.4	5
1124	Detection of Hypermethylated Genes in Women with and Without Cervical Neoplasia. <i>Journal of the National Cancer Institute</i> , 2005, 97, 273-282.	3.0	168
1125	Comparison of non-invasive sampling methods for detection of HPV in rural African women. <i>Sexually Transmitted Infections</i> , 2005, 81, 239-241.	0.8	37

#	ARTICLE	IF	CITATIONS
1126	Papillomavirus E2 Protein Induces Expression of the Matrix Metalloproteinase-9 via the Extracellular Signal-Regulated Kinase/Activator Protein-1 Signaling Pathway. <i>Cancer Research</i> , 2005, 65, 11613-11621.	0.4	45
1127	Seroprevalence of Human Papillomavirus Type 16 in Children. <i>Journal of Infectious Diseases</i> , 2005, 191, 1817-1819.	1.9	43
1128	Semiquantitative Human Papillomavirus Type 16 Viral Load and the Prospective Risk of Cervical Precancer and Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005, 14, 1311-1314.	1.1	36
1129	Potential of telomerase expression and activity in cervical specimens as a diagnostic tool. <i>Journal of Clinical Pathology</i> , 2005, 58, 911-914.	1.0	25
1130	Association of Tumor Necrosis Factor α -2 and α -8 Microsatellite Alleles with Human Papillomavirus and Squamous Intraepithelial Lesions among Women in Brazil. <i>Journal of Clinical Microbiology</i> , 2005, 43, 3932-3937.	1.8	7
1131	First-Generation Vaccines against Human Papillomavirus. <i>Women's Health</i> , 2005, 1, 223-229.	0.7	0
1132	Vaccination strategies for the prevention of cervical cancer. <i>Expert Review of Anticancer Therapy</i> , 2005, 5, 97-107.	1.1	17
1133	Plasma Uric Acid Levels in Women With Cervical Intraepithelial Neoplasia. <i>Nutrition and Cancer</i> , 2005, 51, 25-31.	0.9	5
1134	The HPV-16 E7 Oncogene Sensitizes Malignant Cells to IFN- γ -Induced Apoptosis. <i>Journal of Interferon and Cytokine Research</i> , 2005, 25, 63-72.	0.5	8
1135	Cervical human papillomavirus infection and squamous intraepithelial lesions in rural Gambia, West Africa: viral sequence analysis and epidemiology. <i>British Journal of Cancer</i> , 2005, 93, 1068-1076.	2.9	51
1136	Type distribution, viral load and integration status of high-risk human papillomaviruses in pre-stages of cervical cancer (CIN). <i>British Journal of Cancer</i> , 2005, 92, 2195-2200.	2.9	107
1137	Antigen-Specific CD8+ T Lymphocytes Generated from a DNA Vaccine Control Tumors Through the Fas α -FasL Pathway. <i>Molecular Therapy</i> , 2005, 12, 960-968.	3.7	16
1138	Routine cervical screening with primary HPV testing and cytology triage protocol in a randomised setting. <i>British Journal of Cancer</i> , 2005, 93, 862-867.	2.9	93
1139	Strong association between infection with human papillomavirus and oral and oropharyngeal squamous cell carcinoma: A population-based case-control study in southern Sweden. <i>Acta Oto-Laryngologica</i> , 2005, 125, 1337-1344.	0.3	192
1140	Cervical human papillomavirus screening by PCR: advantages of targeting the E6/E7 region. <i>Clinical Chemistry and Laboratory Medicine</i> , 2005, 43, 1171-7.	1.4	68
1141	Cervical Cancer in Women With Comprehensive Health Care Access: Attributable Factors in the Screening Process. <i>Journal of the National Cancer Institute</i> , 2005, 97, 675-683.	3.0	307
1142	Comparison of Human Papillomavirus Messenger RNA and DNA Detection: A Cross-sectional Study of 4,136 Women >30 Years of Age with a 2-Year Follow-up of High-Grade Squamous Intraepithelial Lesion. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005, 14, 367-372.	1.1	132
1143	Smoking Is a Risk Factor for Cervical Intraepithelial Neoplasia Grade 3 among Oncogenic Human Papillomavirus DNA-Positive Women with Equivocal or Mildly Abnormal Cytology. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005, 14, 1165-1170.	1.1	106

#	ARTICLE	IF	CITATIONS
1144	Incidence Trends of Adenocarcinoma of the Cervix in 13 European Countries. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005, 14, 2191-2199.	1.1	314
1145	Diversifying Selection in Human Papillomavirus Type 16 Lineages Based on Complete Genome Analyses. <i>Journal of Virology</i> , 2005, 79, 7014-7023.	1.5	148
1146	Human Papillomavirus Type 16 Infections and 2-Year Absolute Risk of Cervical Precancer in Women With Equivocal or Mild Cytologic Abnormalities. <i>Journal of the National Cancer Institute</i> , 2005, 97, 1066-1071.	3.0	273
1147	Epidemiological Study in Okinawa, Japan, of Human Papillomavirus Infection of the Uterine Cervix. <i>Infectious Diseases in Obstetrics and Gynecology</i> , 2005, 13, 77-80.	0.4	17
1148	Immunization with Virus-Like Particle of Human Papillomavirus Type 16 L1 Elicits CTL Immune Response in C57BL/6 Mice. <i>Key Engineering Materials</i> , 2005, 277-279, 119-124.	0.4	0
1149	Comparison of Two Commercial Assays for Detection of Human Papillomavirus (HPV) in Cervical Scrape Specimens: Validation of the Roche AMPLICOR HPV Test as a Means To Screen for HPV Genotypes Associated with a Higher Risk of Cervical Disorders. <i>Journal of Clinical Microbiology</i> , 2005, 43, 2662-2667.	1.8	73
1150	Variants of human papillomaviruses 16 and 18 and their natural history in human immunodeficiency virus-positive women. <i>Journal of General Virology</i> , 2005, 86, 2709-2720.	1.3	47
1151	Photodynamic Therapy for Cervical Intraepithelial Neoplasia. <i>Oncology</i> , 2005, 69, 110-116.	0.9	61
1152	HLA genes and other candidate genes involved in susceptibility for (pre)neoplastic cervical disease. <i>International Journal of Oncology</i> , 2005, 26, 769.	1.4	13
1153	Human Papillomavirus Vaccines: What Does the Future Hold for Preventing Cervical Cancer in Resource-Poor Settings Through Immunization Programs?. <i>Sexually Transmitted Diseases</i> , 2005, 32, 635-640.	0.8	25
1154	HPV in sub-Saharan Africa. <i>Papillomavirus Report</i> , 2005, 16, 322-326.	0.2	13
1157	The Elevated 10-Year Risk of Cervical Precancer and Cancer in Women With Human Papillomavirus (HPV) Type 16 or 18 and the Possible Utility of Type-Specific HPV Testing in Clinical Practice. <i>Journal of the National Cancer Institute</i> , 2005, 97, 1072-1079.	3.0	921
1158	Human Papillomavirus Vaccine for Cervical Cancer: Where Are We Now?. <i>Taiwanese Journal of Obstetrics and Gynecology</i> , 2005, 44, 232-241.	0.5	6
1160	A simple method for the detection and genotyping of high-risk human papillomavirus using seminested polymerase chain reaction and reverse hybridization. <i>Gynecologic Oncology</i> , 2005, 96, 84-91.	0.6	20
1161	Epidemiology of STIs: UK. <i>Medicine</i> , 2005, 33, 1-4.	0.2	4
1162	A tailored multi-media campaign to promote the human papillomavirus cohort study to young women. <i>Preventive Medicine</i> , 2005, 41, 98-101.	1.6	8
1163	HUMAN PAPILOMAVIRUS HPV-16 DNA AS AN EPITHELIOTROPIC VIRUS THAT INDUCES HYPERPROLIFERATION IN SQUAMOUS PENILE TISSUE. <i>Archives of Andrology</i> , 2005, 51, 327-334.	1.0	12
1164	Immunogenicity and Reactogenicity of a Novel Vaccine for Human Papillomavirus 16: A 2-Year Randomized Controlled Clinical Trial. <i>Mayo Clinic Proceedings</i> , 2005, 80, 601-610.	1.4	68

#	ARTICLE	IF	CITATIONS
1165	Kinetic Analysis of the Interactions of Human Papillomavirus E6 Oncoproteins with the Ubiquitin Ligase E6AP Using Surface Plasmon Resonance. <i>Journal of Molecular Biology</i> , 2005, 349, 401-412.	2.0	56
1166	Multiplex nested PCR (MNP) assay for the detection of 15 high risk genotypes of human papillomavirus. <i>Journal of Clinical Virology</i> , 2005, 33, 116-122.	1.6	17
1167	Human Papillomavirus L1L2-E7 Virus-Like Particles Partially Mature Human Dendritic Cells and Elicit E7-Specific T-Helper Responses From Patients With Cervical Intraepithelial Neoplasia or Cervical Cancer In Vitro. <i>Human Immunology</i> , 2005, 66, 762-772.	1.2	17
1168	Tissues from population-based cancer registries: a novel approach to increasing research potential. <i>Human Pathology</i> , 2005, 36, 812-820.	1.1	41
1169	Vaccination against multiple HPV types. <i>Mathematical Biosciences</i> , 2005, 197, 88-117.	0.9	87
1170	Aberrant expression of caspase-14 in epithelial tumors. <i>Biochemical and Biophysical Research Communications</i> , 2005, 335, 309-313.	1.0	19
1171	Cervical squamous intraepithelial lesions of low-grade in HIV-infected women: recurrence, persistence, and progression, in treated and untreated women. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2005, 121, 226-232.	0.5	61
1172	Lymphotoxin- α polymorphism and the risk of cervical cancer in Japanese subjects. <i>Cancer Letters</i> , 2005, 218, 63-68.	3.2	15
1173	Immunohistochemical evaluation of heat shock proteins in normal and preinvasive lesions of the cervix. <i>Cancer Letters</i> , 2005, 229, 245-252.	3.2	49
1175	Risk for recurrence and death from preexisting cancers after transplantation. <i>Transplantation Reviews</i> , 2005, 19, 151-163.	1.2	14
1176	Immunotherapy with CTL peptide and VSSP eradicated established human papillomavirus (HPV) type 16 E7-expressing tumors. <i>Vaccine</i> , 2005, 23, 5768-5774.	1.7	30
1177	Low folate status as a risk factor for cervical dysplasia in Thai women. <i>Nutrition Research</i> , 2005, 25, 641-654.	1.3	11
1178	Reproducibility of HPV DNA Testing by Hybrid Capture 2 in a Screening Setting. <i>American Journal of Clinical Pathology</i> , 2005, 124, 716-721.	0.4	90
1179	Type-Specific Multiple Sequencing Primers. <i>Journal of Molecular Diagnostics</i> , 2005, 7, 198-205.	1.2	50
1180	The Role of Human Papillomaviruses in Cancer. <i>American Journal of Cancer</i> , 2005, 4, 49-64.	0.4	24
1181	Laser Capture Microdissection. , 2005, , .		13
1182	Condom Use and the Risk of Genital Human Papillomavirus Infection in Young Women. <i>New England Journal of Medicine</i> , 2006, 354, 2645-2654.	13.9	609
1183	Molecular Biomarkers for Cancer Detection in Blood and Bodily Fluids. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2006, 43, 497-560.	2.7	24

#	ARTICLE	IF	CITATIONS
1184	The Human Papillomavirus Type 16 E7 Protein Binds Human Interferon Regulatory Factor-9 via a Novel PEST Domain Required for Transformation. <i>Journal of Interferon and Cytokine Research</i> , 2006, 26, 455-461.	0.5	47
1185	Knowledge and Beliefs About Abnormal Pap Test Results and HPV Among Women with High-Risk HPV: Results from In-Depth Interviews. <i>Women and Health</i> , 2006, 42, 107-133.	0.4	31
1186	Novel methods to treat and prevent human papillomavirus infection. <i>Expert Review of Anti-Infective Therapy</i> , 2006, 4, 593-600.	2.0	3
1187	Genital human papillomavirus infection in men. <i>Lancet Infectious Diseases</i> , The, 2006, 6, 21-31.	4.6	220
1191	Epidemiology of STIs: UK. <i>Women's Health Medicine</i> , 2006, 3, 234-236.	0.0	0
1192	HPV DNA Testing for Cervical Cancer Screening. <i>International Journal of Gynecology and Obstetrics</i> , 2006, 95, S239-S246.	1.0	26
1193	CHAPTER 2 The epidemiology of human papillomavirus infection and its association with cervical cancer. <i>International Journal of Gynecology and Obstetrics</i> , 2006, 94, S8-S21.	1.0	64
1194	Vaccination anti-HPV : perspectives et conséquences potentielles pour le dépistage du cancer du col utérin. <i>Annales De Pathologie</i> , 2006, 26, 41-42.	0.1	0
1195	Sensitive detection of human papillomavirus type 16 E7-specific T cells by ELISPOT after multiple in vitro stimulations of CD8+ T cells with peptide-pulsed autologous dendritic cells. <i>Molecular Cancer</i> , 2006, 5, 49.	7.9	4
1196	Quantitative Screening of Single Copies of Human Papilloma Viral DNA without Amplification. <i>Analytical Chemistry</i> , 2006, 78, 6490-6496.	3.2	30
1197	Prevalence of cervical human papillomavirus in women undergoing in vitro fertilization and association with outcome. <i>Fertility and Sterility</i> , 2006, 86, 765-767.	0.5	59
1198	Nucleic acid testing for viral burden and viral genotyping. <i>Clinica Chimica Acta</i> , 2006, 363, 197-205.	0.5	16
1199	Haemochromatosis gene (HFE) mutations in viral-associated neoplasia: Linkage to cervical cancer. <i>Biochemical and Biophysical Research Communications</i> , 2006, 341, 232-238.	1.0	15
1201	Expression of p16INK4a in relation to histopathology and viral load of "high-risk" HPV types in cervical neoplastic lesions. <i>European Journal of Cancer</i> , 2006, 42, 2815-2820.	1.3	11
1202	Duration of HPV-associated risk for high-grade cervical intraepithelial neoplasia. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2006, 125, 114-119.	0.5	10
1203	Associations of high-risk HPV types and viral load with cervical cancer in China. <i>Journal of Clinical Virology</i> , 2006, 35, 264-269.	1.6	99
1204	Dynamics of HPV16 DNA load reflect the natural history of cervical HPV-associated lesions. <i>Journal of Clinical Virology</i> , 2006, 35, 270-277.	1.6	60
1205	Human papillomavirus typing with GP5+/6+ polymerase chain reaction reverse line blotting and with commercial type-specific PCR kits. <i>Journal of Clinical Virology</i> , 2006, 36, 126-132.	1.6	19

#	ARTICLE	IF	CITATIONS
1206	Primary screening for cervical cancer through self sampling. International Journal of Gynecology and Obstetrics, 2006, 95, 179-184.	1.0	40
1207	The epidemiology of genital human papillomavirus infection. Vaccine, 2006, 24, S4-S15.	1.7	383
1208	An improved rearranged Human Papillomavirus Type 16 E7 DNA vaccine candidate (HPV-16 E7SH) induces an E7 wildtype-specific T cell response. Vaccine, 2006, 24, 2880-2893.	1.7	48
1209	Eradication of established HPV 16-expressing tumors by a single administration of a vaccine composed of a liposome-encapsulated CTL-T helper fusion peptide in a water-in-oil emulsion. Vaccine, 2006, 24, 5235-5244.	1.7	78
1210	Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. Vaccine, 2006, 24, 5571-5583.	1.7	380
1211	Chapter 28: Studies to assess the long-term efficacy and effectiveness of HPV vaccination in developed and developing countries. Vaccine, 2006, 24, S233-S241.	1.7	52
1212	Chapter 1: HPV in the etiology of human cancer. Vaccine, 2006, 24, S1-S10.	1.7	933
1213	Chapter 23: International Standard reagents for harmonization of HPV serology and DNA assays—an update. Vaccine, 2006, 24, S193-S200.	1.7	35
1214	Perspectives of contemporary papillomavirus research. Vaccine, 2006, 24, iii-iv.	1.7	18
1215	Chapter 30: HPV vaccines and screening in the prevention of cervical cancer; conclusions from a 2006 workshop of international experts. Vaccine, 2006, 24, S251-S261.	1.7	44
1216	Human papillomavirus status and cervical abnormalities in women from public and private health care in Rio de Janeiro State, Brazil. Revista Do Instituto De Medicina Tropical De Sao Paulo, 2006, 48, 279-285.	0.5	13
1217	High-Risk Human Papillomavirus Testing in Cervical Cancer Screening. , 2006, , 612-621.		0
1218	Human Papillomavirus Detection and Genotyping by Hybrid Capture II in the Cervical Smears of Women at High-Risk for HIV Infection. International Journal of Human Genetics, 2006, 6, 185-190.	0.1	1
1219	Emerging Infectious Determinants of Chronic Diseases. Emerging Infectious Diseases, 2006, 12, 1051-1057.	2.0	86
1220	HPV Testing in Patient Management: Atypical Squamous Cells of Undetermined Significance and Low-Grade Squamous Intraepithelial Lesion. , 2006, , 120-139.		1
1221	Epidemiology of Oncogenic and Nononcogenic HPV Types, and the Evidence for Differences in Their Sexual Transmissibility. , 2006, , 20-33.		0
1222	Prevalence and typing of human papilloma virus (HPV) among female sex workers and outpatient women in southern Thailand. Sexual Health, 2006, 3, 11.	0.4	20
1223	Association between HLA-DQB1 and cervical dysplasia in Vietnamese women. International Journal of Gynecological Cancer, 2006, 16, 1269-1277.	1.2	1

#	ARTICLE	IF	CITATIONS
1224	Valutazione del ruolo dell'HPV-DNA test nei programmi di prevenzione del cancro cervicale. <i>Microbiologia Medica</i> , 2006, 21, .	0.3	1
1225	Promoter methylation of p16, DAPK, CDH1, and TIMP-3 genes in cervical cancer: correlation with clinicopathologic characteristics. <i>International Journal of Gynecological Cancer</i> , 2006, 16, 1234-1240.	1.2	16
1226	Detection and Quantification of Residual Cellular DNA in the Production of Recombinant HPV-16 L1 Virus-Like Particles. <i>Journal of Bacteriology and Virology</i> , 2006, 36, 271.	0.0	0
1227	Development and evaluation of a colorimetric PCR system for the detection and typing of human papillomaviruses. <i>International Journal of Molecular Medicine</i> , 2006, 18, 995.	1.8	3
1228	Human Papillomavirus: The Burden of Infection. <i>Obstetrical and Gynecological Survey</i> , 2006, 61, S3-S14.	0.2	80
1230	Human papillomavirus in cervical screening and vaccination. <i>Clinical Science</i> , 2006, 110, 543-552.	1.8	21
1231	HLA B*1301 and B*1801 Alleles are Positively Associated with HPV Related Cervical Cancer in Women from Kolkata, Eastern India. <i>International Journal of Human Genetics</i> , 2006, 6, 139-144.	0.1	3
1232	Human Papillomavirus Type Distribution in Cervical Cancer in Delhi, India. <i>International Journal of Gynecological Pathology</i> , 2006, 25, 398-402.	0.9	36
1233	Vaccines for cervical cancer. <i>Epidemiology and Infection</i> , 2006, 134, 1-12.	1.0	49
1234	Methylation of p16INK4a Is a Non-Rare Event in Cervical Intraepithelial Neoplasia. <i>Diagnostic Molecular Pathology</i> , 2006, 15, 74-82.	2.1	25
1235	Vulvar Squamous Cell Carcinoma is a Multifactorial Disease Following Two Separate and Independent Pathways. <i>International Journal of Gynecological Pathology</i> , 2006, 25, 22-29.	0.9	220
1236	Human papillomavirus in lung carcinomas among three Latin American countries. <i>Oncology Reports</i> , 2006, 15, 883.	1.2	12
1237	Single or multiple HPV types in cervical cancer and associated metastases. <i>Oncology Reports</i> , 2006, 15, 143.	1.2	4
1238	Human papillomavirus infections in women seeking cervical Papanicolaou cytology of Durango, Mexico: prevalence and genotypes. <i>BMC Infectious Diseases</i> , 2006, 6, 27.	1.3	24
1239	Sensation Seeking, the Activation Model, and Mass Media Health Campaigns: Current Findings and Future Directions for Cancer Communication. <i>Journal of Communication</i> , 2006, 56, S38-S56.	2.1	55
1240	Assembly of Human Papillomavirus Type-16 Virus-Like Particles: Multifactorial Study of Assembly and Competing Aggregation. <i>Biotechnology Progress</i> , 2006, 22, 554-560.	1.3	32
1241	Serum/Plasma Viral DNA. <i>Annals of the New York Academy of Sciences</i> , 2001, 945, 59-67.	1.8	16
1242	The role of human papilloma virus in skin cancer " current status. <i>Journal of the European Academy of Dermatology and Venereology</i> , 1997, 9, 103-110.	1.3	1

#	ARTICLE	IF	CITATIONS
1243	Detection of Chlamydia trachomatis and herpes simplex virus type 1 or 2 in cervical samples in human papilloma virus (HPV)-positive and HPV-negative women. <i>Clinical Microbiology and Infection</i> , 2006, 12, 927-930.	2.8	40
1244	Prediction of recurrence after treatment for high-grade cervical intraepithelial neoplasia: the role of human papillomavirus testing and age at conisation. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2006, 113, 1303-1307.	1.1	112
1245	Knowledge and attitudes about human papillomavirus, Pap smears, and cervical cancer among young women in Brazil: implications for health education and prevention. <i>International Journal of Gynecological Cancer</i> , 2006, 16, 599-603.	1.2	70
1246	Differential viral loads of human papillomavirus 16 and 58 infections in the spectrum of cervical carcinogenesis. <i>International Journal of Gynecological Cancer</i> , 2006, 16, 730-735.	1.2	15
1247	Human papillomavirus genotype prevalence in cervical biopsies from women diagnosed with cervical intraepithelial neoplasia or cervical cancer in Melbourne, Australia. <i>International Journal of Gynecological Cancer</i> , 2006, 16, 1017-1024.	1.2	50
1248	Human papillomavirus-specific viral types are common in Mexican women affected by cervical lesions. <i>International Journal of Gynecological Cancer</i> , 2006, 16, 1041-1047.	1.2	27
1249	Association between HLA-DQB1 and cervical dysplasia in Vietnamese women. <i>International Journal of Gynecological Cancer</i> , 2006, 16, 1269-1277.	1.2	8
1250	Promoter methylation of p16, DAPK, CDH1, and TIMP-3 genes in cervical cancer: correlation with clinicopathologic characteristics. <i>International Journal of Gynecological Cancer</i> , 2006, 16, 1234-1240.	1.2	75
1251	Human papillomavirus prevalence in postradiotherapy uterine cervical carcinoma patients: correlation with recurrence of the disease. <i>International Journal of Gynecological Cancer</i> , 2006, 16, 1048-1054.	1.2	34
1252	Phenotypic features with p53 alterations related to human papillomavirus and prognostic evaluation in cervical cancer. <i>International Journal of Gynecological Cancer</i> , 2006, 16, 708-717.	1.2	10
1253	Human papillomavirus genotypes associated with cervical neoplasia in India. <i>International Journal of Gynecological Cancer</i> , 2006, 16, 1591-1595.	1.2	26
1254	The distribution and differential risks of human papillomavirus genotypes in cervical preinvasive lesions: a Taiwan Cooperative Oncologic Group Study. <i>International Journal of Gynecological Cancer</i> , 2006, 16, 1801-1808.	1.2	44
1255	Human papillomavirus type 18 and other risk factors for cervical cancer in Jakarta, Indonesia. <i>International Journal of Gynecological Cancer</i> , 2006, 16, 1809-1814.	1.2	18
1256	Cervical carcinoma: A common and preventable problem in developing countries. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2006, 2, 69-70.	0.7	1
1257	Biopsy vs. superficial scraping: detection of human papillomavirus 6, 11, 16, and 18 in potentially malignant and malignant oral lesions. <i>Journal of Oral Pathology and Medicine</i> , 2006, 35, 338-344.	1.4	47
1258	E6/E7 expression of human papillomavirus types in cutaneous squamous cell dysplasia and carcinoma in immunosuppressed organ transplant recipients. <i>British Journal of Dermatology</i> , 2006, 155, 129-136.	1.4	66
1259	Detection of mucosal human papilloma virus DNA in bowenoid papulosis, Bowen's disease and squamous cell carcinoma of the skin. <i>Journal of Dermatology</i> , 2006, 33, 331-337.	0.6	53
1260	Human papillomavirus infection: an Anonymous Prevalence Study in South Wales, UK. <i>British Journal of Cancer</i> , 2006, 95, 226-232.	2.9	30

#	ARTICLE	IF	CITATIONS
1261	Frequent gain of the human telomerase gene TERC at 3q26 in cervical adenocarcinomas. <i>British Journal of Cancer</i> , 2006, 95, 331-338.	2.9	47
1262	Induction of cell death in human papillomavirus 18-positive cervical cancer cells by E6 siRNA. <i>Cancer Gene Therapy</i> , 2006, 13, 234-241.	2.2	53
1263	A combination of DNA vaccines targeting human papillomavirus type 16 E6 and E7 generates potent antitumor effects. <i>Gene Therapy</i> , 2006, 13, 257-265.	2.3	44
1264	MYC activation associated with the integration of HPV DNA at the MYC locus in genital tumors. <i>Oncogene</i> , 2006, 25, 5985-5993.	2.6	115
1265	Controlled release of 5-fluorouridine from radiation-crosslinked poly(ethylene-co-vinyl acetate) films. <i>Acta Biomaterialia</i> , 2006, 2, 641-650.	4.1	21
1266	Genetic mutations in gynaecological cancers. <i>Reviews in Gynaecological and Perinatal Practice</i> , 2006, 6, 115-125.	0.3	4
1267	The Carcinogenic Role of Oncogenic HPV and p53 Gene Mutation in Cervical Adenocarcinomas. <i>Medical Oncology</i> , 2006, 23, 113-120.	1.2	15
1268	Risk of high-grade cervical intraepithelial neoplasia (CIN 2/3) or cancer during follow-up of human papillomavirus (HPV) infection or CIN 1. <i>American Journal of Obstetrics and Gynecology</i> , 2006, 195, 1196-1197.	0.7	1
1269	Covariates of Cervical Cytokine mRNA Expression by Real-Time PCR in Adolescents and Young Women: Effects of Chlamydia trachomatis Infection, Hormonal Contraception, and Smoking. <i>Journal of Clinical Immunology</i> , 2006, 26, 222-232.	2.0	48
1270	Patterns of cancer incidence among US Hispanics/Latinos, 1995-2000. <i>Cancer Causes and Control</i> , 2006, 17, 1067-1075.	0.8	20
1271	Correlation between serological immune response analyzed by a new ELISA for HPV-16/18 E7 oncoprotein and clinical characteristics of cervical cancer patients. <i>Archives of Virology</i> , 2006, 151, 1899-1916.	0.9	17
1273	A study of abnormal cervical cytology in pregnant women. <i>Archives of Gynecology and Obstetrics</i> , 2006, 273, 274-277.	0.8	3
1274	A study of abnormal cervical cytology in pregnant women. <i>Archives of Gynecology and Obstetrics</i> , 2006, 273, 355-359.	0.8	0
1277	Advances in molecular diagnostics and therapeutics in head and neck cancer. <i>Current Treatment Options in Oncology</i> , 2006, 7, 3-11.	1.3	28
1278	New antiviral agents. <i>Indian Journal of Pediatrics</i> , 2006, 73, 313-321.	0.3	22
1279	Induction of productive human papillomavirus type 11 life cycle in epithelial cells grown in organotypic raft cultures. <i>Virology</i> , 2006, 347, 28-35.	1.1	21
1280	Papillomavirus virus-like particles activate the PI3-kinase pathway via alpha-6 beta-4 integrin upon binding. <i>Virology</i> , 2006, 352, 319-328.	1.1	49
1281	Cellular immune responses to HPV-18, -31, and -53 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles. <i>Virology</i> , 2006, 353, 451-462.	1.1	53

#	ARTICLE	IF	CITATIONS
1282	Human papillomavirus E6/E7 mRNA expression in women younger than 30 years of age. <i>Gynecologic Oncology</i> , 2006, 100, 95-100.	0.6	66
1283	Detection of cervical abnormalities in a developing country using measurement of Brn-3a in cervical smears. <i>Gynecologic Oncology</i> , 2006, 100, 89-94.	0.6	5
1284	HPV16 E2 gene disruption and polymorphisms of E2 and LCR: Some significant associations with cervical cancer in Indian women. <i>Gynecologic Oncology</i> , 2006, 100, 372-378.	0.6	37
1285	High prevalence of genital human papillomavirus type 52 and 58 infection in women attending gynecologic practitioners in South Taiwan. <i>Gynecologic Oncology</i> , 2006, 101, 40-45.	0.6	66
1286	HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities. <i>Gynecologic Oncology</i> , 2006, 100, 469-478.	0.6	90
1287	CYP1A1 gene polymorphism as a risk factor for cervical intraepithelial neoplasia and invasive cervical cancer. <i>Gynecologic Oncology</i> , 2006, 101, 503-506.	0.6	18
1288	Integrated human papillomavirus types 52 and 58 are infrequently found in cervical cancer, and high viral loads predict risk of cervical cancer. <i>Gynecologic Oncology</i> , 2006, 102, 54-60.	0.6	72
1289	Immunohistochemical analysis of CD4+ and CD8+ T-cell subsets in high risk human papillomavirus-associated pre-malignant and malignant lesions of the uterine cervix. <i>Gynecologic Oncology</i> , 2006, 102, 22-31.	0.6	81
1290	Are women ready for the HPV vaccine?. <i>Gynecologic Oncology</i> , 2006, 103, 151-154.	0.6	94
1291	Evaluation of HPV 16 PCR detection in self- compared with clinician-collected samples in women referred for colposcopy. <i>Gynecologic Oncology</i> , 2006, 103, 463-466.	0.6	22
1292	Malignancies following in situ cervical cancer in Hispanic Americans and non-Hispanic Whites. <i>Gynecologic Oncology</i> , 2006, 103, 1012-1016.	0.6	6
1293	Reproduction beyond cancer: A message of hope for young women. <i>Gynecologic Oncology</i> , 2006, 103, 1109-1121.	0.6	85
1294	Using small molecules to overcome drug resistance induced by a viral oncogene. <i>Cancer Cell</i> , 2006, 9, 133-146.	7.7	21
1296	Cyclin A1 promoter hypermethylation in human papillomavirus-associated cervical cancer. <i>BMC Cancer</i> , 2006, 6, 55.	1.1	67
1297	HPV vaccine development: A case study of prevention and politics. <i>Biochemistry and Molecular Biology Education</i> , 2006, 34, 148-154.	0.5	7
1298	Exposure to wood smoke, HPV infection, and genetic susceptibility for cervical neoplasia among women in Colombia. <i>Environmental and Molecular Mutagenesis</i> , 2006, 47, 553-561.	0.9	22
1299	Comparison of human papillomavirus distribution in cytologic subgroups of low-grade squamous intraepithelial lesion. <i>Cancer</i> , 2006, 108, 288-297.	2.0	10
1300	Definition of an HPV18/45 cross-reactive human T-cell epitope after DNA immunisation of HLA-A2/KB transgenic mice. <i>International Journal of Cancer</i> , 2006, 118, 2514-2521.	2.3	12

#	ARTICLE	IF	CITATIONS
1301	Polymorphic amino acids at codons 9 and 37 of HLA-DQB1 alleles may confer susceptibility to cervical cancer among Chinese women. <i>International Journal of Cancer</i> , 2006, 118, 3006-3011.	2.3	27
1302	Presence of high-risk human papillomavirus DNA in penile carcinoma predicts favorable outcome in survival. <i>International Journal of Cancer</i> , 2006, 119, 1078-1081.	2.3	214
1303	Oral administration of human papillomavirus type 16 E7 displayed on <i>Lactobacillus casei</i> induces E7-specific antitumor effects in C57/BL6 mice. <i>International Journal of Cancer</i> , 2006, 119, 1702-1709.	2.3	66
1304	Detection of specific human papillomavirus types in paraffin-embedded sections of cervical carcinomas. <i>Journal of Medical Virology</i> , 2006, 78, 117-124.	2.5	27
1305	Determination of HPV type 16 and 18 viral load in cervical smears of women referred to colposcopy. <i>Journal of Medical Virology</i> , 2006, 78, 1131-1140.	2.5	60
1306	Incidence of and Risk Factors for Genital Human Papillomavirus Infection in Women Drug Users. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2006, 41, 527-529.	0.9	13
1307	Therapeutic potential of an adenovirus expressing p73beta, a p53 homologue, against human papilloma virus positive cervical cancer in vitro and in vivo. <i>Cancer Biology and Therapy</i> , 2006, 5, 210-217.	1.5	22
1308	Different T-cell Receptor (TCR) Zeta Chain Expression in Cervical Cancer and its Precursor Lesions. <i>Zentralblatt Fur Gynakologie</i> , 2006, 128, 266-270.	0.6	6
1309	Seminal Plasma Promotes the Expression of Tumorigenic and Angiogenic Genes in Cervical Adenocarcinoma Cells via the E-Series Prostanoid 4 Receptor. <i>Endocrinology</i> , 2006, 147, 3356-3365.	1.4	29
1310	Cervical Cancer Screening in Older Women. <i>Clinical Journal of Oncology Nursing</i> , 2006, 10, 31-33.	0.3	2
1311	Early integration of high copy HPV16 detectable in women with normal and low grade cervical cytology and histology. <i>Journal of Clinical Pathology</i> , 2006, 59, 513-517.	1.0	97
1312	Reversal of the Malignant Phenotype of Cervical Cancer CaSki Cells through Adeno-Associated Virus-Mediated Delivery of HPV16 E7 Antisense RNA. <i>Clinical Cancer Research</i> , 2006, 12, 2032-2037.	3.2	20
1313	p16INK4a and laminin-5 β 2 chain expression during the progression of cervical neoplasia. <i>Acta Oncologica</i> , 2006, 45, 676-684.	0.8	3
1314	Factors That Are Associated With Parental Acceptance of Human Papillomavirus Vaccines: A Randomized Intervention Study of Written Information About HPV. <i>Pediatrics</i> , 2006, 117, 1486-1493.	1.0	397
1315	Incident High-Grade Squamous Intraepithelial Lesions in Senegalese Women With and Without Human Immunodeficiency Virus Type 1 (HIV-1) and HIV-2. <i>Journal of the National Cancer Institute</i> , 2006, 98, 100-109.	3.0	91
1316	A Qualitative Evaluation of a Faith-Based Breast and Cervical Cancer Screening Intervention for African American Women. <i>Health Education and Behavior</i> , 2006, 33, 643-663.	1.3	51
1317	Structure of the Human Papillomavirus E7 Oncoprotein and Its Mechanism for Inactivation of the Retinoblastoma Tumor Suppressor. <i>Journal of Biological Chemistry</i> , 2006, 281, 578-586.	1.6	186
1318	Age-period-cohort analysis of cervical cancer incidence in Hong Kong from 1972 to 2001 using maximum likelihood and Bayesian methods. <i>Journal of Epidemiology and Community Health</i> , 2006, 60, 712-720.	2.0	13

#	ARTICLE	IF	CITATIONS
1319	Human Papillomavirus Type-Specific 18-Month Risk of High-Grade Cervical Intraepithelial Neoplasia in Women with a Normal or Borderline/Mildly Dyskaryotic Smear. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2006, 15, 1268-1273.	1.1	60
1320	Presence of E6 and E7 mRNA from Human Papillomavirus Types 16, 18, 31, 33, and 45 in the Majority of Cervical Carcinomas. <i>Journal of Clinical Microbiology</i> , 2006, 44, 1310-1317.	1.8	100
1321	Age-Related Changes of the Cervix Influence Human Papillomavirus Type Distribution. <i>Cancer Research</i> , 2006, 66, 1218-1224.	0.4	95
1322	Human Papillomavirus Genotypes and the Cumulative 2-Year Risk of Cervical Precancer. <i>Journal of Infectious Diseases</i> , 2006, 194, 1291-1299.	1.9	120
1323	HPV16 Variants in Squamous Intraepithelial Lesions in Human Immunodeficiency Virus-Negative and -Positive Brazilian Women. <i>Viral Immunology</i> , 2006, 19, 340-345.	0.6	6
1324	Selection of cervical keratinocytes containing integrated HPV16 associates with episome loss and an endogenous antiviral response. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 3822-3827.	3.3	134
1325	Assessment of MagNA Pure LC Extraction System for Detection of Human Papillomavirus (HPV) DNA in PreservCyt Samples by the Roche AMPLICOR and LINEAR ARRAY HPV Tests. <i>Journal of Clinical Microbiology</i> , 2006, 44, 2428-2433.	1.8	53
1326	Human Papillomavirus Type 16 E6 Activates NF- κ B, Induces cIAP-2 Expression, and Protects against Apoptosis in a PDZ Binding Motif-Dependent Manner. <i>Journal of Virology</i> , 2006, 80, 5301-5307.	1.5	131
1327	Relationships of Human Papillomavirus Type, Qualitative Viral Load, and Age with Cytologic Abnormality. <i>Cancer Research</i> , 2006, 66, 10112-10119.	0.4	105
1328	Human papillomavirus vaccines for the treatment of cervical cancer. <i>Expert Review of Vaccines</i> , 2006, 5, 783-792.	2.0	11
1329	Inhibition of DNA Replication of Human Papillomavirus by Artificial Zinc Finger Proteins. <i>Journal of Virology</i> , 2006, 80, 5405-5412.	1.5	25
1330	Comparison of the Digene HC2 Assay and the Roche AMPLICOR Human Papillomavirus (HPV) Test for Detection of High-Risk HPV Genotypes in Cervical Samples. <i>Journal of Clinical Microbiology</i> , 2006, 44, 2141-2146.	1.8	87
1331	Smokers at Higher Risk for Undetected Antibody for Oncogenic Human Papillomavirus Type 16 Infection. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2006, 15, 915-920.	1.1	37
1332	Detection of Carcinogenic Human Papillomavirus in Specimens Collected with a Novel Self-Sampling Device. <i>Journal of Clinical Microbiology</i> , 2006, 44, 2158-2159.	1.8	11
1333	Production of Human Papillomavirus Type 16 L1 Virus-Like Particles by Recombinant <i>Lactobacillus casei</i> Cells. <i>Applied and Environmental Microbiology</i> , 2006, 72, 745-752.	1.4	72
1334	Indications, interpr�tation du test HPV et des marqueurs mol�culaires. , 2006, , 169-187.		0
1335	Telomerase activity as an adjunct to high-risk human papillomavirus types 16 and 18 and cytology screening in cervical cancer. <i>British Journal of Cancer</i> , 2006, 95, 1250-1257.	2.9	35
1336	Human papillomaviral load changes in low-grade squamous intraepithelial lesions of the uterine cervix. <i>British Journal of Cancer</i> , 2006, 95, 1384-1389.	2.9	27

#	ARTICLE	IF	CITATIONS
1337	Adeno-Associated Virus Type 2 Increases Proteasome-Dependent Degradation of p21 WAF1 in a Human Papillomavirus Type 31b-Positive Cervical Carcinoma Line. <i>Journal of Virology</i> , 2006, 80, 4927-4939.	1.5	17
1338	Oncogenic Human Papillomavirus (HPV) Type Distribution and HPV Type 16 E6 Variants in Two Spanish Population Groups with Different Levels of HPV Infection Risk. <i>Journal of Clinical Microbiology</i> , 2006, 44, 1428-1434.	1.8	33
1339	Worldwide Human Papillomavirus Etiology of Cervical Adenocarcinoma and Its Cofactors: Implications for Screening and Prevention. <i>Journal of the National Cancer Institute</i> , 2006, 98, 303-315.	3.0	568
1340	Human Papillomavirus Risk Type Classification from Protein Sequences Using Support Vector Machines. <i>Lecture Notes in Computer Science</i> , 2006, , 57-66.	1.0	4
1341	Effect of Alternative Aluminum Adjuvants on the Absorption and Immunogenicity of HPV16 L1 VLPs in Mice. <i>Hum Vaccin</i> , 2007, 3, 139-145.	2.4	72
1342	Indications, interprÃ©tation du test HPV et des marqueurs molÃ©culaires. , 2007, , 205-213.		0
1343	Comparison of the SPF 10 -LiPA System to the Hybrid Capture 2 Assay for Detection of Carcinogenic Human Papillomavirus Genotypes among 5,683 Young Women in Guanacaste, Costa Rica. <i>Journal of Clinical Microbiology</i> , 2007, 45, 1447-1454.	1.8	74
1344	Human Papillomavirus Type 31 Uses a Caveolin 1- and Dynamin 2-Mediated Entry Pathway for Infection of Human Keratinocytes. <i>Journal of Virology</i> , 2007, 81, 9922-9931.	1.5	113
1345	Association of cervical cancer with the presence of CD4 ⁺ regulatory T cells specific for human papillomavirus antigens. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 12087-12092.	3.3	201
1346	HPV type-specific risks of high-grade CIN during 4 years of follow-up: A population-based prospective study. <i>British Journal of Cancer</i> , 2007, 97, 129-132.	2.9	72
1347	Seroprevalence and Risk Factors for Human Papillomavirus in Taiwan. <i>Journal of Tropical Pediatrics</i> , 2007, 54, 14-18.	0.7	10
1348	Human papillomavirus vaccine: progress and the future. <i>Expert Opinion on Biological Therapy</i> , 2007, 7, 479-485.	1.4	0
1351	Seroprevalence of human papillomaviruses and Chlamydia trachomatis and cervical cancer risk: nested caseâ€”control study. <i>Journal of General Virology</i> , 2007, 88, 814-822.	1.3	58
1352	Interleukin-10 Gene (<i>IL10</i>) Polymorphisms and Human Papillomavirus Clearance among Immunosuppressed Adolescents. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2007, 16, 1626-1632.	1.1	36
1353	Evaluation of a Digene-Recommended Algorithm for Human Papillomavirus Low-Positive Results Present in a "Retest Zone". <i>American Journal of Clinical Pathology</i> , 2007, 127, 97-102.	0.4	16
1354	Mouthwash as a Low-Cost and Safe Specimen Transport Medium for Human Papillomavirus DNA Testing of Cervicovaginal Specimens. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2007, 16, 840-843.	1.1	13
1355	The Relationship of Community Biopsy-Diagnosed Cervical Intraepithelial Neoplasia Grade 2 to the Quality Control Pathology-Reviewed Diagnoses. <i>American Journal of Clinical Pathology</i> , 2007, 127, 805-815.	0.4	186
1356	Modeling Human Papillomavirus Vaccine Effectiveness: Quantifying the Impact of Parameter Uncertainty. <i>American Journal of Epidemiology</i> , 2007, 165, 762-775.	1.6	102

#	ARTICLE	IF	CITATIONS
1357	Deletion of a major neutralizing epitope of human papillomavirus type 16 virus-like particles. <i>Journal of General Virology</i> , 2007, 88, 792-802.	1.3	28
1358	Hawaii Cohort Study of Serum Micronutrient Concentrations and Clearance of Incident Oncogenic Human Papillomavirus Infection of the Cervix. <i>Cancer Research</i> , 2007, 67, 5987-5996.	0.4	32
1359	High Number of Intraepithelial CD8+ Tumor-Infiltrating Lymphocytes Is Associated with the Absence of Lymph Node Metastases in Patients with Large Early-Stage Cervical Cancer. <i>Cancer Research</i> , 2007, 67, 354-361.	0.4	369
1360	HLA-DQB1*02-Restricted HPV-16 E7 Peptide-Specific CD4+ T-Cell Immune Responses Correlate with Regression of HPV-16-Associated High-Grade Squamous Intraepithelial Lesions. <i>Clinical Cancer Research</i> , 2007, 13, 2479-2487.	3.2	68
1362	Cervical screening in the 21st century: the case for human papillomavirus testing of self-collected specimens. <i>Clinical Chemistry and Laboratory Medicine</i> , 2007, 45, 577-91.	1.4	28
1363	HLA Polymorphisms and Cervical Human Papillomavirus Infection in a Cohort of Montreal University Students. <i>Journal of Infectious Diseases</i> , 2007, 196, 82-90.	1.9	36
1364	Comparison of the Digene Hybrid Capture 2 Assay and Roche AMPLICOR and LINEAR ARRAY Human Papillomavirus (HPV) Tests in Detecting High-Risk HPV Genotypes in Specimens from Women with Previous Abnormal Pap Smear Results. <i>Journal of Clinical Microbiology</i> , 2007, 45, 2130-2137.	1.8	77
1365	Mechanisms Used by Human Papillomaviruses to Escape the Host Immune Response. <i>Current Cancer Drug Targets</i> , 2007, 7, 79-89.	0.8	187
1366	Identification of HLA-DR1- and HLA-DR15-restricted human papillomavirus type 16 (HPV16) and HPV18 E6 epitopes recognized by CD4+ T cells from healthy young women. <i>Journal of General Virology</i> , 2007, 88, 1470-1478.	1.3	23
1367	Optically Encoded Particles and Their Applications in Multiplexed Biomedical Assays. <i>Australian Journal of Chemistry</i> , 2007, 60, 343.	0.5	18
1369	A case-control study of cancer of the uterine cervix in Uganda. <i>European Journal of Cancer Prevention</i> , 2007, 16, 555-558.	0.6	5
1370	CIN2 Is a Much Less Reproducible and Less Valid Diagnosis than CIN3. <i>International Journal of Gynecological Pathology</i> , 2007, 26, 441-446.	0.9	200
1371	Antioxidant status in advanced cervical cancer patients undergoing neoadjuvant chemoradiation. <i>British Journal of Biomedical Science</i> , 2007, 64, 23-27.	1.2	51
1372	Human Papillomavirus Seroprevalence Among Young Male and Female Drug Users. <i>Sexually Transmitted Diseases</i> , 2007, 34, 676-680.	0.8	8
1373	Human Papilloma Viruses: Realities and Perspectives. <i>Biotechnology and Biotechnological Equipment</i> , 2007, 21, 137-144.	0.5	3
1374	RETIRED: Vaccines. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2007, 29, S51-S54.	0.3	2
1375	Safety and Persistent Immunogenicity of a Quadrivalent Human Papillomavirus Types 6, 11, 16, 18 L1 Virus-Like Particle Vaccine in Preadolescents and Adolescents. <i>Pediatric Infectious Disease Journal</i> , 2007, 26, 201-209.	1.1	276
1376	Detection of human papillomavirus type 16 DNA in formalin-fixed, paraffin-embedded tissue specimens of gastric carcinoma. <i>European Journal of Gastroenterology and Hepatology</i> , 2007, 19, 1090-1096.	0.8	11

#	ARTICLE	IF	CITATIONS
1377	Molecular targets in gynaecological cancers. <i>Pathology</i> , 2007, 39, 26-45.	0.3	13
1378	Anal squamous intraepithelial lesions and condyloma in HIV-infected heterosexual men, homosexual men and women: prevalence and associated factors. <i>Aids</i> , 2007, 21, 1457-1465.	1.0	124
1379	A comparison of liquid-based cytology and Pap smear as a screening method for cervical cancer. <i>Oncology Reports</i> , 0, , .	1.2	17
1380	Anti-cancer activity of plant-produced HPV16 E7 vaccine. <i>Vaccine</i> , 2007, 25, 3018-3021.	1.7	90
1381	Costâ€“utility analysis of vaccination against HPV in Israel. <i>Vaccine</i> , 2007, 25, 6677-6691.	1.7	35
1383	Prevalence and distribution of single and multiple HPV infections in cytologically abnormal cervical samples from Italian women. <i>Virus Research</i> , 2007, 125, 176-182.	1.1	65
1384	Formation of well-defined soluble aggregates upon fusion to MBP is a generic property of E6 proteins from various human papillomavirus species. <i>Protein Expression and Purification</i> , 2007, 51, 59-70.	0.6	48
1387	Role of hormone cofactors in the human papillomavirus-induced carcinogenesis of the uterine cervix. <i>Molecular and Cellular Endocrinology</i> , 2007, 264, 1-5.	1.6	33
1388	Seroprevalence of human papillomavirus types 16 and 18 in the general population in Taiwan: Implication for optimal age of human papillomavirus vaccination. <i>Journal of Clinical Virology</i> , 2007, 38, 126-130.	1.6	22
1389	A built-in co-carcinogenic effect due to viruses involved in latent or persistent infections. <i>Medical Hypotheses</i> , 2007, 68, 1001-1008.	0.8	2
1390	Detection and typing of minimal human papillomavirus DNA in plasma. <i>International Journal of Gynecology and Obstetrics</i> , 2007, 96, 112-116.	1.0	26
1391	Human papillomavirus subtype 16 is common in Pakistani women with cervical carcinoma. <i>International Journal of Infectious Diseases</i> , 2007, 11, 313-317.	1.5	51
1393	Human Papillomavirus and Vaccination in Cervical Cancer. <i>Taiwanese Journal of Obstetrics and Gynecology</i> , 2007, 46, 352-362.	0.5	12
1394	Overview of Microarray Analysis of Gene Expression and its Applications to Cervical Cancer Investigation. <i>Taiwanese Journal of Obstetrics and Gynecology</i> , 2007, 46, 363-373.	0.5	13
1395	Chromosomal Gain of 3q and Loss of 11q Often Associated with Nodal Metastasis in Early Stage Cervical Squamous Cell Carcinoma. <i>Journal of the Formosan Medical Association</i> , 2007, 106, 894-902.	0.8	12
1396	Human papillomavirus infection and the development of cervical cancer and related genital neoplasias. <i>International Journal of Infectious Diseases</i> , 2007, 11, S3-S9.	1.5	86
1397	Overview of the clinical development and results of a quadrivalent HPV (types 6, 11, 16, 18) vaccine. <i>International Journal of Infectious Diseases</i> , 2007, 11, S17-S25.	1.5	52
1398	Advances in primary and secondary interventions for cervical cancer: human papillomavirus prophylactic vaccines and testing. <i>Nature Clinical Practice Oncology</i> , 2007, 4, 224-235.	4.3	64

#	ARTICLE	IF	CITATIONS
1399	Analyses of Bcl-2, Survivin, and CD44v6 expressions and human papillomavirus infection in cervical carcinomas. <i>Scandinavian Journal of Infectious Diseases</i> , 2007, 39, 441-448.	1.5	10
1400	General Principles of Tumor Immunotherapy. , 2007, , .		3
1401	Implementation of an HPV-Vaccination Program. <i>Disease Management and Health Outcomes</i> , 2007, 15, 141-149.	0.3	3
1402	Molecular Pathology in Clinical Practice. , 2007, , .		8
1403	Economic evaluations of human papillomavirus vaccines. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2007, 7, 251-267.	0.7	12
1404	Advances in dendritic cell-based therapeutic vaccines for cervical cancer. <i>Expert Review of Anticancer Therapy</i> , 2007, 7, 1473-1486.	1.1	32
1405	Human Papillomavirus Infection in Malignant and Benign Gynaecological Conditions: A Study in Greek Women. <i>Health Care for Women International</i> , 2007, 28, 182-191.	0.6	9
1406	Pap Smear Screening Among Women ≥40 years Residing at the United States-Mexico Border. <i>Health Care for Women International</i> , 2007, 28, 799-816.	0.6	13
1407	Ã©pidÃ©miologie et histoire naturelle. , 2007, , 11-30.		0
1408	Prophylactic Human Papillomavirus Vaccination: A Breakthrough in Primary Cervical Cancer Prevention. <i>Obstetrics and Gynecology Clinics of North America</i> , 2007, 34, 761-781.	0.7	6
1409	Prevention, Diagnosis, and Treatment of Cervical Cancer. <i>Mayo Clinic Proceedings</i> , 2007, 82, 1566-1574.	1.4	14
1410	Cervical Cancer Preventionâ€”Cervical Screening: Science in Evolution. <i>Obstetrics and Gynecology Clinics of North America</i> , 2007, 34, 739-760.	0.7	177
1413	Genome wide expression analysis in HPV16 Cervical Cancer: identification of altered metabolic pathways. <i>Infectious Agents and Cancer</i> , 2007, 2, 16.	1.2	52
1414	A cost-effectiveness analysis of adding a human papillomavirus vaccine to the Australian National Cervical Cancer Screening Program. <i>Sexual Health</i> , 2007, 4, 165.	0.4	91
1416	The Epidemiology of Human Papillomavirus Infection and Cervical Cancer. <i>Disease Markers</i> , 2007, 23, 213-227.	0.6	274
1417	Molecular detection of HPV 16 and 18 in cervical samples of patients from Belo Horizonte, Minas Gerais, Brazil. <i>Revista Do Instituto De Medicina Tropical De Sao Paulo</i> , 2007, 49, 297-301.	0.5	12
1419	Human papillomavirus genotype in cervical cancer: A population-based study. <i>International Journal of Cancer</i> , 2007, 120, 1999-2006.	2.3	65
1420	HPV prevalence, viral load and physical state of HPVâ€”16 in cervical smears of patients with different grades of CIN. <i>International Journal of Cancer</i> , 2007, 121, 2198-2204.	2.3	63

#	ARTICLE	IF	CITATIONS
1421	High load for most high risk human papillomavirus genotypes is associated with prevalent cervical cancer precursors but only HPV16 load predicts the development of incident disease. <i>International Journal of Cancer</i> , 2007, 121, 2787-2793.	2.3	134
1422	Vaccination trial with HPV16 L1E7 chimeric virus-like particles in women suffering from high grade cervical intraepithelial neoplasia (CIN 2/3). <i>International Journal of Cancer</i> , 2007, 121, 2794-2800.	2.3	118
1423	Early detection of cervical neoplasia by Raman spectroscopy. <i>International Journal of Cancer</i> , 2007, 121, 2723-2728.	2.3	150
1424	Vaccine-related HPV genotypes in women with and without cervical cancer in Mozambique: Burden and potential for prevention. <i>International Journal of Cancer</i> , 2008, 122, 1901-1904.	2.3	46
1425	Evaluation of quantity and staining pattern of human papillomavirus (HPV)-infected epithelial cells in thin-layer cervical specimens using optimized HPV-CARD assay. <i>Cancer</i> , 2007, 111, 330-338.	2.0	13
1426	HPV16 E6 variants and HLA class II polymorphism among Chinese women with cervical cancer. <i>Journal of Medical Virology</i> , 2007, 79, 439-446.	2.5	16
1427	Prevalence of the most common high-risk HPV genotypes among women in three new independent states of the former Soviet Union. <i>Journal of Medical Virology</i> , 2007, 79, 771-781.	2.5	31
1428	Population-based study of screening test performance indices of three human papillomavirus DNA tests. <i>Journal of Medical Virology</i> , 2007, 79, 1169-1175.	2.5	24
1429	Prevalence of human papillomavirus types 6, 11, 16, 18, 31, and 33 in a cohort of Greek women. <i>Journal of Medical Virology</i> , 2007, 79, 1898-1905.	2.5	18
1430	Biofunctional organic nanocrystals for quantitative detection of pathogen deoxyribonucleic acid. <i>Analytica Chimica Acta</i> , 2007, 584, 7-11.	2.6	24
1431	Efficiency of immunohistochemical p16 expression and HPV typing in cervical squamous intraepithelial lesion grading and review of the p16 literature. <i>Pathology Research and Practice</i> , 2007, 203, 445-449.	1.0	50
1432	Modeling human papillomavirus and cervical cancer in the United States for analyses of screening and vaccination. <i>Population Health Metrics</i> , 2007, 5, 11.	1.3	74
1433	Integration of high-risk human papillomavirus: a key event in cervical carcinogenesis?. <i>Journal of Pathology</i> , 2007, 212, 356-367.	2.1	360
1434	Regulation of matrix metalloproteinase-9 transcription in squamous cell carcinoma of uterine cervix: the role of human papillomavirus gene E2 expression and activation of transcription factor NF- κ B. <i>Biochemistry (Moscow)</i> , 2007, 72, 848-853.	0.7	10
1435	Distribution of HPV genotypes in 282 women with cervical lesions: evidence for three categories of intraepithelial lesions based on morphology and HPV type. <i>Modern Pathology</i> , 2007, 20, 167-174.	2.9	48
1436	Distribution and viral load of eight oncogenic types of human papillomavirus (HPV) and HPV 16 integration status in cervical intraepithelial neoplasia and carcinoma. <i>Modern Pathology</i> , 2007, 20, 256-266.	2.9	58
1437	A comparative profile of the prevalence and age distribution of human papillomavirus type 16/18 infections among three states of India with focus on northeast India. <i>International Journal of Gynecological Cancer</i> , 2007, 17, 107-117.	1.2	51
1438	Differentially expressed genes between high-risk human papillomavirus types in human cervical cancer cells. <i>International Journal of Gynecological Cancer</i> , 2007, 17, 484-491.	1.2	20

#	ARTICLE	IF	CITATIONS
1439	Human papillomavirus prevalence and predictors for cervical cancer among high-risk women from Rio de Janeiro, Brazil. <i>International Journal of Gynecological Cancer</i> , 2007, 17, 651-660.	1.2	24
1440	Human papillomavirus genotyping using HPV DNA chip analysis in Korean women. <i>International Journal of Gynecological Cancer</i> , 2007, 17, 497-501.	1.2	24
1441	Human papillomavirus genotype as a prognostic factor in carcinoma of the uterine cervix. <i>International Journal of Gynecological Cancer</i> , 2007, 17, 1307-1313.	1.2	26
1442	The relationship between human papillomavirus infection and cervical intraepithelial neoplasia in Turkish women. <i>International Journal of Gynecological Cancer</i> , 2007, 17, 1266-1270.	1.2	41
1443	Human papillomavirus infection and primary fallopian tube carcinoma: a seroepidemiological study. <i>IJOG: an International Journal of Obstetrics and Gynaecology</i> , 2007, 114, 425-429.	1.1	13
1444	Concurrent HPV infection in oral and genital mucosa. <i>Journal of Oral Pathology and Medicine</i> , 1998, 27, 130-134.	1.4	41
1445	Characteristics of vulvar squamous cell carcinoma in Japanese women. <i>Pathology International</i> , 2007, 57, 322-327.	0.6	6
1446	American Cancer Society Guideline for Human Papillomavirus (HPV) Vaccine Use to Prevent Cervical Cancer and Its Precursors. <i>Ca-A Cancer Journal for Clinicians</i> , 2007, 57, 7-28.	157.7	443
1447	The full-length E1 ^{E4} protein of human papillomavirus type 18 modulates differentiation-dependent viral DNA amplification and late gene expression. <i>Virology</i> , 2007, 362, 453-460.	1.1	56
1448	Oral immunization with different assembly forms of the HPV 16 major capsid protein L1 induces neutralizing antibodies and cytotoxic T-lymphocytes. <i>Virology</i> , 2007, 369, 375-388.	1.1	43
1449	HPV prevalence, E6 sequence variation and physical state of HPV16 isolates from patients with cervical cancer in Sichuan, China. <i>Gynecologic Oncology</i> , 2007, 104, 77-85.	0.6	21
1450	The expressions of the Rb pathway in cervical intraepithelial neoplasia; predictive and prognostic significance. <i>Gynecologic Oncology</i> , 2007, 104, 207-211.	0.6	38
1451	Predictive value of HPV DNA in lymph nodes in surgically treated cervical carcinoma patients—a prospective study. <i>Gynecologic Oncology</i> , 2007, 104, 721-726.	0.6	21
1452	The relationship between cytokines and HPV-16, HPV-16 E6, E7, and high-risk HPV viral load in the uterine cervix. <i>Gynecologic Oncology</i> , 2007, 104, 732-738.	0.6	25
1453	Viral DNA load, physical status and E2/E6 ratio as markers to grade HPV16 positive women for high-grade cervical lesions. <i>Gynecologic Oncology</i> , 2007, 106, 549-557.	0.6	100
1454	COX-2 overexpression as a biomarker of early cervical carcinogenesis: A pilot study. <i>Gynecologic Oncology</i> , 2007, 107, S155-S162.	0.6	19
1455	The impact of cervical cancer on quality of life—the components and means for management. <i>Gynecologic Oncology</i> , 2007, 107, 572-577.	0.6	78
1456	The use of HPV Linear Array Assay for multiple HPV typing on archival frozen tissue and DNA specimens. <i>Journal of Virological Methods</i> , 2007, 142, 226-230.	1.0	38

#	ARTICLE	IF	CITATIONS
1457	PreTectâ„¢ HPV-Proofer: Real-time detection and typing of E6/E7 mRNA from carcinogenic human papillomaviruses. <i>Journal of Virological Methods</i> , 2007, 142, 204-212.	1.0	78
1458	Role of HPV testing in the NHS Cervical Screening Programme. <i>Trends in Urology Gynaecology & Sexual Health</i> , 2007, 12, 7-10.	0.1	0
1459	Reducing the burden of glandular carcinomas of the uterine cervix. <i>American Journal of Obstetrics and Gynecology</i> , 2007, 197, 566-571.	0.7	36
1460	Molecular detection of <i>Chlamydia trachomatis</i> and HPV infections in cervical samples with normal and abnormal cytopathological findings. <i>Diagnostic Cytopathology</i> , 2007, 35, 198-202.	0.5	21
1461	DNA extraction: An understudied and important aspect of HPV genotyping using PCR-based methods. <i>Journal of Virological Methods</i> , 2007, 143, 45-54.	1.0	45
1462	Photodynamic Effects Induced by Aminolevulinic Acid Esters on Human Cervical Carcinoma Cells in Culture. <i>Photochemistry and Photobiology</i> , 2007, 74, 617-623.	1.3	0
1463	Accuracy of HPV testing of vaginal smear obtained with a novel self-sampling device. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2007, 86, 16-21.	1.3	20
1469	Adjuvant properties of listeriolysin O protein in a DNA vaccination strategy. <i>Cancer Immunology, Immunotherapy</i> , 2007, 56, 797-806.	2.0	28
1470	Vaccination with an adenoviral vector expressing calreticulin-human papillomavirus 16 E7 fusion protein eradicates E7 expressing established tumors in mice. <i>Cancer Immunology, Immunotherapy</i> , 2007, 56, 997-1007.	2.0	76
1471	Thermosensitive mucoadhesive gel formulation loaded with 5-Fu: cyclodextrin complex for HPV-induced cervical cancer. <i>Journal of Inclusion Phenomena and Macrocyclic Chemistry</i> , 2007, 57, 363-370.	1.6	64
1472	Racial and ethnic disparities in cervical cancer incidence rates in the United States, 1992â€“2003. <i>Cancer Causes and Control</i> , 2007, 18, 1175-1186.	0.8	94
1473	A non-radioactive PCR-SSCP analysis allows to distinguish between HPV 16 European and Asian-American variants in squamous cell carcinomas of the uterine cervix in Colombia. <i>Virus Genes</i> , 2008, 37, 22-30.	0.7	12
1474	Expression of human papilloma virus type 16 antigens, specific targeting as well as formation of virus-like particles by HSV-1 amplicon vectors. <i>Virus Genes</i> , 2008, 37, 131-143.	0.7	3
1476	Electrically detected displacement assay (EDDA): a practical approach to nucleic acid testing in clinical or medical diagnosis. <i>Analytical and Bioanalytical Chemistry</i> , 2008, 391, 1759-1772.	1.9	47
1478	Expression and purification of human papillomavirus 18 L1 virus-like particle from <i>Saccharomyces cerevisiae</i> . <i>Archives of Pharmacal Research</i> , 2008, 31, 205-209.	2.7	27
1479	Cell-permeable artificial zinc-finger proteins as potent antiviral drugs for human papillomaviruses. <i>Archives of Virology</i> , 2008, 153, 1291-1298.	0.9	30
1480	Impact of polymorphism in IL-1RA gene on the risk of cervical cancer. <i>Archives of Gynecology and Obstetrics</i> , 2008, 277, 527-533.	0.8	19
1481	Recurrent respiratory papillomatosis: an overview of current thinking and treatment. <i>European Archives of Oto-Rhino-Laryngology</i> , 2008, 265, 147-151.	0.8	121

#	ARTICLE	IF	CITATIONS
1482	The physical state of HPV16 infection and its clinical significance in cancer precursor lesion and cervical carcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2008, 134, 1355-61.	1.2	49
1484	Human Papillomavirus type distribution in invasive cervical cancer in Uganda. <i>BMC Infectious Diseases</i> , 2008, 8, 85.	1.3	32
1485	Cervical dysplasia and cancer and the use of hormonal contraceptives in Jamaican women. <i>BMC Women's Health</i> , 2008, 8, 9.	0.8	26
1486	Human papillomavirus and mutated Hras oncogene in cervical carcinomas and pathological negative pelvic lymph nodes: A retrospective follow-up. <i>Journal of Medical Virology</i> , 2008, 80, 694-701.	2.5	12
1487	The p53 R72P polymorphism does not influence cervical cancer development in a portuguese population: A study in exfoliated cervical cells. <i>Journal of Medical Virology</i> , 2008, 80, 424-429.	2.5	18
1488	Prevalence and genotype distribution of multiple human papillomavirus infection in the uterine cervix: A 7.5-year longitudinal study in a routine cytology-based screening population in West Germany. <i>Journal of Medical Virology</i> , 2008, 80, 1814-1823.	2.5	25
1489	Photodynamic therapy of cervical intraepithelial neoplasia with hexaminolevulinate. <i>Lasers in Surgery and Medicine</i> , 2008, 40, 611-615.	1.1	71
1490	Cervical cancer in patients infected with the human immunodeficiency virus. <i>Cancer</i> , 2008, 112, 2683-2689.	2.0	22
1491	Distribution of treatment for human papillomavirus-associated gynecologic carcinomas before prophylactic vaccine. <i>Cancer</i> , 2008, 113, 2926-2935.	2.0	2
1492	Cancer registries and monitoring the impact of prophylactic human papillomavirus vaccines: The potential role. <i>Cancer</i> , 2008, 113, 3047-3057.	2.0	17
1493	Are adjunctive markers useful in routine cervical cancer screening? Application of p16 ^{INK4a} and HPV-PCR on ThinPrep samples with histological follow-up. <i>Diagnostic Cytopathology</i> , 2008, 36, 453-459.	0.5	18
1494	Human papillomavirus genotypes and HPV16 variants in penile carcinoma. <i>International Journal of Cancer</i> , 2008, 122, 132-137.	2.3	50
1495	Human papillomavirus (HPV) genotype distribution in invasive cervical cancers in France: EDITH study. <i>International Journal of Cancer</i> , 2008, 122, 428-432.	2.3	84
1496	Endogenous optical biomarkers of normal and human papillomavirus immortalized epithelial cells. <i>International Journal of Cancer</i> , 2008, 122, 363-371.	2.3	54
1497	Human papilloma virus specific T cells infiltrating cervical cancer and draining lymph nodes show remarkably frequent use of HLA-DQ and -DP as a restriction element. <i>International Journal of Cancer</i> , 2008, 122, 486-494.	2.3	74
1498	Recent advances in strategies for immunotherapy of human papillomavirus-induced lesions. <i>International Journal of Cancer</i> , 2008, 122, 247-259.	2.3	59
1499	A panel of p16 ^{INK4A} , MIB1 and p53 proteins can distinguish between the 2 pathways leading to vulvar squamous cell carcinoma. <i>International Journal of Cancer</i> , 2008, 123, 2767-2773.	2.3	88
1500	Inactivation of the cystatin E/M tumor suppressor gene in cervical cancer. <i>Genes Chromosomes and Cancer</i> , 2008, 47, 740-754.	1.5	31

#	ARTICLE	IF	CITATIONS
1501	Pharmacokinetics and selectivity of porphyrin synthesis after topical application of hexaminolevulinate in patients with cervical intraepithelial neoplasia. <i>American Journal of Obstetrics and Gynecology</i> , 2008, 198, 300.e1-300.e7.	0.7	33
1502	Evaluation of primary cervical cancer screening with an oncogenic human papillomavirus DNA test and cervical cytologic findings among women who attended family planning clinics in the United States. <i>American Journal of Obstetrics and Gynecology</i> , 2008, 199, 26.e1-26.e8.	0.7	18
1503	Persistence and clearance of human papillomavirus infection: a prospective cohort study. <i>American Journal of Obstetrics and Gynecology</i> , 2008, 199, 617.e1-617.e7.	0.7	50
1504	Detection of integrated human papillomavirus by human papillomavirus types 16 and 18 in situ hybridization: a valuable diagnostic tool in diagnosing cervical carcinoma?. <i>American Journal of Obstetrics and Gynecology</i> , 2008, 199, e8-e10.	0.7	3
1505	A Review of the Evidence Comparing the Human Papillomavirus Vaccine Versus Condoms in the Prevention of Human Papillomavirus Infections. <i>JOGNN - Journal of Obstetric, Gynecologic, and Neonatal Nursing</i> , 2008, 37, 329-337.	0.2	17
1506	Connective tissue growth factor linked to the E7 tumor antigen generates potent antitumor immune responses mediated by an antiapoptotic mechanism. <i>Gene Therapy</i> , 2008, 15, 1007-1016.	2.3	28
1507	Prevalence of human papillomavirus in Indonesia: a population-based study in three regions. <i>British Journal of Cancer</i> , 2008, 99, 214-218.	2.9	49
1508	Human papillomavirus "reflex"™ testing as a screening method in cases of minor cytological abnormalities. <i>British Journal of Cancer</i> , 2008, 99, 563-568.	2.9	17
1509	Human papillomavirus prevalence in women attending routine cervical screening in South Wales, UK: a cross-sectional study. <i>British Journal of Cancer</i> , 2008, 99, 1929-1933.	2.9	28
1510	Genital human papillomavirus screening by gene chip in Chinese women of Guangdong province. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2008, 48, 189-194.	0.4	29
1511	Human Papillomavirus Type 73 in Primary and Recurrent Periungual Squamous Cell Carcinoma. <i>Dermatologic Surgery</i> , 2008, 34, 407-413.	0.4	13
1512	Human papillomavirus type distribution in women from Asia: a meta-analysis. <i>International Journal of Gynecological Cancer</i> , 2008, 18, 71-79.	1.2	167
1513	Association between human papillomavirus DNA load and development of cervical intraepithelial neoplasia and cervical cancer. <i>International Journal of Gynecological Cancer</i> , 2008, 18, 755-760.	1.2	12
1514	Pitfalls in the epidemiologic classification of human papillomavirus types associated with cervical cancer using polymerase chain reaction: driver and passenger. <i>International Journal of Gynecological Cancer</i> , 2008, 18, 1042-1050.	1.2	29
1515	Head and neck cancer in the betel quid chewing area: recent advances in molecular carcinogenesis. <i>Cancer Science</i> , 2008, 99, 1507-1514.	1.7	264
1516	Characterization of sequence variations within HPV16 isolates among Indian women: Prediction of causal role of rare non-synonymous variations within intact isolates in cervical cancer pathogenesis. <i>Virology</i> , 2008, 377, 143-150.	1.1	23
1517	Human papillomavirus type 45 E7 is a transforming protein inducing retinoblastoma protein degradation and anchorage-independent cell cycle progression. <i>Virology</i> , 2008, 379, 20-29.	1.1	9
1518	Natural history and epidemiology of HPV infection and cervical cancer. <i>Gynecologic Oncology</i> , 2008, 110, S4-S7.	0.6	401

#	ARTICLE	IF	CITATIONS
1519	Cervix carcinoma is associated with an up-regulation and nuclear localization of the dual-specificity protein phosphatase VHR. <i>BMC Cancer</i> , 2008, 8, 147.	1.1	53
1520	Evaluation of high-risk Human papillomaviruses type distribution in cervical cancer in Sichuan province of China. <i>BMC Cancer</i> , 2008, 8, 202.	1.1	20
1521	Distribution of HPV genotypes in uterine cervical lesions in Yanbian, northern China. <i>Pathology International</i> , 2008, 58, 643-647.	0.6	12
1523	Detection of human papillomavirus genotypes with liquid bead microarray in cervical lesions of northern Chinese patients. <i>Cancer Genetics and Cytogenetics</i> , 2008, 182, 12-17.	1.0	10
1524	Update on Molecular Diagnostic Tests in Head and Neck Cancer. <i>Seminars in Oncology</i> , 2008, 35, 198-210.	0.8	16
1525	Prevalence and Significance of Human Papillomavirus in Oral Tongue Cancer: The Mayo Clinic Experience. <i>Journal of Oral and Maxillofacial Surgery</i> , 2008, 66, 1875-1880.	0.5	97
1526	Prevalence of high-risk human papillomavirus types in Mexican women with cervical intraepithelial neoplasia and invasive carcinoma. <i>Infectious Agents and Cancer</i> , 2008, 3, 3.	1.2	36
1527	Evolutionary and structural analyses of alpha-papillomavirus capsid proteins yields novel insights into L2 structure and interaction with L1. <i>Virology Journal</i> , 2008, 5, 150.	1.4	30
1528	Diagnostic utility of p16INK4a: a reappraisal of its use in cervical biopsies. <i>Pathology</i> , 2008, 40, 335-344.	0.3	70
1529	Clinical trial experience with prophylactic HPV 6/11/16/18 VLP vaccine in young women from the Asia-Pacific region. <i>International Journal of Gynecology and Obstetrics</i> , 2008, 102, 275-283.	1.0	26
1532	Comparison of a novel HPV test with the Hybrid Capture II (hcII) and a reference PCR method shows high specificity and positive predictive value for 13 high-risk human papillomavirus infections. <i>Journal of Clinical Virology</i> , 2008, 42, 22-26.	1.6	27
1533	Prevalence and genotypes identification of human papillomavirus infection in a population of South Italy. <i>Journal of Clinical Virology</i> , 2008, 42, 211-214.	1.6	15
1534	Optimum conditions for production and purification of human papillomavirus type 16 L1 protein from <i>Saccharomyces cerevisiae</i> . <i>Protein Expression and Purification</i> , 2008, 59, 175-181.	0.6	38
1535	Optimization of primary and secondary cervical cancer prevention strategies in an era of cervical cancer vaccination: A multi-regional health economic analysis. <i>Vaccine</i> , 2008, 26, F46-F58.	1.7	48
1536	A meta-analysis of human papillomavirus type-distribution in women from South Asia: Implications for vaccination. <i>Vaccine</i> , 2008, 26, 2811-2817.	1.7	91
1537	Prospects and prejudices of human papillomavirus vaccines in India. <i>Vaccine</i> , 2008, 26, 2669-2679.	1.7	84
1538	Cellular immunity induced by a novel HPV18 DNA vaccine encoding an E6/E7 fusion consensus protein in mice and rhesus macaques. <i>Vaccine</i> , 2008, 26, 5210-5215.	1.7	61
1539	Vaccination and the evolutionary ecology of human papillomavirus. <i>Vaccine</i> , 2008, 26, C25-C30.	1.7	20

#	ARTICLE	IF	CITATIONS
1540	Evaluation of systemic and mucosal anti-HPV16 and anti-HPV18 antibody responses from vaccinated women. <i>Vaccine</i> , 2008, 26, 3608-3616.	1.7	77
1541	Human papillomavirus, cervical cancer prevention, and more. <i>Vaccine</i> , 2008, 26, iii-iv.	1.7	11
1542	Asia Pacific: Cervical Cancer Screening and Human Papillomavirus Vaccination Policy and Delivery. <i>Vaccine</i> , 2008, 26, iii-iv.	1.7	2
1543	Cervical cancer vaccination: The real meaning of cross-protection and its impact on the prevention. <i>Vaccine</i> , 2008, 26, 6293-6294.	1.7	2
1544	The Role of Infectious Agents in the Etiology of Ocular Adnexal Neoplasia. <i>Survey of Ophthalmology</i> , 2008, 53, 312-331.	1.7	113
1545	Two types of squamous cell carcinoma of the palatine tonsil characterized by distinct etiology, molecular features and outcome. <i>Cancer Letters</i> , 2008, 260, 72-78.	3.2	63
1546	Establishment and validation of an ex vivo human cervical tissue model for local delivery studies. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2008, 68, 390-399.	2.0	10
1548	High-Throughput Genotyping of Oncogenic Human Papilloma Viruses with MALDI-TOF Mass Spectrometry. <i>Clinical Chemistry</i> , 2008, 54, 86-92.	1.5	50
1549	Molecular Epidemiology of Human Papillomavirus. <i>Journal of the Formosan Medical Association</i> , 2008, 107, 198-217.	0.8	68
1550	Salvage Chemotherapy in Recurrent Cervical Cancer With Biweekly Pegylated Liposomal Doxorubicin (Lipo-Dox). <i>Taiwanese Journal of Obstetrics and Gynecology</i> , 2008, 47, 322-326.	0.5	9
1551	Diagnosis of Human Papillomavirus Infection by Abnormal Cervical Cytology is Highly Reproducible After Vaginal Douching. <i>Taiwanese Journal of Obstetrics and Gynecology</i> , 2008, 47, 412-416.	0.5	4
1552	Natural History of Human Papillomavirus Infections, Cytologic and Histologic Abnormalities, and Cancer. <i>Obstetrics and Gynecology Clinics of North America</i> , 2008, 35, 519-536.	0.7	82
1553	Human Papillomavirus in HNSCC: Recognition of a Distinct Disease Type. <i>Hematology/Oncology Clinics of North America</i> , 2008, 22, 1125-1142.	0.9	143
1554	Anal Cancer Screening: Barriers and Facilitators Among Ethnically Diverse Gay, Bisexual, Transgender, and Other Men Who Have Sex With Men. <i>Journal of Gay and Lesbian Social Services</i> , 2008, 20, 328-353.	0.9	54
1555	Therapeutic human papillomavirus vaccines: current clinical trials and future directions. <i>Expert Opinion on Biological Therapy</i> , 2008, 8, 421-439.	1.4	156
1556	Cervical Human Papillomavirus (HPV) Infection and HPV Type 16 Antibodies in South African Women. <i>Journal of Clinical Microbiology</i> , 2008, 46, 732-739.	1.8	29
1557	Caveolin-1-Dependent Infectious Entry of Human Papillomavirus Type 31 in Human Keratinocytes Proceeds to the Endosomal Pathway for pH-Dependent Uncoating. <i>Journal of Virology</i> , 2008, 82, 9505-9512.	1.5	94
1558	Cytological distinction between high-risk and low-risk human papillomavirus infections in SurePath liquid-based cell preparations. <i>Journal of Clinical Pathology</i> , 2008, 61, 1317-1322.	1.0	9

#	ARTICLE	IF	CITATIONS
1559	HPV Typing in Women with Cervical Precancerous and Cancerous Lesions in Northwestern Iran. <i>Gynecologic and Obstetric Investigation</i> , 2008, 66, 68-72.	0.7	25
1560	Prevalence of High-Risk Human Papillomavirus Among Older Women. <i>Obstetrics and Gynecology</i> , 2008, 112, 979-989.	1.2	30
1561	Distribution of Six Oncogenic Types of Human Papillomavirus and Type 16 Integration Analysis in Chinese Women with Cervical Precancerous Lesions and Carcinomas. <i>Tumor Biology</i> , 2008, 29, 105-113.	0.8	16
1562	Comparison of Linear Array and Line Blot Assay for Detection of Human Papillomavirus and Diagnosis of Cervical Precancer and Cancer in the Atypical Squamous Cell of Undetermined Significance and Low-Grade Squamous Intraepithelial Lesion Triage Study. <i>Journal of Clinical Microbiology</i> , 2008, 46, 109-117.	1.8	91
1563	Induction of Tumor-Specific CD4+ and CD8+ T-Cell Immunity in Cervical Cancer Patients by a Human Papillomavirus Type 16 E6 and E7 Long Peptides Vaccine. <i>Clinical Cancer Research</i> , 2008, 14, 178-187.	3.2	346
1564	The Regulatory Element in the 3' Untranslated Region of Human Papillomavirus 16 Inhibits Expression by Binding CUG-binding Protein 1. <i>Journal of Biological Chemistry</i> , 2008, 283, 2286-2296.	1.6	29
1565	Silencing of E7 oncogene restores functional E-cadherin expression in human papillomavirus 16-transformed keratinocytes. <i>Carcinogenesis</i> , 2008, 29, 1441-1447.	1.3	79
1566	Human papillomavirus disease and vaccines. <i>American Journal of Health-System Pharmacy</i> , 2008, 65, 2105-2112.	0.5	30
1567	Comparison of the Third Wave Invader Human Papillomavirus (HPV) Assay and the Digene HPV Hybrid Capture 2 Assay for Detection of High-Risk HPV DNA. <i>Journal of Clinical Microbiology</i> , 2008, 46, 1641-1646.	1.8	59
1568	Human Papillomavirus Genotype Specificity of Hybrid Capture 2. <i>Journal of Clinical Microbiology</i> , 2008, 46, 2595-2604.	1.8	156
1569	Analysis of Human Papillomavirus Type 16 (HPV16) DNA Load and Physical State for Identification of HPV16-Infected Women with High-Grade Lesions or Cervical Carcinoma. <i>Journal of Clinical Microbiology</i> , 2008, 46, 3678-3685.	1.8	92
1570	Human Papillomavirus Type 16 and 18 E7-Pulsed Dendritic Cell Vaccination of Stage IB or IIA Cervical Cancer Patients: a Phase I Escalating-Dose Trial. <i>Journal of Virology</i> , 2008, 82, 1968-1979.	1.5	124
1571	Eps8 decreases chemosensitivity and affects survival of cervical cancer patients. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 1376-1385.	1.9	48
1572	Human papillomavirus type-distribution in the cervix of Chinese women: a meta-analysis. <i>International Journal of STD and AIDS</i> , 2008, 19, 106-111.	0.5	55
1573	Human papillomavirus (HPV) genotypes and HPV16 variants in human immunodeficiency virus-positive Italian women. <i>Journal of General Virology</i> , 2008, 89, 1380-1389.	1.3	40
1574	Validation of an Automated Detection Platform for Use with the Roche Linear Array Human Papillomavirus Genotyping Test. <i>Journal of Clinical Microbiology</i> , 2008, 46, 3813-3816.	1.8	29
1575	Evaluation of a Commercialized In Situ Hybridization Assay for Detecting Human Papillomavirus DNA in Tissue Specimens from Patients with Cervical Intraepithelial Neoplasia and Cervical Carcinoma. <i>Journal of Clinical Microbiology</i> , 2008, 46, 274-280.	1.8	91
1576	Human Papillomavirus Vaccine Legislation in Kentucky. <i>Policy, Politics, and Nursing Practice</i> , 2008, 9, 40-49.	0.8	4

#	ARTICLE	IF	CITATIONS
1577	A Comparison of Linear Array and Hybrid Capture 2 for Detection of Carcinogenic Human Papillomavirus and Cervical Precancer in ASCUS-LSIL Triage Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008, 17, 1248-1254.	1.1	60
1578	Human Papillomavirus Vaccines and Vaccine Implementation. <i>Women's Health</i> , 2008, 4, 595-604.	0.7	8
1579	Effective Induction of Type 1 Helper IgG _{2a} and Cytotoxic T-Cell Responses in Mice Following Immunization with Human Papillomavirus Type 16 E2 in MF59. <i>Viral Immunology</i> , 2008, 21, 225-234.	0.6	8
1580	Human Papillomavirus Type 73 in Primary and Recurrent Perungual Squamous Cell Carcinoma. <i>Dermatologic Surgery</i> , 2008, 34, 407-413.	0.4	9
1581	Predictive testing of early cervical pre-cancer by detecting human papillomavirus E6/E7 mRNA in cervical cytologies up to high-grade squamous intraepithelial lesions: Diagnostic and prognostic implications. <i>Oncology Reports</i> , 0, , .	1.2	15
1582	Molecular Epidemiology of Human Papillomavirus Infection. <i>Translational Research in Biomedicine</i> , 2008, , 1-19.	0.4	0
1583	Geographical relationships between sociodemographic factors and incidence of cervical cancer in the Netherlands 1989–2003. <i>European Journal of Cancer Prevention</i> , 2008, 17, 453-459.	0.6	27
1584	Factors Influencing Histologic Confirmation of High-Grade Squamous Intraepithelial Lesion Cytology. <i>Obstetrics and Gynecology</i> , 2008, 112, 637-645.	1.2	17
1585	Seroepidemiology of Human Papillomavirus Type 11 in the United States: Results From the Third National Health and Nutrition Examination Survey, 1991–1994. <i>Sexually Transmitted Diseases</i> , 2008, 35, 298-303.	0.8	21
1586	HIV, human papillomavirus, and cervical neoplasia and cancer in the era of highly active antiretroviral therapy. <i>European Journal of Cancer Prevention</i> , 2008, 17, 545-554.	0.6	174
1587	Early identification of cervical neoplasia with Raman spectroscopy and advanced methods for biomedical applications. , 2008, , .		0
1588	Association of DRB1 and DQB1 HLA Class II Polymorphisms in High-Grade and Neoplastic Cervical Lesions of Women From Argentina. <i>Journal of Lower Genital Tract Disease</i> , 2008, 12, 262-268.	0.9	11
1589	Prevalence of high-risk human papillomavirus infection in different cervical lesion among organized health-examination women in Shanghai, China. <i>Chinese Medical Journal</i> , 2008, 121, 1578-1582.	0.9	14
1591	Association of genetic polymorphism of the DNA base excision repair gene (APE-1 Asp/148 Glu) and HPV type (16/18) with the risk of cervix cancer in north Indian population. <i>Cancer Biomarkers</i> , 2008, 4, 63-71.	0.8	13
1592	Benign Proliferative Reactions, Intraepithelial Neoplasia, and Invasive Cancer of the Uterine Cervix. , 2008, , 131-212.		8
1593	Expression of p16INK4a and MIB-1 in relation to histopathology and HPV types in cervical adenocarcinoma. <i>International Journal of Oncology</i> , 2008, , .	1.4	2
1594	Does pretreatment HPV viral load correlate with prognosis in patients with early stage cervical carcinoma?. <i>Journal of Gynecologic Oncology</i> , 2008, 19, 113.	1.0	17
1595	Expression of the p16INK4a and Ki-67 in relation to the grade of cervical intraepithelial neoplasia and high-risk human papillomavirus infection. <i>Journal of Gynecologic Oncology</i> , 2008, 19, 162.	1.0	55

#	ARTICLE	IF	CITATIONS
1596	Papillomavirus 3' UTR regulatory elements. <i>Frontiers in Bioscience - Landmark</i> , 2008, Volume, 5646.	3.0	26
1597	<i>Microbiology, Inflammation, and Viral infections.</i> , 2008, , 91-129.		4
1599	Human Papillomavirus Infection: Low-Risk and High-Risk Genotypes in Women in Catania, Sicily. <i>International Journal of Gynecological Cancer</i> , 2009, 19, 1094-1098.	1.2	11
1600	Prevalence of Human Papillomavirus Genotypes in Routine Pap Smear of 2,562 Korean Women Determined by PCR-DNA Sequencing. <i>Journal of Bacteriology and Virology</i> , 2009, 39, 337.	0.0	2
1601	Cervical human papillomavirus infection in accra, Ghana. <i>Ghana Medical Journal</i> , 2009, 42, 71-8.	0.2	31
1602	Human Papilloma Virus and Other Risk Factors of Carcinoma Cervix. <i>Bangladesh Medical Journal</i> , 2009, 38, 18-23.	0.1	1
1603	Comparison of the Novel Human Papillomavirus 4 Auto-capillary Electrophoresis Test with the Hybrid Capture 2 Assay and with the PCR HPV Typing Set Test in the Detection of High-Risk HPV Including HPV 16 and 18 Genotypes in Cervical Specimens. <i>Journal of Korean Medical Science</i> , 2009, 24, 579.	1.1	13
1604	Expression of Heat Shock Protein 60 kDa Is Upregulated in Cervical Cancer. <i>Yonsei Medical Journal</i> , 2009, 50, 399.	0.9	58
1606	Clinical Significance of Human Papillomavirus Genotype by Linear Array Assay in Japanese Women With Uterine Cervical Lesions and Type 16 Physical Status by In Situ Hybridization. <i>International Journal of Gynecological Cancer</i> , 2009, 19, 1396-1401.	1.2	1
1607	Comparison of the Hybrid Capture II Assay With the Human Papillomavirus DNA Chip Test for the Detection of High-Grade Cervical Lesions. <i>International Journal of Gynecological Cancer</i> , 2009, 19, 924-928.	1.2	20
1609	The HPV Cellular Transactivator Brn-3a Can Be Used to Predict Cervical Adenocarcinoma and Squamous Carcinoma Precancer Lesions in the Developed and Developing Worlds. <i>Obstetrics and Gynecology International</i> , 2009, 2009, 1-8.	0.5	3
1610	The Papanicolaou smear and cervical cancer. , 0, , 175-180.		0
1613	Human Papillomavirus Type 16 Exists in Bacteria Isolated from Cervical Cancer Biopsies. <i>Journal of International Medical Research</i> , 2009, 37, 1065-1074.	0.4	10
1614	A Whole Genome Study and Identification of Specific Carcinogenic Regions of the Human Papilloma Viruses. <i>Journal of Computational Biology</i> , 2009, 16, 1461-1473.	0.8	6
1615	Modified General Primer PCR System for Sensitive Detection of Multiple Types of Oncogenic Human Papillomavirus. <i>Journal of Clinical Microbiology</i> , 2009, 47, 541-546.	1.8	130
1616	Analysis of Modified Human Papillomavirus Type 16 L1 Capsomeres: the Ability To Assemble into Larger Particles Correlates with Higher Immunogenicity. <i>Journal of Virology</i> , 2009, 83, 7690-7705.	1.5	57
1617	Epidemiology of Mucosal Human Papillomavirus Infection and Associated Diseases. <i>Public Health Genomics</i> , 2009, 12, 291-307.	0.6	127
1618	Epidemiology of HPV in HIV-Positive and HIV-Negative Fertile Women in Cameroon, West Africa. <i>Infectious Diseases in Obstetrics and Gynecology</i> , 2009, 2009, 1-6.	0.4	24

#	ARTICLE	IF	CITATIONS
1619	Sequence Variation of Human Papillomavirus Type 16 and Measurement of Viral Integration by Quantitative PCR. <i>Journal of Clinical Microbiology</i> , 2009, 47, 521-526.	1.8	11
1620	Relationship of serum antioxidant micronutrients and sociodemographic factors to cervical neoplasia: a case-control study. <i>Clinical Chemistry and Laboratory Medicine</i> , 2009, 47, 1005-12.	1.4	13
1621	Lymph Node-Targeted Immunotherapy Mediates Potent Immunity Resulting in Regression of Isolated or Metastatic Human Papillomavirus-Transformed Tumors. <i>Clinical Cancer Research</i> , 2009, 15, 6167-6176.	3.2	28
1622	Prevalence of Single and Multiple Human Papillomavirus Types in Cervical Cancer and Precursor Lesions in Hubei, China. <i>Oncology</i> , 2009, 76, 157-161.	0.9	15
1623	Identification of HLA-A11-restricted CTL epitopes derived from HPV type 18 using DNA immunization. <i>Cancer Biology and Therapy</i> , 2009, 8, 2025-2032.	1.5	14
1624	Evolutionary Dynamics of Variant Genomes of Human Papillomavirus Types 18, 45, and 97. <i>Journal of Virology</i> , 2009, 83, 1443-1455.	1.5	82
1625	HPV type 18 is more oncopotent than HPV16 in uterine cervical carcinogenesis although HPV16 is the prevalent type in Chennai, India. <i>Indian Journal of Cancer</i> , 2009, 46, 203.	0.2	11
1626	RNA (E6 and E7) Assays versus DNA (E6 and E7) Assays for Risk Evaluation for Women Infected with Human Papillomavirus. <i>Journal of Clinical Microbiology</i> , 2009, 47, 2136-2141.	1.8	42
1627	<i>Cervix.</i> , 2009, , 1263-1294.		0
1628	Persistence of High-Grade Cervical Dysplasia and Cervical Cancer Requires the Continuous Expression of the Human Papillomavirus Type 16 <i>E7</i> Oncogene. <i>Cancer Research</i> , 2009, 69, 4407-4414.	0.4	81
1629	Male Circumcision for the Prevention of HSV-2 and HPV Infections and Syphilis. <i>New England Journal of Medicine</i> , 2009, 360, 1298-1309.	13.9	461
1630	Influence of Loop Electrosurgical Excision Procedure on Subsequent Acquisition of New Human Papillomavirus Infections. <i>Journal of Infectious Diseases</i> , 2009, 199, 1612-1620.	1.9	8
1631	Three novel canine papillomaviruses support taxonomic clade formation. <i>Journal of General Virology</i> , 2009, 90, 2615-2621.	1.3	45
1632	Tumor-Expressed B7-H1 and B7-DC in Relation to PD-1+ T-Cell Infiltration and Survival of Patients with Cervical Carcinoma. <i>Clinical Cancer Research</i> , 2009, 15, 6341-6347.	3.2	230
1633	Clinical Performance of Human Papillomavirus E6 and E7 mRNA Testing for High-Grade Lesions of the Cervix. <i>Journal of Clinical Microbiology</i> , 2009, 47, 3895-3901.	1.8	63
1634	Development and evaluation of a PCR and mass spectroscopy (PCR-MS)-based method for quantitative, type-specific detection of human papillomavirus. <i>Journal of Virological Methods</i> , 2009, 160, 78-84.	1.0	16
1635	A cost-utility analysis of cervical cancer vaccination in preadolescent Canadian females. <i>BMC Public Health</i> , 2009, 9, 401.	1.2	30
1636	Identification of human papillomavirus type 16 integration sites in high-grade precancerous cervical lesions. <i>Gynecologic Oncology</i> , 2009, 113, 120-127.	0.6	59

#	ARTICLE	IF	CITATIONS
1637	Proteomics analysis of protein expression and specific protein oxidation in human papillomavirus transformed keratinocytes upon UVB irradiation. <i>Journal of Cellular and Molecular Medicine</i> , 2009, 13, 1809-1822.	1.6	23
1638	Clinical follow-up of women infected with human papillomavirus-16, either alone or with other human papillomavirus types: identification of different risk groups. <i>American Journal of Obstetrics and Gynecology</i> , 2009, 200, 286.e1-286.e6.	0.7	2
1639	The Role of Retinoid Deficiency and Estrogens as Cofactors in Cervical Cancer. <i>Archives of Medical Research</i> , 2009, 40, 449-465.	1.5	32
1640	Advantages and Disadvantages of Current Prophylactic Vaccines Against HPV. <i>Archives of Medical Research</i> , 2009, 40, 471-477.	1.5	29
1641	Gene expression profiles in HPV-immortalized human cervical cells treated with the nicotine-derived carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. <i>Chemico-Biological Interactions</i> , 2009, 177, 173-180.	1.7	16
1642	Cervical carcinoma in Southern Mexico: Human papillomavirus and cofactors. <i>Cancer Detection and Prevention</i> , 2009, 32, 300-307.	2.1	22
1643	HPV16/18 vaccination to prevent cervical cancer in The Netherlands: Model-based cost-effectiveness. <i>International Journal of Cancer</i> , 2009, 124, 970-978.	2.3	39
1644	Different outcome of invasive cervical cancer associated with high-risk versus intermediate-risk HPV genotype. <i>International Journal of Cancer</i> , 2009, 124, 778-782.	2.3	50
1645	Molecular variants of HPV16 associated with cervical cancer in Indian population. <i>International Journal of Cancer</i> , 2009, 125, 91-103.	2.3	51
1646	Enhancement of immunogenicity of a therapeutic cervical cancer DNA-based vaccine by co-application of sequence-optimized genetic adjuvants. <i>International Journal of Cancer</i> , 2009, 125, 189-198.	2.3	36
1647	High prevalence of human papillomavirus infection in the female population of Guatemala. <i>International Journal of Cancer</i> , 2009, 125, 1161-1167.	2.3	28
1648	The potential impact of human papillomavirus vaccination in contemporary cytologically screened populations may be underestimated: An observational retrospective analysis of invasive cervical cancers. <i>International Journal of Cancer</i> , 2009, 125, 2425-2427.	2.3	12
1649	Association of HPV16 E6 variants with diagnostic severity in cervical cytology samples of 354 women in a US population. <i>International Journal of Cancer</i> , 2009, 125, 2609-2613.	2.3	69
1650	Human papillomaviruses are identified in a subgroup of sinonasal squamous cell carcinomas with favorable outcome. <i>Cancer</i> , 2009, 115, 2701-2709.	2.0	150
1651	Hybrid capture 2 human papillomavirus DNA testing for women with atypical squamous cells of undetermined significance papanicolaou results in SurePath and ThinPrep specimens. <i>Cancer Cytopathology</i> , 2009, 117, 318-325.	1.4	17
1652	Molecular detection and genotyping of human papillomavirus in cervical carcinoma biopsies in an area of high incidence of cancer from Moroccan women. <i>Journal of Medical Virology</i> , 2009, 81, 678-684.	2.5	27
1653	Typing of human papillomavirus in women with cervical lesions: Prevalence and distribution of different genotypes. <i>Journal of Medical Virology</i> , 2009, 81, 271-277.	2.5	49
1654	High prevalence of human papillomavirus type 58 in patients with cervical pre-malignant lesions in southern Brazil. <i>Journal of Medical Virology</i> , 2009, 81, 1270-1275.	2.5	20

#	ARTICLE	IF	CITATIONS
1655	High-risk HPV types in lesions of the uterine cervix of female commercial sex workers in the Philippines. <i>Journal of Medical Virology</i> , 2009, 81, 545-551.	2.5	27
1656	Detection of HPV types and neutralizing antibodies in Gansu province, China. <i>Journal of Medical Virology</i> , 2009, 81, 693-702.	2.5	26
1657	HPV genotype prevalence in women with abnormal pap smears in Melbourne, Australia. <i>Journal of Medical Virology</i> , 2009, 81, 1283-1291.	2.5	35
1658	Importance of specimen type in detecting human papillomavirus DNA from the female genital tract. <i>Journal of Medical Virology</i> , 2009, 81, 1620-1626.	2.5	6
1659	Expression and characterization of HPV-16 L1 capsid protein in <i>Pichia pastoris</i> . <i>Archives of Virology</i> , 2009, 154, 1609-1617.	0.9	52
1660	Baseline characteristics and prevalence of HPV 6, 11, 16, 18 in young German women participating in phase III clinical trials of a quadrivalent HPV (6/11/16/18) vaccine. <i>Archives of Gynecology and Obstetrics</i> , 2009, 279, 803-807.	0.8	4
1661	Evaluation of the compatibility of the Digene media when performing the Roche linear array human papillomavirus genotyping test. <i>Archives of Gynecology and Obstetrics</i> , 2009, 280, 613-618.	0.8	0
1662	Overexpression of STAT3 in HPV-mediated cervical cancer in a North Indian population. <i>Molecular and Cellular Biochemistry</i> , 2009, 330, 193-199.	1.4	33
1663	Human papillomavirus infection in honduran women with normal cytology. <i>Cancer Causes and Control</i> , 2009, 20, 1663-1670.	0.8	20
1664	Association between human papillomavirus in men and their sexual partners and uterine cervical intraepithelial neoplasia. <i>International Urology and Nephrology</i> , 2009, 41, 335-340.	0.6	7
1665	Entire genome characterization of human papillomavirus type 16 from infected Thai women with different cytological findings. <i>Virus Genes</i> , 2009, 39, 30-38.	0.7	12
1666	Epidemiological studies of women under age 30 infected with human papillomavirus. <i>Frontiers of Medicine in China</i> , 2009, 3, 459-462.	0.1	1
1667	Minimally Invasive Therapy of Cervical Intraepithelial Neoplasia for Fertility Preservation. <i>Pathology and Oncology Research</i> , 2009, 15, 521-525.	0.9	8
1668	Bacterial expression and purification of human papillomavirus type 18 L1. <i>Biotechnology and Bioprocess Engineering</i> , 2009, 14, 168-174.	1.4	9
1669	Human papillomavirus 16 and 18 L1 serology in Korean women with high-grade cervical intraepithelial neoplasia and cervical cancer. <i>Archives of Pharmacal Research</i> , 2009, 32, 1013-1018.	2.7	7
1670	A method for removing contaminating protein during purification of human papillomavirus type 18 L1 protein from <i>Saccharomyces cerevisiae</i> . <i>Archives of Pharmacal Research</i> , 2009, 32, 1759-1766.	2.7	6
1673	Developing vaccines against minor capsid antigen L2 to prevent papillomavirus infection. <i>Immunology and Cell Biology</i> , 2009, 87, 287-299.	1.0	57
1674	Paclitaxel combined with siRNA targeting HPV16 oncogenes improves cytotoxicity for cervical carcinoma. <i>Cancer Gene Therapy</i> , 2009, 16, 764-775.	2.2	20

#	ARTICLE	IF	CITATIONS
1675	Expression of CPEB, GAPDH and U6snRNA in cervical and ovarian tissue during cancer development. <i>Apmis</i> , 2009, 117, 53-59.	0.9	61
1676	Comparison of human papillomavirus genotyping using commercial assays based on PCR and reverse hybridization methods. <i>Apmis</i> , 2009, 117, 708-715.	0.9	22
1677	The prevalence and significance of high-risk human papillomavirus DNA test in southern Malaysia and Singapore. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2009, 49, 323-327.	0.4	8
1678	Sequence-based genotyping HPV L1 DNA and RNA transcripts in clinical specimens. <i>Pathology Research and Practice</i> , 2009, 205, 863-869.	1.0	8
1679	The Prevalence of Human Papillomavirus Type 58 in Chinese Patients with Cervical Carcinoma and its Influence on Survival. <i>Clinical Oncology</i> , 2009, 21, 768-774.	0.6	7
1680	Ensembled support vector machines for human papillomavirus risk type prediction from protein secondary structures. <i>Computers in Biology and Medicine</i> , 2009, 39, 187-193.	3.9	15
1681	Feasibility of focused ultrasound therapy for recurrent cervicitis with high-risk human papillomavirus infection. <i>Ultrasound in Obstetrics and Gynecology</i> , 2009, 34, 590-594.	0.9	15
1682	CXC chemokine ligand 10 gene therapy efficiently inhibits the growth of cervical carcinoma on the basis of its anti-angiogenic and antiviral activity. <i>Biotechnology and Applied Biochemistry</i> , 2009, 53, 209-216.	1.4	23
1683	Value of high-risk HPV-DNA testing in the triage of ASCUS. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2009, 88, 1006-1010.	1.3	10
1684	What's next? Perspectives and future needs of cervical screening in Europe in the era of molecular testing and vaccination. <i>European Journal of Cancer</i> , 2009, 45, 2714-2721.	1.3	44
1685	Shape of age-specific prevalence of high-risk human papillomavirus infection in women attending hospitals in Shanghai, China. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2009, 145, 214-218.	0.5	12
1686	Drugs, sex, money and power: An HPV vaccine case study. <i>Health Policy</i> , 2009, 92, 288-295.	1.4	44
1687	Induction of antitumor immunity in vivo following delivery of a novel HPV-16 DNA vaccine encoding an E6/E7 fusion antigen. <i>Vaccine</i> , 2009, 27, 431-440.	1.7	73
1688	An E7-based therapeutic vaccine protects mice against HPV16 associated cancer. <i>Vaccine</i> , 2009, 27, 3395-3397.	1.7	47
1689	Cost-effectiveness analysis of a cervical cancer vaccine in five Latin American countries. <i>Vaccine</i> , 2009, 27, 5519-5529.	1.7	35
1690	Screening, prevention and treatment of cervical cancer: A global and regional generalized cost-effectiveness analysis. <i>Vaccine</i> , 2009, 27, 6060-6079.	1.7	51
1692	Adolescent Girls' Attitudes on Human Papillomavirus Vaccination. <i>Journal of Pediatric and Adolescent Gynecology</i> , 2009, 22, 85-90.	0.3	28
1693	Human papillomavirus profile of women in Belize City, Belize: correlation with cervical cytopathologic findings. <i>Human Pathology</i> , 2009, 40, 942-949.	1.1	8

#	ARTICLE	IF	CITATIONS
1694	HPV genotyping from invasive cervical cancer in Chile. <i>International Journal of Gynecology and Obstetrics</i> , 2009, 105, 150-153.	1.0	27
1696	HPV genotypes in women with squamous intraepithelial lesions and normal cervixes participating in a community-based microbicide study in Pretoria, South Africa. <i>Journal of Clinical Virology</i> , 2009, 44, 318-321.	1.6	26
1697	Comparison between the Hybrid Capture 2 and the hpVIR real-time PCR for detection of human papillomavirus in women with ASCUS or low grade dysplasia. <i>Journal of Clinical Virology</i> , 2009, 45, 85-89.	1.6	34
1698	Use of FTA card for dry collection, transportation and storage of cervical cell specimen to detect high-risk HPV. <i>Journal of Clinical Virology</i> , 2009, 46, 112-116.	1.6	75
1700	The Epidemiology behind the HPV Vaccine Discovery. <i>Annals of Epidemiology</i> , 2009, 19, 239-244.	0.9	26
1701	Human papillomavirus type 16 variants in cervical intraepithelial neoplasia and invasive carcinoma in San Luis Potosí-City, Mexico. <i>Infectious Agents and Cancer</i> , 2009, 4, 3.	1.2	10
1702	Incidence of cervical disease associated to HPV in human immunodeficiency infected women under highly active antiretroviral therapy. <i>Infectious Agents and Cancer</i> , 2009, 4, 9.	1.2	26
1703	Therapeutic Human Papillomavirus Vaccination. <i>Public Health Genomics</i> , 2009, 12, 331-342.	0.6	20
1704	HPV knowledge, attitudes, and cultural beliefs among Hispanic men and women living on the Texas-Mexico border. <i>Ethnicity and Health</i> , 2009, 14, 607-624.	1.5	79
1705	Analysis of Human Papillomavirus Type 18 Load and Integration Status from Low-Grade Cervical Lesion to Invasive Cervical Cancer. <i>Journal of Clinical Microbiology</i> , 2009, 47, 287-293.	1.8	29
1706	Effect of Male Circumcision on the Prevalence of High-Risk Human Papillomavirus in Young Men: Results of a Randomized Controlled Trial Conducted in Orange Farm, South Africa. <i>Journal of Infectious Diseases</i> , 2009, 199, 14-19.	1.9	252
1707	The Relationship Between Human Papillomavirus and Epstein-Barr Virus Infections in Relation to Age Of Patients With Cervical Adenocarcinoma. <i>Taiwanese Journal of Obstetrics and Gynecology</i> , 2009, 48, 370-374.	0.5	1
1708	Analytical characterization of the APTIMA® HPV Assay. <i>Journal of Clinical Virology</i> , 2009, 45, S39-S47.	1.6	65
1709	A comparative review of laboratory-developed tests utilizing Invader® HPV analyte-specific reagents for the detection of high-risk human papillomavirus. <i>Journal of Clinical Virology</i> , 2009, 45, S73-S77.	1.6	25
1710	Occurrence of human papillomavirus in pterygia. <i>Acta Ophthalmologica</i> , 2009, 87, 890-895.	0.6	20
1712	Prevalence of High-Risk Human Papillomavirus in an Inner-City Population With Atypical Squamous Cells of Undetermined Significance. <i>Journal of Lower Genital Tract Disease</i> , 2009, 13, 63-65.	0.9	4
1713	Treatment of vulvar/vaginal condyloma by HPV: developed instrumentation and clinical report. <i>Proceedings of SPIE</i> , 2009, , .	0.8	3
1714	Human Papillomavirus Types in Invasive Cervical Cancer Specimens From Turkey. <i>International Journal of Gynecological Pathology</i> , 2009, 28, 541-548.	0.9	23

#	ARTICLE	IF	CITATIONS
1715	A 7.5-year prospective study of longer than 18 months type-specific human papillomavirus persistence in a routine cytology-based cervical screening population of about 31â€‰%000 women in West Germany. <i>European Journal of Cancer Prevention</i> , 2009, 18, 307-315.	0.6	10
1716	Epidemiological Data of Different Human Papillomavirus Genotypes in Cervical Specimens of HIV-1-Infected Women Without History of Cervical Pathology. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2009, 50, 168-175.	0.9	24
1717	Human Papillomavirus Infection and Its Possible Correlation with p63 Expression in Cervical Cancer in Japan, Mongolia, and Myanmar. <i>Acta Histochemica Et Cytochemica</i> , 2009, 42, 181-190.	0.8	42
1719	Genital warts: New approaches to the treatment / Genitalne bradavice - novi pristupi u leÄenju. <i>Serbian Journal of Dermatology and Venereology</i> , 2009, 1, 107-114.	0.2	1
1720	Microarray Analysis Identifies Differentially Expressed Genes Induced by Human Papillomavirus Type 18 E6 Silencing RNA. <i>International Journal of Gynecological Cancer</i> , 2009, 19, 547-563.	1.2	9
1721	Comparison of Human Papillomavirus Detection and Typing by Hybrid Capture 2, Linear Array, DNA Chip, and Cycle Sequencing in Cervical Swab Samples. <i>International Journal of Gynecological Cancer</i> , 2009, 19, 266-272.	1.2	19
1722	Effect of the Number of Biopsies on the Subsequent Acquisition of New Human Papillomavirus Infections. <i>Obstetrics and Gynecology</i> , 2009, 114, 1057-1062.	1.2	6
1723	HPV as a Model for the Development of Prophylactic and Therapeutic Cancer Vaccines. <i>Current Molecular Medicine</i> , 2009, 9, 766-773.	0.6	3
1724	Lessons From Practice. <i>Journal of Lower Genital Tract Disease</i> , 2010, 14, 97-102.	0.9	21
1725	Seroprevalence and Correlates of Human Papillomavirus 16/18 Seropositivity Among Young Women in Costa Rica. <i>Sexually Transmitted Diseases</i> , 2010, 37, 706-714.	0.8	27
1726	Role of ProExC: A Novel Immunoperoxidase Marker in the Evaluation of Dysplastic Squamous and Glandular Lesions in Cervical Specimens. <i>International Journal of Gynecological Pathology</i> , 2010, 29, 79-87.	0.9	36
1727	Cervical Adenocarcinoma Resembling Breast Lobular Carcinoma. <i>International Journal of Gynecological Pathology</i> , 2010, 29, 594-599.	0.9	8
1728	Clinical Trial and Post-Licensure Safety Profile of a Prophylactic Human Papillomavirus (Types 6, 11, 16,) Tj ETQq0 0,0,rgBT /Oyerlock 10	1.1	98
1729	Perceived Uncertainty, Coping Strategies, and Adaptation in Women With Human Papillomavirus on Pap Smear. <i>Journal of Lower Genital Tract Disease</i> , 2010, 14, 81-89.	0.9	4
1731	The role of hLHX6-HMR as a methylation biomarker for early diagnosis of cervical cancer. <i>Oncology Reports</i> , 2010, 23, 1675-82.	1.2	13
1732	The role of ADCYAP1, adenylate cyclase activating polypeptide 1, as a methylation biomarker for the early detection of cervical cancer. <i>Oncology Reports</i> , 2010, 25, .	1.2	20
1733	Association Between Serum Cytokine Profiles and Clearance or Persistence of High-Risk Human Papillomavirus Infection: A Prospective Study. <i>International Journal of Gynecological Cancer</i> , 2010, 20, 1011-1016.	1.2	13
1734	Hybrid capture II for high-risk human papillomavirus DNA testing to detect cervical precancerous lesions: A qualitative and quantitative study. <i>Experimental and Therapeutic Medicine</i> , 2010, 1, 193-198.	0.8	5

#	ARTICLE	IF	CITATIONS
1735	Ki-67 Quantitative Evaluation as a Marker of Cervical Intraepithelial Neoplasia and Human Papillomavirus Infection. <i>International Journal of Gynecological Cancer</i> , 2010, 20, 116-119.	1.2	24
1737	Naturally occurring systemic immune responses to HPV antigens do not predict regression of CIN2/3. <i>Cancer Immunology, Immunotherapy</i> , 2010, 59, 799-803.	2.0	40
1738	Human papillomavirus type 16 E6-specific antitumor immunity is induced by oral administration of HPV16 E6-expressing <i>Lactobacillus casei</i> in C57BL/6 mice. <i>Cancer Immunology, Immunotherapy</i> , 2010, 59, 1727-1737.	2.0	28
1739	Detection of HPV types and neutralizing antibodies in women with genital warts in Tianjin City, China. <i>Virologica Sinica</i> , 2010, 25, 8-17.	1.2	17
1741	Human papillomavirus and tar hypothesis for squamous cell cervical cancer. <i>Journal of Biosciences</i> , 2010, 35, 331-337.	0.5	6
1742	HLA-B*6701 as a subtype performing post-selected marking gene for cervical cancer. <i>Wuhan University Journal of Natural Sciences</i> , 2010, 15, 539-543.	0.2	0
1743	Epidemiology of STIs: UK. <i>Medicine</i> , 2010, 38, 211-215.	0.2	4
1745	Identification of a better Homo sapiens Class II HDAC inhibitor through binding energy calculations and descriptor analysis. <i>BMC Bioinformatics</i> , 2010, 11, S16.	1.2	19
1746	Human Papilloma Virus prevalence and type-specific relative contribution in invasive cervical cancer specimens from Italy. <i>BMC Cancer</i> , 2010, 10, 259.	1.1	33
1747	Hybrid capture vs. PCR screening of cervical human papilloma virus infections. Cytological and histological associations in 1270 women. <i>BMC Cancer</i> , 2010, 10, 53.	1.1	28
1748	Prevalence of human papillomavirus in archival samples obtained from patients with cervical pre-malignant and malignant lesions from Northeast Brazil. <i>BMC Research Notes</i> , 2010, 3, 96.	0.6	22
1749	Usage of heparan sulfate, integrins, and FAK in HPV16 infection. <i>Virology</i> , 2010, 403, 1-16.	1.1	73
1750	Human papillomavirus vaccine acceptability: Is multimedia education ready for prime time?. <i>Gynecologic Oncology</i> , 2010, 118, 101-102.	0.6	2
1751	Distribution of human papillomavirus 58 and 52 E6/E7 variants in cervical neoplasia in Chinese women. <i>Gynecologic Oncology</i> , 2010, 119, 436-443.	0.6	30
1752	The influence of proteasome inhibitor MG132, external radiation, and unlabeled antibody on the tumor uptake and biodistribution of ¹⁸⁸ Re-labeled anti-E6 C1P5 antibody in cervical cancer in mice. <i>Cancer</i> , 2010, 116, 1067-1074.	2.0	19
1753	Mechanisms by which inflammation may increase intestinal cancer risk in inflammatory bowel disease. <i>Inflammatory Bowel Diseases</i> , 2010, 16, 1411-1420.	0.9	123
1754	Human papillomavirus testing and cervical cytology in primary screening for cervical cancer among women in rural China: Comparison of sensitivity, specificity, and frequency of referral. <i>International Journal of Cancer</i> , 2010, 127, 646-656.	2.3	31
1755	Type-specific human papillomavirus oncogene messenger RNA levels correlate with the severity of cervical neoplasia. <i>International Journal of Cancer</i> , 2010, 127, 622-632.	2.3	36

#	ARTICLE	IF	CITATIONS
1756	Enhancing the scope of conventional cervical cytology for detecting HPV infection. <i>Diagnostic Cytopathology</i> , 2010, 38, 645-651.	0.5	9
1757	The L1 major capsid protein of HPV16 differentially modulates APC trafficking according to the vaccination or natural infection context. <i>European Journal of Immunology</i> , 2010, 40, 3075-3084.	1.6	10
1758	Prevalence of human papillomavirus genotypes in northern Taiwanese women. <i>Journal of Medical Virology</i> , 2010, 82, 1739-1745.	2.5	15
1759	Identification of suitable reference genes for measurement of gene expression in human cervical tissues. <i>Analytical Biochemistry</i> , 2010, 405, 224-229.	1.1	64
1760	Clinical Effect of Human Papillomavirus Genotypes in Patients With Cervical Cancer Undergoing Primary Radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 78, 1111-1120.	0.4	49
1761	Human papillomavirus infection and risk factors in a cohort of Tuscan women aged 18-24: results at recruitment. <i>BMC Infectious Diseases</i> , 2010, 10, 157.	1.3	25
1762	Prevalence of HPV infection among Greek women attending a gynecological outpatient clinic. <i>BMC Infectious Diseases</i> , 2010, 10, 27.	1.3	31
1763	The impact of highly active antiretroviral therapy on prevalence and incidence of cervical human papillomavirus infections in HIV-positive adolescents. <i>BMC Infectious Diseases</i> , 2010, 10, 295.	1.3	36
1764	Rapid, sensitive, type specific PCR detection of the E7 region of human papillomavirus type 16 and 18 from paraffin embedded sections of cervical carcinoma. <i>Infectious Agents and Cancer</i> , 2010, 5, 2.	1.2	21
1765	New molecular method for the detection of human papillomavirus type 16 integration. <i>Clinical Microbiology and Infection</i> , 2010, 16, 836-842.	2.8	13
1766	p16 Immunoreactivity in unusual types of cervical adenocarcinoma does not reflect human papillomavirus infection. <i>Histopathology</i> , 2010, 57, 342-350.	1.6	94
1767	The cellular transcription factor Brn-3a and the smoking-related substance nicotine interact to regulate the activity of the HPV URR in the cervix. <i>Oncogene</i> , 2010, 29, 2701-2711.	2.6	12
1768	Vector prime protein boost vaccination in the setting of myeloablative-induced lymphopenia suppresses growth of leukemia and solid tumors. <i>Bone Marrow Transplantation</i> , 2010, 45, 550-557.	1.3	1
1769	Human papillomavirus DNA and P16INK4A expression in concurrent esophageal and gastric cardia cancers. <i>World Journal of Gastroenterology</i> , 2010, 16, 5901.	1.4	39
1770	Progression Model Tissue Microarray (TMA) for the Study of Uterine Carcinomas. <i>Disease Markers</i> , 2010, 28, 267-272.	0.6	7
1771	International Cancer Care: What Is the Role of Oncology Nursing?. <i>Clinical Journal of Oncology Nursing</i> , 2010, 14, 539-541.	0.3	8
1772	Impact of human papillomavirus genotype on response to treatment and survival in patients receiving radiotherapy for squamous cell carcinoma of the cervix. <i>Experimental and Therapeutic Medicine</i> , 2010, 1, 525-530.	0.8	9
1773	Biotecnologia aplicada ao desenvolvimento de vacinas. <i>Estudos Avancados</i> , 2010, 24, 19-30.	0.2	8

#	ARTICLE	IF	CITATIONS
1774	High prevalence and low E6 genetic variability of human papillomavirus 58 in women with cervical cancer and precursor lesions in Southeast Mexico. <i>Memorias Do Instituto Oswaldo Cruz</i> , 2010, 105, 144-148.	0.8	16
1776	Risk of Invasive Cervical Cancer and Cervical Intraepithelial Neoplasia Grade Iii in Central Italy by Area of Birth. <i>Journal of Medical Screening</i> , 2010, 17, 87-90.	1.1	7
1777	Prevalence of Human Papillomavirus Types in High-Grade Cervical Intraepithelial Neoplasia and Cancer in Italy. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 2389-2400.	1.1	64
1778	Male Circumcision Decreases Acquisition and Increases Clearance of High-Risk Human Papillomavirus in HIV-Negative Men: A Randomized Trial in Rakai, Uganda. <i>Journal of Infectious Diseases</i> , 2010, 201, 1455-1462.	1.9	146
1779	Impact of Improved Classification on the Association of Human Papillomavirus With Cervical Precancer. <i>American Journal of Epidemiology</i> , 2010, 171, 155-163.	1.6	26
1780	Comparison of Subtypes of Penile Squamous Cell Carcinoma From High and Low Incidence Geographical Regions. <i>International Journal of Surgical Pathology</i> , 2010, 18, 268-277.	0.4	40
1781	NFX1 Plays a Role in Human Papillomavirus Type 16 E6 Activation of NF- κ B Activity. <i>Journal of Virology</i> , 2010, 84, 11461-11469.	1.5	37
1782	Human Papillomavirus 16-Associated Cervical Intraepithelial Neoplasia in Humans Excludes CD8 T Cells from Dysplastic Epithelium. <i>Journal of Immunology</i> , 2010, 185, 7107-7114.	0.4	109
1783	Microbe Hunting. <i>Microbiology and Molecular Biology Reviews</i> , 2010, 74, 363-377.	2.9	102
1784	Immune Responses and Therapeutic Antitumor Effects of an Experimental DNA Vaccine Encoding Human Papillomavirus Type 16 Oncoproteins Genetically Fused to Herpesvirus Glycoprotein D. <i>Vaccine</i> , 2010, 28, 1576-1583.	3.2	27
1785	The psychological impact of illness among women experiencing human papillomavirus-related illness or screening interventions. <i>Journal of Psychosomatic Obstetrics and Gynaecology</i> , 2010, 31, 16-23.	1.1	43
1786	Human papillomavirus prevalence in invasive cervical carcinomas in Bulgaria. <i>Journal of Clinical Pathology</i> , 2010, 63, 1121-1123.	1.0	5
1787	The association between cervical human papillomavirus infection and HIV acquisition among women in Zimbabwe. <i>Aids</i> , 2010, 24, 1035-1042.	1.0	75
1788	Seroprevalence and Determinants of Eight High-Risk Human Papillomavirus Types in Homosexual Men, Heterosexual Men, and Women: A Population-Based Study in Amsterdam. <i>Sexually Transmitted Diseases</i> , 2010, 37, 672-680.	0.8	34
1789	Further Good News from Prophylactic Human Papillomavirus Vaccines: Long-Term Duration of Immunity. <i>Women's Health</i> , 2010, 6, 361-363.	0.7	1
1790	Radioimmunotherapy with an antibody to the HPV16 E6 oncoprotein is effective in an experimental cervical tumor expressing low levels of E6. <i>Cancer Biology and Therapy</i> , 2010, 10, 1041-1047.	1.5	11
1791	Signature sequence validation of human papillomavirus type 16 (HPV-16) in clinical specimens. <i>Journal of Clinical Pathology</i> , 2010, 63, 235-239.	1.0	6
1792	Virus of Sexual transmission: Semen and virus relationship. <i>Actas Urológicas Españolas (English)</i> Tj ETQq1 1 0.784314 rgB7 /Overlook	0.2	7

#	ARTICLE	IF	CITATIONS
1793	Cryotherapy for HPV clearance in women with biopsy-confirmed cervical low-grade squamous intraepithelial lesions. <i>International Journal of Gynecology and Obstetrics</i> , 2010, 108, 119-122.	1.0	17
1794	Natural history of infections with high-risk HPV in Chinese women with abnormal cervical cytology findings at baseline. <i>International Journal of Gynecology and Obstetrics</i> , 2010, 110, 137-140.	1.0	6
1795	A nontoxic derivative of lipopolysaccharide increases immune responses to Gardasil® HPV vaccine in mice. <i>International Immunopharmacology</i> , 2010, 10, 169-176.	1.7	12
1796	E6 Proteins from Diverse Papillomaviruses Self-Associate Both In Vitro and In Vivo. <i>Journal of Molecular Biology</i> , 2010, 396, 90-104.	2.0	24
1797	Recovery of DNA from BD SurePath cytology specimens and compatibility with the Roche AMPLICOR Human Papillomavirus (HPV) Test. <i>Journal of Clinical Virology</i> , 2010, 48, 31-35.	1.6	8
1798	Human papillomavirus HPV-16, 18, 52 and 58 integration in cervical cells of HIV-1-infected women. <i>Journal of Clinical Virology</i> , 2010, 48, 198-201.	1.6	23
1799	Frequent presence of incomplete HPV16 E7 ORFs in lung carcinomas: Memories of viral infection. <i>Journal of Clinical Virology</i> , 2010, 49, 169-174.	1.6	12
1800	Selective targeting of HPV-16 E6/E7 in cervical cancer cells with a potent oncolytic adenovirus and its enhanced effect with radiotherapy in vitro and vivo. <i>Cancer Letters</i> , 2010, 291, 67-75.	3.2	32
1801	Cost-effectiveness of human papillomavirus vaccination and screening in Spain. <i>European Journal of Cancer</i> , 2010, 46, 2973-2985.	1.3	38
1802	Prevalence of genital human papillomavirus infection and genotypes among women from Fujian province, PR China. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2010, 151, 86-90.	0.5	25
1803	Human papillomavirus type 16 E6 gene variations in Chinese population. <i>European Journal of Surgical Oncology</i> , 2010, 36, 160-163.	0.5	29
1804	One-step chromatographic purification of human papillomavirus type 16 L1 protein from <i>Saccharomyces cerevisiae</i> . <i>Protein Expression and Purification</i> , 2010, 70, 68-74.	0.6	45
1805	Oral immunization with a <i>Lactobacillus casei</i> vaccine expressing human papillomavirus (HPV) type 16 E7 is an effective strategy to induce mucosal cytotoxic lymphocytes against HPV16 E7. <i>Vaccine</i> , 2010, 28, 2810-2817.	1.7	79
1806	Conjugation of HPV16 E7 to cholera toxin enhances the HPV-specific T-cell recall responses to pulsed dendritic cells in vitro in women with cervical dysplasia. <i>Vaccine</i> , 2010, 28, 5828-5836.	1.7	14
1807	<i>Equus caballus</i> papillomavirus (EcPV2): An infectious cause for equine genital cancer?. <i>Equine Veterinary Journal</i> , 2010, 42, 738-745.	0.9	82
1808	Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. <i>Lancet Oncology</i> , The, 2010, 11, 1048-1056.	5.1	2,093
1809	The role of human papillomavirus Infection in prostate carcinoma. <i>International Journal of Infectious Diseases</i> , 2010, 14, e468.	1.5	0
1810	Modern Infectious Disease Epidemiology. <i>Statistics in the Health Sciences</i> , 2010, , .	0.2	47

#	ARTICLE	IF	CITATIONS
1811	Radiation therapy of recurrent anal squamous cell carcinoma in-situ: a case report. Journal of Medical Case Reports, 2010, 4, 67.	0.4	2
1812	A comparison of risk factors for atypical squamous cells and squamous intraepithelial lesions in a sample of US- and African-born HIV-positive women. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2010, 22, 1115-1122.	0.6	2
1813	Human Papillomavirus and Cardiovascular Disease Among U.S. Women in the National Health and Nutrition Examination Survey, 2003 to 2006. Journal of the American College of Cardiology, 2011, 58, 2001-2006.	1.2	45
1814	Human Papillomavirus infection in asymptomatic population. Sexual and Reproductive Healthcare, 2011, 2, 7-11.	0.5	24
1815	Anal Cancer. , 2011, , 423-450.		0
1816	Immunogenicity in mice and rhesus monkeys vaccinated with recombinant vaccinia virus expressing bivalent E7E6 fusion proteins from human papillomavirus types 16 and 18. Virology Journal, 2011, 8, 302.	1.4	13
1817	The role of human papillomavirus infection in prostate carcinoma. Scandinavian Journal of Infectious Diseases, 2011, 43, 64-69.	1.5	39
1818	Gastrointestinal Oncology. , 2011, , .		2
1819	Prevalencia del virus papiloma humano y sus factores de riesgo en hombres: revisi3n sistem4tica. Infectio, 2011, 15, 268-276.	0.4	4
1820	Clinical laboratory evaluation of Invader® chemistry and hybrid capture for detection of high-risk human papillomavirus in liquid-based cytology specimens. Diagnostic Microbiology and Infectious Disease, 2011, 71, 230-235.	0.8	8
1822	Efficacy of TRAIL treatment against HPV16 infected cervical cancer cells undergoing senescence following siRNA knockdown of E6/E7 genes. Biochemical and Biophysical Research Communications, 2011, 405, 1-6.	1.0	9
1823	Cervical Human Papillomavirus in transplanted Italian women: A long-term prospective follow-up study. Journal of Clinical Virology, 2011, 51, 250-254.	1.6	28
1824	Human papillomavirus genotype distribution among French women with and without cervical abnormalities. International Journal of Gynecology and Obstetrics, 2011, 114, 116-119.	1.0	11
1825	Chemical neurolysis of the superior hypogastric plexus for chronic non-cancer pelvic pain. International Journal of Gynecology and Obstetrics, 2011, 114, 160-161.	1.0	8
1826	Cervical and vaginal cancer in a woman with chronic graft-versus-host disease. International Journal of Gynecology and Obstetrics, 2011, 114, 159-160.	1.0	1
1827	Development of interdigitated arrays coated with functional polyaniline/MWCNT for electrochemical biodetection: Application for human papilloma virus. Talanta, 2011, 85, 1560-1565.	2.9	58
1828	Effect of ferric ions on reactive oxygen species formation, cervical cancer cell lines growth and E6/E7 oncogene expression. Toxicology in Vitro, 2011, 25, 160-166.	1.1	29
1829	Expression of Human papillomavirus 16 E7ggg oncoprotein on N- and C-terminus of Potato virus X coat protein in bacterial and plant cells. Protein Expression and Purification, 2011, 77, 146-152.	0.6	29

#	ARTICLE	IF	CITATIONS
1830	Strategies for bacterial expression of protein-peptide complexes: Application to solubilization of papillomavirus E6. <i>Protein Expression and Purification</i> , 2011, 80, 8-16.	0.6	11
1831	Making sense of therapeutics using antisense technology. <i>Expert Opinion on Drug Discovery</i> , 2011, 6, 507-526.	2.5	25
1832	Prevalence and risk factors for human papillomavirus DNA in cervical cytology. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2011, 159, 168-171.	0.5	26
1834	Prevalence of Human Papilloma Virus Infection in Perimenopausal Women in Bucheon Province. <i>The Journal of Korean Society of Menopause</i> , 2011, 17, 155.	0.6	5
1835	Role and uptake of human papillomavirus vaccine in adolescent health in the United States. <i>Adolescent Health, Medicine and Therapeutics</i> , 2011, 2011, 63.	0.7	7
1836	Knowledge about Cervical Cancer, Health Beliefs and Human Papillomavirus Vaccination Rate in Female University Students. <i>Journal of Korean Oncology Nursing</i> , 2011, 11, 65.	0.5	49
1837	Inverse Association between Methylation of Human Papillomavirus Type 16 DNA and Risk of Cervical Intraepithelial Neoplasia Grades 2 or 3. <i>PLoS ONE</i> , 2011, 6, e23897.	1.1	24
1838	Type-Specific HPV Prevalence in Cervical Cancer and High-Grade Lesions in Latin America and the Caribbean: Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2011, 6, e25493.	1.1	93
1839	Human Papillomavirus Persistence in Young Unscreened Women, a Prospective Cohort Study. <i>PLoS ONE</i> , 2011, 6, e27937.	1.1	37
1840	Clinicopathologic Implications of the Epidermal Growth Factor Receptor, Cyclooxygenase 2 Expression, and Human Papillomavirus Status in Squamous Cell Carcinoma of the Uterine Cervix in the Elderly. <i>International Journal of Gynecological Cancer</i> , 2011, 21, 337-348.	1.2	7
1841	Detection and Genotyping of Human Papilloma Virus in Cervical Cancer Specimens From Saudi Patients. <i>International Journal of Gynecological Cancer</i> , 2011, 21, 907-910.	1.2	32
1842	Epigenetic regulation of the potential tumor suppressor gene, hLHX6.1, in human cervical cancer. <i>International Journal of Oncology</i> , 2011, 38, 859-69.	1.4	11
1843	Prevalence of human papillomavirus in university young women. <i>Oncology Letters</i> , 2011, 2, 701-706.	0.8	3
1844	Production of L1 protein from different types of HPV in <i>Pichia pastoris</i> using an integrative vector. <i>Brazilian Journal of Medical and Biological Research</i> , 2011, 44, 1209-1214.	0.7	23
1845	Enhanced anti-tumor effect of a gene gun-delivered DNA vaccine encoding the human papillomavirus type 16 oncoproteins genetically fused to the herpes simplex virus glycoprotein D. <i>Brazilian Journal of Medical and Biological Research</i> , 2011, 44, 421-427.	0.7	11
1846	Human papillomavirus in cervical cancers of Malaysians. <i>Journal of Obstetrics and Gynaecology Research</i> , 2011, 37, 489-495.	0.6	6
1847	Distribution of HPV genotypes in women with cervical cancer in Auckland, New Zealand; a review of 50 specimens between 2000-2006. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2011, 51, 67-70.	0.4	4
1848	HPV infection and cervical disease: A review. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2011, 51, 103-108.	0.4	80

#	ARTICLE	IF	CITATIONS
1849	Cell-mediated immune response to human papillomavirus 16 E7 peptide pools in patients with cervical neoplasia. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2011, 90, 1350-1356.	1.3	6
1850	A reversed CD4/CD8 ratio of tumor-infiltrating lymphocytes and a high percentage of CD4+FOXP3+ regulatory T cells are significantly associated with clinical outcome in squamous cell carcinoma of the cervix. <i>Cellular and Molecular Immunology</i> , 2011, 8, 59-66.	4.8	204
1851	Identification of two novel equine papillomavirus sequences suggests three genera in one cluster. <i>Veterinary Microbiology</i> , 2011, 149, 85-90.	0.8	38
1852	Subcellular localization of the human papillomavirus 16 E7 oncoprotein in CaSki cells and its detection in cervical adenocarcinoma and adenocarcinoma in situ. <i>Virology</i> , 2011, 409, 54-68.	1.1	23
1853	E6 molecular variants of human papillomavirus (HPV) type 16: An updated and unified criterion for clustering and nomenclature. <i>Virology</i> , 2011, 410, 201-215.	1.1	45
1854	A cyclin-binding motif in human papillomavirus type 18 (HPV18) E1^E4 is necessary for association with CDK-cyclin complexes and G2/M cell cycle arrest of keratinocytes, but is not required for differentiation-dependent viral genome amplification or L1 capsid protein expression. <i>Virology</i> , 2011, 412, 196-210.	1.1	31
1855	Prospective evaluation of longitudinal changes in human papillomavirus genotype and phylogenetic clade associated with cervical disease progression. <i>Gynecologic Oncology</i> , 2011, 120, 284-290.	0.6	5
1856	Long-term persistence of human papillomavirus in environments. <i>Gynecologic Oncology</i> , 2011, 121, 148-151.	0.6	21
1857	Human papillomavirus (HPV) genotypes and HPV16 variants and risk of adenocarcinoma and squamous cell carcinoma of the cervix. <i>Gynecologic Oncology</i> , 2011, 121, 32-42.	0.6	77
1858	Prevalence and genotypes' distribution of human papillomavirus in invasive cervical cancer in Saudi Arabia. <i>Gynecologic Oncology</i> , 2011, 121, 522-526.	0.6	37
1859	Human papillomavirus (HPV) type distribution in cervical carcinoma, low-grade, and high-grade squamous intraepithelial lesions in Venezuelan women. <i>Gynecologic Oncology</i> , 2011, 121, 527-531.	0.6	24
1860	Risk factors for HPV infection among American Indian and white women in the Northern Plains. <i>Gynecologic Oncology</i> , 2011, 121, 532-536.	0.6	31
1861	Clinical, colposcopic and pathological characteristics of cervical and vaginal high-grade lesions negative for HPV by Hybrid Capture 2. <i>Gynecologic Oncology</i> , 2011, 122, 515-520.	0.6	12
1862	New variants of E6 and E7 oncogenes of human papillomavirus type 31 identified in Northeastern Brazil. <i>Gynecologic Oncology</i> , 2011, 123, 284-288.	0.6	16
1863	Genetic and epigenetic changes of HPV16 in cervical cancer differentially regulate E6/E7 expression and associate with disease progression. <i>Gynecologic Oncology</i> , 2011, 123, 597-604.	0.6	60
1864	Epidemiology and burden of HPV infection and related diseases: Implications for prevention strategies. <i>Preventive Medicine</i> , 2011, 53, S12-S21.	1.6	201
1865	Towards the detection of human papillomavirus infection by a reagentless electrochemical peptide biosensor. <i>Electrochimica Acta</i> , 2011, 56, 10688-10693.	2.6	24
1866	Passive smoke exposure and abnormal cervical cytology in a predominantly Hispanic population. <i>American Journal of Obstetrics and Gynecology</i> , 2011, 204, 213.e1-213.e6.	0.7	10

#	ARTICLE	IF	CITATIONS
1867	History of human papillomavirus, warts and cancer: What do we know today?. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2011, 25, 565-574.	1.4	15
1868	Cancer Incidence Among Canadian Immigrants, 1980â€“1998: Results from a National Cohort Study. Journal of Immigrant and Minority Health, 2011, 13, 15-26.	0.8	47
1869	Human papillomavirus genotype distribution in cervical samples collected in routine clinical practice at the Nantes University Hospital, France. Archives of Gynecology and Obstetrics, 2011, 284, 989-998.	0.8	8
1870	A survey on the prevalence of high-risk subtypes of human papilloma virus among women with cervical neoplasia in Isfahan University of Medical Science. Archives of Gynecology and Obstetrics, 2011, 284, 1509-1513.	0.8	21
1871	The Role of Vimentin as a Methylation Biomarker for Early Diagnosis of Cervical Cancer. Molecules and Cells, 2011, 31, 405-412.	1.0	36
1872	Canadian oncogenic human papillomavirus cervical infection prevalence: Systematic review and meta-analysis. BMC Infectious Diseases, 2011, 11, 235.	1.3	23
1873	HPV infection among rural American Indian women and urban white women in South Dakota: an HPV prevalence study. BMC Infectious Diseases, 2011, 11, 252.	1.3	17
1874	Efficient production of chimeric Human papillomavirus 16 L1 protein bearing the M2e influenza epitope in Nicotiana benthamiana plants. BMC Biotechnology, 2011, 11, 106.	1.7	70
1875	Construction and characterisation of a recombinant fowlpox virus that expresses the human papilloma virus L1 protein. Journal of Translational Medicine, 2011, 9, 190.	1.8	12
1876	Human papillomavirus detection in moroccan patients with nasopharyngeal carcinoma. Infectious Agents and Cancer, 2011, 6, 3.	1.2	38
1877	HPV types, HIV and invasive cervical carcinoma risk in Kampala, Uganda: a case-control study. Infectious Agents and Cancer, 2011, 6, 8.	1.2	26
1878	Detecting genomic regions associated with a disease using variability functions and Adjusted Rand Index. BMC Bioinformatics, 2011, 12, S9.	1.2	6
1879	The potential role of self-sampling for high-risk human papillomavirus detection in cervical cancer screening. Reviews in Medical Virology, 2011, 21, 139-153.	3.9	72
1880	Viral nanoparticles and virus-like particles: platforms for contemporary vaccine design. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2011, 3, 174-196.	3.3	189
1881	Clinical performance of the CLART human papillomavirus 2 assay compared with the hybrid capture 2 test. Journal of Medical Virology, 2011, 83, 272-276.	2.5	41
1882	Analytical and clinical performances of a restriction fragment mass polymorphism assay for detection and genotyping of a wide spectrum of human papillomaviruses. Journal of Medical Virology, 2011, 83, 471-482.	2.5	10
1883	Genotyping of human papillomavirus in cervical intraepithelial neoplasia in a high-risk population. Journal of Medical Virology, 2011, 83, 833-837.	2.5	14
1884	Distribution of human papillomavirus genotypes in cervical intraepithelial neoplasia and invasive cervical cancer in Canada. Journal of Medical Virology, 2011, 83, 1034-1041.	2.5	61

#	ARTICLE	IF	CITATIONS
1885	High prevalence of intermediate-risk human papillomavirus infection in uterine cervixes of Kenyan women infected with human immunodeficiency virus. <i>Journal of Medical Virology</i> , 2011, 83, 1988-1996.	2.5	17
1886	FTS (fused toes homolog) a novel oncoprotein involved in uterine cervical carcinogenesis and a potential diagnostic marker for cervical cancer. <i>Journal of Cellular Physiology</i> , 2011, 226, 1564-1572.	2.0	19
1887	Testing for human papillomavirus in cervical cancer screening. <i>Cancer Cytopathology</i> , 2011, 119, 219-227.	1.4	26
1888	The combination of TLR9 adjuvantation and electroporation-mediated delivery enhances <i>in vivo</i> antitumor responses after vaccination with HPV16 E7 encoding DNA. <i>International Journal of Cancer</i> , 2011, 128, 473-481.	2.3	35
1889	Association between toll-like receptor expression and human papillomavirus type 16 persistence. <i>International Journal of Cancer</i> , 2011, 128, 879-886.	2.3	134
1890	Prevalence of genotype-specific human papillomavirus infection and cervical neoplasia in Taiwan: A community-based survey of 10,602 women. <i>International Journal of Cancer</i> , 2011, 128, 1192-1203.	2.3	29
1891	Human papillomavirus: science and technologies for the elimination of cervical cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 2189-2204.	0.9	32
1892	Knowledge, Attitudes, and Demographic Factors Influencing Cervical Cancer Screening Behavior of Zimbabwean Women. <i>Journal of Women's Health</i> , 2011, 20, 943-952.	1.5	106
1893	Risk Factors for Persistent Cervical Intraepithelial Neoplasia Grades 1 and 2. <i>Journal of Lower Genital Tract Disease</i> , 2011, 15, 268-275.	0.9	28
1894	A Long-term Prospective Study of Type-Specific Human Papillomavirus Infection and Risk of Cervical Neoplasia Among 20,000 Women in the Portland Kaiser Cohort Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 1398-1409.	1.1	121
1895	Structural Basis of Oligosaccharide Receptor Recognition by Human Papillomavirus. <i>Journal of Biological Chemistry</i> , 2011, 286, 2617-2624.	1.6	86
1896	Estimating the Impact of Human Papillomavirus (HPV) Vaccination on HPV Prevalence and Cervical Cancer Incidence in Mali. <i>Clinical Infectious Diseases</i> , 2011, 52, 641-645.	2.9	21
1897	Human Papillomavirus 16 E5 Modulates the Expression of Host MicroRNAs. <i>PLoS ONE</i> , 2011, 6, e21646.	1.1	82
1898	High-Risk Human Papillomavirus Is Associated with HIV Acquisition among South African Female Sex Workers. <i>Infectious Diseases in Obstetrics and Gynecology</i> , 2011, 2011, 1-9.	0.4	49
1899	Biophysical Characterization of the Complex between Human Papillomavirus E6 Protein and Synapse-associated Protein 97. <i>Journal of Biological Chemistry</i> , 2011, 286, 3597-3606.	1.6	18
1900	Evaluation of the Combination of Cytology and Hybrid Capture to Safely Predict the High-Grade Lesion Status of Patients Treated with Conization with Large Loop Excision of the Transformation Zone. <i>Acta Cytologica</i> , 2011, 55, 421-425.	0.7	4
1901	Vacunación para virus papiloma humano: prevención de entidades precursoras del Cáncer de Cuello Uterino. <i>Revista Médica Clínica Las Condes</i> , 2011, 22, 445-452.	0.2	0
1902	The possibility of vertical transmission of human papillomavirus through maternal milk. <i>Journal of Obstetrics and Gynaecology</i> , 2011, 31, 503-506.	0.4	22

#	ARTICLE	IF	CITATIONS
1903	Persistence of Type-Specific Human Papillomavirus Infection and Increased Long-term Risk of Cervical Cancer. <i>Journal of the National Cancer Institute</i> , 2011, 103, 1387-1396.	3.0	150
1904	Human papillomavirus vaccination uptake and factors related to uptake in a traditional desert city in the United Arab Emirates. <i>International Journal of STD and AIDS</i> , 2011, 22, 400-404.	0.5	16
1905	Assessment of Immunohistochemistry for p16INK4 and High-Risk HPV DNA by In Situ Hybridization in Esophageal Squamous Cell Carcinoma. <i>International Journal of Surgical Pathology</i> , 2011, 19, 31-34.	0.4	15
1906	Viral Load in the Natural History of Human Papillomavirus Type 16 Infection: A Nested Case-€Control Study. <i>Journal of Infectious Diseases</i> , 2011, 203, 1425-1433.	1.9	61
1907	The Persistence And Clearence Rate Of Hpv Genotypes In Urban Turkish Women After One Year. <i>Marmara Medical Journal</i> , 2011, , .	0.1	0
1908	Correlation of human papilloma virus presence with precancerous and cancerous lesions of uterine cervix by immunohistochemistry. <i>Annals of Tropical Medicine and Public Health</i> , 2012, 5, 313.	0.1	1
1909	Evolutionary Ecology of Human Papillomavirus: Trade-offs, Coexistence, and Origins of High-Risk and Low-Risk Types. <i>Journal of Infectious Diseases</i> , 2012, 205, 272-279.	1.9	41
1910	Cervical cancer screening. <i>Series in Maternal-fetal Medicine</i> , 2012, , 270-274.	0.1	0
1911	Longitudinal Analysis of Carcinogenic Human Papillomavirus Infection and Associated Cytologic Abnormalities in the Guanacaste Natural History Study: Looking Ahead to Cotesting. <i>Journal of Infectious Diseases</i> , 2012, 205, 498-505.	1.9	5
1912	Survival of cervical cancer patients in Germany in the early 21st century: A period analysis by age, histology, and stage. <i>Acta OncolÁgica</i> , 2012, 51, 915-921.	0.8	29
1913	Genetic Variability and Phylogeny of High Risk HPV Type 16, 18, 31, 33 and 45 L1 Gene in Greek Women. <i>International Journal of Molecular Sciences</i> , 2012, 13, 1-17.	1.8	34
1914	MetastamiRs: Non-Coding MicroRNAs Driving Cancer Invasion and Metastasis. <i>International Journal of Molecular Sciences</i> , 2012, 13, 1347-1379.	1.8	53
1915	Human Papillomavirus Type 16 Genetic Variants: Phylogeny and Classification Based on E6 and LCR. <i>Journal of Virology</i> , 2012, 86, 6855-6861.	1.5	136
1916	Clinical Performance Characteristics of the Cervista HPV HR Test Kit in Cervical Cancer Screening in China. <i>Journal of Lower Genital Tract Disease</i> , 2012, 16, 358-363.	0.9	6
1917	Burden of Human Papillomavirus-Related Cervical Disease in the Extended Middle East and North Africa-€A Comprehensive Literature Review. <i>Journal of Lower Genital Tract Disease</i> , 2012, 16, 106-120.	0.9	34
1918	Advances in Peptide-based Human Papillomavirus Therapeutic Vaccines. <i>Current Topics in Medicinal Chemistry</i> , 2012, 12, 1581-1592.	1.0	52
1919	Lipoprotein lipase is frequently overexpressed or translocated in cervical squamous cell carcinoma and promotes invasiveness through the non-catalytic C terminus. <i>British Journal of Cancer</i> , 2012, 107, 739-747.	2.9	9
1920	Diagnostic and therapeutic challenges in the management of glandular abnormalities of the cervix. <i>Expert Review of Obstetrics and Gynecology</i> , 2012, 7, 49-58.	0.4	3

#	ARTICLE	IF	CITATIONS
1921	CD8 T-Cell Responses in Incident and Prevalent Human Papillomavirus Types 16 and 18 Infections. <i>ISRN Obstetrics & Gynecology</i> , 2012, 2012, 1-4.	1.2	4
1922	Effectiveness of Glycyrrhizinic Acid (Glizigen) and an Immunostimulant (Viusid) to Treat Anogenital Warts. <i>ISRN Dermatology</i> , 2012, 2012, 1-6.	1.9	8
1923	Occupational Trichloroethylene Exposure and Cervical Pathology: A Caseâ€“Control Study. <i>Annals of Occupational Hygiene</i> , 2013, 57, 407-16.	1.9	3
1924	Diagnosis of HPV infection. , 2012, , 65-86.		1
1925	Cytomorphological Analysis of Uterine Cervical Pap Smears in Relation to Human Papillomavirus Infection in Indonesian Women. <i>Acta Cytologica</i> , 2012, 56, 171-176.	0.7	6
1926	Role of p16INK4aCytology Testing as an Adjunct to Enhance the Diagnostic Specificity and Accuracy in Human Papillomavirus-Positive Women within an Organized Cervical Cancer Screening Program. <i>Acta Cytologica</i> , 2012, 56, 506-514.	0.7	28
1927	HPV-16 E6 and E7 oncogene expression is downregulated as a result of Mdm2 knockdown. <i>International Journal of Oncology</i> , 2012, 41, 141-6.	1.4	2
1928	Let Sleeping Dogs Lieâ€“Unleashing the Transforming Power of Dormant HPV. <i>Biotechnology and Biotechnological Equipment</i> , 2012, 26, 2689-2694.	0.5	1
1929	HPV, KRAS mutations, alcohol consumption and tobacco smoking effects on esophageal squamous-cell carcinoma carcinogenesis. <i>International Journal of Biological Markers</i> , 2012, 27, 1-12.	0.7	38
1930	Cervical Cancer in Sub Sahara Africa. , 0, , .		29
1931	Potential Benefits of Second-Generation Human Papillomavirus Vaccines. <i>PLoS ONE</i> , 2012, 7, e48426.	1.1	13
1932	Effect of an educational intervention on Hungarian adolescentsâ€™ awareness, beliefs and attitudes on the prevention of cervical cancer. <i>Vaccine</i> , 2012, 30, 6824-6832.	1.7	45
1933	Analytical Comparison of the cobas HPV Test with Hybrid Capture 2 for the Detection of High-Risk HPV Genotypes. <i>Journal of Molecular Diagnostics</i> , 2012, 14, 65-70.	1.2	48
1934	Photodiagnosis and treatment of condyloma acuminatum using 5-aminolevulinic acid and homemade devices. <i>Photodiagnosis and Photodynamic Therapy</i> , 2012, 9, 60-68.	1.3	38
1935	Time for change? An economic evaluation of integrated cervical screening and HPV immunization programs in Canada. <i>Vaccine</i> , 2012, 30, 425-435.	1.7	19
1936	Multiply-primed rolling circle amplification of human papillomavirus using sequence-specific primers. <i>Virology</i> , 2012, 432, 57-62.	1.1	12
1937	Preinvasive Disease of the Cervix. , 2012, , 1-30.e6.		1
1938	Cost effectiveness of strategies to combat breast, cervical, and colorectal cancer in sub-Saharan Africa and South East Asia: mathematical modelling study. <i>BMJ: British Medical Journal</i> , 2012, 344, e614-e614.	2.4	104

#	ARTICLE	IF	CITATIONS
1940	Brush-based self-sampling in combination with GP5+/6+-PCR-based hrHPV testing: High concordance with physician-taken cervical scrapes for HPV genotyping and detection of high-grade CIN. <i>Journal of Clinical Virology</i> , 2012, 54, 147-151.	1.6	40
1941	A Clinical Study of Cervical Dysplasia in Long-Term Survivors of Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 747-753.	2.0	31
1942	Human papillomavirus infection in oral papillary and verrucous lesions is a prognostic indicator of malignant transformation. <i>Cancer Epidemiology</i> , 2012, 36, e122-e127.	0.8	6
1943	Comparison between two human papillomavirus genotyping assays targeting the L1 or E6/E7 region in cervical cancer biopsies. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2012, 30, 225-229.	0.3	9
1944	The PEI-introduced CS shell/PMMA core nanoparticle for silencing the expression of E6/E7 oncogenes in human cervical cells. <i>Carbohydrate Polymers</i> , 2012, 90, 1323-1329.	5.1	27
1945	Type-specific human papillomavirus distribution in invasive cervical carcinomas in Paraguay. A study of 432 cases. <i>Journal of Medical Virology</i> , 2012, 84, 1628-1635.	2.5	17
1946	Human papillomavirus distribution in invasive cervical carcinoma in sub-Saharan Africa: could HIV explain the differences?. <i>Tropical Medicine and International Health</i> , 2012, 17, 1432-1440.	1.0	32
1947	Cervical human papillomavirus infection among young women engaged in sex work in Phnom Penh, Cambodia: prevalence, genotypes, risk factors and association with HIV infection. <i>BMC Infectious Diseases</i> , 2012, 12, 166.	1.3	40
1948	The prevalence and role of human papillomavirus genotypes in primary cervical screening in the northeast of China. <i>BMC Cancer</i> , 2012, 12, 160.	1.1	32
1949	Determinants of acceptance of cervical cancer screening in Dar es Salaam, Tanzania. <i>BMC Public Health</i> , 2012, 12, 1093.	1.2	46
1950	Immunomarkers in Gynecologic Cytology: The Search for the Ideal "Biomolecular Papanicolaou Test"™. <i>Acta Cytologica</i> , 2012, 56, 109-121.	0.7	46
1951	The Epidemiology of Cervical Cancer. , 2012, , 63-83.		3
1952	HPV-related (pre)malignancies of the female anogenital tract in renal transplant recipients. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 84, 161-180.	2.0	58
1953	Anal human papillomavirus DNA in women at a colposcopy clinic. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2012, 164, 69-73.	0.5	10
1954	Cost and Effectiveness Evaluation of Prophylactic HPV Vaccine in Developing Countries. <i>Value in Health</i> , 2012, 15, S29-S34.	0.1	40
1956	Guidelines for the Use of Molecular Tests for the Detection and Genotyping of Human Papilloma Virus from Clinical Specimens. <i>Methods in Molecular Biology</i> , 2012, 903, 65-101.	0.4	9
1957	Current Treatment of Anal Squamous Cell Carcinoma. <i>Hematology/Oncology Clinics of North America</i> , 2012, 26, 1315-1350.	0.9	20
1958	HAMLET: functional properties and therapeutic potential. <i>Future Oncology</i> , 2012, 8, 1301-1313.	1.1	22

#	ARTICLE	IF	CITATIONS
1959	Different domains of glycoprotein 96 influence HPV16 E7 DNA vaccine potency via electroporation mediated delivery in tumor mice model. <i>Immunology Letters</i> , 2012, 148, 117-125.	1.1	13
1960	DNA Methylation Changes in Cervical Cancers. <i>Methods in Molecular Biology</i> , 2012, 863, 155-176.	0.4	26
1961	Cancer Epigenetics. <i>Methods in Molecular Biology</i> , 2012, , .	0.4	5
1962	Anti-HPV16 E2 Protein T-Cell Responses and Viral Control in Women with Usual Vulvar Intraepithelial Neoplasia and Their Healthy Partners. <i>PLoS ONE</i> , 2012, 7, e36651.	1.1	7
1963	Reasons for Receiving or Not Receiving HPV Vaccination in Primary Schoolgirls in Tanzania: A Case Control Study. <i>PLoS ONE</i> , 2012, 7, e45231.	1.1	41
1964	High Risk HPV Contamination of Endocavity Vaginal Ultrasound Probes: An Underestimated Route of Nosocomial Infection?. <i>PLoS ONE</i> , 2012, 7, e48137.	1.1	82
1965	Epidemiology of HPV in Head and Neck Cancer. , 0, , .		0
1966	Breakthroughs and Issues in HPV Genital Infections in relation to Cervical Cancer. <i>Journal of Shaheed Suhrawardy Medical College</i> , 2012, 1, 27-30.	0.1	0
1967	Evaluation of p53, p16INK4a and E-Cadherin Status as Biomarkers for Cervical Cancer Diagnosis. , 0, , .		2
1968	Prevalence of Human Papillomavirus Types 16, 18, and 45 in Women With Cervical Intraepithelial Changes: Associations With Colposcopic and Histological Findings. <i>Medicina (Lithuania)</i> , 2012, 48, 4.	0.8	4
1969	Eficacia y seguridad de la vacuna contra el virus de papiloma humano para la prevención del cáncer de cuello uterino: revisión sistemática y metaanálisis. <i>Archivos Argentinos De Pediatría</i> , 2012, 110, 483-489.	0.3	11
1970	S100, CD68, and MHC class II molecule expression in cervical high- and low-grade HPV-induced lesions. <i>Revista Da Sociedade Brasileira De Medicina Tropical</i> , 2012, 45, 3-8.	0.4	2
1971	Prevalence and Distribution of Human Papillomavirus Infection in Korean Women as Determined by Restriction Fragment Mass Polymorphism Assay. <i>Journal of Korean Medical Science</i> , 2012, 27, 1091.	1.1	36
1972	Clinical Guidelines for the Treatment and Prevention of Opportunistic Infections in HIV-infected Koreans. <i>Infection and Chemotherapy</i> , 2012, 44, 93.	1.0	7
1973	The HPV Vaccine Controversy. <i>AMA Journal of Ethics</i> , 2012, 14, 39-49.	0.4	18
1974	The psychosocial impact of an abnormal cervical smear result. <i>Psycho-Oncology</i> , 2012, 21, 1071-1081.	1.0	80
1975	Prevalence of Human Papillomavirus Infection in a Kashmiri Ethnic Female Population. <i>Genetic Testing and Molecular Biomarkers</i> , 2012, 16, 904-909.	0.3	10
1976	Viral Vaccines in India: An Overview. <i>Proceedings of the National Academy of Sciences India Section B - Biological Sciences</i> , 2012, 82, 181-198.	0.4	9

#	ARTICLE	IF	CITATIONS
1977	Health economics of screening for gynaecological cancers. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2012, 26, 163-173.	1.4	4
1978	Solution Structure Analysis of the HPV16 E6 Oncoprotein Reveals a Self-Association Mechanism Required for E6-Mediated Degradation of p53. <i>Structure</i> , 2012, 20, 604-617.	1.6	104
1979	Human papillomavirus genotype distribution in cervical cancer cases in Spain. Implications for prevention. <i>Gynecologic Oncology</i> , 2012, 124, 512-517.	0.6	27
1980	Potential of tumor radiotherapy by a radiation-inducible oncolytic and oncoapoptotic adenovirus in cervical cancer xenografts. <i>International Journal of Cancer</i> , 2012, 130, 443-453.	2.3	22
1981	HPV typing and its relation with apoptosis in cervical carcinoma from Indian population. <i>Tumor Biology</i> , 2012, 33, 17-22.	0.8	13
1982	A population-based study of human papillomavirus genotype prevalence in the United States: Baseline measures prior to mass human papillomavirus vaccination. <i>International Journal of Cancer</i> , 2013, 132, 198-207.	2.3	137
1983	HPV vaccination programs have not been shown to be cost-effective in countries with comprehensive Pap screening and surgery. <i>Infectious Agents and Cancer</i> , 2013, 8, 21.	1.2	9
1984	HPV prevalence and genetic predisposition to cervical cancer in Saudi Arabia. <i>Infectious Agents and Cancer</i> , 2013, 8, 15.	1.2	53
1986	An interleukin-10 gene polymorphism associated with the development of cervical lesions in women infected with Human Papillomavirus and using oral contraceptives. <i>Infection, Genetics and Evolution</i> , 2013, 19, 32-37.	1.0	25
1987	Biolytic DNA Delivery. <i>Methods in Molecular Biology</i> , 2013, , .	0.4	7
1988	Human papillomavirus genotypes distribution in 175 invasive cervical cancer cases from Brazil. <i>BMC Cancer</i> , 2013, 13, 357.	1.1	28
1989	Comparison of hybrid capture 2 High-Risk HPV results in the low positive range with cobas® HPV Test results from the ATHENA study. <i>Journal of Clinical Virology</i> , 2013, 58, 161-167.	1.6	11
1990	Cell cycle suppressor proteins are not related to HPV status or clinical outcome in patients with vulvar carcinoma. <i>Tumor Biology</i> , 2013, 34, 3713-3720.	0.8	9
1991	Factors influencing the willingness of US women to vaccinate their daughters against the human papillomavirus to prevent cervical cancer. <i>Medical Oncology</i> , 2013, 30, 582.	1.2	21
1992	Genetic variant in APE1 gene promoter contributes to cervical cancer risk. <i>American Journal of Obstetrics and Gynecology</i> , 2013, 209, 360.e1-360.e7.	0.7	17
1993	Prospective evaluation of the Amplicor HPV test for predicting progression of cervical intraepithelial neoplasia 2. <i>Journal of Obstetrics and Gynaecology Research</i> , 2013, 39, 1347-1353.	0.6	2
1994	Malignant diseases and mortality in blood donors infected with human T-lymphotropic virus type 1 in Israel. <i>International Journal of Infectious Diseases</i> , 2013, 17, e1022-e1024.	1.5	7
1995	Detection of mucosal type human papillomavirus in cutaneous squamous cell carcinoma in Iran. <i>Pathology Research and Practice</i> , 2013, 209, 90-94.	1.0	22

#	ARTICLE	IF	CITATIONS
1996	Prevalence of human papillomavirus genotypes among women in Hunan province, China. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2013, 170, 202-205.	0.5	18
1997	HPV16 genetic variation and the development of cervical cancer worldwide. <i>British Journal of Cancer</i> , 2013, 108, 240-244.	2.9	123
1998	Characterization of human papillomavirus by capillary isoelectric focusing with whole-column imaging detection. <i>Electrophoresis</i> , 2013, 34, 3046-3053.	1.3	7
1999	Non-steroidal anti-inflammatory drug use and cervical cancer risk: A case-control study using the Clinical Practice Research Datalink. <i>Cancer Epidemiology</i> , 2013, 37, 897-904.	0.8	11
2000	Cervical samples dried on filter paper and dried vaginal tampons can be useful to investigate the circulation of high-risk HPV in Congo. <i>Journal of Clinical Virology</i> , 2013, 57, 161-164.	1.6	10
2001	The Burden of Human Papillomavirus Infections and Related Diseases in Sub-Saharan Africa. <i>Vaccine</i> , 2013, 31, F32-F46.	1.7	178
2002	Gynecologic Cancer. <i>Medical Radiology</i> , 2013, , 185-219.	0.0	0
2003	High-risk human papillomavirus, other than type 16/18, in predominantly older Taiwanese women with high-grade cervical preinvasive lesions. <i>Taiwanese Journal of Obstetrics and Gynecology</i> , 2013, 52, 222-226.	0.5	10
2004	High expression of prolactin receptor is associated with cell survival in cervical cancer cells. <i>Cancer Cell International</i> , 2013, 13, 103.	1.8	30
2005	Retrieval of HPV oncogenes E6 and E7 mRNA from cervical specimens using a manual open technology protocol. <i>SpringerPlus</i> , 2013, 2, 473.	1.2	3
2006	The Use of Transient Expression Systems for the Rapid Production of Virus-like Particles in Plants. <i>Current Pharmaceutical Design</i> , 2013, 19, 5564-5573.	0.9	62
2007	HPV Has Left the Building—the Absence of Detectable HPV DNA and the Presence of R Allele/S for the P72R Polymorphism in the TP53 Gene May Call for More Aggressive Therapeutic Approach in HPV-Associated Tumours. <i>Biotechnology and Biotechnological Equipment</i> , 2013, 27, 4217-4221.	0.5	1
2008	Prevalence, incidence and persistence of genital HPV infections in a large cohort of sexually active young women in the Netherlands. <i>Vaccine</i> , 2013, 31, 394-401.	1.7	40
2009	Quantivirus® HPV E6/E7 RNA 3.0 assay (bDNA) is as sensitive, but less specific than Hybrid Capture 2 test. <i>Journal of Virological Methods</i> , 2013, 187, 288-293.	1.0	14
2010	Epidemiology of cervical cancer and human papilloma virus infection among Iranian women — Analyses of national data and systematic review of the literature. <i>Gynecologic Oncology</i> , 2013, 128, 277-281.	0.6	93
2011	Codon 72 polymorphism of p53 and HPV type 16 E6 variants as risk factors for patients with squamous epithelial lesion of the uterine cervix. <i>Journal of Medical Virology</i> , 2013, 85, 83-90.	2.5	15
2012	Genotyping of human papillomavirus in paraffin embedded cervical tissue samples from women in ethiopia and the Sudan. <i>Journal of Medical Virology</i> , 2013, 85, 282-287.	2.5	30
2013	Prevalence of human papillomavirus in women attending cervical screening in the UK and Ireland: New data from northern Ireland and a systematic review and meta-analysis. <i>Journal of Medical Virology</i> , 2013, 85, 295-308.	2.5	18

#	ARTICLE	IF	CITATIONS
2015	Occurrence of Dysplasia and Human Papilloma Virus Typing in Penile Condylomas. <i>Urology</i> , 2013, 81, 211.e9-211.e15.	0.5	4
2016	Comparison Between p16INK4A Immunohistochemistry and Human Papillomavirus Polymerase Chain Reaction Assay in Oral Papillary Squamous Cell Carcinoma. <i>Journal of Oral and Maxillofacial Surgery</i> , 2013, 71, 1676-1682.	0.5	10
2018	Female genital mutilation and female genital schistosomiasis-bourouwel, the worm: Traditional belief or medical explanation for a cruel practice?. <i>Midwifery</i> , 2013, 29, e73-e77.	1.0	1
2019	Predictors of absence of cervical intraepithelial neoplasia in the conization specimen. <i>Gynecologic Oncology</i> , 2013, 128, 271-276.	0.6	33
2020	HPV-16 E6 and E7 protein T cell epitopes prediction analysis based on distributions of HLA-A loci across populations: An in silico approach. <i>Vaccine</i> , 2013, 31, 2289-2294.	1.7	36
2021	Risk factors for cervical cancer among young women. <i>Open Medicine (Poland)</i> , 2013, 8, 22-29.	0.6	1
2022	Human papillomavirus genotypes distribution in cervical samples from Uruguayan women. <i>Journal of Medical Virology</i> , 2013, 85, 845-851.	2.5	7
2023	Biolistic DNA Vaccination Against Cervical Cancer. , 2013, 940, 339-355.		0
2024	Human papillomavirus proteins as prospective therapeutic targets. <i>Microbial Pathogenesis</i> , 2013, 58, 55-65.	1.3	19
2025	Risk factors for and prevention of human papillomaviruses (HPV), genital warts and cervical cancer. <i>Journal of Infection</i> , 2013, 66, 207-217.	1.7	209
2026	Association between two genetic variants of CD226 gene and Cervical Squamous Cell Carcinoma: A caseâ€“control study. <i>Gene</i> , 2013, 519, 159-163.	1.0	6
2027	Immunomodulatory effects of IP-10 chemokine along with PEI600-Tat delivery system in DNA vaccination against HPV infections. <i>Molecular Immunology</i> , 2013, 53, 149-160.	1.0	20
2028	Induction of Antitumor Immunity Against Cervical Cancer by Protein HPV-16 E7 in Fusion With Ricin B Chain in Tumor-Bearing Mice. <i>International Journal of Gynecological Cancer</i> , 2013, 23, 809-814.	1.2	18
2029	Prevalence and Distribution of High-Risk Human Papillomavirus Genotypes in Invasive Carcinoma of the Uterine Cervix in Uruguay. <i>International Journal of Gynecological Cancer</i> , 2013, 23, 527-532.	1.2	12
2030	Human Papillomavirus Type Distribution in Invasive Cervical Cancer and High-Grade Cervical Intraepithelial Neoplasia Across 5 Countries in Asia. <i>International Journal of Gynecological Cancer</i> , 2013, 23, 148-156.	1.2	54
2031	New Strategies for Human Papillomavirus-Based Cervical Screening. <i>Women's Health</i> , 2013, 9, 443-452.	0.7	26
2033	Tackling Non-Communicable Diseases In Low- and Middle-Income Countries: Is the Evidence from High-Income Countries All We Need?. <i>PLoS Medicine</i> , 2013, 10, e1001377.	3.9	131
2034	Detection of hpv positivity by immunohistochemistry in colposcopic cervical biopsies with a cytological diagnosis of ascus. <i>Turk Patoloji Dergisi</i> , 2013, 30, 166-70.	0.1	1

#	ARTICLE	IF	CITATIONS
2035	Evaluation of HIV and Highly Active Antiretroviral Therapy on the Natural History of Human Papillomavirus Infection and Cervical Cytopathologic Findings in HIV-Positive and High-Risk HIV-Negative Women. <i>Journal of Infectious Diseases</i> , 2013, 208, 454-462.	1.9	96
2036	Human papillomavirus detection in Moroccan patients with bladder cancer. <i>Journal of Infection in Developing Countries</i> , 2013, 7, 586-592.	0.5	17
2037	Prognostic Significance of Immunohistochemical Phenotypes in Patients Treated for High-Grade Cervical Intraepithelial Neoplasia. <i>BioMed Research International</i> , 2013, 2013, 1-7.	0.9	16
2038	Inactivation of p53 Rescues the Maintenance of High Risk HPV DNA Genomes Deficient in Expression of E6. <i>PLoS Pathogens</i> , 2013, 9, e1003717.	2.1	26
2039	Human Papillomavirus Vaccination for the Prevention of Cervical and Other Related Cancers. <i>Statistics in the Health Sciences</i> , 2013, , 45-64.	0.2	2
2040	It must be true â€œ I read it in <i>Seventeen</i> magazine: US popular culture and sexual messages in an era of abstinence-only education. <i>Sex Education</i> , 2013, 13, 494-508.	1.5	2
2041	Mortality trends and prediction of HPV-related cancers in Brazil. <i>European Journal of Cancer Prevention</i> , 2013, 22, 380-387.	0.6	15
2042	Multiple Heparan Sulfate Binding Site Engagements Are Required for the Infectious Entry of Human Papillomavirus Type 16. <i>Journal of Virology</i> , 2013, 87, 11426-11437.	1.5	93
2043	HPV16 infection regulates RASSF1A transcription mediated by p53. <i>Molecular Medicine Reports</i> , 2013, 8, 413-418.	1.1	4
2044	Squamous Premalignancy of the Cervix. , 2013, 18, 177-182.		1
2045	Microarray detection of human papilloma virus genotypes among Turkish women with abnormal cytology at a colposcopy unit. <i>Journal of the Turkish German Gynecology Association</i> , 2013, 14, 23-27.	0.2	4
2046	HPV genotypes in high-grade intraepithelial cervical lesions in Danish women. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2013, 92, 1032-1040.	1.3	13
2047	Portuguese Women's Knowledge and Health Beliefs about Cervical Cancer and Its Screening. <i>Social Work in Public Health</i> , 2013, 28, 150-157.	0.7	7
2048	HPV genotypes in invasive cervical cancer in Danish women. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2013, 92, 1023-1031.	1.3	9
2050	Methylation of Human Papillomavirus Type 16 CpG Sites at E2-Binding Site 1 (E2BS1), E2BS2, and the Sp1-Binding Site in Cervical Cancer Samples as Determined by High-Resolution Melting Analysisâ€œPCR. <i>Journal of Clinical Microbiology</i> , 2013, 51, 3207-3215.	1.8	22
2051	Prevalence of Human Papillomavirus Genotypes Associated with Cervical and Breast Cancers in Iran. <i>Monoclonal Antibodies in Immunodiagnosis and Immunotherapy</i> , 2013, 32, 399-403.	0.8	18
2052	Using risk to target HPV vaccines in high-risk, low-resource organizations. <i>Human Vaccines and Immunotherapeutics</i> , 2013, 9, 1146-1152.	1.4	1
2053	HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial. <i>Journal of Translational Medicine</i> , 2013, 11, 88.	1.8	165

#	ARTICLE	IF	CITATIONS
2054	Merkel Cell Polyomavirus and HPV-17 Associated With Cutaneous Squamous Cell Carcinoma Arising in a Patient With Melanoma Treated With the BRAF Inhibitor Dabrafenib. <i>JAMA Dermatology</i> , 2013, 149, 322.	2.0	32
2055	Prevalence and incidence of cervical intra-epithelial neoplasia among female sex workers in Korogocho, Kenya. <i>Public Health Action</i> , 2013, 3, 271-275.	0.4	2
2056	Human Papillomavirus DNA and E6/E7 mRNA Testing as Triage in Liquid-Based Cytology Samples from Primary Screening. <i>Current Pharmaceutical Design</i> , 2013, 19, 1508-1515.	0.9	1
2057	Economic evaluation of a public health strategy: an examination of the human papillomavirus vaccine. <i>International Journal of Behavioural and Healthcare Research</i> , 2013, 4, 158.	0.0	0
2058	Degradation of p53 by natural variants of the E6 protein of human papillomavirus type 16. <i>Oncology Reports</i> , 2013, 29, 1617-1622.	1.2	18
2059	Quinone-Based Polymers for Label-Free and Reagentless Electrochemical Immunosensors: Application to Proteins, Antibodies and Pesticides Detection. <i>Biosensors</i> , 2013, 3, 58-76.	2.3	27
2061	HPV prevalence at enrollment and baseline results from the Carolina Women's Care Study, a longitudinal study of HPV persistence in women of college age. <i>International Journal of Women's Health</i> , 2013, 5, 379.	1.1	9
2062	Role of TSG101 in cancer. <i>Frontiers in Bioscience - Landmark</i> , 2013, 18, 279.	3.0	18
2063	DNA vaccines targeting human papillomavirus-associated diseases: progresses in animal and clinical studies. <i>Clinical and Experimental Vaccine Research</i> , 2013, 2, 106.	1.1	9
2064	Post Approval Human Papillomavirus Vaccine Uptake Is Higher in Minorities Compared to Whites in Girls Presenting for Well-Child Care. <i>Vaccines</i> , 2013, 1, 250-261.	2.1	6
2065	Gene- and Protein-Delivered Zinc Finger-Staphylococcal Nuclease Hybrid for Inhibition of DNA Replication of Human Papillomavirus. <i>PLoS ONE</i> , 2013, 8, e56633.	1.1	21
2066	An Enhanced Heterologous Virus-Like Particle for Human Papillomavirus Type 16 Tumour Immunotherapy. <i>PLoS ONE</i> , 2013, 8, e66866.	1.1	32
2067	The Overexpression of Scaffolding Protein NEDD9 Promotes Migration and Invasion in Cervical Cancer via Tyrosine Phosphorylated FAK and SRC. <i>PLoS ONE</i> , 2013, 8, e74594.	1.1	49
2068	Human papillomavirus types 16 and 18 and the prognosis of patients with stage I cervical cancer. <i>Clinics</i> , 2013, 68, 809-814.	0.6	21
2069	El acceso de la mujer a la "alta cultura" en la Europa del Renacimiento. <i>Arbor</i> , 2013, 189, a020.	0.1	2
2070	HPV Diagnosis in Vaccination Era. , 2013, , .		0
2071	Recommended Managements for the Male Human Papillomavirus Infection. <i>The Korean Journal of Urogenital Tract Infection and Inflammation</i> , 2014, 9, 79.	0.1	1
2072	Human papilloma virus and cervical neoplasia in HIV positive women: A non systematic review. <i>African Journal of Microbiology Research</i> , 2014, 8, 2193-2201.	0.4	1

#	ARTICLE	IF	CITATIONS
2073	Seroprevalence of human papillomavirus immunoglobulin G antibodies among women presenting at the reproductive health clinic of a university teaching hospital in Nigeria. <i>International Journal of Women's Health</i> , 2014, 6, 479.	1.1	10
2074	Clinicopathological Implications of Human Papilloma Virus (HPV) L1 Capsid Protein Immunoreactivity in HPV16-Positive Cervical Cytology. <i>International Journal of Medical Sciences</i> , 2014, 11, 80-86.	1.1	15
2076	Detection and estimation of human papillomavirus viral load in patients with cervical lesions. <i>Bangladesh Medical Research Council Bulletin</i> , 2014, 39, 86-90.	0.1	4
2077	Human papillomaviruses-related cancers. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 1812-1821.	1.4	39
2078	Correlation between human papillomavirus and p16 overexpression in oropharyngeal tumours: a systematic review. <i>British Journal of Cancer</i> , 2014, 110, 1587-1594.	2.9	175
2079	Inhibition of Langerhans Cell Maturation by Human Papillomavirus Type 16: A Novel Role for the Annexin A2 Heterotetramer in Immune Suppression. <i>Journal of Immunology</i> , 2014, 192, 4748-4757.	0.4	38
2080	Human Papillomavirus Species-Specific Interaction with the Basement Membrane-Resident Non-Heparan Sulfate Receptor. <i>Viruses</i> , 2014, 6, 4856-4879.	1.5	25
2081	A risk evaluation model of cervical cancer based on etiology and human leukocyte antigen allele susceptibility. <i>International Journal of Infectious Diseases</i> , 2014, 28, 8-12.	1.5	12
2082	Human papilloma virus 16/18 genotypes in patients with squamous cell carcinoma of cervix in northeast Iran. <i>Nigerian Medical Journal</i> , 2014, 55, 495.	0.6	7
2083	Metagenomic analysis of a sample from a patient with respiratory tract infection reveals the presence of a λ -papillomavirus. <i>Frontiers in Microbiology</i> , 2014, 5, 347.	1.5	15
2084	Prevalence and Genotyping of High Risk Human Papillomavirus in Cervical Cancer Samples from Punjab, Pakistan. <i>Viruses</i> , 2014, 6, 2762-2777.	1.5	28
2085	Function of inducible nitric oxide synthase in the regulation of cervical cancer cell proliferation and the expression of vascular endothelial growth factor. <i>Molecular Medicine Reports</i> , 2014, 9, 583-589.	1.1	24
2086	Prognostic Factors Influencing Decisions About Surgical Treatment of Villoglandular Adenocarcinoma of the Uterine Cervix. <i>International Journal of Gynecological Cancer</i> , 2014, 24, 1299-1305.	1.2	12
2087	Incidence and clinical management of oral human papillomavirus infection in men: a series of key short messages. <i>Expert Review of Anti-Infective Therapy</i> , 2014, 12, 947-957.	2.0	5
2088	Aberrant promoter methylation and silencing of <i>RASSF2A</i> gene in cervical cancer. <i>Journal of Obstetrics and Gynaecology Research</i> , 2014, 40, 1375-1381.	0.6	4
2089	p16 ^{INK4a} overexpression is not linked to oncogenic human papillomaviruses in patients with high-grade urothelial cancer cells. <i>Cancer Cytopathology</i> , 2014, 122, 760-769.	1.4	15
2090	Pathogenic role of the eight probably/possibly carcinogenic HPV types 26, 53, 66, 67, 68, 70, 73 and 82 in cervical cancer. <i>Journal of Pathology</i> , 2014, 234, 441-451.	2.1	119
2091	Prevalence of Genital Warts Among Sexually Transmitted Disease Clinic Patients—Sexually Transmitted Disease Surveillance Network, United States, January 2010 to December 2011. <i>Sexually Transmitted Diseases</i> , 2014, 41, 89-93.	0.8	19

#	ARTICLE	IF	CITATIONS
2092	“Equivocal” High-Risk HPV DNA Tests Performed on ThinPrep Specimens After ASC-US Diagnoses Are Associated With an Increased Incidence of CIN3. <i>Journal of Lower Genital Tract Disease</i> , 2014, 18, 291-297.	0.9	1
2093	Seroprevalence of 8 Oncogenic Human Papillomavirus Genotypes and Acquired Immunity Against Reinfection. <i>Journal of Infectious Diseases</i> , 2014, 210, 448-455.	1.9	33
2094	5-Aminolevulinic acid-based fluorescence diagnostics of cervical preinvasive changes. <i>Medicina (Lithuania)</i> , 2014, 50, 137-143.	0.8	8
2095	The History of Physics in Cuba. <i>Boston Studies in the Philosophy and History of Science</i> , 2014, , .	0.4	2
2096	The Epidemiology of Human Papillomaviruses. <i>Current Problems in Dermatology</i> , 2014, 45, 75-91.	0.8	25
2098	Human Papillomavirus Vaccination: A Case Study in Translational Science. <i>Clinical and Translational Science</i> , 2014, 7, 420-424.	1.5	6
2099	Epidemiology of sexually transmitted infections: UK. <i>Medicine</i> , 2014, 42, 281-286.	0.2	4
2100	What is the future burden of HPV-related cancers in Spain?. <i>Clinical and Translational Oncology</i> , 2014, 16, 213-219.	1.2	3
2101	Decision Tools for Radiation Oncology. <i>Medical Radiology</i> , 2014, , .	0.0	2
2102	Human papillomavirus prevalence and type-distribution in women with cervical lesions: a cross-sectional study in Sri Lanka. <i>BMC Cancer</i> , 2014, 14, 116.	1.1	7
2103	Comparison of Digene Hybrid Capture 2, GeneMatrix PapilloScreen, and a PCR sequencing assay in detecting high-risk and probable high-risk oncogenic HPV genotypes in specimens from Korean women. <i>Archives of Virology</i> , 2014, 159, 1909-1916.	0.9	0
2104	Promoter methylation of DAPK1, FHIT, MGMT, and CDKN2A genes in cervical carcinoma. <i>International Journal of Clinical Oncology</i> , 2014, 19, 127-132.	1.0	43
2105	In Silico Comparison of Low- and High-Risk Human Papillomavirus Proteins. <i>Applied Biochemistry and Biotechnology</i> , 2014, 172, 188-195.	1.4	10
2106	The burden, distribution and risk factors for cervical oncogenic human papilloma virus infection in HIV positive Nigerian women. <i>Virology Journal</i> , 2014, 11, 5.	1.4	56
2107	Characterization and evaluation of the immune responses elicited by a novel human papillomavirus (HPV) therapeutic vaccine: HPV 16E7-HBcAg-Hsp65 fusion protein. <i>Journal of Virological Methods</i> , 2014, 197, 1-6.	1.0	9
2108	Prevalence of Human Papillomavirus in endometrial cancer: A systematic review and meta-analysis. <i>Gynecologic Oncology</i> , 2014, 134, 206-215.	0.6	29
2109	HPV16 E6 variants: Frequency, association with HPV types and in silico analysis of the identified novel variants. <i>Journal of Medical Virology</i> , 2014, 86, 968-974.	2.5	6
2110	HPV genotype prevalence in Australian women undergoing routine cervical screening by cytology status prior to implementation of an HPV vaccination program. <i>Journal of Clinical Virology</i> , 2014, 60, 250-256.	1.6	31

#	ARTICLE	IF	CITATIONS
2111	The incidence of human papillomavirus infection following treatment for cervical neoplasia: A systematic review. <i>Gynecologic Oncology</i> , 2014, 132, 767-779.	0.6	35
2112	Prevalence of high-risk human papillomavirus by cobas 4800 HPV test in urban Peru. <i>Brazilian Journal of Infectious Diseases</i> , 2014, 18, 469-472.	0.3	19
2113	Inhibition of DNA Replication of Human Papillomavirus by Using Zinc Fingerâ€“Single-Chain FokI Dimer Hybrid. <i>Molecular Biotechnology</i> , 2014, 56, 731-737.	1.3	10
2114	Human papillomavirus 33 worldwide genetic variation and associated risk of cervical cancer. <i>Virology</i> , 2014, 448, 356-362.	1.1	29
2115	The immunoinhibitory B7-H1 molecule as a potential target in cancer: Killing many birds with one stone. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2014, 7, 1-17.	0.6	83
2116	A synthetic chimeric peptide harboring human papillomavirus 16 cytotoxic T lymphocyte epitopes shows therapeutic potential in a murine model of cervical cancer. <i>Immunologic Research</i> , 2014, 58, 132-138.	1.3	11
2117	Human papillomavirus typeâ€“specific persistence and recurrence after treatment for cervical dysplasia. <i>Journal of Medical Virology</i> , 2014, 86, 634-641.	2.5	44
2118	Prognostic value of p16â€“INK4A protein in women with negative or CIN1 histology result: A followâ€“up study. <i>International Journal of Cancer</i> , 2014, 134, 897-904.	2.3	24
2119	Convenient detection of HPV virus in a clinical sample using concurrent rolling circle and junction probe amplifications. <i>Chemical Communications</i> , 2014, 50, 7147-7149.	2.2	5
2120	Human Papillomavirus 45 Genetic Variation and Cervical Cancer Risk Worldwide. <i>Journal of Virology</i> , 2014, 88, 4514-4521.	1.5	30
2121	In vitro and in vivo growth suppression of human papillomavirus 16-positive cervical cancer cells by CRISPR/Cas9. <i>Biochemical and Biophysical Research Communications</i> , 2014, 450, 1422-1426.	1.0	183
2122	CT Virtual Hysterosalpingography. , 2014, , .		1
2123	Cervical Pathology. , 2014, , 67-87.		0
2124	Prevalence of HPV and variation of HPV 16/HPV 18 E6/E7 genes in cervical cancer in women in South West China. <i>Journal of Medical Virology</i> , 2014, 86, 1926-1936.	2.5	27
2125	Type distribution of human papillomavirus among adult women diagnosed with invasive cervical cancer (stage 1b or higher) in New Zealand. <i>BMC Infectious Diseases</i> , 2014, 14, 374.	1.3	8
2127	HPV genotypes and cervical intraepithelial neoplasia in a multiethnic cohort in the southeastern USA. <i>Cancer Causes and Control</i> , 2014, 25, 1055-1062.	0.8	62
2128	Risk - A Multidisciplinary Introduction. , 2014, , .		15
2129	Modeling optimal cervical cancer prevention strategies in Nigeria. <i>BMC Cancer</i> , 2014, 14, 365.	1.1	20

#	ARTICLE	IF	CITATIONS
2130	Risk factors for human papillomavirus persistence among women undergoing cold-knife conization for treatment of high-grade cervical intraepithelial neoplasia. <i>International Journal of Gynecology and Obstetrics</i> , 2014, 125, 275-278.	1.0	16
2131	Comparative study of HPV16 integration in cervical lesions between ethnicities with high and low rates of infection with high-risk HPV and the correlation between integration rate and cervical neoplasia. <i>Experimental and Therapeutic Medicine</i> , 2015, 10, 2169-2174.	0.8	16
2132	Human papillomavirus genotypes among women with or without HIV infection: an epidemiological study of Moroccan women from the Souss area. <i>Infectious Agents and Cancer</i> , 2015, 10, 44.	1.2	16
2133	German-Austrian guidelines on anal dysplasia and anal cancer in HIV-positive individuals: prevention, diagnosis, and treatment. <i>JDDG - Journal of the German Society of Dermatology</i> , 2015, 13, 1302-1319.	0.4	51
2134	The existence of Th22, pure Th17 and Th1 cells in CIN and Cervical Cancer along with their frequency variation in different stages of cervical cancer. <i>BMC Cancer</i> , 2015, 15, 717.	1.1	24
2135	An analysis of discrepancies between United Kingdom cancer research funding and societal burden and a comparison to previous and United States values. <i>Health Research Policy and Systems</i> , 2015, 13, 62.	1.1	19
2136	Local immunosuppression induced by high viral load of human papillomavirus: characterization of cellular phenotypes producing interleukin-10 in cervical neoplastic lesions. <i>Immunology</i> , 2015, 146, 113-121.	2.0	39
2137	Oral Lopinavir Use and Human Papillomavirus Infection in HIV-Positive Women. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2015, 70, e63-e66.	0.9	5
2138	Clinical performance of multiplex high-risk e6 mRNA expression in comparison with hpv dna subtypes for the identification of women at risk of cervical cancer. <i>Journal of Medical Virology</i> , 2015, 87, 1404-1412.	2.5	0
2139	Deutsche-Österreichische S2-Leitlinie: anale Dysplasien und Analkarzinome bei HIV-Infizierten: Prävention, Diagnostik und Therapie. <i>JDDG - Journal of the German Society of Dermatology</i> , 2015, 13, e1.	0.4	6
2140	Comparison of Human Papillomavirus Infection and Cervical Cytology in Women Using Copper-Containing and Levonorgestrel-Containing Intrauterine Devices. <i>Obstetrics and Gynecology</i> , 2015, 125, 1101-1105.	1.2	19
2141	A Population-based Study of Invasive Cervical Cancer Patients in Beijing. <i>Chinese Medical Journal</i> , 2015, 128, 3298-3304.	0.9	28
2142	The role of human papillomaviruses in carcinogenesis. <i>Ecancermedicalscience</i> , 2015, 9, 526.	0.6	123
2143	Trifluoromethyl-phenyl-triazolyl derivative of beta-bisabolol induces cell death in ME-180 cervical cancer cells through induction of apoptosis and ROS generation. <i>Bangladesh Journal of Pharmacology</i> , 2015, 11, 43.	0.1	0
2144	Mate-Pair Sequencing as a Powerful Clinical Tool for the Characterization of Cancers with a DNA Viral Etiology. <i>Viruses</i> , 2015, 7, 4507-4528.	1.5	6
2145	Prevalence of Human Papillomavirus Genotypes among African Women with Normal Cervical Cytology and Neoplasia: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2015, 10, e0122488.	1.1	89
2146	Knowledge on HPV Vaccine and Cervical Cancer Facilitates Vaccine Acceptability among School Teachers in Kitui County, Kenya. <i>PLoS ONE</i> , 2015, 10, e0135563.	1.1	48
2147	Epidemiology of cervical cancer with special focus on India. <i>International Journal of Women's Health</i> , 2015, 7, 405.	1.1	176

#	ARTICLE	IF	CITATIONS
2148	Prediction of High-Risk Types of Human Papillomaviruses Using Statistical Model of Protein Sequence Space. Computational and Mathematical Methods in Medicine, 2015, 2015, 1-9.	0.7	8
2149	Detection and Typing of Human Papilloma Viruses by Nested Multiplex Polymerase Chain Reaction Assay in Cervical Cancer. Jundishapur Journal of Microbiology, 2015, 8, e26441.	0.2	13
2150	Age and Ethnic Differences in the Occurrence of Cervical Dysplasia, Cervical Cancer, and Cervical Cancer Deaths in Suriname. Translational Biomedicine, 2015, 6, .	0.1	1
2151	Altered Salivary Protein Profiles among Individuals Diagnosed with Cervical Dysplasia and Cervical Carcinoma in Situ. Cancer and Clinical Oncology, 2015, 5, 63.	0.2	1
2152	New approaches in vaccine-based immunotherapy for human papillomavirus-induced cancer. Current Opinion in Immunology, 2015, 35, 9-14.	2.4	12
2153	Retrospective analysis of patients with cancer of the cervix attending a radiotherapy outpatient department: experience from a university-based hospital in eastern Uttar Pradesh, India. Southern African Journal of Gynaecological Oncology, 2015, 7, 5-12.	0.3	3
2154	The prognostic value of p53 expression for patients with cervical cancer: a meta analysis. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2015, 195, 210-213.	0.5	15
2155	Human papillomavirus-related carcinoma with adenoid cystic-like features of the inferior turbinate: A case report. Auris Nasus Larynx, 2015, 42, 53-55.	0.5	41
2156	High-resolution anoscopy in women with cervical neoplasia. International Journal of Gynecology and Obstetrics, 2015, 128, 216-219.	1.0	8
2157	The epidemiology of sexually transmitted infections in the UK: impact of behavior, services and interventions. Future Microbiology, 2015, 10, 35-51.	1.0	73
2158	Sensitivity of high-risk HPV hybrid capture II (hrHPV HC2) test using SurePath TM specimens in the prediction of cervical high-grade squamous lesions. Diagnostic Cytopathology, 2015, 43, 381-387.	0.5	5
2159	In planta produced virus-like particles as candidate vaccines. , 2015, , 73-85.		1
2160	The comparative and cost-effectiveness of HPV-based cervical cancer screening algorithms in El Salvador. International Journal of Cancer, 2015, 137, 893-902.	2.3	38
2161	p16INK4a overexpression is associated with CDKN2A mutation and worse prognosis in HPV-negative laryngeal squamous cell carcinomas. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2015, 466, 375-382.	1.4	33
2162	A Cryo-Electron Microscopy Study Identifies the Complete H16.V5 Epitope and Reveals Global Conformational Changes Initiated by Binding of the Neutralizing Antibody Fragment. Journal of Virology, 2015, 89, 1428-1438.	1.5	54
2163	Knowledge and Acceptability of Human Papillomavirus Vaccination and Cervical Cancer Screening among Women in Karnataka, India. Journal of Cancer Education, 2015, 30, 130-137.	0.6	33
2164	Does Human Papillomavirus Cause Esophageal Adenocarcinoma?. Clinical Gastroenterology and Hepatology, 2015, 13, 1369-1370.	2.4	3
2165	Structural comparison of four different antibodies interacting with human papillomavirus 16 and mechanisms of neutralization. Virology, 2015, 483, 253-263.	1.1	47

#	ARTICLE	IF	CITATIONS
2166	A prospective double-blind cross-sectional study of the accuracy of the use of dry vaginal tampons for self-sampling of human papillomaviruses. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2015, 122, 388-394.	1.1	5
2167	High-risk Oncogenic Human Papilloma Virus Infection of the Foreskin and Microbiology of Smegma in Prepubertal Boys. <i>Urology</i> , 2015, 86, 368-372.	0.5	12
2168	Immunization with mutant HPV16 E7 protein inhibits the growth of TC-1 cells in tumor-bearing mice. <i>Oncology Letters</i> , 2015, 9, 1851-1856.	0.8	6
2169	Metastasis suppressors Nm23H1 and Nm23H2 differentially regulate neoplastic transformation and tumorigenesis. <i>Cancer Letters</i> , 2015, 361, 207-217.	3.2	21
2170	Vaccine-Induced Tumor Necrosis Factor-Producing T Cells Synergize with Cisplatin to Promote Tumor Cell Death. <i>Clinical Cancer Research</i> , 2015, 21, 781-794.	3.2	81
2171	Human papillomavirus genotyping by Linear Array and Next-Generation Sequencing in cervical samples from Western Mexico. <i>Virology Journal</i> , 2015, 12, 161.	1.4	30
2172	Human papillomavirus infection and cervical dysplasia in female sex workers in Northeast China: an observational study. <i>BMC Public Health</i> , 2015, 15, 695.	1.2	11
2173	Human papillomavirus vaccine trials and tribulations. <i>Journal of the American Academy of Dermatology</i> , 2015, 73, 743-756.	0.6	25
2174	Genotyping of high-risk human papillomaviruses in p16/Ki67-positive urothelial carcinoma cells: even a worm will turn. <i>Cytopathology</i> , 2015, 26, 106-113.	0.4	4
2175	Reduced dose human papillomavirus vaccination: An update of the current state-of-the-art. <i>Vaccine</i> , 2015, 33, 5042-5050.	1.7	16
2176	HMGB1 overexpression correlates with poor prognosis in early-stage squamous cervical cancer. <i>Tumor Biology</i> , 2015, 36, 9039-9047.	0.8	14
2177	Human Papillomavirus 18 Genetic Variation and Cervical Cancer Risk Worldwide. <i>Journal of Virology</i> , 2015, 89, 10680-10687.	1.5	78
2178	Performance of the HPV-16 L1 methylation assay and HPV E6/E7 mRNA test for the detection of squamous intraepithelial lesions in cervical cytological samples. <i>Journal of Virological Methods</i> , 2015, 224, 35-41.	1.0	4
2179	A lectin-based diagnostic system using circulating antibodies to detect cervical intraepithelial neoplasia and cervical cancer. <i>Glycobiology</i> , 2016, 26, cwv075.	1.3	14
2180	The HLA-DQB1 gene polymorphisms associated with cervical cancer risk: A meta-analysis. <i>Biomedicine and Pharmacotherapy</i> , 2015, 73, 58-64.	2.5	25
2181	Assessing genital human papillomavirus genoprevalence in young Australian women following the introduction of a national vaccination program. <i>Vaccine</i> , 2015, 33, 201-208.	1.7	51
2183	Distribution of high-risk human papillomavirus genotypes in HPV-infected women in Beijing, China. <i>Journal of Medical Virology</i> , 2015, 87, 504-507.	2.5	18
2184	A brief history of cancer: Age-old milestones underlying our current knowledge database. <i>International Journal of Cancer</i> , 2015, 136, 2022-2036.	2.3	108

#	ARTICLE	IF	CITATIONS
2185	Viral infections and colorectal cancer: A systematic review of epidemiological studies. <i>International Journal of Cancer</i> , 2015, 137, 12-24.	2.3	64
2186	Chitosan nanoparticles as a potential nonviral gene delivery for HPV-16 E7 into mammalian cells. <i>Artificial Cells, Nanomedicine and Biotechnology</i> , 2015, 43, 366-372.	1.9	17
2187	Human Papillomaviruses. , 2016, , 413-426.		0
2188	Non-therapeutic infant male circumcision. <i>Journal of King Abdulaziz University, Islamic Economics</i> , 2016, 37, 941-947.	0.5	13
2189	Human Papilloma Virus (HPV) Vaccines: Scope and Implications. <i>Translational Medicine (Sunnyvale)</i> , 2016, 6, 10-15.	0.4	0
2190	Interaction between susceptibility loci in cGAS-STING pathway, MHC gene and HPV infection on the risk of cervical precancerous lesions in Chinese population. <i>Oncotarget</i> , 2016, 7, 84228-84238.	0.8	13
2191	Circulating interleukin-10 levels and human papilloma virus and Epstein–Barr virus-associated cancers: evidence from a Mendelian randomization meta-analysis based on 11,170 subjects. <i>OncoTargets and Therapy</i> , 2016, 9, 1251.	1.0	6
2192	Ellagitannins in Cancer Chemoprevention and Therapy. <i>Toxins</i> , 2016, 8, 151.	1.5	83
2193	Molecular analyses of unselected head and neck cancer cases demonstrates that human papillomavirus transcriptional activity is positively associated with survival and prognosis. <i>BMC Cancer</i> , 2016, 16, 367.	1.1	3
2194	Cost-Effectiveness of Different Cervical Screening Strategies in Islamic Republic of Iran: A Middle-Income Country with a Low Incidence Rate of Cervical Cancer. <i>PLoS ONE</i> , 2016, 11, e0156705.	1.1	17
2195	New challenges for cervical cancer. <i>Journal of Health Inequalities</i> , 2016, 1, 77-88.	0.1	0
2196	Comparison of Three Different Commercial Kits for the Human Papilloma Virus Genotyping. <i>Journal of Clinical Laboratory Analysis</i> , 2016, 30, 1110-1115.	0.9	10
2197	Sensitivity of APTIMA HPV E6/E7 mRNA test in comparison with hybrid capture 2 HPV DNA test for detection of high risk oncogenic human papillomavirus in 396 biopsy confirmed cervical cancers. <i>Journal of Medical Virology</i> , 2016, 88, 1271-1278.	2.5	14
2198	Accuracy of urinary human papillomavirus testing for the presence of cervical human papillomaviruses and higher grades of cervical intraepithelial neoplasia. <i>Cancer</i> , 2016, 122, 2836-2844.	2.0	15
2200	Incidence and duration of type-specific human papillomavirus infection in high-risk HPV-naïve women: results from the control arm of a phase II HPV-16/18 vaccine trial. <i>BMJ Open</i> , 2016, 6, e011371.	0.8	34
2201	Nitrative and oxidative DNA damage in infection-related carcinogenesis in relation to cancer stem cells. <i>Genes and Environment</i> , 2016, 38, 26.	0.9	79
2202	The combination of <i>Pleurotus ferulae</i> water extract and CpG-ODN enhances the immune responses and antitumor efficacy of HPV peptides pulsed dendritic cell-based vaccine. <i>Vaccine</i> , 2016, 34, 3568-3575.	1.7	21
2204	Human papillomavirus detection using in situ hybridization and correlations with histological and cytological findings. <i>Médecine Et Maladies Infectieuses</i> , 2016, 46, 380-384.	5.1	2

#	ARTICLE	IF	CITATIONS
2205	Identification of genetic variation in the lncRNA HOTAIR associated with HPV16-related cervical cancer pathogenesis. <i>Cellular Oncology (Dordrecht)</i> , 2016, 39, 559-572.	2.1	39
2206	Society of behavioral medicine supports increasing HPV vaccination uptake: an urgent opportunity for cancer prevention. <i>Translational Behavioral Medicine</i> , 2016, 6, 672-675.	1.2	6
2207	Genetic variants within microRNA binding site of <i>RAD51B</i> are associated with risk of cervical cancer in Chinese women. <i>Cancer Medicine</i> , 2016, 5, 2596-2601.	1.3	18
2208	Viral-associated malignancies in Africa: are viruses "infectious traces" or "dominant drivers"? <i>Current Opinion in Virology</i> , 2016, 20, 28-33.	2.6	8
2209	Techniques for cervical cancer screening and diagnosis. , 2016, , 345-375.		2
2210	CRISPR-Cas9 therapeutics in cancer: promising strategies and present challenges. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2016, 1866, 197-207.	3.3	45
2212	Cancer Incidence and Mortality Among Filipinos in the USA and the Philippines: Patterns and Trends. , 2016, , 47-79.		0
2213	HPV Awareness, Knowledge and Vaccination Attitudes among Church-going African-American Women. <i>American Journal of Health Behavior</i> , 2016, 40, 771-778.	0.6	20
2214	Characterization of microbiome in bronchoalveolar lavage fluid of patients with lung cancer comparing with benign mass like lesions. <i>Lung Cancer</i> , 2016, 102, 89-95.	0.9	223
2215	L1 and L2 gene polymorphisms in HPV-58 and HPV-33: implications for vaccine design and diagnosis. <i>Virology Journal</i> , 2016, 13, 167.	1.4	13
2216	Analysis of Human Papillomavirus Using Datamining - Apriori, Decision Tree, and Support Vector Machine (SVM) and its Application Field. <i>MATEC Web of Conferences</i> , 2016, 56, 04002.	0.1	3
2217	High-risk HPV is not associated with epithelial ovarian cancer in a Caucasian population. <i>Infectious Agents and Cancer</i> , 2016, 11, 39.	1.2	20
2218	Factors related to HPV vaccine uptake and 3-dose completion among women in a low vaccination region of the USA: an observational study. <i>BMC Women's Health</i> , 2016, 16, 41.	0.8	55
2219	Ethnic and geographic variations in HPV prevalence and genotype distribution in northwestern Yunnan, China. <i>Journal of Medical Virology</i> , 2016, 88, 532-540.	2.5	20
2220	Detection of Human Papillomavirus Genotypes and Major BRCA Mutations in Familial Breast Cancer. <i>Monoclonal Antibodies in Immunodiagnosis and Immunotherapy</i> , 2016, 35, 135-140.	0.8	7
2221	Expression quantitative trait loci in long non-coding RNA PAX8-AS1 are associated with decreased risk of cervical cancer. <i>Molecular Genetics and Genomics</i> , 2016, 291, 1743-1748.	1.0	34
2222	High-risk oncogenic HPV genotype infection associates with increased immune activation and T cell exhaustion in ART-suppressed HIV-1-infected women. <i>Oncolmmunology</i> , 2016, 5, e1128612.	2.1	21
2223	Practical issues in the application of p16 immunohistochemistry in diagnostic pathology. <i>Human Pathology</i> , 2016, 51, 64-74.	1.1	52

#	ARTICLE	IF	CITATIONS
2224	Optimal control with multiple human papillomavirus vaccines. <i>Journal of Theoretical Biology</i> , 2016, 393, 179-193.	0.8	26
2225	Single-Nucleotide Polymorphisms and Haplotypes of Intercellular Adhesion Molecule-1 in Uterine Cervical Carcinogenesis in Taiwanese Women. <i>Reproductive Sciences</i> , 2016, 23, 401-408.	1.1	7
2226	Substantial contribution of extrinsic risk factors to cancer development. <i>Nature</i> , 2016, 529, 43-47.	13.7	508
2227	Prevention of cervical cancer: journey to develop the first human papillomavirus virus-like particle vaccine and the next generation vaccine. <i>Current Opinion in Chemical Biology</i> , 2016, 32, 34-47.	2.8	50
2228	Argentina's Successful Implementation Of A National Human Papillomavirus Vaccination Program. <i>Health Affairs</i> , 2016, 35, 301-308.	2.5	13
2229	Human papillomavirus genotypes distribution among Gabonese women with normal cytology and cervical abnormalities. <i>Infectious Agents and Cancer</i> , 2016, 11, 2.	1.2	19
2230	Current therapeutic vaccination and immunotherapy strategies for HPV-related diseases. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 1418-1429.	1.4	70
2231	Harnessing the Prokaryotic Adaptive Immune System as a Eukaryotic Antiviral Defense. <i>Trends in Microbiology</i> , 2016, 24, 294-306.	3.5	25
2232	Prevalence of Human Papillomavirus Genotypes Among Women With High-Grade Cervical Lesions in Beijing, China. <i>Medicine (United States)</i> , 2016, 95, e2555.	0.4	10
2233	Multi-scale hyperspectral imaging of cervical neoplasia. <i>Archives of Gynecology and Obstetrics</i> , 2016, 293, 1309-1317.	0.8	14
2234	LncRNAs: key players and novel insights into cervical cancer. <i>Tumor Biology</i> , 2016, 37, 2779-2788.	0.8	176
2235	The Dynamics of HPV Infection and Cervical Cancer Cells. <i>Bulletin of Mathematical Biology</i> , 2016, 78, 4-20.	0.9	27
2236	Genetic variation of high-risk HPV-16 from a cervical cancer biopsy collected in Pakistan. <i>Future Virology</i> , 2016, 11, 31-38.	0.9	1
2237	The complex relationship between human papillomavirus and cervical adenocarcinoma. <i>International Journal of Cancer</i> , 2016, 138, 409-416.	2.3	69
2238	Detection of Human Papilloma Virus (Type 16) among HIV-Positive Women in Ogbomoso, South-Western Nigeria. <i>Journal of Immunoassay and Immunochemistry</i> , 2016, 37, 130-140.	0.5	0
2239	Viewing Focus Groups Through a Critical Incident Lens. <i>Qualitative Health Research</i> , 2016, 26, 750-762.	1.0	6
2240	Physical Status and Variant Analysis of Human Papillomavirus 16 in Women from Shanghai. <i>Gynecologic and Obstetric Investigation</i> , 2016, 81, 61-70.	0.7	3
2242	Distinctive distribution of HPV genotypes in cervical cancers in multi-ethnic Suriname: implications for prevention and vaccination. <i>Epidemiology and Infection</i> , 2017, 145, 245-253.	1.0	10

#	ARTICLE	IF	CITATIONS
2243	Two-step chromatographic purification of glutathione S-transferase-tagged human papillomavirus type 16 E6 protein and its application for serology. <i>Protein Expression and Purification</i> , 2017, 132, 19-26.	0.6	3
2244	Patterns of persistent HPV infection after treatment for cervical intraepithelial neoplasia (CIN): A systematic review. <i>International Journal of Cancer</i> , 2017, 141, 8-23.	2.3	87
2245	Human papillomavirus genotypes associated with cervical precancerous lesions and cancer in the highest area of cervical cancer mortality, Longnan, China. <i>Infectious Agents and Cancer</i> , 2017, 12, 8.	1.2	22
2246	Human papillomavirus (HPV) vaccine initiation in minority Americans. <i>Public Health</i> , 2017, 144, 86-91.	1.4	34
2247	Stop codon mutagenesis for homogenous expression of human papillomavirus L1 protein in <i>Escherichia coli</i> . <i>Protein Expression and Purification</i> , 2017, 133, 110-120.	0.6	7
2248	<i>Glycyrrhiza uralensis</i> water extract enhances dendritic cell maturation and antitumor efficacy of HPV dendritic cell-based vaccine. <i>Scientific Reports</i> , 2017, 7, 43796.	1.6	27
2249	Comparison of FFPE histological versus LBP cytological samples for HPV detection and typing in cervical cancer. <i>Experimental and Molecular Pathology</i> , 2017, 102, 321-326.	0.9	7
2250	Differential HPV16 variant distribution in squamous cell carcinoma, adenocarcinoma and adenosquamous cell carcinoma. <i>International Journal of Cancer</i> , 2017, 140, 2092-2100.	2.3	35
2251	Genotypic diversity of anogenital human papillomavirus in women attending cervical cancer screening in Harare, Zimbabwe. <i>Journal of Medical Virology</i> , 2017, 89, 1671-1677.	2.5	15
2253	LALF32-51-E7 therapeutic vaccine induces antitumor immunity against human papillomavirus type 16 E7-expressing murine tumor metastases in the lungs. <i>Clinical and Experimental Metastasis</i> , 2017, 34, 241-249.	1.7	3
2254	Impact of viral and host DNA methylations on HPV16-related cervical cancer pathogenesis. <i>Tumor Biology</i> , 2017, 39, 101042831769979.	0.8	9
2255	Microwave-assisted synthesis of polypyridyl ruthenium complexes as potential tumor-targeting inhibitors against the migration and invasion of Hela cells through G2/M phase arrest. <i>RSC Advances</i> , 2017, 7, 26625-26632.	1.7	13
2256	A review of the use of human papilloma virus (HPV) in cervical screening. <i>British Journal of Biomedical Science</i> , 2017, 74, 105-109.	1.2	5
2257	Investigation of Methylenetetrahydrofolate Reductase C677T Polymorphism and Human Papilloma Virus Genotypes in Iranian Breast Cancer. <i>Monoclonal Antibodies in Immunodiagnosis and Immunotherapy</i> , 2017, 36, 124-128.	0.8	5
2258	Clinical progress of human papillomavirus genotypes and their persistent infection in subjects with atypical squamous cells of undetermined significance cytology: Statistical and latent Dirichlet allocation analysis. <i>Experimental and Therapeutic Medicine</i> , 2017, 13, 3032-3038.	0.8	3
2259	Interplay between viruses and bacterial microbiota in cancer development. <i>Seminars in Immunology</i> , 2017, 32, 14-24.	2.7	35
2261	Codon optimization of Iranian human papillomavirus Type 16 <i>E6</i> oncogene for <i>Lactococcus lactis</i> subsp. <i>cremoris</i> MG1363. <i>Future Virology</i> , 2017, 12, 499-511.	0.9	15
2262	Estimating the epidemiological burden of pathologies associated with 9 human papillomavirus genotypes in Spain: Literature review. <i>Vacunas (English Edition)</i> , 2017, 18, 36-42.	0.3	0

#	ARTICLE	IF	CITATIONS
2263	A Behavioral Economic Approach to Improving Human Papillomavirus Vaccination. <i>Journal of Adolescent Health</i> , 2017, 61, 755-760.	1.2	13
2264	HPV16 E7 Genetic Conservation Is Critical to Carcinogenesis. <i>Cell</i> , 2017, 170, 1164-1174.e6.	13.5	221
2266	HPV prevalence in the foreskins of asymptomatic healthy infants and children: Systematic review and meta-analysis. <i>Scientific Reports</i> , 2017, 7, 7050.	1.6	5
2269	The role of TLRs in cervical cancer with HPV infection: a review. <i>Signal Transduction and Targeted Therapy</i> , 2017, 2, 17055.	7.1	61
2270	Human papillomavirus vaccine initiation in Asian Indians and Asian subpopulations: a case for examining disaggregated data in public health research. <i>Public Health</i> , 2017, 153, 111-117.	1.4	14
2272	HPV prevalence and type distribution in Cypriot women with cervical cytological abnormalities. <i>BMC Infectious Diseases</i> , 2017, 17, 346.	1.3	22
2273	Women's intention to screen and willingness to vaccinate their daughters against cervical cancer – a cross sectional study in eastern Uganda. <i>BMC Public Health</i> , 2017, 17, 255.	1.2	6
2274	Unique LCR variations among lineages of HPV16, 18 and 45 isolates from women with normal cervical cytology in Ghana. <i>Virology Journal</i> , 2017, 14, 85.	1.4	8
2276	Opportunistic Viral Infections. , 2017, , 17-51.		0
2277	Socio-Demographic, Reproductive and Clinical Profile of Women Diagnosed with Advanced Cervical Cancer in a Tertiary Care Institute of Delhi. <i>Journal of Obstetrics and Gynecology of India</i> , 2017, 67, 53-60.	0.3	8
2278	Long non-coding RNAs on the stage of cervical cancer. <i>Oncology Reports</i> , 2017, 38, 1923-1931.	1.2	70
2279	High prevalence of co-infection between human papillomavirus (HPV) 51 and 52 in Mexican population. <i>BMC Cancer</i> , 2017, 17, 531.	1.1	23
2280	Expression signatures of HOX cluster genes in cervical cancer pathogenesis: Impact of human papillomavirus type 16 oncoprotein E7. <i>Oncotarget</i> , 2017, 8, 36591-36602.	0.8	22
2281	The challenges of human papillomavirus and cervical cancer therapy and control in Nigeria: A review. <i>Bayero Journal of Pure and Applied Sciences</i> , 2017, 9, 9.	0.1	1
2282	Molecular Testing in Gynecologic Cancer. , 2017, , 361-379.		0
2283	All sites but skin cancer incidences analyzed worldwide by sex, age, and skin type over time (1955-2007), advancing age, and UVB dose reveals important carcinogenic drivers. <i>Journal of Epidemiological Research</i> , 2017, 3, 65.	0.6	0
2284	Low prevalence of human papillomavirus in head and neck squamous cell carcinoma in the northwest region of the Philippines. <i>PLoS ONE</i> , 2017, 12, e0172240.	1.1	14
2285	Prevalence of HPV 16 and 18 and attitudes toward HPV vaccination trials in patients with cervical cancer in Mali. <i>PLoS ONE</i> , 2017, 12, e0172661.	1.1	11

#	ARTICLE	IF	CITATIONS
2286	E6 and E7 Gene Polymorphisms in Human Papillomavirus Types-58 and 33 Identified in Southwest China. PLoS ONE, 2017, 12, e0171140.	1.1	16
2287	PREVALENCE OF HUMAN PAPILLOMA VIRUS TYPES 16 AND 18 AMONG WOMEN WITH CERVICAL CANCER IN ALEPPO, SYRIA. International Journal of Pharmacy and Pharmaceutical Sciences, 2017, 9, 90.	0.3	1
2288	Molecular Testing for Human Papillomaviruses. , 2017, , 75-87.		0
2289	Comparison of the efficacy among multiple chemotherapeutic interventions combined with radiation therapy for patients with cervix cancer after surgery: A network meta-analysis. Oncotarget, 2017, 8, 49515-49533.	0.8	8
2290	Comprehensive Human Papillomavirus Genotyping in Cervical Squamous Cell Carcinomas and Its Relevance to Cervical Cancer Prevention in Malawian Women. Journal of Global Oncology, 2017, 3, 227-234.	0.5	10
2291	Acceptability of Human Papillomavirus Self-Sampling for Cervical Cancer Screening in an Indigenous Community in Guatemala. Journal of Global Oncology, 2017, 3, 444-454.	0.5	46
2292	Prognostic value of HPV DNA status in cervical cancer before treatment: a systematic review and meta-analysis. Oncotarget, 2017, 8, 66352-66359.	0.8	55
2293	Immunogold-agglutination assay for direct detection of HPV-16 E6 and L1 proteins from clinical specimens. Journal of Virological Methods, 2018, 255, 60-65.	1.0	7
2294	What information can change the attitude of teachers toward the human papillomavirus vaccine?. Journal of Obstetrics and Gynaecology Research, 2018, 44, 778-787.	0.6	3
2295	Uniplex E6/E7 PCR method detecting E6 or E7 genes in 39 human papillomavirus types. Journal of Medical Virology, 2018, 90, 981-988.	2.5	28
2296	Prevalence and type distribution of human papillomavirus (HPV) in Malaysian women with and without cervical cancer: an updated estimate. Bioscience Reports, 2018, 38, .	1.1	19
2297	Ten years of human papillomavirus vaccination. From dermatology to oncology via infectology. Anales De PediatrÃa (English Edition), 2018, 88, 289.e1-289.e6.	0.1	0
2298	Deregulated TNF-Alpha Levels Along with HPV Genotype 16 Infection Are Associated with Pathogenesis of Cervical Neoplasia in Northeast Indian Patients. Viral Immunology, 2018, 31, 282-291.	0.6	12
2299	Trends in Insect Molecular Biology and Biotechnology. , 2018, , .		10
2300	Impact of Human Immunodeficiency Virus Infection on Survival and Acute Toxicities From Chemoradiation Therapy for Cervical Cancer Patients in a Limited-Resource Setting. International Journal of Radiation Oncology Biology Physics, 2018, 101, 201-210.	0.4	47
2302	Expression of cell cycle proteins according to HPV status in oral squamous cell carcinoma affecting young patients: a pilot study. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2018, 125, 317-325.	0.2	5
2303	High Rate of Infection by Only Oncogenic Human Papillomavirus in Amerindians. MSphere, 2018, 3, .	1.3	11
2304	Prevalence and age-wise distribution of Human Papillomavirus type 16/18 infections among hospital screened women of a peri-urban area in West Bengal: Impact of socio-demographic factors. Cancer Epidemiology, 2018, 54, 31-37.	0.8	4

#	ARTICLE	IF	CITATIONS
2305	Quality Improvement to Demonstrate the Lack of Reliability of the Human Papillomavirus mRNA Assay to Identify Women With Latent Human Papillomavirus Infections. <i>Obstetrics and Gynecology</i> , 2018, 131, 681-687.	1.2	8
2306	Designing of Epitope-Focused Vaccine by Targeting E6 and E7 Conserved Protein Sequences: An Immuno-Informatics Approach in Human Papillomavirus 58 Isolates. <i>Interdisciplinary Sciences, Computational Life Sciences</i> , 2018, 10, 251-260.	2.2	11
2307	Awareness and Knowledge About HPV and HPV Vaccine Among Romanian Women. <i>Journal of Cancer Education</i> , 2018, 33, 154-159.	0.6	25
2308	Cytology and high risk <scp>HPV</scp> testing in cervical cancer screening program: Outcome of 3â€year followâ€up in an academic institute. <i>Diagnostic Cytopathology</i> , 2018, 46, 22-27.	0.5	6
2309	Knowledge, Beliefs and Attitudes of Somali Men in Olmsted County, Minnesota, U.S., on the Human Papillomavirus Vaccine and Cervical Cancer Screening: January 17, 2015. <i>Journal of Immigrant and Minority Health</i> , 2018, 20, 1230-1235.	0.8	12
2310	Human papillomavirus infection in females with normal cervical cytology: Genotyping and phylogenetic analysis among women in Punjab, Pakistan. <i>International Journal of Infectious Diseases</i> , 2018, 66, 83-89.	1.5	24
2311	Prevalence of High Risk Human Papillomavirus (type-16 and 18) in High-Grade Cervical Intraepithelial Neoplasia (CIN) and Cervical Cancer in a Tertiary Hospital of Bangladesh. <i>Journal of Bangladesh College of Physicians & Surgeons</i> , 2018, 36, 112-117.	0.0	1
2312	Genetic variability in E5, E6, E7 and L1 genes of human papillomavirus type 31. <i>Molecular Medicine Reports</i> , 2018, 17, 5498-5507.	1.1	6
2313	Epidemiological science and cancer control. <i>Clinics</i> , 2018, 73, e627s.	0.6	23
2314	MYPT1 is targeted by miR-145 inhibiting viability, migration and invasion in 2D and 3D HeLa cultures. <i>Biochemical and Biophysical Research Communications</i> , 2018, 507, 348-354.	1.0	11
2315	Design of Peptide-Based Nanovaccines Targeting Leading Antigens From Gynecological Cancers to Induce HLA-A2.1 Restricted CD8+ T Cell Responses. <i>Frontiers in Immunology</i> , 2018, 9, 2968.	2.2	23
2317	An Overview on the Anticancer Activity of <i>Azadirachta indica</i> (Neem) in Gynecological Cancers. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3898.	1.8	40
2318	Low-cost HPV testing and the prevalence of cervical infection in asymptomatic populations in Guatemala. <i>BMC Cancer</i> , 2018, 18, 562.	1.1	9
2319	IntegraciÃ³n, carga viral y niveles de ARN mensajero de E2 de VPH 16 en la progresiÃ³n de lesiones intraepiteliales cervicales. <i>Acta Biologica Colombiana</i> , 2018, 23, 80-87.	0.1	0
2320	Bacterial infections and cancer. <i>EMBO Reports</i> , 2018, 19, .	2.0	141
2321	Down-regulation of HPGD by miR-146b-3p promotes cervical cancer cell proliferation, migration and anchorage-independent growth through activation of STAT3 and AKT pathways. <i>Cell Death and Disease</i> , 2018, 9, 1055.	2.7	56
2322	Human papillomavirus genotype and prognosis of cervical cancer: Favorable survival of patients with HPV16-positive tumors. <i>Papillomavirus Research (Amsterdam, Netherlands)</i> , 2018, 6, 41-45.	4.5	24
2323	Light/Laser Applications in Gynecology. , 2018, , 115-134.		0

#	ARTICLE	IF	CITATIONS
2324	Evaluating intrinsic and non-intrinsic cancer risk factors. <i>Nature Communications</i> , 2018, 9, 3490.	5.8	218
2325	Prevalence and distribution of HPV genotypes and cervical-associated lesions in sexually active young French women following HPV vaccine. <i>Journal of Gynecology Obstetrics and Human Reproduction</i> , 2018, 47, 525-531.	0.6	7
2326	National cervical cancer prevention program in the Arab States: Strategies and cost-minimization study of the Tunisian case. <i>Vaccine</i> , 2018, 36, 5091-5096.	1.7	3
2327	The Correlation Between TNF- α Promoter Gene Polymorphism and Genetic Susceptibility to Cervical Cancer. <i>Technology in Cancer Research and Treatment</i> , 2018, 17, 153303381878279.	0.8	13
2328	Prediction and identification of human leukocyte antigen-A2-restricted cytotoxic T lymphocyte epitope peptides from the human papillomavirus 58 E7 protein. <i>Oncology Letters</i> , 2018, 16, 2003-2008.	0.8	1
2329	The association of human papillomavirus type 16 E2 variations with cervical cancer in a Han Chinese population. <i>Infection, Genetics and Evolution</i> , 2018, 64, 241-248.	1.0	7
2330	The human papillomavirus (HPV)-related cancer biology: An overview. <i>Biomedicine and Pharmacotherapy</i> , 2018, 106, 1537-1556.	2.5	96
2331	The Pivotal Role of DNA Repair in Infection Mediated-Inflammation and Cancer. <i>Frontiers in Microbiology</i> , 2018, 9, 663.	1.5	36
2332	Nanoparticles as Precious Stones in the Crown of Modern Molecular Biology. , 2018, , 331-351.		0
2333	High-Risk Human Papillomaviral Oncogenes E6 and E7 Target Key Cellular Pathways to Achieve Oncogenesis. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1706.	1.8	137
2334	Comparison of Siriraj liquid-based solution and standard transport media for the detection of high-risk human papillomavirus in cervical specimens. <i>Journal of Medical Virology</i> , 2018, 90, 1793-1799.	2.5	0
2335	Preclinical Development of Oncolytic Immunovirotherapy for Treatment of HPVPOS Cancers. <i>Molecular Therapy - Oncolytics</i> , 2018, 10, 1-13.	2.0	7
2336	Will increasing dosing intervals decrease the loss of anti-HPV seropositivity over time?. <i>Vaccine</i> , 2018, 36, 4966.	1.7	1
2337	Liquid-based cytology: do ancillary techniques enhance detection of epithelial abnormalities?. <i>Archives of Gynecology and Obstetrics</i> , 2018, 298, 159-169.	0.8	2
2338	Targeting Cyclin-Dependent Kinases for Treatment of Gynecologic Cancers. <i>Frontiers in Oncology</i> , 2018, 8, 303.	1.3	48
2339	Follow-up study of HPV58 variants in women with incident HPV58 infection from a Colombian cohort. <i>Oncology Letters</i> , 2018, 16, 2511-2516.	0.8	2
2340	Health and Prevention Enhancement (H-PEACE): a retrospective, population-based cohort study conducted at the Seoul National University Hospital Gangnam Center, Korea. <i>BMJ Open</i> , 2018, 8, e019327.	0.8	40
2341	Exploration of the molecular mechanisms of cervical cancer based on mRNA expression profiles and predicted microRNA interactions. <i>Oncology Letters</i> , 2018, 15, 8965-8972.	0.8	13

#	ARTICLE	IF	CITATIONS
2342	A study of association between cervical cytology and period of co-habitation with husbands in the wives of serving soldiers. <i>Medical Journal Armed Forces India</i> , 2019, 75, 293-296.	0.3	0
2343	Effectiveness of Community Intervention Program on Knowledge and Practice of HPV Prevention Among Married Females in Vietnam Rural Areas. <i>Cancer Control</i> , 2019, 26, 107327481986279.	0.7	3
2344	High Incidence of Human Papillomavirus Types 16 and 18 in Cervical Carcinoma Patients in a Tertiary Care Unit, Jabalpur, MP, India. <i>Indian Journal of Gynecologic Oncology</i> , 2019, 17, 1.	0.1	1
2345	The psychosexual impact of testing positive for high-risk cervical human papillomavirus (HPV): A systematic review. <i>Psycho-Oncology</i> , 2019, 28, 1959-1970.	1.0	27
2347	Persistence rate of cervical human papillomavirus infections and abnormal cytology in Rwanda. <i>HIV Medicine</i> , 2019, 20, 485-495.	1.0	8
2348	A triphenylethylene nonsteroidal SERM attenuates cervical cancer growth. <i>Scientific Reports</i> , 2019, 9, 10917.	1.6	8
2349	Co-infections of HPV16/18 with other high-risk HPV types and the risk of cervical carcinogenesis: A large population-based study. <i>Gynecologic Oncology</i> , 2019, 155, 436-443.	0.6	27
2350	Prevalence of human papillomavirus genotypes in cervical cancer in Maiduguri, Nigeria. <i>Pan African Medical Journal</i> , 2019, 33, 284.	0.3	8
2351	Carcinogenic risk of human papillomavirus (HPV) genotypes and potential effects of HPV vaccines in Korea. <i>Scientific Reports</i> , 2019, 9, 12556.	1.6	23
2352	Isolated Non-16/18 High-Risk Human Papillomavirus Cervical Infection: Re-Evaluation After One Year. <i>Acta Medica Portuguesa</i> , 2019, 32, 588-592.	0.2	4
2353	<p>Ormeloxifene nanotherapy for cervical cancer treatment</p>. <i>International Journal of Nanomedicine</i> , 2019, Volume 14, 7107-7121.	3.3	12
2354	Genetic variants of the dUTPase-encoding gene DUT increase HR-HPV infection rate and cervical squamous cell carcinoma risk. <i>Scientific Reports</i> , 2019, 9, 513.	1.6	0
2355	PP2A: A Promising Biomarker and Therapeutic Target in Endometrial Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 462.	1.3	41
2356	Practice parameters for the diagnosis and treatment of anal intraepithelial neoplasia (AIN) on behalf of the Italian Society of Colorectal Surgery (SICCR). <i>Techniques in Coloproctology</i> , 2019, 23, 513-528.	0.8	18
2357	The high-risk HPV oncogene E7 upregulates miR-182 expression through the TGF- β /Smad pathway in cervical cancer. <i>Cancer Letters</i> , 2019, 460, 75-85.	3.2	35
2358	Immunohistochemical Biomarkers of Survival in Patients With Adenocarcinoma of the Uterine Cervix Receiving Chemoradiotherapy. <i>Anticancer Research</i> , 2019, 39, 3231-3240.	0.5	4
2359	Recent advances in the management of penile cancer. <i>F1000Research</i> , 2019, 8, 558.	0.8	8
2360	Evidence on the prevalence, incidence, mortality and trends of human papilloma virus-associated cancers in sub-Saharan Africa: systematic scoping review. <i>BMC Cancer</i> , 2019, 19, 563.	1.1	24

#	ARTICLE	IF	CITATIONS
2361	A water-focused one-health approach for early detection and prevention of viral outbreaks. <i>One Health</i> , 2019, 7, 100094.	1.5	60
2362	Human papillomavirus type 16 E6 and E7 gene variations associated with cervical cancer in a Han Chinese population. <i>Infection, Genetics and Evolution</i> , 2019, 73, 13-20.	1.0	17
2363	microRNAs: New prognostic, diagnostic, and therapeutic biomarkers in cervical cancer. <i>Journal of Cellular Physiology</i> , 2019, 234, 17064-17099.	2.0	150
2364	Nanodrug delivery systems in cancer. , 2019, , 31-62.		4
2365	The Epidemiology of Cancer Among Homeless Adults in Metropolitan Detroit. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz006.	1.4	18
2366	HIV infection is not associated with the initiation of curative treatment in women with cervical cancer in Botswana. <i>Cancer</i> , 2019, 125, 1645-1653.	2.0	8
2367	Genotype distribution and prevalence of human papillomavirus among women with cervical cytological abnormalities in Xinjiang, China. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 1889-1896.	1.4	20
2368	Human papillomavirus 16 sub-lineage dispersal and cervical cancer risk worldwide: Whole viral genome sequences from 7116 HPV16-positive women. <i>Papillomavirus Research (Amsterdam,)</i> Tj ETQq1 1 0.784314.rgBT /Overlock 10 T		
2369	Building research capacity through programme development and research implementation in resource-limited settings - the Ipabalele study protocol: observational cohort studies determining the effect of HIV on the natural history of cervical cancer in Botswana. <i>BMJ Open</i> , 2019, 9, e031103.	0.8	4
2370	Multicentre, randomised controlled trial of adjuvant chemotherapy in cervical cancer with residual human papilloma virus DNA following primary radiotherapy or chemoradiotherapy: a study protocol. <i>BMJ Open</i> , 2019, 9, e028171.	0.8	2
2372	Human Papillomavirus Genotyping Compared With a Qualitative High-Risk Human Papillomavirus Test After Treatment of High-Grade Cervical Intraepithelial Neoplasia. <i>Obstetrics and Gynecology</i> , 2019, 134, 452-462.	1.2	18
2373	Guidelines for Cervical Cancer Screening in Immunosuppressed Women Without HIV Infection. <i>Journal of Lower Genital Tract Disease</i> , 2019, 23, 87-101.	0.9	79
2374	Detection of human papillomavirus in cases of head and neck squamous cell carcinoma by RNA-seq and VirTect. <i>Molecular Oncology</i> , 2019, 13, 829-839.	2.1	10
2375	The interplay between viruses and TRIM family proteins. <i>Reviews in Medical Virology</i> , 2019, 29, e2028.	3.9	37
2376	<i>Pleurotus ferulae</i> polysaccharides improve the antitumor efficacy of therapeutic human papillomavirus dendritic cell-based vaccine. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 611-619.	1.4	16
2377	High-risk Human Papillomavirus Determination in Formalin-fixed, Paraffin-embedded Cervical Tissue Using the Roche Cobas 4800 System. <i>International Journal of Gynecological Pathology</i> , 2019, 38, 11-16.	0.9	4
2378	The vaginal microbiota and its association with human papillomavirus, Chlamydia trachomatis, Neisseria gonorrhoeae and Mycoplasma genitalium infections: a systematic review and meta-analysis. <i>Clinical Microbiology and Infection</i> , 2019, 25, 35-47.	2.8	101
2379	LncRNA PTCSC3 inhibits the proliferation, invasion and migration of cervical cancer cells via sponging miR-574-5p. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2020, 47, 439-448.	0.9	20

#	ARTICLE	IF	CITATIONS
2380	Cancers of the Cervix, Vulva, and Vagina. , 2020, , 1468-1507.e8.		5
2381	Correlation of human papillomavirus 16 and 18 with cervical cancer and their diagnosis methods in Iranian women: A systematic review and meta-analysis. <i>Current Problems in Cancer</i> , 2020, 44, 100493.	1.0	10
2382	Human papillomavirus as a driver of head and neck cancers. <i>British Journal of Cancer</i> , 2020, 122, 306-314.	2.9	154
2383	The prevalence of oral high-risk HPV infection in Indonesian oral squamous cell carcinoma patients. <i>Oral Diseases</i> , 2020, 26, 72-80.	1.5	11
2384	Demonstrating the Importance of Different HPVs in Cervical Cancer and Other HPV-Related Cancers. , 2020, , 41-51.		1
2385	Comparison of the Hybrid Capture II Method with a PCR-Based Screening Method Using a Carboxyfluorescein-Labeled Primer for Detecting Human Papillomavirus in Cervicovaginal Liquid-Based Cytology. <i>Journal of Molecular Pathology</i> , 2020, 1, 9-18.	0.5	3
2386	Prediction of High-Risk Types of Human Papillomaviruses Using Reduced Amino Acid Modes. <i>Computational and Mathematical Methods in Medicine</i> , 2020, 2020, 1-10.	0.7	1
2387	High frequency of HPV genotypes 59, 66, 52, 51, 39 and 56 in women from Western Mexico. <i>BMC Infectious Diseases</i> , 2020, 20, 889.	1.3	19
2388	B7-H6, an immunoligand for the natural killer cell activating receptor NKp30, reveals inhibitory effects on cell proliferation and migration, but not apoptosis, in cervical cancer derived-cell lines. <i>BMC Cancer</i> , 2020, 20, 1083.	1.1	10
2389	The Debate About the Human Papilloma Virus Vaccine: The Impact of an Evidence-Based Communicative Method on Increasing Free Choice. <i>Qualitative Inquiry</i> , 2020, 26, 989-995.	1.0	2
2390	Prevalence of Equus caballus Papillomavirus Type-2 Infection and Seropositivity in Asymptomatic Western Canadian Horses. <i>Veterinary Pathology</i> , 2020, 57, 632-641.	0.8	7
2391	Targeting HPV in gynaecological cancers – Current status, ongoing challenges and future directions. <i>Women's Health</i> , 2020, 16, 174550652096170.	0.7	3
2392	Prevalence and Prognostic Value of HPV among Tunisian Patients with Laryngeal Cancer and Relationship between DNA HPV and p16, IGF-1R, Survivin, p53 Expressions. <i>Annals of Otolaryngology, Rhinology and Laryngology</i> , 2020, 129, 863-871.	0.6	2
2393	Society for Maternal-Fetal Medicine Special Statement: Reducing the risk of transmitting infection by transvaginal ultrasound examination. <i>American Journal of Obstetrics and Gynecology</i> , 2020, 223, B2-B6.	0.7	14
2394	Genomic Biomarkers of Survival in Patients with Adenocarcinoma of the Uterine Cervix Receiving Chemoradiotherapy. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4117.	1.8	2
2395	Barriers and facilitators to HPV vaccine uptake among US rural populations: a scoping review. <i>Cancer Causes and Control</i> , 2020, 31, 801-814.	0.8	31
2396	Long non-coding RNA HOTAIR in cervical cancer: Molecular marker, mechanistic insight, and therapeutic target. <i>Advances in Clinical Chemistry</i> , 2020, 97, 117-140.	1.8	25
2397	Clinical significance of peripheral blood and tumor tissue lymphocyte subsets in cervical cancer patients. <i>BMC Cancer</i> , 2020, 20, 173.	1.1	29

#	ARTICLE	IF	CITATIONS
2398	Cervical carcinoma risk associate with genetic polymorphisms of NEIL2 gene in Chinese population and its significance as predictive biomarker. <i>Scientific Reports</i> , 2020, 10, 5136.	1.6	5
2399	A New World of Biomarkers and Therapeutics for Female Reproductive System and Breast Cancers: Circular RNAs. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 50.	1.8	48
2400	Preparation, Characterization and Diagnostic Valuation of Two Novel Anti-HPV16 E7 Oncoprotein Monoclonal Antibodies. <i>Viruses</i> , 2020, 12, 333.	1.5	3
2401	Mutations in the HPV16 genome induced by APOBEC3 are associated with viral clearance. <i>Nature Communications</i> , 2020, 11, 886.	5.8	52
2402	Human papillomavirus E6: Host cell receptor, GRP78, binding site prediction. <i>Journal of Medical Virology</i> , 2020, 92, 3759-3765.	2.5	20
2403	High prevalent human papillomavirus infections of the oral cavity of asymptomatic HIV-positive men. <i>BMC Infectious Diseases</i> , 2020, 20, 27.	1.3	11
2404	The interplay of HIV and human papillomavirus-related cancers in sub-Saharan Africa: scoping review. <i>Systematic Reviews</i> , 2020, 9, 88.	2.5	30
2405	Concerns about disclosing a high-risk cervical human papillomavirus (HPV) infection to a sexual partner: a systematic review and thematic synthesis. <i>BMJ Sexual and Reproductive Health</i> , 2021, 47, 17-26.	0.9	12
2406	The effect of human papilloma virus vaccination on embryo yield and clinical <i>in vitro</i> fertilisation outcomes: a matched retrospective cohort study. <i>Journal of Obstetrics and Gynaecology</i> , 2021, 41, 421-427.	0.4	3
2407	Aberrant Methylation of the SOX21-AS1 Promoter Region Promotes Gene Expression and Its Clinical Value in Cervical Cancer. <i>Reproductive Sciences</i> , 2021, 28, 532-540.	1.1	10
2408	Cervical cancer in low-income countries: A Bangladeshi perspective. <i>International Journal of Gynecology and Obstetrics</i> , 2021, 152, 19-25.	1.0	15
2409	Infiltrating T-cell markers in cervical carcinogenesis: a systematic review and meta-analysis. <i>British Journal of Cancer</i> , 2021, 124, 831-841.	2.9	39
2410	Potential Association between Vaginal Microbiota and Cervical Carcinogenesis in Korean Women: A Cohort Study. <i>Microorganisms</i> , 2021, 9, 294.	1.6	27
2411	Microorganisms, infection and the role of medical textiles. , 2021, , 45-85.		2
2412	Human Viruses: Infection, Prevention and Potential Target(s) for Therapy. <i>Comprehensive Review</i> . , 2021, , 3-54.		0
2413	Synthesis and Cytotoxic Studies of Pyrrolopyrimidine Derivatives. <i>Asian Journal of Chemistry</i> , 2021, 33, 1855-1860.	0.1	0
2414	Role of Bacteria in the Development of Cancer. , 2021, , 91-108.		1
2415	Cervical Cancer Screening in Arab Countries. , 2021, , 413-433.		1

#	ARTICLE	IF	CITATIONS
2416	Nonclinical safety evaluation of oral recombinant anti-human papilloma virus vaccine (RHPV 16 & 18): Regulatory toxicology studies in mice, rats and rabbits – An innovative approach. <i>Vaccine</i> , 2021, 39, 853-863.	1.7	4
2417	Human papilloma virus genotype distribution in women with premalignant or malignant lesions of the uterine cervix. <i>Archives of Gynecology and Obstetrics</i> , 2021, 304, 751-758.	0.8	14
2418	High resolution cryo EM analysis of HPV16 identifies minor structural protein L2 and describes capsid flexibility. <i>Scientific Reports</i> , 2021, 11, 3498.	1.6	19
2419	Increased Risk of High-grade Cervical Neoplasia in Women with Inflammatory Bowel Disease: A Case-controlled Cohort Study. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 1464-1473.	0.6	10
2420	Transcriptomic Profiling of Fibropapillomatosis in Green Sea Turtles (<i>Chelonia mydas</i>) From South Texas. <i>Frontiers in Immunology</i> , 2021, 12, 630988.	2.2	10
2421	AvaliaÃ§Ã£o da sexualidade de pacientes com cÃ¢ncer do colo do Ãºtero em Sergipe. <i>Research, Society and Development</i> , 2021, 10, e41710212375.	0.0	0
2422	Advances in Targeting HPV Infection as Potential Alternative Prophylactic Means. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2201.	1.8	10
2423	Molecular and biological functions of gingerol as a natural effective therapeutic drug for cervical cancer. <i>Journal of Ovarian Research</i> , 2021, 14, 43.	1.3	15
2424	Molecular Detection and Typing of Cervical Human Papillomavirus in a Selected Population in Bayelsa State: Comparison with the National and International Trend and Clinical Significance. <i>Biotechnology Journal International</i> , 0, , 1-16.	0.2	0
2425	Reducing cervical cancer deaths in women living with HIV: PEPFAR and the Go Further partnership. <i>Preventive Medicine</i> , 2021, 144, 106295.	1.6	7
2426	Knowledge and Perception about Risk Factors and Symptoms of Cervical Cancer in Female Teachers of Government and Private Schools of Chandigarh. <i>Healthline</i> , 2021, 12, 70-75.	0.0	0
2427	Mutational profiles of marker genes of cervical carcinoma in Bangladeshi patients. <i>BMC Cancer</i> , 2021, 21, 289.	1.1	4
2428	Split-type electrochemiluminescent gene assay platform based on gold nanocluster probe for human papillomavirus diagnosis. <i>Biosensors and Bioelectronics</i> , 2021, 178, 113044.	5.3	19
2429	KLF5-mediated Eppk1 expression promotes cell proliferation in cervical cancer via the p38 signaling pathway. <i>BMC Cancer</i> , 2021, 21, 377.	1.1	12
2430	The Immune Microenvironment in Human Papilloma Virus-Induced Cervical Lesions – Evidence for Estrogen as an Immunomodulator. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 649815.	1.8	27
2433	Implementation of HPV Self-sampling in Cervical Screening Programs Increases Participation Rates: A Literature Review. <i>Indian Journal of Gynecologic Oncology</i> , 2021, 19, 1.	0.1	1
2434	–A HISTOPATHOLOGICAL STUDY OF TUMORS OF ORAL CAVITY–, 2021, , 1-5.		0
2435	Recomendaciones SER sobre prevenciÃ³n de infecciÃ³n en enfermedades reumÃ¡ticas autoinmunes sistÃ©micas. <i>ReumatologÃa ClÃnica</i> , 2022, 18, 317-330.	0.2	2

#	ARTICLE	IF	CITATIONS
2436	Association between PEG3 DNA methylation and high-grade cervical intraepithelial neoplasia. <i>Infectious Agents and Cancer</i> , 2021, 16, 42.	1.2	3
2437	Expression of Retroelements in Cervical Cancer and Their Interplay with HPV Infection and Host Gene Expression. <i>Cancers</i> , 2021, 13, 3513.	1.7	7
2438	The effect of the Affordable Care Act dependent coverage provision on HPV vaccine uptake in young adult women, National Health and Nutrition Examination Survey 2007-2016. <i>Preventive Medicine</i> , 2021, 148, 106536.	1.6	1
2439	YAP1 and its fusion proteins in cancer initiation, progression and therapeutic resistance. <i>Developmental Biology</i> , 2021, 475, 205-221.	0.9	62
2440	Synthesis and Characterization of Zinc Oxide Nanoparticles of Solanum nigrum and Its Anticancer Activity via the Induction of Apoptosis in Cervical Cancer. <i>Biological Trace Element Research</i> , 2022, 200, 2684-2697.	1.9	31
2441	Identifying False Human Papillomavirus (HPV) Vaccine Information and Corresponding Risk Perceptions From Twitter: Advanced Predictive Models. <i>Journal of Medical Internet Research</i> , 2021, 23, e30451.	2.1	12
2442	Human Papillomavirus (HPV) Prevalence and Type Distribution in Urban Areas of Malaysia. <i>Asian Pacific Journal of Cancer Prevention</i> , 2021, 22, 2969-2976.	0.5	9
2443	Molecular profiling and identification of prognostic factors in Chinese patients with small bowel adenocarcinoma. <i>Cancer Science</i> , 2021, 112, 4758-4771.	1.7	7
2444	Squamous cell carcinoma antigen combined with HPV-16 infection in predicting high-grade squamous intraepithelial lesions of the cervix. <i>Journal of Obstetrics and Gynaecology</i> , 2021, , 1-5.	0.4	0
2445	Phylogenomic Analysis of Human Papillomavirus Type 31 and Cervical Carcinogenesis: A Study of 2093 Viral Genomes. <i>Viruses</i> , 2021, 13, 1948.	1.5	7
2446	Clinical performance of methylation as a biomarker for cervical carcinoma <i>in situ</i> and cancer diagnosis: A worldwide study. <i>International Journal of Cancer</i> , 2022, 150, 290-302.	2.3	18
2447	Implications of viral infection in cancer development. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1876, 188622.	3.3	5
2448	Malignant diseases of the cervix. , 2022, , 674-690.e3.		0
2449	Successful endoscopic treatment for high-grade cervical intraepithelial neoplasia with gross lesions of the vagina. <i>Gynecology and Minimally Invasive Therapy</i> , 2021, 10, 124.	0.2	1
2450	A hybrid HPV capsid protein L1 with giant Mo-containing polyoxometalate improves the stability of virus-like particles and the anti-tumor effect of [Mo154]. <i>Biomaterials Science</i> , 2021, 9, 3875-3883.	2.6	10
2451	Human Papillomavirus 58 E7 T20I/G63S Variant Confers More Aggressive Phenotypes to Cervical Cancer Cell with In vitro and In vivo. , 0, 83, .		0
2458	Cancer Metastasis: Biological and Clinical Aspects, <i>Gynaecological Cancer</i> . , 2000, , 381-420.		2
2459	Principles of Screening for Cancer. , 2006, , 161-176.		2

#	ARTICLE	IF	CITATIONS
2460	The Pathology of Cervical Neoplasia. Cancer Prevention, Cancer Causes, 2004, , 3-59.	0.3	6
2461	Preventive Human Papillomavirus Vaccines. Cancer Prevention, Cancer Causes, 2004, , 325-343.	0.3	3
2462	The Biology of Human Papillomavirus Infections. Cancer Prevention, Cancer Causes, 2004, , 81-99.	0.3	3
2463	Chapter 5 Measurement of Exposure to Human Papillomaviruses. Cancer Prevention, Cancer Causes, 2004, , 119-141.	0.3	7
2464	The Epidemiology of Human Papillomavirus Infections. Cancer Prevention, Cancer Causes, 2004, , 143-187.	0.3	6
2465	Aids Malignancies. Cancer Treatment and Research, 2007, 133, 21-67.	0.2	11
2466	Disparities and Cervical Cancer. , 2009, , 203-225.		1
2467	Host and Viral Genetics and Risk of Cervical Cancer. , 2009, , 263-284.		1
2468	Epidemiology and Clinical Characteristics of Non-AIDS-Defining Malignancies. , 2010, , 17-40.		4
2469	Hereditary gynecologic cancer. Cancer Treatment and Research, 1998, 95, 1-102.	0.2	3
2470	Generation of in Vitro Autologous Human Cytotoxic T-Cell Response to E7 and HER-2/Neu Oncogene Products Using Ex-Vivo Peptide Loaded Dendritic Cells. Advances in Experimental Medicine and Biology, 1997, 417, 583-589.	0.8	10
2471	Human Papillomaviruses. , 1997, , 983-1023.		10
2472	Ubiquitination of the p53 Tumor Suppressor. , 1998, , 323-343.		6
2473	Molecular Analysis of Human Papillomavirus Virus-Like Particle Activated Langerhans Cells In Vitro. Methods in Molecular Biology, 2015, 1249, 135-149.	0.4	4
2474	Functional Analysis of HPV-Like Particle-Activated Langerhans Cells In Vitro. Methods in Molecular Biology, 2015, 1249, 333-350.	0.4	10
2475	Risk Reduction of Cervical Cancer Through HPV Screening and Vaccinationâ€™ Assumptions and Reality. , 2014, , 459-476.		2
2476	Cancer Trends and Risk Factors in Morocco. , 2016, , 25-45.		1
2477	Cervical Cancer. Medical Radiology, 2007, , 121-179.	0.0	1

#	ARTICLE	IF	CITATIONS
2478	Epidemiology of Genitoanal HPV Infections and Associated Cancer. , 2011, , 427-439.		2
2479	Intraepithelial Neoplasia of the Lower Genital Tract (Cervix, Vulva). , 2007, , 743-758.		2
2481	Female reproductive system. , 2011, , 1399-1657.		1
2482	Cancers of the Cervix, Vulva, and Vagina. , 2008, , 1745-1791.		2
2484	THERAPEUTIC VACCINES FOR CONTROL OF HUMAN PAPILLOMAVIRUS CHRONIC INFECTIONS. , 2000, , 273-293.		2
2485	Preinvasive Disease of the Cervix. , 2007, , 1-36.		7
2486	Cancers of the Cervix, Vulva, and Vagina. , 2014, , 1534-1574.e8.		7
2487	Cervical cancer vaccines: progress and prospects. Journal of the Society for Gynecologic Investigation, 2002, 9, 254-264.	1.9	18
2489	The use of human papillomavirus typing in detection of cervical neoplasia in Recife (Brazil). International Journal of Gynecological Cancer, 2000, 10, 143-150.	1.2	42
2490	IgG antibodies against human papillomavirus type 16 E7 proteins in cervicovaginal washing fluid from patients with cervical neoplasia. International Journal of Gynecological Cancer, 2000, 10, 296-304.	1.2	9
2491	Label-free detection of high-risk human papillomaviruses infection using Raman spectroscopy and multivariate analysis. Laser Physics Letters, 2020, 17, 115601.	0.6	3
2492	Infectious Agents. , 2006, , 507-548.		8
2494	Cancers of the Vulva and Vagina. , 2006, , 1068-1074.		10
2495	Penile Cancer. , 2006, , 1166-1172.		8
2496	Epidemiologic Studies of a Necessary Causal Risk Factor: Human Papillomavirus Infection and Cervical Neoplasia. Journal of the National Cancer Institute, 2003, 95, 2E-2E.	3.0	94
2497	Human papillomavirus in head and neck squamous cell carcinoma: are some head and neck cancers a sexually transmitted disease?. Current Opinion in Oncology, 1999, 11, 191.	1.1	113
2498	Prospects for human papillomavirus vaccine development: emerging HPV vaccines. Current Opinion in Obstetrics and Gynecology, 1998, 10, 15-19.	0.9	20
2499	Cancer of the uterine cervix. Current Opinion in Obstetrics and Gynecology, 1998, 10, 41-45.	0.9	10

#	ARTICLE	IF	CITATIONS
2500	Advances in the Diagnosis and Treatment of Human Papillomavirus Infections. <i>Clinical Obstetrics and Gynecology</i> , 1999, 42, 206-220.	0.6	43
2501	Human Papillomavirus Infection and Cervical Carcinoma. <i>Clinical Obstetrics and Gynecology</i> , 2000, 43, 363-380.	0.6	20
2502	LOW INCIDENCE OF HUMAN PAPILLOMAVIRUS TYPE 16 ANTIBODY SEROCONVERSION IN YOUNG CHILDREN. <i>Pediatric Infectious Disease Journal</i> , 1999, 18, 833-835.	1.1	20
2503	One-Step Detection and Genotyping of Human Papillomavirus in Cervical Samples by Reverse Hybridization. <i>Diagnostic Molecular Pathology</i> , 2001, 10, 200-206.	2.1	10
2504	Detection and characterization of human papillomavirus type 45 DNA in the cervical carcinoma cell line MS751.. <i>Journal of General Virology</i> , 1997, 78, 655-658.	1.3	15
2505	Immune responses against human papillomavirus (HPV) type 16 virus-like particles in a cohort study of women with cervical intraepithelial neoplasia. II. Systemic but not local IgA responses correlate with clearance of HPV-16.. <i>Journal of General Virology</i> , 1999, 80, 409-417.	1.3	99
2506	Human papillomavirus type 16 variant lineages characterized by nucleotide sequence analysis of the E5 coding segment and the E2 hinge region.. <i>Journal of General Virology</i> , 1999, 80, 595-600.	1.3	47
2507	A recombinant human papillomavirus (HPV) type 16 L1 vaccine virus murine challenge model demonstrates cell-mediated immunity against HPV virus-like particles. <i>Journal of General Virology</i> , 1999, 80, 2471-2475.	1.3	30
2508	The effects of interferon on the expression of human papillomavirus oncogenes. <i>Journal of General Virology</i> , 2000, 81, 695-700.	1.3	43
2509	Sequence analysis of the long control region of human papillomavirus type 16 variants and functional consequences for P97 promoter activity. <i>Journal of General Virology</i> , 2000, 81, 1975-1981.	1.3	81
2510	Distinct patterns of alteration of myc genes associated with integration of human papillomavirus type 16 or type 45 DNA in two genital tumours. <i>Journal of General Virology</i> , 2000, 81, 1983-1993.	1.3	36
2511	Oestrogen and progesterone increase the levels of apoptosis induced by the human papillomavirus type 16 E2 and E7 proteins. <i>Journal of General Virology</i> , 2001, 82, 201-213.	1.3	36
2512	Characterization of a novel genital human papillomavirus by overlapping PCR: candHPV86 identified in cervicovaginal cells of a woman with cervical neoplasia. <i>Journal of General Virology</i> , 2001, 82, 2035-2040.	1.3	25
2513	Herpes simplex virus downregulation of secretory leukocyte protease inhibitor enhances human papillomavirus type 16 infection. <i>Journal of General Virology</i> , 2016, 97, 422-434.	1.3	21
2514	Oncogenicity Comparison of Human Papillomavirus Type 52 E6 Variants. <i>Journal of General Virology</i> , 2019, 100, 484-496.	1.3	8
2516	DNA analysis indicates patient-specific human papillomavirus type 16 strains in Bowen's disease on fingers and in archival samples from genital dysplasia. <i>British Journal of Dermatology</i> , 1997, 136, 678-682.	1.4	42
2517	Epidemiology of Viruses Associated with Human Cancer. , 0, , 1-49.		4
2518	Serological responses to human papillomavirus type 6 and 16 virus-like particles in patients with cervical neoplastic lesions. <i>Vaccine Journal</i> , 1996, 3, 403-410.	2.6	12

#	ARTICLE	IF	CITATIONS
2519	Self-assembly of in vitro-translated human papillomavirus type 16 L1 capsid protein into virus-like particles and antigenic reactivity of the protein. <i>Vaccine Journal</i> , 1996, 3, 733-739.	2.6	9
2520	Human papillomavirus type 16 virus-like particles expressed in attenuated <i>Salmonella typhimurium</i> elicit mucosal and systemic neutralizing antibodies in mice. <i>Infection and Immunity</i> , 1997, 65, 3328-3336.	1.0	155
2521	The Nature of the Attenuation of <i>Salmonella typhimurium</i> Strains Expressing Human Papillomavirus Type 16 Virus-Like Particles Determines the Systemic and Mucosal Antibody Responses in Nasally Immunized Mice. <i>Infection and Immunity</i> , 1999, 67, 3674-3679.	1.0	38
2522	A novel genital human papillomavirus (HPV), HPV type 74, found in immunosuppressed patients. <i>Journal of Clinical Microbiology</i> , 1996, 34, 1859-1862.	1.8	23
2523	Use of multiple PCR primer sets for optimal detection of human papillomavirus. <i>Journal of Clinical Microbiology</i> , 1996, 34, 2095-2100.	1.8	217
2524	Human papillomavirus type 16 sequence variants: identification by E6 and L1 lineage-specific hybridization. <i>Journal of Clinical Microbiology</i> , 1997, 35, 11-19.	1.8	110
2525	Human papillomavirus and host variables as predictors of clinical course in patients with juvenile-onset recurrent respiratory papillomatosis. <i>Journal of Clinical Microbiology</i> , 1997, 35, 3098-3103.	1.8	80
2526	Comparison of PCR and hybrid capture methods for detection of human papillomavirus in injection drug-using women at high risk of human immunodeficiency virus infection. <i>Journal of Clinical Microbiology</i> , 1997, 35, 517-519.	1.8	37
2527	A general primer GP5+/GP6(+)-mediated PCR-enzyme immunoassay method for rapid detection of 14 high-risk and 6 low-risk human papillomavirus genotypes in cervical scrapings. <i>Journal of Clinical Microbiology</i> , 1997, 35, 791-795.	1.8	507
2528	A sensitive, type-specific, fluorogenic probe assay for detection of human papillomavirus DNA. <i>Journal of Clinical Microbiology</i> , 1997, 35, 886-891.	1.8	52
2529	PCR detection of human papillomavirus: comparison between MY09/MY11 and GP5+/GP6+ primer systems. <i>Journal of Clinical Microbiology</i> , 1997, 35, 1304-1310.	1.8	403
2530	Detection of human papillomavirus type 16 early-gene transcription by reverse transcription-PCR is associated with abnormal cervical cytology. <i>Journal of Clinical Microbiology</i> , 1997, 35, 1560-1564.	1.8	22
2531	Comparison of the hybrid capture tube test and PCR for detection of human papillomavirus DNA in cervical specimens. <i>Journal of Clinical Microbiology</i> , 1997, 35, 2262-2265.	1.8	88
2532	Antibodies against Early Proteins of Human Papillomaviruses as Diagnostic Markers for Invasive Cervical Cancer. <i>Journal of Clinical Microbiology</i> , 1998, 36, 475-480.	1.8	112
2533	Low False-Negative Rate of PCR Analysis for Detecting Human Papillomavirus-Related Cervical Lesions. <i>Journal of Clinical Microbiology</i> , 1998, 36, 2708-2713.	1.8	14
2534	Analysis by Multiplex PCR of the Physical Status of Human Papillomavirus Type 16 DNA in Cervical Cancers. <i>Journal of Clinical Microbiology</i> , 1999, 37, 3514-3517.	1.8	46
2535	Comparison of Variant-Specific Hybridization and Single-Strand Conformational Polymorphism Methods for Detection of Mixed Human Papillomavirus Type 16 Variant Infections. <i>Journal of Clinical Microbiology</i> , 1999, 37, 3627-3633.	1.8	11
2536	Detection and Quantitation of Human Papillomavirus by Using the Fluorescent 5' Exonuclease Assay. <i>Journal of Clinical Microbiology</i> , 1999, 37, 490-496.	1.8	73

#	ARTICLE	IF	CITATIONS
2537	Human Papillomavirus (HPV) DNA Copy Number Is Dependent on Grade of Cervical Disease and HPV Type. <i>Journal of Clinical Microbiology</i> , 1999, 37, 1030-1034.	1.8	205
2538	Nonisotopic Detection and Typing of Human Papillomavirus DNA in Genital Samples by the Line Blot Assay. <i>Journal of Clinical Microbiology</i> , 1999, 37, 1852-1857.	1.8	50
2539	Development and Clinical Evaluation of a Highly Sensitive PCR-Reverse Hybridization Line Probe Assay for Detection and Identification of Anogenital Human Papillomavirus. <i>Journal of Clinical Microbiology</i> , 1999, 37, 2508-2517.	1.8	588
2540	Detection of Human Papillomavirus Type 16 DNA in Consecutive Genital Samples Does Not Always Represent Persistent Infection as Determined by Molecular Variant Analysis. <i>Journal of Clinical Microbiology</i> , 2000, 38, 3388-3393.	1.8	43
2541	Human papillomavirus type 16 variant lineages in United States populations characterized by nucleotide sequence analysis of the E6, L2, and L1 coding segments. <i>Journal of Virology</i> , 1995, 69, 7743-7753.	1.5	209
2542	Intratype variation in 12 human papillomavirus types: a worldwide perspective. <i>Journal of Virology</i> , 1996, 70, 3127-3136.	1.5	116
2543	Assessment of the serological relatedness of genital human papillomaviruses by hemagglutination inhibition. <i>Journal of Virology</i> , 1996, 70, 3298-3301.	1.5	153
2544	In vitro generation and type-specific neutralization of a human papillomavirus type 16 virion pseudotype. <i>Journal of Virology</i> , 1996, 70, 5875-5883.	1.5	270
2545	Identification of the alpha6 integrin as a candidate receptor for papillomaviruses. <i>Journal of Virology</i> , 1997, 71, 2449-2456.	1.5	299
2546	Human papillomavirus type 16 sequence variation in cervical cancers: a worldwide perspective. <i>Journal of Virology</i> , 1997, 71, 2463-2472.	1.5	373
2547	Characterization of a human papillomavirus type 16 variant-dependent neutralizing epitope. <i>Journal of Virology</i> , 1997, 71, 6247-6252.	1.5	109
2548	Nasal Immunization of Mice with Human Papillomavirus Type 16 Virus-Like Particles Elicits Neutralizing Antibodies in Mucosal Secretions. <i>Journal of Virology</i> , 1998, 72, 8220-8229.	1.5	149
2549	In Vitro Infection and Type-Restricted Antibody-Mediated Neutralization of Authentic Human Papillomavirus Type 16. <i>Journal of Virology</i> , 1998, 72, 959-964.	1.5	117
2550	Isolation and Propagation of Human Papillomavirus Type 16 in Human Xenografts Implanted in the Severe Combined Immunodeficiency Mouse. <i>Journal of Virology</i> , 1998, 72, 5256-5261.	1.5	53
2551	Human Papillomavirus Type 11 Recombinant L1 Capsomeres Induce Virus-Neutralizing Antibodies. <i>Journal of Virology</i> , 1998, 72, 6151-6154.	1.5	115
2552	Nasal Immunization of Mice with Human Papillomavirus Type 16 (HPV-16) Virus-Like Particles or with the HPV-16 L1 Gene Elicits Specific Cytotoxic T Lymphocytes in Vaginal Draining Lymph Nodes. <i>Journal of Virology</i> , 1999, 73, 9063-9071.	1.5	94
2553	Mucosal but Not Parenteral Immunization with Purified Human Papillomavirus Type 16 Virus-Like Particles Induces Neutralizing Titers of Antibodies throughout the Estrous Cycle of Mice. <i>Journal of Virology</i> , 1999, 73, 9609-9613.	1.5	69
2554	Characterization of a Major Neutralizing Epitope on Human Papillomavirus Type 16 L1. <i>Journal of Virology</i> , 1999, 73, 4882-4889.	1.5	109

#	ARTICLE	IF	CITATIONS
2555	Immunohistochemical Analysis, Human Papillomavirus DNA Detection, Hormonal Manipulation, and Exogenous Gene Expression of Normal and Dysplastic Human Cervical Epithelium in Severe Combined Immunodeficiency Mice. <i>Journal of Virology</i> , 1999, 73, 5144-5148.	1.5	4
2556	Induction of Human Papillomavirus-Specific CD4 ⁺ and CD8 ⁺ Lymphocytes by E7-Pulsed Autologous Dendritic Cells in Patients with Human Papillomavirus Type 16- and 18-Positive Cervical Cancer. <i>Journal of Virology</i> , 1999, 73, 5402-5410.	1.5	142
2557	The Human Papillomavirus Type 16 E6 Oncoprotein Can Down-Regulate p53 Activity by Targeting the Transcriptional Coactivator CBP/p300. <i>Journal of Virology</i> , 1999, 73, 6209-6219.	1.5	284
2558	The E7 Oncoprotein of Human Papillomavirus Type 16 Stabilizes p53 through a Mechanism Independent of p19 ^{ARF} . <i>Journal of Virology</i> , 1999, 73, 7590-7598.	1.5	60
2559	Human papillomavirus infection. <i>BMJ: British Medical Journal</i> , 1996, 312, 522-523.	2.4	3
2560	Prospective seroepidemiological study of role of human papillomavirus in non-cervical anogenital cancers. <i>BMJ: British Medical Journal</i> , 1997, 315, 646-649.	2.4	65
2561	The causal relation between human papillomavirus and cervical cancer. <i>Journal of Clinical Pathology</i> , 2002, 55, 244-265.	1.0	2,777
2562	Virus del papiloma humano y virus de la inmunodeficiencia humana/sida. <i>Enfermedades Infecciosas Y MicrobiologÍa ClÁnica</i> , 2006, 24, 40-46.	0.3	3
2563	Biomarkers in Cervical Cancer:: DNA HR-HPV, p16INK4a, Ki-67, and RNA-m E6/E7. , 2015, , 257-284.		1
2564	Short-term follow up of cervical squamous intraepithelial lesions associated with HIV and human papillomavirus infections in Africa. <i>International Journal of STD and AIDS</i> , 1999, 10, 363-368.	0.5	21
2565	Reproducibility of HPV DNA Testing by Hybrid Capture 2 in a Screening Setting. <i>American Journal of Clinical Pathology</i> , 2005, 124, 716-21.	0.4	54
2566	Interlaboratory reliability of Hybrid Capture 2. <i>American Journal of Clinical Pathology</i> , 2004, 122, 238-45.	0.4	59
2567	Efficiency of the hybrid capture 2 HPV DNA test in cervical cancer screening. A study by the French Society of Clinical Cytology. <i>American Journal of Clinical Pathology</i> , 2003, 120, 492-9.	0.4	38
2568	Treating Cancer as an Infectious Disease—Viral Antigens as Novel Targets for Treatment and Potential Prevention of Tumors of Viral Etiology. <i>PLoS ONE</i> , 2007, 2, e1114.	1.1	34
2569	HPV Infection and EGFR Activation/Alteration in HIV-Infected East African Patients with Conjunctival Carcinoma. <i>PLoS ONE</i> , 2010, 5, e10477.	1.1	21
2570	Human Papillomavirus Deregulates the Response of a Cellular Network Comprising of Chemotactic and Proinflammatory Genes. <i>PLoS ONE</i> , 2011, 6, e17848.	1.1	145
2571	Prevalence and Risk Factors of Human Papillomavirus (HPV) Infection in Southern Chinese Women — A Population-Based Study. <i>PLoS ONE</i> , 2011, 6, e19244.	1.1	59
2572	The S100A10 Subunit of the Annexin A2 Heterotetramer Facilitates L2-Mediated Human Papillomavirus Infection. <i>PLoS ONE</i> , 2012, 7, e43519.	1.1	134

#	ARTICLE	IF	CITATIONS
2573	Genetic Variability in L1 and L2 Genes of HPV-16 and HPV-58 in Southwest China. PLoS ONE, 2013, 8, e55204.	1.1	25
2574	A Cross-Sectional Study to Assess HPV Knowledge and HPV Vaccine Acceptability in Mali. PLoS ONE, 2013, 8, e56402.	1.1	52
2575	Differential Expression of HPV16 L2 Gene in Cervical Cancers Harboring Episomal HPV16 Genomes: Influence of Synonymous and Non-Coding Region Variations. PLoS ONE, 2013, 8, e65647.	1.1	14
2576	Interferon- β Induced microRNA-129-5p Down-Regulates HPV-18 E6 and E7 Viral Gene Expression by Targeting SP1 in Cervical Cancer Cells. PLoS ONE, 2013, 8, e81366.	1.1	56
2577	The Antiviral Restriction Factors IFITM1, 2 and 3 Do Not Inhibit Infection of Human Papillomavirus, Cytomegalovirus and Adenovirus. PLoS ONE, 2014, 9, e96579.	1.1	67
2578	Parents' Knowledge, Risk Perception and Willingness to Allow Young Males to Receive Human Papillomavirus (HPV) Vaccines in Uganda. PLoS ONE, 2014, 9, e106686.	1.1	17
2579	Design of a Highly Effective Therapeutic HPV16 E6/E7-Specific DNA Vaccine: Optimization by Different Ways of Sequence Rearrangements (Shuffling). PLoS ONE, 2014, 9, e113461.	1.1	15
2580	The Role of Polymerase Chain Reaction of High-Risk Human Papilloma Virus in the Screening of High-Grade Squamous Intraepithelial Lesions in the Anal Mucosa of Human Immunodeficiency Virus-Positive Males Having Sex with Males. PLoS ONE, 2015, 10, e0123590.	1.1	19
2581	Identification of HPV Types and Mycobacterium Tuberculosis Complex in Historical Long-Term Preserved Formalin Fixed Tissues in Different Human Organs. PLoS ONE, 2017, 12, e0170353.	1.1	6
2582	Knowledge, attitudes, practices and willingness to vaccinate in preparation for the introduction of HPV vaccines in Bamako, Mali. PLoS ONE, 2017, 12, e0171631.	1.1	27
2583	Immunotherapy of a human papillomavirus type 16 E7-expressing tumor by administration of fusion protein comprised of Mycobacterium bovis BCG Hsp65 and HPV16 E7. Cell Stress and Chaperones, 2000, 5, 401.	1.2	35
2584	Anogenital Squamous Cell Cancer and Its Precursors: Natural History, Diagnosis, and Treatment. , 0, , 263-287.		3
2585	Genotype Analysis of Human Papilloma Virus Infection in Accordance with Cytological Diagnoses. Korean Journal of Clinical Laboratory Science, 2015, 47, 39-45.	0.1	3
2586	Bibliometry of Panama publications in the Science Citation Index Expanded: publication type, language, fields, authors and institutions. Revista De Biología Tropical, 2015, 63, 1255.	0.1	10
2587	Cervical cancer and human papillomavirus: Epidemiological evidence and perspectives for prevention. Salud Publica De Mexico, 1997, 39, 274-282.	0.1	52
2588	Screening for cervical cancer: new alternatives and research. Salud Publica De Mexico, 2003, 45, 376-387.	0.1	26
2589	AgNOR polymorphism association with squamous intraepithelial lesions and invasive carcinoma with HPV infection. Salud Publica De Mexico, 2009, 51, 134-140.	0.1	13
2591	HPV 16 detection in cervical lesions, physical state of viral DNA and changes in p53 gene. Sao Paulo Medical Journal, 2003, 121, 67-71.	0.4	19

#	ARTICLE	IF	CITATIONS
2592	Hereditary Factors in Gynecologic Cancer. <i>Oncologist</i> , 1998, 3, 319-338.	1.9	23
2593	¿Es el momento de vacunar contra el Virus del Papiloma Humano en Colombia?. <i>Revista Colombiana De Obstetricia Y Ginecología</i> , 2010, 61, 136-145.	0.2	1
2594	Factores de riesgo para cáncer de cuello uterino. <i>Revista Colombiana De Obstetricia Y Ginecología</i> , 2004, 55, 146-160.	0.2	9
2595	Persistence of type-specific human papillomavirus infection among Daqing City women in China with normal cytology: a pilot prospective study. <i>Oncotarget</i> , 2017, 8, 81455-81461.	0.8	10
2596	Actividad antibacteriana de la Sangre de Grado (<i>Croton lechleri</i>) frente al <i>Helicobacter pylori</i> . <i>Revista Médica Herediana</i> , 2013, 14, 81.	0.0	2
2597	Aspectos inmunológicos de la infección por papilomavirus humano. Rol del complejo mayor de histocompatibilidad. <i>Revista Médica Herediana</i> , 2013, 14, 94.	0.0	4
2598	Progress in the development of a cervical cancer vaccine. <i>Therapeutics and Clinical Risk Management</i> , 2006, 2, 259-269.	0.9	6
2599	Cervical Cancer Prevention in Saudi Arabia: It is Time to Call for Action. <i>The Open Women's Health Journal</i> , 2012, 6, 1-5.	0.5	7
2600	Therapeutic Vaccines Against Human Papillomavirus and Cervical Cancer. <i>The Open Virology Journal</i> , 2009, 3, 67-83.	1.8	21
2601	Comparison of the DiagCor GenoFlow Human Papillomavirus Array Test and Roche Linear Array HPV Genotyping Test. <i>The Open Virology Journal</i> , 2010, 4, 169-174.	1.8	12
2602	Expression of p16 in Conjunctival Intraepithelial Neoplasia Does Not Correlate with HPV-Infection. <i>Open Ophthalmology Journal</i> , 2008, 2, 48-56.	0.1	21
2603	An Approach to Formative Research in HPV Vaccine Introduction Planning in Low-Resource Settings. <i>The Open Vaccine Journal</i> , 2009, 2, 1-16.	0.6	26
2604	A Thematic Analysis of Attitudes Toward Changes to Cervical Screening in Australia. <i>JMIR Cancer</i> , 2019, 5, e12307.	0.9	18
2605	Cervical Cancer Prevalence, Incidence and Mortality in Low and Middle Income Countries: A Systematic Review. <i>Asian Pacific Journal of Cancer Prevention</i> , 2018, 19, 319-324.	0.5	167
2606	Therapeutic human papillomavirus vaccination. <i>Therapy: Open Access in Clinical Medicine</i> , 2008, 5, 339-348.	0.2	3
2607	Developments in therapeutic human papillomavirus vaccination. <i>Acta Chirurgica Iugoslavica</i> , 2009, 56, 29-37.	0.0	2
2608	Vaccines against human papillomavirus. <i>Frontiers in Bioscience - Landmark</i> , 2007, 12, 246.	3.0	14
2609	Peptide vaccines against cancer, infectious diseases, and conception. <i>Frontiers in Bioscience - Landmark</i> , 2007, 12, 1833.	3.0	51

#	ARTICLE	IF	CITATIONS
2610	Papillomavirus E6 and E7 proteins and their cellular targets. <i>Frontiers in Bioscience - Landmark</i> , 2008, 13, 1003.	3.0	147
2611	Phylogeny and Classification of Human Papillomavirus (HPV) 16 and HPV18 Variants Based on E6 and L1 genes in Tunisian Women with Cervical Lesions. <i>Asian Pacific Journal of Cancer Prevention</i> , 2018, 19, 3361-3366.	0.5	9
2612	Association of PIK3CA and MDM2 SNP309 with Cervical Squamous Cell Carcinoma in a Philippine Population. <i>Asian Pacific Journal of Cancer Prevention</i> , 2019, 20, 2103-2107.	0.5	5
2613	Cáncer cervicouterino: má todos actuales para su detección. <i>Revista Biomedica</i> , 2004, 15, 233-241.	0.0	5
2614	The impact of the National Institute for Health Research Health Technology Assessment programme, 2003-13: a multimethod evaluation. <i>Health Technology Assessment</i> , 2015, 19, 1-292.	1.3	22
2615	Comparative Evaluation of the HPV28 Detection and HPV DNA Chip Test for Detecting and Genotyping Human Papillomaviruses. <i>Laboratory Medicine Online</i> , 2013, 3, 234.	0.0	3
2616	Human papillomavirus in esophageal squamous cell carcinoma in Colombia and Chile. <i>World Journal of Gastroenterology</i> , 2006, 12, 6188.	1.4	48
2617	Importance of investigating high-risk human papillomavirus in lymph node metastasis of esophageal adenocarcinoma. <i>World Journal of Gastroenterology</i> , 2020, 26, 2729-2739.	1.4	2
2618	Correlates of HPV: a cross-sectional study in women with normal cytology in north-central Morocco. <i>Journal of Infection in Developing Countries</i> , 2012, 6, 543-550.	0.5	19
2619	Morphogenetic Variation for Essential Oils in <i>Salvia palaestina</i> Bentham Leaves and Bracts from Turkey. <i>Pakistan Journal of Biological Sciences</i> , 2006, 9, 2720-2722.	0.2	3
2620	Update on the diagnosis and treatment of human papillomavirus infection.. <i>Cleveland Clinic Journal of Medicine</i> , 2002, 69, 948-948.	0.6	11
2621	Prevalence and Genotype Distribution of Human Papillomavirus in Cheonan, Korea. <i>Journal of Microbiology and Biotechnology</i> , 2014, 24, 1143-1147.	0.9	6
2622	LESIONES PREINVASORAS DE CUELLO UTERINO: UNA VISIÓN ACTUAL. <i>Revista Chilena De Obstetricia Y Ginecologia</i> , 2006, 71, .	0.1	5
2623	Relationship between circumcision and human papillomavirus infection: a systematic review and meta-analysis. <i>Asian Journal of Andrology</i> , 2017, 19, 125.	0.8	39
2624	The Analysis and Clinical Usefulness of HPV DNA Chip Test in the Uterine Cervix. <i>Korean Journal of Pathology</i> , 2010, 44, 77.	1.2	3
2625	Human Papillomavirus Prevalence in Gangwon Province Using Reverse Blot Hybridization Assay. <i>Korean Journal of Pathology</i> , 2011, 45, 348.	1.2	5
2626	Type-Specific Viral Load and Physical State of HPV Type 16, 18, and 58 as Diagnostic Biomarkers for High-Grade Squamous Intraepithelial Lesions or Cervical Cancer. <i>Cancer Research and Treatment</i> , 2020, 52, 396-405.	1.3	16
2627	Vaccine Strategies against Human Papillomavirus: A Discussion Focused on Developing Countries. <i>Journal of Clinical & Cellular Immunology</i> , 2012, 01, .	1.5	1

#	ARTICLE	IF	CITATIONS
2628	Designing Vaccines against Human Papillomavirus and Hepatitis B Virus: Similarities and Differences for Preventable Viral Infections and role of AS04 Adjuvant System in Addressing Specific Challenges. <i>Journal of Vaccines & Vaccination</i> , 2012, 03, .	0.3	1
2629	Dietary patterns and risk of cervical cancer: a case-control study in Uruguay. <i>Open Journal of Obstetrics and Gynecology</i> , 2011, 01, 25-30.	0.1	4
2630	Same day colposcopic examination and loop electrosurgical excision procedure (LEEP) presents minimal overtreatment and averts delay in treatment of cervical intraepithelial neoplasia in Kenyatta National Hospital, Kenya. <i>Open Journal of Obstetrics and Gynecology</i> , 2013, 03, 313-318.	0.1	6
2631	Genotypic Distribution of Different Variants of Oncogenic Human Papilloma Virus (HPV) among the Sexually Active HIV-1 Positive Female Population from Manipur, India. <i>World Journal of AIDS</i> , 2012, 02, 71-77.	0.1	1
2632	Infec�o por Papilomav�rus Humano e C�ncer Oral: Revis�o da literatura atual. <i>Cadernos UniFOA</i> , 2017, 6, 103.	0.0	1
2633	Human papilloma virus-16/18 cervical infection among women attending a family medical clinic in Riyadh. <i>Annals of Saudi Medicine</i> , 2007, 27, 1-5.	0.5	24
2634	Pattern of abnormal Pap smears in developing countries: A report from a large referral hospital in Saudi Arabia using the revised 2001 Bethesda System. <i>Annals of Saudi Medicine</i> , 2007, 27, 268-272.	0.5	24
2635	Prevalence of high-risk human papillomavirus infections in healthy Saudi women attending gynecologic clinics in the western region of Saudi Arabia. <i>Annals of Saudi Medicine</i> , 2013, 33, 13-17.	0.5	27
2636	Burden of gynaecological cancers in developing countries. <i>World Journal of Obstetrics and Gynecology</i> , 2013, 2, 1.	0.5	17
2637	Analysis of Human Papillomavirus and Herpes Simplex Virus Genus -2 from Patients with Cervical Cancer in Isfahan, Iran. <i>Materia Socio-medica</i> , 2014, 26, 234.	0.3	7
2638	Cytohistological discrepancies of cervico-vaginal smears and HPV status. <i>Ginekologia Polska</i> , 2017, 88, 235-238.	0.3	9
2639	Distribution of Human Papillomavirus Genotypes in Iranian Women According to the Severity of the Cervical Lesion. <i>Iranian Red Crescent Medical Journal</i> , 2016, 18, e24458.	0.5	42
2640	Human Papillomavirus Infection of the Epididymis and Ductus Deferens: An Evaluation by Nested Polymerase Chain Reaction. <i>Archives of Pathology and Laboratory Medicine</i> , 2003, 127, 1471-1474.	1.2	27
2641	Human Papillomavirus DNA Testing as an Adjunct to Cytology in Cervical Screening Programs. <i>Archives of Pathology and Laboratory Medicine</i> , 2003, 127, 959-968.	1.2	130
2642	Risk of Oral Nonmalignant Lesions Associated With Human Papillomavirus Infection, Betel Quid Chewing, and Cigarette Smoking in Taiwan: An Integrated Molecular and Epidemiologic Study. <i>Archives of Pathology and Laboratory Medicine</i> , 2006, 130, 57-61.	1.2	44
2643	Whole Genome Analysis of Human Papillomavirus Type 16 Multiple Infection in Cervical Cancer Patients. <i>Asian Pacific Journal of Cancer Prevention</i> , 2012, 13, 599-606.	0.5	18
2644	Cost and Effectiveness Comparison of Immediate Colposcopy Versus Human Papillomavirus DNA Testing in Management of Atypical Squamous Cells of Undetermined Significance in Turkish Women. <i>Asian Pacific Journal of Cancer Prevention</i> , 2013, 14, 511-514.	0.5	12
2645	Human Papillomavirus (HPV) Infection in Women Participating in Cervical Cancer Screening from 2006 to 2010 in Shenzhen City, South China. <i>Asian Pacific Journal of Cancer Prevention</i> , 2013, 14, 7483-7487.	0.5	31

#	ARTICLE	IF	CITATIONS
2646	Clinicopathology Significance of p53 and p63 Expression in Indonesian Cervical Squamous Cell Carcinomas. <i>Asian Pacific Journal of Cancer Prevention</i> , 2013, 14, 7737-7741.	0.5	3
2647	Nested Multiplex PCR Based Detection of Human Papillomavirus in Cervical Carcinoma Patients of North- East India. <i>Asian Pacific Journal of Cancer Prevention</i> , 2013, 14, 785-790.	0.5	14
2648	Knowledge, Attitude and Practice of the Pap Smear as a Screening Procedure Among Nurses in a Tertiary Hospital in North Eastern India. <i>Asian Pacific Journal of Cancer Prevention</i> , 2013, 14, 849-852.	0.5	32
2649	Prevalence of Human Papillomavirus in Women from Saudi Arabia. <i>Asian Pacific Journal of Cancer Prevention</i> , 2013, 14, 3177-3181.	0.5	40
2650	Immune and Anti-oxidant Functions of Ethanol Extracts of <i>Scutellaria baicalensis</i> Georgi in Mice Bearing U14 Cervical Cancers. <i>Asian Pacific Journal of Cancer Prevention</i> , 2014, 15, 4129-4133.	0.5	16
2651	HPV Vaccination for Cervical Cancer Prevention is not Cost-Effective in Japan. <i>Asian Pacific Journal of Cancer Prevention</i> , 2014, 15, 6177-6180.	0.5	4
2652	Type-specific Prevalence of Human Papillomavirus by Cervical Cytology among Women in Brasov, Romania. <i>Asian Pacific Journal of Cancer Prevention</i> , 2014, 15, 6887-6892.	0.5	10
2653	Pap Smear Combined with HPV Testing: A Reasonable Tool for Women with High-grade Cervical Intraepithelial Neoplasia Treated by LEEP. <i>Asian Pacific Journal of Cancer Prevention</i> , 2015, 16, 4297-4302.	0.5	6
2654	Association between RASSF1A Promoter Hypermethylation and Oncogenic HPV Infection Status in Invasive Cervical Cancer: a Meta-analysis. <i>Asian Pacific Journal of Cancer Prevention</i> , 2015, 16, 5749-5754.	0.5	20
2655	Impact of exposure to tobacco smoke, arsenic, and phthalates on locally advanced cervical cancer treatment—preliminary results. <i>PeerJ</i> , 2016, 4, e2448.	0.9	5
2656	Recommendations for prevention of infection in systemic autoimmune rheumatic diseases. <i>ReumatologĀa ClĀnica (English Edition)</i> , 2022, 18, 317-330.	0.2	1
2657	The Awareness of the Human Papillomavirus Infection and Oropharyngeal Cancer in People to Improve the Health Care System at Al Qunfudhah Region, Kingdom of Saudi Arabia. <i>Journal of Healthcare Engineering</i> , 2021, 2021, 1-8.	1.1	2
2658	GENITAL PAPILLOMAVIRUS INFECTION. , 2000, , 259-272.		1
2659	Population-Based Study of Human Papillomavirus Infection and Cervical Neoplasia in Rural Costa Rica. <i>Obstetrical and Gynecological Survey</i> , 2000, 55, 619-621.	0.2	0
2660	Dysplasien und Neoplasien des Plattenepithels der Zervix. <i>Spezielle Pathologische Anatomie</i> , 2001, , 257-331.	0.0	0
2661	Einsatz molekularbiologischer Methoden zu FrĀherkennung und klinischem Management des Zervixkarzinoms. , 2001, , 189-208.		0
2662	Conization in pregnant women with uterine cervical intraepithelial neoplasia III.. <i>The Journal of the Japanese Society of Clinical Cytology</i> , 2001, 40, 107-113.	0.0	0
2664	Epidemiology of STIs: UK. <i>Medicine</i> , 2001, 29, 1-3.	0.2	0

#	ARTICLE	IF	CITATIONS
2665	Genomic Diversity of Human Papillomaviruses and its Impact on Molecular Epidemiological Research. , 2002, , 419-438.		0
2666	Two Color Multiplexing and Typing of Human Papillomavirus Types 16,18 and 45 on LightCycler. , 2002, , 147-157.		0
2667	Papillomaviruses. , 2002, , 257-278.		1
2668	Molekulare Diagnostik. , 2002, , 309-387.		0
2669	Factores asociados al papilomavirus humano en mujeres Mexicanas. Revista Colombiana De Obstetricia Y Ginecologia, 2002, 53, 255-262.	0.2	2
2670	Infections and the Etiology of Human Cancer: Epidemiological Evidence and Opportunities for Prevention. Handbook of Experimental Pharmacology, 2003, , 229-251.	0.9	0
2671	Cervical, Vulvar, and Vaginal Cancer. , 2003, , 545-561.		0
2672	DISEASE STATES AND VACCINES: SELECTED CASES. , 2003, , 311-322.		1
2673	Aerodigestive Tract Chemoprevention Trials and Prevention of Second Primary Tumors. , 2003, , 271-285.		0
2674	Cervical Dysplasia Diagnosis With Fluorescence Spectroscopy. , 2003, , .		0
2675	Human Papillomavirus Biology and Cervical Neoplasia: Implications for Diagnostic Criteria and Testing. Archives of Pathology and Laboratory Medicine, 2003, 127, 935-939.	1.2	30
2676	Human Papillomaviruses. , 2003, , 243-274.		0
2677	Prevention of Gynecologic Malignancies. , 2004, , 883-919.		0
2678	The Etiology of Squamous Cell Cervical Cancer. Cancer Prevention, Cancer Causes, 2004, , 191-216.	0.3	2
2679	Policies for Implementing Cervical Cancer Preventive and Control Strategies. Cancer Prevention, Cancer Causes, 2004, , 377-402.	0.3	0
2680	Haut- und Weichteilinfektionen. , 2004, , 438-468.		1
2681	Adenocarcinoma of the Cervix. , 2004, , 149-160.		0
2682	Spectral fluorescence imaging for the characterization of HPV16 transfected cells. , 2004, , .		0

#	ARTICLE	IF	CITATIONS
2683	Epidemiology of Cervical, Vulvar, and Vaginal Cancers. , 2004, , 3-30.		2
2684	Zervixkarzinom. , 2004, , 1113-1151.		0
2685	Human Papillomavirus Typing of Rare Cervical Carcinomas. Archives of Pathology and Laboratory Medicine, 2004, 128, 553-556.	1.2	25
2686	The human papillomavirus. , 2006, , 11-26.		3
2687	Understanding the origin of cervical cancer. , 2006, , 41-54.		0
2690	The Prevalence of HIV Infection in Preoperative Patients with Benign anal Diseases. Nihon Daicho Komonbyo Gakkai Zasshi, 2006, 59, 827-831.	0.1	1
2691	Isolation of Iranian Human Papillomavirus Type 16 E6 Gene and Construction of its Cloning Vector. Pakistan Journal of Biological Sciences, 2006, 9, 2652-2656.	0.2	0
2692	Prognostic significance of serum antibodies to HPV-16 L1 virus-like particles in patients with invasive cervical cancer. Geburtshilfe Und Frauenheilkunde, 2006, 66, 4921-6.	0.8	8
2694	CONDYLOMATA ACLUMINATA TREATMENT WITH CARBON DIOXIDE LASER IN COMPARISON WITH 0.15% PODOPHYLLOTOXIN CREAM. Laser Therapy, 2007, 16, 67-73.	0.8	0
2696	C�ncer de cuello uterino: Estado actual de las vacunas frente al virus del papiloma humano (VPH). Oncología, 2007, 30, .	0.0	6
2697	Surgical Treatment Outcomes in Patients with Stage pT1a and pT1b1 Cervical Cancer. Journal of Rural Medicine: JRM, 2007, 2, 126-131.	0.2	0
2699	Cuello uterino. , 2007, , 1-159.		0
2700	Prevalence of Oncogenic HPV Types in Sardinia (Italy): Implications for the Impact of Prophylactic Anti-HPV Vaccines. American Journal of Infectious Diseases, 2007, 3, 134-141.	0.1	0
2701	The development of epidemiology: the United States of America. , 2007, , 373-384.		0
2702	Cervical cancer screening. Series in Maternal-fetal Medicine, 2007, , 224-228.	0.1	0
2703	The Value of Monitoring Human Papillomavirus DNA Results for Papanicolaou Tests Diagnosed as Atypical Squamous Cells of Undetermined Significance: A College of American Pathologists Q-Probes Study of 68 Institutions. Archives of Pathology and Laboratory Medicine, 2007, 131, 1525-1531.	1.2	27
2705	An Evolutionary Study of the Human Papillomavirus Genomes. Lecture Notes in Computer Science, 2008, , 128-142.	1.0	1
2709	LINEAR ARRAY Human Papillomavirus Genotyping Test Amenable to Automation by Implementation of GT-Blot 48 - A Pilot Study. The Open Infectious Diseases Journal, 2008, 2, 40-44.	0.6	1

#	ARTICLE	IF	CITATIONS
2710	Uterus transplantation and ovarian cryopreservation for fertility reconstruction in female genital cancer patients. Academic Collaborations for Sick Children, 2009, 1, 20-23.	0.3	0
2711	Infectious Diseases and Cancer: HPV. Statistics in the Health Sciences, 2009, , 409-429.	0.2	0
2712	Uterus transplantation and ovarian cryopreservation for fertility reconstruction in female genital cancer patients. Academic Collaborations for Sick Children, 2009, 1, 46-49.	0.3	1
2715	Prevalence and Genotypic Identification of Human Papillomavirus Infection in a Population from Northwestern Spain. Open Dermatology Journal, 2009, 3, 18-21.	0.5	5
2716	Cidofovir Against Human Papillomavirus-Associated Diseases. , 2010, , 235-245.		0
2717	Comparison of cell growth suppression in SiHa cervical carcinoma cell line by human papillomavirus type 16 E6/E7 siRNAs. Korean Journal of Obstetrics and Gynecology, 2010, 53, 35.	0.1	0
2718	Awareness and knowledge of human papillomavirus infection among female public health personnel. Korean Journal of Obstetrics and Gynecology, 2010, 53, 410.	0.1	2
2719	Cervical Cancer Screening and Prevention. , 2010, , 1212-1216.e2.		1
2720	Papillomaviruses. , 2010, , 1565-1569.		2
2722	The prevalence of human papilloma virus infections according to Pap smear results in Jeju island. Korean Journal of Obstetrics & Gynecology, 2011, 54, 689.	0.1	5
2723	Screening women. , 2011, , 197-224.		0
2724	A case of squamous cell carcinoma of the uterine cervix with diffuse hematogenous lung metastasis in a 36-year-old virgin. Korean Journal of Obstetrics & Gynecology, 2011, 54, 634.	0.1	0
2725	Biomarkers in Head and Neck Cancer. , 2011, , 157-167.		0
2726	Genital tract disorders. , 2011, , 225-254.		0
2728	Cervical cancer prevention in settings of high HIV prevalence. Southern African Journal of HIV Medicine, 2011, 12, 18-20.	0.3	0
2729	Prevalence and Determinants of High-risk Human Papillomavirus Infection in Women with High Socioeconomic Status in Seoul, Republic of Korea. Asian Pacific Journal of Cancer Prevention, 2012, 13, 269-273.	0.5	10
2730	Intramuscular metastatic squamous cell carcinoma of the cervix: autopsy case report. Autopsy and Case Reports, 2012, 2, 15-25.	0.2	0
2731	Current Status of Plants as Vaccine Production Platforms. Journal of Clinical & Cellular Immunology, 2012, 01, .	1.5	2

#	ARTICLE	IF	CITATIONS
2732	Current Insight into Anti-HPV Immune Responses and Lessons for Prophylactic and Therapeutic Vaccines. , 0, , .		0
2733	Human Papillomavirus Genotype Spectrum in Studied Group of Montenegrin Women. Acta Medica (Hradec Kralove), 2012, 55, 130-132.	0.2	6
2734	Human Papillomavirus Vaccination Status and Related Factors among Some Female College Students. Journal of the Korean Society of Maternal and Child Health, 2012, 16, 186-194.	0.1	4
2735	HPV Detection. , 2013, , 196-214.		0
2737	Quel est le risque de cancer et de lymphome dans le lupus Å©rythÅ©mateux systÅ©mique ?. , 2013, , 183-191.		0
2738	HPV and Cervical Cancer. , 2013, , 83-98.		0
2739	Low and High Risk Human Papillomavirus in the Oral Mucosa of Mexican Women with Genital Papillomavirus. Open Journal of Medical Microbiology, 2013, 03, 62-69.	0.1	0
2740	Health providers opinions on the utility of the HPV vaccination-Are guidelines being Followed?. International Journal of Medical Science and Public Health, 2013, 2, 916.	0.2	0
2741	Frecuencia de sÃntomas del SÃndrome Apnea hipopnea del sueÃ±o e insomnio en mÃ©dicos de una clÃnica privada peruana.. Revista MÃ©dica Herediana, 2013, 14, 53.	0.0	2
2742	The Role of Human Papillomaviruses in the Development of Non-Melanoma Skin Cancers. Turkiye Klinikleri Journal of Medical Sciences, 2013, 33, 1112-1118.	0.1	0
2743	Comparison of ASCUS and Human Papilloma Virus. The Journal of the Korea Contents Association, 2013, 13, 308-313.	0.0	0
2746	HPV Genotypes and Cervical Intraepithelial Neoplasia in a Multiethnic Cohort in the Southeastern United States. Journal of Vaccines & Vaccination, 2014, 05, .	0.3	0
2747	Distribution of Human papilloma virus genotypes in cervical cancer tissues. Archives of Biological Sciences, 2014, 66, 573-577.	0.2	0
2748	Human papillomavirus infection in healthy women in Japan. The Journal of the Japanese Society of Clinical Cytology, 2014, 53, 366-370.	0.0	0
2749	Physics in Cuba from the Perspective of Bibliometrics. Boston Studies in the Philosophy and History of Science, 2014, , 423-437.	0.4	1
2750	Immunological study of cervical biopsy specimen for human papiloma virus. , 2014, 2, 145-148.		0
2751	Pap test for Screening of Carcinoma of Cervix: Analysis of one Hundred Patients. TAJ Journal of Teachers Association, 2009, 19, 76-80.	0.1	0
2752	Human papillomaviruses and cancer of the cervix. , 1996, , 83-91.		1

#	ARTICLE	IF	CITATIONS
2753	Viral Infections: Human Papillomavirus Infections Treated with Immunostimulatory Drugs and Vaccination Therapies. , 1997, , 293-305.		2
2754	Human Papillomaviruses and Cancer: A Retrospective. , 1997, , 1-24.		1
2755	Preventive vaccines for cervical cancer. Salud Publica De Mexico, 1997, 39, 283-287.	0.1	3
2756	Hybrid Captureâ„¢ A Sensitive Signal-Amplified Test for the Detection and Quantitation of Human Viral and Bacterial Pathogens. , 1998, , 225-249.		0
2757	KrebsprÃvention durch Vakzination. , 1998, , 201-217.		0
2758	Effect of Nonionic Detergents on Amplification of Human Papillomavirus DNA with Consensus Primers MY09 and MY11. Journal of Clinical Microbiology, 1998, 36, 1164-1164.	1.8	2
2760	Identifying Women With Cervical Neoplasia. Obstetrical and Gynecological Survey, 1999, 54, 569-571.	0.2	0
2761	Latent Viral Infections. , 0, , 339-369.		0
2762	A Study on the Level of Health Beliefs and Knowledge about Human Papilloma Virus(HPV) Vaccination among Health College Students. Journal of Fisheries and Marine Sciences Education, 2014, 26, 345-356.	0.0	3
2763	Cancer of Cervix. , 2014, , 197-261.		0
2764	DNA-Based Vaccine Is More Efficient than Non-Pathogenic Live Vaccine for the Prevention of HPV16 E7-Overexpressing Cancers. Vaccine Research, 2014, 1, 21-24.	0.3	0
2765	Evaluation of Human Papillomavirus Genotyping from Formalin-fixed Paraffin-embedded Specimens in Cervical Cancers. Journal of Life Science, 2014, 24, 1025-1029.	0.2	0
2767	Specific Type Epigenetic Changes in Cervical Cancers. Methods in Molecular Biology, 2015, 1238, 733-749.	0.4	5
2769	HUMAN-PAPILLOMA VIRUS IN ORAL MUCOSA: AN OVERVIEW. Journal of Biological and Scientific Opinion, 2014, 2, 335-338.	0.1	0
2770	Surveillance of Human Papilloma Virus Using Reference Laboratory Data for the Purpose of Evaluating Vaccine Impact. Online Journal of Public Health Informatics, 2014, 6, e194.	0.4	3
2771	Human papiloma virus testing in the cervix of high-risk women: A hospital-based clinicopathological, colposcopic, and cytogenetic study. International Journal of Medical Science and Public Health, 2015, 4, 538.	0.2	0
2772	Oral/oropharyngeal cancer. , 2015, , 410-417.		0
2773	Human Papillomavirus Prevalence and Genotype Distribution in Normal and ASCUS Specimens: Comparison of a Reverse Blot Hybridization Assay with a DNA Chip Test. Biomedical Science Letters, 2015, 21, 32-39.	0.0	3

#	ARTICLE	IF	CITATIONS
2774	Historia natural de la infección del cÃ©rvix uterino por el virus papiloma humano. Revista Peruana De GinecologÃ­a Y Obstetricia, 2015, 53, 84-92.	0.1	1
2775	Nanoparticles: Cancer Management Applications. , 0, , 5510-5533.		0
2776	Human Papillomavirus Prevalence and Distribution according to Age among Korean and Chinese Women. Korean Journal of Clinical Laboratory Science, 2015, 47, 259-266.	0.1	2
2777	HPV Detection Methods. Advances in Medical Diagnosis, Treatment, and Care, 2016, , 99-132.	0.1	0
2779	Biomarkers in Head and Neck Cancer. , 2016, , 149-162.		0
2780	Molecular Detection and Typing of Human Papillomaviruses in Paraffin-Embedded Cervical Cancer and Pre-Cancer Tissue Specimens. Iranian Journal of Cancer Prevention, 2016, InPress, e3752.	0.7	4
2782	Distribution of Oncogenic Human Papillomavirus Genotypes at High Grade Cervical Lesions above CIN 2 Grade with Histological Diagnosis. Biomedical Science Letters, 2016, 22, 37-45.	0.0	1
2783	Bias Correction in Age-Period-Cohort Models Using Eigen Analysis. ICSA Book Series in Statistics, 2017, , 323-341.	0.0	0
2784	HPV Detection Methods. , 2017, , 267-301.		0
2785	InfecÃ§Ã£o por PapilomavÃ­rus Humano e CÃ¢ncer Oral: RevisÃ£o da literatura atual. Cadernos UniFOA, 2017, 6, 103-110.	0.0	0
2786	Nanoparticles: Cancer Management Applications. , 2017, , 1182-1205.		0
2787	PREVALENCE OF HUMAN PAPILLOMA VIRUS AND ITS ASSOCIATED RISK FACTORS IN WOMEN WITH ABNORMAL CYTOLOGY AT A TERTIARY CARE HOSPITAL OF NORTH INDIA. Journal of Evolution of Medical and Dental Sciences, 2017, 6, 6172-6174.	0.1	0
2788	THE PLACE OF Â«EPIGEN SPRAYÂ» IN THE TREATMENT AND PREVENTION HPV-ASSOCIATED LESIONS OF THE CERVIX. Meditsinskiy Sovet, 2017, , 116-121.	0.1	3
2789	Human Papillomavirusâ€”The Cause of Human Cervical Cancer. Journal of Biosciences and Medicines, 2018, 06, 106-125.	0.1	2
2790	Morbidity and Mortality for Cervical Cancer in the Isle of Youth, 2003-2015. Obstetrics & Gynecology International Journal, 2018, 9, .	0.0	0
2792	Sexually Transmitted and Infectious Diarrheal Diseases. , 2019, , 495-515.		0
2793	The Cytotoxic Effect of Metformin on Cervical Cancer (Hela) Cells in Comparison with Non-Cancerous Kidney Cells. Majallah-i DÃ¢nishgÃ¢h-i IÃºlÃ­m-i PizishkÃ¢i Qum, 2018, 12, 9-15.	0.2	0
2794	Lower Genital Tract Precancer and Cancer in Hematopoietic Cell Transplant Survivors and the Role of HPV: A Systematic Review and Future Perspectives. Clinical Hematology International, 2019, 1, 142-153.	0.7	0

#	ARTICLE	IF	CITATIONS
2795	Diverse Roles of Heat Shock Proteins in Immune Activation and Tolerance: A Comprehensive Review of Mechanisms and Therapeutic Relevance. <i>Heat Shock Proteins</i> , 2019, , 183-215.	0.2	0
2796	Recent Advances on Prediction of Human Papillomaviruses Risk Types. <i>Current Drug Metabolism</i> , 2019, 20, 236-243.	0.7	1
2797	The Association Between Acculturation and Social Determinants with Young Hispanic Women's Decision to Obtain the HPV Vaccine. , 0, , .		0
2798	Analysis of Cervical Cytology Using PAP Smear in Women Residing in Bangalore Rural, India. <i>Journal of Evidence Based Medicine and Healthcare</i> , 2019, 6, 3156-3159.	0.0	0
2799	Current Perspectives in Human Papilloma Virus: Where We are and What We Need?. <i>Biomedical and Pharmacology Journal</i> , 2019, 12, 1683-1700.	0.2	1
2800	Vitamins as Possible Cancer Biomarkers: Significance and Limitations. <i>Nutrients</i> , 2021, 13, 3914.	1.7	17
2801	Cervical Cancer Screening in Arab Countries. , 2021, , 1-22.		0
2802	Synergistic Therapeutic Effects of Probiotic <i>Lactobacillus casei</i> TD-2 Consumption on GM-CSF-Induced Immune Responses in a Murine Model of Cervical Cancer. <i>Nutrition and Cancer</i> , 2022, 74, 372-382.	0.9	6
2805	Molecular Heterogeneity of Cervical Cancer Among Different Ethnic/Racial Populations. <i>Journal of Racial and Ethnic Health Disparities</i> , 2022, 9, 2441-2450.	1.8	3
2806	Genomic Epidemiology of Human Papillomavirus (HPV), Prostate Cancer, and Diabetes. <i>Health Information Systems and the Advancement of Medical Practice in Developing Countries</i> , 0, , 43-75.	0.1	0
2807	Anus. , 2002, , 151-163.		0
2808	A Scientific Understanding of the Development of Penile Tumors. , 2005, , 275-282.		0
2810	Peptide and Protein Vaccines for Cancer. , 2007, , 171-192.		0
2811	Nitrative and oxidative DNA damage in infection-related carcinogenesis in relation to cancer stem cells. <i>Genes and Environment</i> , 2017, 39, .	0.9	0
2812	Immunoprevention of Cervical Cancer. , 2005, , 449-459.		0
2814	HPV and Cervical Cancer Control Programs: Effective Translation of Knowledge into Practice. , 0, , .		1
2815	PROGNOSTIC SIGNIFICANCE OF VIRAL MARKER DETECTION IN PROGRESSION OF HIGH RISK HUMAN PAPILLOMA VIRUS ASSOCIATED CANCER CERVIX. , 2020, , 1-4.		0
2817	Human Papillomavirus. , 2021, , 189-198.		0

#	ARTICLE	IF	CITATIONS
2818	Progression model tissue microarray (TMA) for the study of uterine carcinomas. <i>Disease Markers</i> , 2010, 28, 267-72.	0.6	6
2819	Prevalence and predictors of human papillomavirus infection in women in Ontario, Canada. <i>Survey of HPV in Ontario Women (SHOW) Group. Cmaj</i> , 2000, 163, 503-8.	0.9	52
2820	Screening for cervical cancer: should we test for infection with high-risk HPV?. <i>Cmaj</i> , 2000, 163, 535-8.	0.9	11
2821	Cervical cancer: epidemiology, prevention and the role of human papillomavirus infection. <i>Cmaj</i> , 2001, 164, 1017-25.	0.9	102
2866	Multifactorial etiology of cervical cancer: a hypothesis. <i>MedGenMed: Medscape General Medicine</i> , 2005, 7, 57.	0.2	19
2867	Papillary squamous cell carcinoma of the cervix in Uganda: a report of 20 cases. <i>African Health Sciences</i> , 2005, 5, 291-4.	0.3	5
2868	The HPV vaccine: an analysis of the FUTURE II study. <i>Canadian Family Physician</i> , 2007, 53, 2157-9.	0.1	4
2869	Complete health checkup for adults: Update on the Preventive Care Checklist Form. <i>Canadian Family Physician</i> , 2008, 54, 84-8.	0.1	6
2870	DNA vaccines for cervical cancer. <i>American Journal of Translational Research (discontinued)</i> , 2010, 2, 75-87.	0.0	16
2871	Knowledge of cervical cancer and screening practices of nurses at a regional hospital in Tanzania. <i>African Health Sciences</i> , 2011, 11, 48-57.	0.3	62
2872	Physical state and viral load as predictive biomarkers for persistence and progression of HPV16-positive cervical lesions: results from a population based long-term prospective cohort study. <i>American Journal of Cancer Research</i> , 2012, 2, 192-203.	1.4	8
2873	Preventive and Therapeutic Vaccines against Human Papillomaviruses Associated Cervical Cancers. <i>Iranian Journal of Basic Medical Sciences</i> , 2012, 15, 585-601.	1.0	13
2874	Potential diagnostic value of P16 expression in premalignant and malignant cervical lesions. <i>Journal of Research in Medical Sciences</i> , 2012, 17, 428-33.	0.4	19
2875	Prevention and Inhibition of TC-1 Cell Growth in Tumor Bearing Mice by HPV16 E7 Protein in Fusion with Shiga Toxin B-Subunit from shigella dysenteriae. <i>Cell Journal</i> , 2013, 15, 176-81.	0.2	6
2876	Human Papillomavirus Type16- L1 VLP Production in Insect Cells. <i>Iranian Journal of Basic Medical Sciences</i> , 2013, 16, 891-5.	1.0	18
2878	Variations in immunogenetics, human papillomavirus (HPV) infection & predisposition to cervical cancer in Indian women. <i>Indian Journal of Medical Research</i> , 2014, 140 Suppl, S36-43.	0.4	4
2879	Further Stimulation of Cellular Immune Responses through Association of HPV-16 E6, E7 and L1 Genes in order to produce more Effective Therapeutic DNA Vaccines in Cervical Cancer Model. <i>Iranian Journal of Cancer Prevention</i> , 2015, 8, 18-23.	0.7	3
2880	Knowledge of Saudi female university students regarding cervical cancer and acceptance of the human papilloma virus vaccine. <i>Journal of King Abdulaziz University, Islamic Economics</i> , 2014, 35, 1223-30.	0.5	31

#	ARTICLE	IF	CITATIONS
2881	Woman with rectal condyloma acuminatum: a case report. <i>International Journal of Clinical and Experimental Medicine</i> , 2015, 8, 6365-8.	1.3	1
2882	CXCL12 rs266085 and TNF- α rs1799724 polymorphisms and susceptibility to cervical cancer in a Chinese population. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 5768-74.	0.5	5
2883	TP53 codon 72 polymorphism and susceptibility to cervical cancer in the Chinese population: an update meta-analysis. <i>International Journal of Clinical and Experimental Medicine</i> , 2015, 8, 9055-62.	1.3	7
2884	Frequency of Human Papillomavirus Genotypes 6, 11, 16, 18 And 31 in Paraffin-Embedded Tissue Samples of Invasive Breast Carcinoma, North- East of Iran. <i>Iranian Journal of Pathology</i> , 2015, 10, 192-8.	0.2	10
2885	Developing Michigan Cancer Foundation 7 Cells with Stable Expression of E7 Gene of Human Papillomavirus Type 16. <i>Iranian Journal of Pathology</i> , 2016, 11, 41-6.	0.2	0
2886	DLEU2 participates in lymphovascular invasion and inhibits cervical cancer cell proliferation, migration, and invasion. <i>International Journal of Clinical and Experimental Pathology</i> , 2020, 13, 2018-2026.	0.5	0
2887	Relationship of P16 and Ki67 in recurrence of HPV infection and cervical intraepithelial neoplasia. <i>International Journal of Clinical and Experimental Pathology</i> , 2020, 13, 3174-3180.	0.5	2
2888	Epidemiological study and cervical cancer screening by pap smear in Delhi. <i>Journal of Preventive Medicine and Holistic Health</i> , 2021, 7, 84-88.	0.2	0
2889	HPV Type Distribution in HIV Positive and Negative Women With or Without Cervical Dysplasia or Cancer in East Africa. <i>Frontiers in Oncology</i> , 2021, 11, 763717.	1.3	5
2890	Cervical cancer prevention: Human papillomavirus testing as primary screening. <i>Cancer</i> , 2022, 128, 939-943.	2.0	3
2891	Expression of Chimeric HPV-HIV Protein L1P18 in <i>Pichia pastoris</i> ; Purification and Characterization of the Virus-like Particles. <i>Pharmaceutics</i> , 2021, 13, 1967.	2.0	6
2892	A retrospective analysis of clinical profile of patients with cancer cervix in a rural medical college in Karnataka. <i>Indian Journal of Obstetrics and Gynecology Research</i> , 2021, 8, 502-506.	0.0	0
2893	Papillomavirus vaccination for prevention and treatment of cervical carcinoma. , 2001, 3, 231-240.		0
2894	The viral etiology of cervical cancer: epidemiological evidence. , 2002, 4, 1-4.		1
2895	Inmunotinci3n dual p16INK4a/ki-67 en citolog3a vaginal en medio l3quido. Prueba piloto de complemento diagn3stico.. <i>Revista Universitas Medica</i> , 2020, 61, .	0.0	0
2896	Prostate cancer and human papillomavirus infection. <i>Reviews in Medical Microbiology</i> , 2020, Publish Ahead of Print, .	0.4	2
2897	An integrated analysis of single-cell and bulk transcriptomics reveals EFNA1 as a novel prognostic biomarker for cervical cancer. <i>Human Cell</i> , 2022, 35, 705-720.	1.2	1
2898	HPV-mediated Cervical Cancer: A Systematic Review on Immunological Basis, Molecular Biology, and Immune Evasion Mechanisms. <i>Current Drug Targets</i> , 2022, 23, 782-801.	1.0	3

#	ARTICLE	IF	CITATIONS
2899	HPV E1 qPCR, a Low-Cost Alternative Assay to Roche Diagnostic Linear Array is Effective in Identifying Women at Risk for Developing Cervical Cancer. <i>International Journal of Women's Health</i> , 2022, Volume 14, 257-266.	1.1	2
2900	The clinical utility of extended high-risk HPV genotyping in risk-stratifying women with SIL cytology: A retrospective study of 8726 cases. <i>Cancer Cytopathology</i> , 2022, 130, 542-550.	1.4	7
2901	Increased CD4+ T cell count is associated with lower anal human papillomavirus prevalence among HIV-positive male cohort in Taizhou, China: a cross-sectional study. <i>BMC Infectious Diseases</i> , 2022, 22, 250.	1.3	3
2902	Genotype-specific high-risk human papillomavirus infections and risk factors for cervical dysplasia in women with human immunodeficiency virus in Germany: results from a single-center cross-sectional study. <i>International Journal of Gynecological Cancer</i> , 2022, 32, 716-723.	1.2	3
2903	Laser induced fluorescence of cervical tissues: an in-vitro study for the diagnosis of cervical cancer from the cervicitis. <i>Journal of Optics (United Kingdom)</i> , 2022, 24, 054002.	1.0	7
2904	Determination of human papillomavirus type in archival tissue specimens of invasive cervical cancer using molecular mapping and E6/E7-based polymerase chain reaction. <i>PLoS ONE</i> , 2022, 17, e0265996.	1.1	3
2905	Elevated serum expression of p53 and association of TP53 codon 72 polymorphisms with risk of cervical cancer in Bangladeshi women. <i>PLoS ONE</i> , 2021, 16, e0261984.	1.1	4
2906	Precancerous Lesions of the Cervix and Associated Factors among Women of East Gojjam, Northwest Ethiopia, 2020. <i>Cancer Management and Research</i> , 2021, Volume 13, 9401-9410.	0.9	6
2907	Sobrevida específica do câncer do colo do útero na Grande Cuiabá, Mato Grosso, Brasil. <i>Revista Brasileira De Epidemiologia</i> , 2022, 25, .	0.3	0
2908	Electroporation and Electrochemotherapy in Gynecological and Breast Cancer Treatment. <i>Molecules</i> , 2022, 27, 2476.	1.7	6
2909	Unraveling diverse roles of noncoding RNAs in various human papillomavirus negative cancers. , 2022, 238, 108188.		15
2910	The uterine cervix. , 0, , 2539-2609.		1
2912	Immune therapy against papillomavirus-related tumors in humans. , 2006, , 373-394.		0
2922	High prevalence of human papillomavirus 16 in penile carcinoma. <i>Histology and Histopathology</i> , 2007, 22, 177-83.	0.5	41
2924	Advances in the Development of Ribozymes and Antisense Oligodeoxynucleotides as Antiviral Agents for Human Papillomaviruses. <i>Antiviral Therapy</i> , 2003, 8, 265-278.	0.6	27
2925	The Impact of HIV Antiviral Therapy on Human Papillomavirus (Hpv) Infections and Hpv-Related Diseases. <i>Antiviral Therapy</i> , 2004, 9, 13-22.	0.6	103
2926	Hpv Proteins as Targets for Therapeutic Intervention. <i>Antiviral Therapy</i> , 2004, 9, 665-678.	0.6	4
2927	DYNAMICS OF CERVICAL CANCER INCIDENCE RATE AND LEVELS OF AWARENESS ABOUT ITS PREVENTION AMONG DIFFERENT POPULATION GROUPS. <i>Problemy Zdorov'ia I Ākologii</i> , 2014, , 25-30.	0.0	1

#	ARTICLE	IF	CITATIONS
2928	The Structural Diagram for the Development of Human Papillomavirus (HPV) and Cervical Cancer Risk Assessment. , 2022, , .		0
2929	Anti-L1 antibody-bound HPV16 pseudovirus is degraded intracellularly via TRIM21/proteasomal pathway. <i>Virology Journal</i> , 2022, 19, .	1.4	4
2930	miR-22-3p and miR-30e-5p Are Associated with Prognosis in Cervical Squamous Cell Carcinoma. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5623.	1.8	5
2934	APTES-Modified Remote Self-Assembled DNA-Based Electrochemical Biosensor for Human Papillomavirus DNA Detection. <i>Biosensors</i> , 2022, 12, 449.	2.3	5
2935	Review of the Standard and Advanced Screening, Staging Systems and Treatment Modalities for Cervical Cancer. <i>Cancers</i> , 2022, 14, 2913.	1.7	12
2936	The potential of B7-H6 as a therapeutic target in cancer immunotherapy. <i>Life Sciences</i> , 2022, 304, 120709.	2.0	7
2937	Assessing the impact of a health education outreach project on cervical cancer awareness among Vietnamese-American women in San Diego. <i>AIMS Public Health</i> , 2022, 9, 552-558.	1.1	1
2938	Cervical cancer specific survival in Grande Cuiabã, Mato Grosso State, Brazil. <i>Revista Brasileira De Epidemiologia</i> , 2022, 25, .	0.3	2
2939	Screening of Anticancer Potential and DNA Damage Ability of <i>Syringodium isoetifolium</i> against HeLa Cell Line. <i>Asian Journal of Organic & Medicinal Chemistry</i> , 2022, 7, 174-178.	0.1	0
2940	Exploring the psychosexual impact and disclosure experiences of women testing positive for high-risk cervical human papillomavirus. <i>British Journal of Health Psychology</i> , 2023, 28, 62-79.	1.9	2
2941	Pap Screening in a U.S. Health Plan. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2004, 13, 355-360.	1.1	49
2942	Eradication of Established Tumors by Vaccination With Recombinant <i>Bordetella pertussis</i> Adenylate Cyclase Carrying the Human Papillomavirus 16 E7 Oncoprotein. <i>Cancer Research</i> , 2005, 65, 641-649.	0.4	81
2943	Is there a biological plausability for p53 codon 72 polymorphism influence on cervical cancer development?. <i>Acta Medica Portuguesa</i> , 2011, 24, 127-134.	0.2	15
2944	A Case-Control Study of Risk Factors for Invasive Cervical Cancer among U.S. Women Exposed to Oncogenic Types of Human Papillomavirus. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2004, 13, 1574-1582.	1.1	76
2945	Cytology and High-Risk Human Papillomavirus Test for Cervical Cancer Screening Assessment. <i>Diagnostics</i> , 2022, 12, 1748.	1.3	5
2946	Mathematical Modeling and Computational Prediction of High-Risk Types of Human Papillomaviruses. <i>Computational and Mathematical Methods in Medicine</i> , 2022, 2022, 1-11.	0.7	1
2947	Malignancies in HIV. , 2021, , 313-354.		0
2949	PCR Testing of Pooled Longitudinally Collected Cervical Specimens of Women to Increase the Efficiency of Studying Human Papillomavirus Infection. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005, 14, 256-260.	1.1	6

#	ARTICLE	IF	CITATIONS
2950	Cancer treatment and survival among cervical cancer patients living with or without HIV in South Africa. <i>Gynecologic Oncology Reports</i> , 2022, 43, 101069.	0.3	1
2951	Recent advances and strategies in vaccine development against HPV. , 2022, , 149-163.		1
2952	Cervicovaginal microbiota and HPV-induced cervical cancer. , 2022, , 81-97.		2
2953	Malignancies associated with HPV. , 2022, , 43-63.		1
2954	An overview of HPV: Causes, symptoms, and clinical manifestations. , 2022, , 1-19.		0
2955	Current diagnostic tools for HPV. , 2022, , 99-118.		0
2956	Pathogenesis and immune response against HPV infection. , 2022, , 21-42.		0
2958	A Therapeutic Antigen-Presenting Cell-Targeting DNA Vaccine VB10.16 in HPV16-Positive High-Grade Cervical Intraepithelial Neoplasia: Results from a Phase I/IIa Trial. <i>Clinical Cancer Research</i> , 2022, 28, 4885-4892.	3.2	12
2959	Epidemiological Trends and Attributable Risk Burden of Cervical Cancer: An Observational Study from 1990 to 2019. <i>International Journal of Clinical Practice</i> , 2022, 2022, 1-15.	0.8	1
2960	Identification of CD8+ T cell infiltration-related genes and their prognostic values in cervical cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	6
2961	A simplified molecular method to detect high-risk HPV using the Aptima HPV assay on head and neck FNA smears. <i>Cancer Cytopathology</i> , 2023, 131, 171-178.	1.4	2
2963	HPV-genotyping versus conventional cervical cytology as a screening method to detect dysplastic cervical epithelial changes. <i>Scientific Reports</i> , 2022, 12, .	1.6	1
2965	Prevention of Cervical Cancer in Low-Resource African Settings. <i>Obstetrics and Gynecology Clinics of North America</i> , 2022, 49, 771-781.	0.7	6
2968	Th2-Type CD4+ Cells Neither Enhance nor Suppress Antitumor CTL Activity in a Mouse Tumor Model. <i>Journal of Immunology</i> , 1998, 161, 2421-2427.	0.4	47
2969	Structural Aspects of the Interaction Between Heterogeneous Human Papillomavirus Type 1 E4-Specific T Cell Receptors and the Same Peptide/HLA-DQ8 Complex. <i>Journal of Immunology</i> , 1998, 161, 4745-4752.	0.4	5
2970	Safety Run-in of Intramuscular pNGVL4a-Sig/E7(detox)/HSP70 DNA and TA-CIN Protein Vaccination as Treatment for HPV16+ ASC-US, ASC-H, or LSIL/CIN1. <i>Cancer Prevention Research</i> , 2023, 16, 219-227.	0.7	2
2971	Structural analysis of human papillomavirus E6 interactions with Scribble PDZ domains. <i>FEBS Journal</i> , 0, , .	2.2	1
2973	Analysis of the Prevalence and Quantification of viral load of different human papillomavirus types in Turkish women population. <i>Asian Pacific Journal of Cancer Prevention</i> , 2022, 23, 4347-4355.	0.5	1

#	ARTICLE	IF	CITATIONS
2974	Diagnosis of Viral Families Using a Nucleic Acid Simplification Technique. <i>Infectious Diseases</i> , 0, , .	4.0	0
2975	CÃ¡ncer anal en la era del VIH: papel de la citologÃ¡a anal. <i>Iatreia</i> , 2004, 17, .	0.1	0
2978	The definition of precision medicine in neurodegenerative disorders and the one disease-many diseases tension. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2023, , 3-20.	1.0	1
2979	The analysis of L1 gene variability of Human papilloma virus type 16 in our population. <i>Medicinski Podmladak</i> , 2022, 73, 40-44.	0.2	0
2980	Circulating HPV DNA in HPV-associated cancers. <i>Clinica Chimica Acta</i> , 2023, 542, 117269.	0.5	6
2981	Determinants of Acquisition, Persistence, and Clearance of Oncogenic Cervical Human Papillomavirus Infection in the Philippines Using a Multi-Omics Approach: DEFEAT HPV Study Protocol. <i>Healthcare (Switzerland)</i> , 2023, 11, 658.	1.0	1
2983	TRANSLACOL project: Nodal human papillomavirus tumoral DNA detection by ddPCR for survival prediction in early cervical cancer patients without pelvic lymph node invasion. <i>Journal of Clinical Virology</i> , 2023, 161, 105418.	1.6	0
2985	Polymorphism of E6 and E7 Genes in Human Papillomavirus Types 31 and 33 in Northeast China. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2023, 2023, 1-12.	0.7	0
2986	Synbiotics in Cervical Cancer. , 2023, , 135-155.		0
2987	Direct Virus Gene Detection: A CRISPR/dCas9-Mediated Surface-Enhanced Raman Scattering Strategy with Enzyme-Catalyzed Signal Amplification. <i>Analytical Chemistry</i> , 2023, 95, 5927-5936.	3.2	8
2988	HPV vaccine narratives on Twitter during the COVID-19 pandemic: a social network, thematic, and sentiment analysis. <i>BMC Public Health</i> , 2023, 23, .	1.2	1
3004	Molecular testing in gynecologic cancer. , 2024, , 421-445.		0
3005	Molecular testing for human papillomaviruses. , 2024, , 79-93.		0